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Abstract
Following the success of the Human Genome Mutation Database, increasing 
numbers of locus-specific mutation databases are being compiled in order to present 
more detailed descriptions of the mutations in specific proteins and diseases. However, 
until now, many coagulation or complement disorders have no up-to-date, accurate 
repository of information. Structural analyses of disease-associated mutations can 
provide important new tools for identifying the underlying biochemical defect of 
disease. Type I mutations may affect the correct folding, secretion, expression or 
degradation of the protein. Alternatively, Type II mutations can disrupt the catalytic or 
substrate-binding functional site of the protein. Alternatively, mutations may not be the 
causative factor for disease. Including sequence and structural information to propose 
consensus domain structures can unravel these effects of mutations. Central repositories 
of data that combine structural, sequence and phenotypic information on mutations and 
proteins can facilitate the diagnosis and understanding of the associated diseases, and 
define the molecular consequences of disease. This thesis describes interactive web 
databases of genotypic, phenotypic, clinical and structural information on mutations 
associated with complement Factor H (FH) and coagulation Factor XI (FXI). Mutations 
within FH are associated with aHUS (atypical Haemolytic Uraemic Syndrome), MPGN 
(Membranoproliferative Glomerulonephritis) and AMD (Age-related Macular 
Degeneration), whereas mutations within FXI are associated with a FXI deficiency 
bleeding disorder. The methods used within the FH and FXI databases were extended 
and combined with a database management system to design a mutation database for the 
five Vitamin K dependent serine proteases of coagulation in order to study the effects of 
mutations within conserved domains. The database management system incorporates 
new tools that have been designed to automatically scan full length references to find 
text describing mutations. This significantly reduces the time and expertise required to 
maintain the databases.
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Chapter 1 
Protein Structures and Mutations
1
1.1 Amino Acids
Proteins are polymers of small units known as amino acids. The sequence of 
amino acids that make up a protein is determined by the genetic code of 
deoxyribonucleic acid (DNA). An amino acid is composed of an amino group and a 
carboxyl group attached to a central a-carbon. There are 20 different amino acids 
seen within proteins with each having a different side chain attached to the a-carbon 
(Figure 1.1).
The a-carbon within amino acids is said to be chiral as it has four different 
atoms attached to it, forming an asymmetrical molecule. When a molecule contains 
an asymmetric carbon, two distinguishable stereoisomers termed L and D forms 
exist. All amino acids except glycine can exist in both L and D forms, however all of 
the amino acids incorporated into proteins are of the L form. D-forms of amino acids 
do exist in nature as peptides but they are never found in proteins.
The 20 different amino acids contain diverse chemical groups, and it is this 
diversity that allows proteins to exhibit such a great variety of structures and 
properties. The chemical properties of side chains allow amino acids to be grouped 
into classes (Figure 1.1). Glycine, alanine, valine, leucine and isoleucine all contain 
straight or branched arrangements of carbon atoms and are said to contain aliphatic 
side chains. As these side chains become more extended, the amino acids become 
more hydrophobic. Isoleucine, for example has a great tendency to transfer from 
water to a hydrocarbon solvent. Although proline is a cyclic imino acid it shares 
many properties with the aliphatic amino acids. The side chain of proline is unique 
as it forms a bond with the N atom of the proline amino group making a cyclic 
structure (Figure 1.1). The side chains of serine, cysteine, threonine and methionine 
all contain hydroxyl or sulphur groups. They are generally more hydrophilic than the 
aliphatic amino acids, however methionine is hydrophobic. Three amino acids, 
phenylalanine, tyrosine and tryptophan carry aromatic side chains. Phenylalanine is 
strongly hydrophobic; however the polar groups in the side chains of tyrosine and 
tryptophan reduce their hydrophobic nature. Histidine, lysine and arginine carry 
basic (positively charged) groups in their side chains. Histidine is the least basic of 
the three and since it can exchange protons near physiological pH, it often plays a 
role in enzymatic catalysis involving proton transfer. Lysine and arginine are more 
basic and strongly polar.
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Phenylalanine M ethionine (Met, M) 
(Phe, F)
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Figure 1.1 The 20 amino acids
3
Aspartic acid and glutamic acid side chains carry negative charges at pH 7. 
Asparagine and glutamine are the amides of these acids and have uncharged polar 
side chains within physiological conditions.
1.2 Peptide Bonds
Amino acids are joined together covalently by formation of a peptide bond 
between the carboxyl group of one amino acid and the amino group of another with 
the elimination of a molecule of water (Figure 1.2). Chains of amino acids joined by 
peptide bonds are referred to as peptides where a dipeptide refers to a chain of two 
amino acids, a tripeptide refers to a chain of three amino acids and a polypeptide 
refers to a chain of many amino acids. The portion of each amino acid remaining in 
the chain is referred to as the amino acid residue. Most peptides contain an un­
reacted amino group at one end (N-terminus) and an un-reacted carboxyl group at 
the other end (C-terminus).
The C=0 and N-H bonds of the carboxyl and amide groups that make up the 
peptide bond are nearly always parallel, and the O, C, N and H atoms are usually 
coplanar. There is little twisting possible around the C-N bond and the group of 
atoms about the peptide bond can exist in two configurations trans and cis (Figure 
1.2). The trans form is usually favoured as the cis form would cause clashes between 
bulky side chains on adjacent a-carbons.
1.3 Secondary Structure
Local regular folding of the polypeptide backbone is known as secondary 
structure. Since atoms within the peptide bond are coplanar, the backbone 
conformation can be described by the torsion angles around the N -Ca bond (phi (<j>) 
angle) or the Ca-C bond (psi (\j/) angle) of each of the amino acid residues (Figure 
1.2a).
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(a) Trans conformation
omega
vCa,
N
N
Ca
(b) Cis conformation
0  H
Figure 1.2 Schematic views of the peptide bond
(a) Three amino acids are shown joined by peptide bonds in the trans 
conformation. R represents a side chain of any residue. The bonds that define 
phi (<()), psi (\\f) and omega angles (C-N bond) are labelled.
(b) Two amino acids are shown joined by a peptide bond in the cis conformation 
where adjacent side chains point the same way.
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1.3.1 Ramachandran Plots
Ramachandran plots show sterically allowed values of <|> and \\f angles 
(Figure 1.3). These are determined by calculating the distances between atoms of a 
tripeptide at all values of <|> and \\/ angles for the central peptide. Conformations 
where any nonbonding interatomic distance is less than its corresponding van der 
Waals distance are termed sterically forbidden. Most combinations of <|> and vj/ angles 
are not allowed because of steric collisions between the side chains of the amino acid 
and the main chain. In fact, only three small regions of the conformational map are 
physically accessible to the polypeptide chain.
Ramachandran plots show similar favoured conformations for all amino acids 
with two exceptions. Glycine is the only residue without a CP atom, and as a result is 
much less sterically hindered than the other amino acids. For this reason, glycine 
often occupies positions where a polypeptide backbone makes a sharp turn. Proline 
is the most conformationally restricted residue due its cyclic side chain.
1.3.2 The a-helix
The a-helix is the classic element of protein structure (Pauling et al., 1951) 
(Figure 1.4a). It is found when a stretch of amino acid residues all have (|) and vj/ 
angle pairs approximately -60° and -50°, corresponding to the allowed region in the 
bottom left quadrant of the Ramachandran plot (Figure 1.3). Helices can be 
characterized by the number of peptide units per helical turn and the distance the 
helix rises along each axis turn (pitch). The a-helix has 3.6 residues per turn and a 
pitch of 5.4 A . Hydrogen bonds between the C=0 of residue n and the NH of residue 
n+4 stabilise the structure. In addition, the core of the helix is packed so that atoms 
are in van der Waals contact across the helix. The side chains of residues within the 
a-helix project outwards to avoid steric interference with the backbone. An a-helix 
can in theory be either right-handed or left-handed, however a left-handed a-helix is 
not allowed for L-amino acids since the side chains and CO groups of the backbone 
are too close to each other. In globular proteins a-helices vary in length from four or 
five amino acids to over 40, with the average length being about ten residues.
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Figure 1.3 Example of a Ramachandran Plot
The black dots show the individual amino acid residues in the protein of interest.
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Side Chain
Hydrogen Bond
a -h e lix  3 10-helix  re-helix
Figure 1.4 Helices found within protein structures
(a) A 13-residue a-helix built from glycine residues. The Ca to which a side 
chain would be attached can be seen within the helix. The N- and C-termini 
are represented by N and C respectively. Hydrogen bonds are represented by 
green dashed lines. Atom colouring follows previous figures.
(b) 13 residue 3io-helix and re-helix presented adjacent to each other.
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Proline residues are not usually seen within a-helices. This is because the N atom of 
the proline backbone is already bonded with the fourth carbon atom of the proline 
side chain and so cannot participate in hydrogen bonding (Figure 1.1). It can usually 
be accommodated within the first turn of the helix, but would introduce a significant 
bend elsewhere in the helix.
1.3.3 Other Polypeptide Helices
There are two variations on the a-helix that are sterically possible but differ 
in the number of residues per turn and pitch. The right-handed 3io helix has three 
residues per turn and hydrogen bonds between residue n and n+3 (Figure 1.4b). It is 
not energetically favourable since the atoms of the backbone are too tightly packed 
and the torsion angles between residues lie within mildly favourable regions of the 
Ramachandran plot. The rc-helix has 4.4 residues per turn and hydrogen bonds 
between residue n and «+5 (Figure 1.4b). This is not energetically favourable since 
the atoms of the backbone are loosely packed so a hole runs through the middle that 
does not allow van der Waals associations. Within protein structures, both the 3 io 
and the rc-helix usually only occur at the ends of a-helices or as single turn helices.
1.3.4 The P-sheet
The second major element of protein structure is the P-sheet (Pauling and 
Corey, 1951) (Figure 1.5). In contrast to the a-helix that is built from a continuous 
region of the polypeptide, the P-sheet is built from a combination of several regions 
of the polypeptide chain known as P-strands. P-strands are stretches of five to ten 
residues with <|> and \\) backbone angles falling within the upper left region of the 
Ramachandran plot (Figure 1.3). p-strands align adjacent to each other with 
hydrogen bonds between C=0 groups of one P-strand and the NH groups of another 
forming a stable sheet structure (Figure 1.5).
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Figure 1.5 Five-stranded anti-parallel p-sheet
Hydrogen bonds are represented by green dashed lines. The N- and C-termini 
are represented by N and C respectively. Atom colouring follows previous figures.
The P-sheet structures formed from two or more P-strands are pleated with 
Ca atoms of each residue alternating above and below the plane of the P-sheet. Side 
chains also alternate to point above and below the P-sheet. P-sheets can be defined as 
parallel where the individual P-strands all run in the same direction (N-terminus to 
C-terminus) or antiparallel where p-strands run in opposite directions (N-terminus to 
C-terminus followed by C-terminus to N-terminus). As each of the two forms has 
distinct hydrogen bonding patterns, it is less common (-20%) that a P-sheet contains 
both parallel and antiparallel P-strands.
1.3.5 Loop Regions
Within protein structures a-helices and P-strands are combined to form a 
stable hydrophobic core within the molecule. These secondary structure elements are 
connected by loop regions of various lengths and conformations. These loop regions 
almost always occur on the surface of the molecule. Main chain C=0 and NH groups 
within these conformations rarely form hydrogen bonds with each other, instead they 
are exposed on the surface of the protein and can form hydrogen bonds to water 
molecules. Surveys of known three-dimensional structures of loops have shown that 
they fall into a rather limited set of structures and are not a random collection of 
possible structures (Sibanda and Thornton, 1985).
1.4 Tertiary Structure
The tertiary structure of a protein is the three-dimensional arrangement of 
secondary structure units and loop regions together with the spatial dispositions of 
the side chains. A number of combinations of secondary structure elements with 
specific geometric arrangements known as super secondary structures have been 
found to occur frequently in unrelated globular proteins. These super secondary 
structures or motifs may be associated with particular functions such as DNA 
binding or be simply part of larger structural assemblies. The most common form of 
super secondary structure is the PaP motif which involves two parallel p-strands 
connected by an a-helix.
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1.5 Domains
Within globular protein structures, several super-secondary motifs combine 
to form compact clusters of structure known as domains. A domain can be defined as 
part of a polypeptide chain that can fold independently into a stable tertiary structure 
independently of its neighbouring sequences (Doolittle, 1995). Domains vary in 
length, with a minimum of about 40 amino acid residues for small domains such as 
the epidermal growth factor domain (Montelione et al., 1987) and a maximum of 
about 400 residues for large domains such as cytochrome p450eryf (Cupp-Vickery 
and Poulos, 1995) (Figure 1.6).
1.5.1 Domains and Protein Evolution
Not only are domains structurally discrete units, they also form discrete 
functional units. Within multi-domain proteins different domains are associated with 
different functions. Due to this functional significance the domain has played an 
integral role in protein evolution. The theory of domain and protein evolution 
suggests that proteins have originated from a relatively small number of primordial 
domain genes that have propagated throughout evolution by continuous duplication, 
shuffling and modification events. Comparing both the amino acid sequence and 
secondary structure elements of proteins can identify evolutionary related domains, 
and related domains can be grouped into domain families (Section 3.8).
Although domain families share common secondary structural motifs, the 
surface loop regions between secondary structure elements can often differ in length 
and amino acid sequence. This occurs throughout evolution as amino acid mutations 
within these regions are more tolerated than those within energetically stable 
secondary structures and motifs. It is these surface exposed regions within structures 
that can give domains of the same family different ligand and substrate specificity.
Domain evolution is a particular feature of biological pathways where a few 
domain fold types perform the characteristic functions of the pathway and dominate 
within the constituent proteins. This is discussed in Chapter 2, with respect to the 
coagulation pathway where serine protease and epidermal growth factor-like 
domains dominate (Stenflo, 1991) and with respect to the complement pathway 
where SCR domains dominate the regulators of complement proteins (Kirkitadze and 
Barlow, 2001).
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EGF Dom ain
C ytochrom e p450eryf Dom ain
Figure 1.6 Secondary structure cartoons of representative protein domains
(a) NMR structure of murine epidermal growth factor (PDB code: 1EGF).
(b) Crystal structure of bacterial cytochrome p450eryf (PDB code: 1EGY).
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1.6 Quaternary Structure
Physiologically, many proteins exist as complexes of more than one 
independently folded polypeptide chain. The individual polypeptide chains are 
referred to as subunits and the quaternary structure of the protein describes how 
these individual tertiary subunits arrange into larger protein assemblies. These types 
of protein assemblies are described by the number of protein units in the complex 
suffixed by the term “meric” or “mer” so that “dimeric” would refer to a protein with 
two subunits and “trimeric” would refer to a protein with three subunits etc. Proteins 
can consist of identical subunits or different subunits. Haemoglobin is probably the 
most obvious example of a multimeric protein, with the most common form, 
Haemoglobin A consisting of two a and two P subunits non-covalently bound, each 
made of 141 and 146 amino acid residues, respectively. Some proteins exist in vivo 
as complexes of the same monomeric protein structure. An example of this can be 
seen with coagulation Factor XI that circulates within blood as a dimer (Bouma and 
Griffin, 1977) of two Factor XI monomeric protein units. Some proteins can exist in 
more than one form, for example immunoglobulin A found within serum is mainly 
monomeric, whereas secretory immunoglobulin A is predominantly dimeric but can 
also exist in higher oligomeric states (Furtado et al., 2004). Although complexes 
higher than octamers are rarely observed for most proteins, there are a few examples 
of protein complexes, such as viral capsids, that are composed of large amounts of 
subunits.
Subunits can function either independently or cooperatively so that function 
of one subunit is dependent on the functional state of the other. These are known as 
allosteric interactions.
1.7 Factors Determining Protein Structure
1.7.1 Thermodynamics
The folding of proteins from an unfolded peptide to a compact stable 
structure is an energetically favoured process under physiological conditions. The 
thermodynamically favoured direction of a reaction is described by the Gibbs free 
energy equation
AG = AH - TAS
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This equation states that the direction of a reaction (AG) is determined by both the 
enthalpy (AH) and entropy (AS) where T is the absolute temperature. For the protein 
folding process to be favoured, AG must be negative. Since folding into a single 
folded structure reduces the entropy of the system and works against folding, an 
increase in enthalpy of the system is required for the process to be favourable. This 
increase in enthalpy comes from favourable interactions between groups within the 
folded protein structure.
1.7.2 Charge-Charge Interactions
The association of two ionic protein groups of opposite charge is known as a 
salt bridge or charge-charge interaction (Figure 1.7a). Salt bridges contribute very 
little stability to a protein’s native structure since the free energy of solvation of two 
separated ions in an aqueous solution is about equal to the free energy of their 
unsolvated ion pairs. In other words the energy change when a salt bridge is formed 
is counter balanced by the entropic penalty of localising the salt bridge side chains. 
This explains the observation that within protein structures the majority of charged 
residues that occur in ion pairs mainly occur on the protein surface and very few 
unsolvated ion pairs are buried.
Many atomic groups within proteins, such as the carbonyl and amide groups 
of the peptide backbone participate in electrostatic interactions even though they do 
not have a net charge. This occurs when electron density is localised because the 
atoms have different electro negativities. The separation of charge within a molecule 
determines its dipole moment. Although dipole-dipole interactions are much weaker 
than the charge-charge interactions of ion pairs, they can significantly stabilize 
protein structures. This is most clearly seen within the a-helix structure, where the 
negative end of the dipolar amide and carbonyl groups of the polypeptide backbone 
all point towards the same direction. The individual dipoles add together to produce 
a significant dipole moment within the a-helix that is positive towards the N- 
terminus and negative towards the C-terminus.
A permanent dipole can also induce a dipole moment on a neighbouring 
group, resulting in an attractive interaction. In addition to these interactions, weaker 
interactions known as London dispersion forces occur between neighbouring 
nonpolar groups when the rapid fluctuating motions of their electrons correlate.
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(a) Salt Bridge (b) Hydrogen Bond (c) Hydrophobic Core
D576
(d) Disulphide Bond (e) Metal binding
Figure 1.7 Factors affecting protein folding
(a) An ionic interaction between the NH1 atom of Arg397 and the OE2 atom of 
Glu605 of human hepatocyte growth factor (PDB code: 1YBW).
(b) Mainchain hydrogen bond shown between the O atom of Tyr573 and the N 
atom of Asp576 of human hepatocyte growth factor.
(c) Hydrophobic interactions of buried residues shown within human hepatocyte 
growth factor.
(d) Disulphide bond between Cys567 and Cy583 of human hepatocyte growth 
factor.
(e) Zinc binding site within zinc-Diphtheria toxin repressor (PDB code: 1BI3). 
The zinc is shown as a grey sphere. The solvent phosphate ion is shown in 
green and hydrogen bonds are depicted as dashed lines.
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These forces combine to form van der Waals interactions that occur between all 
molecules and atoms even in the absence of charged groups. Van der Waals forces 
act as a major influence in determining the large amount of interatomic contacts in 
the closely packed interiors of protein structures.
1.7.3 Hydrogen Bonds
A hydrogen bond occurs when two electronegative atoms compete for the 
same hydrogen atom (Figure 1.7b). The hydrogen atom is covalently bonded to one 
of the atoms, known as the donor atom but interacts favourably with another atom, 
known as the acceptor atom. Hydrogen bonds within protein structures are linear and 
most frequently involve the C=0 and N-H groups of the polypeptide backbone 
stabilising secondary structure. The formation of hydrogen bonds within a protein 
structure removes unsatisfied free polar groups within the hydrophobic core. Most of 
the hydrogen bonds within protein structures occur between donors and acceptors 
that are close together within the sequence and are said to be local.
1.7.4 Hydrophobic Effect
The solubility of substances depends on their energetically favourable 
interaction with water molecules. Substances that can form hydrogen bonds with 
water such as hydroxyl compounds and amides readily dissolve in water. Water is 
also an excellent solvent for ionic compounds. Interactions of the water dipoles with 
cations and anions in aqueous solution cause the ions to become surrounded by water 
molecules called hydration shells. Compounds that interact with water in this way 
are described as hydrophilic. Non-polar and non-ionic substances are hydrophobic 
since they cannot form hydrogen bonds with water and show limited solubility. In 
order to recover the lost hydrogen bonding energy between the non-polar substance 
and the water molecules, the water molecules at the surface of the cavity occupied by 
the non-polar group orientate themselves so as to form a hydrogen bonded network 
enclosing the non-polar group. The aggregation of non-polar groups minimizes the 
surface area of this cavity so it is energetically favourable for hydrophobic groups to 
form aggregates.
When the polypeptide chain is in an unfolded form within solution, the side 
chains of hydrophobic residue (Ala, lie, Leu, Met, Phe, Pro and Val) are in contact 
with water molecules, causing ordering of the surrounding water structure. When the
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protein folds into a globular structure, hydrophobic residues become buried within 
the molecule and the ordering of surrounding water molecules is decreased, yielding 
an entropy increase on folding. This entropy increase makes a negative contribution 
to the free energy and thus increases the stability of the protein. This influence that 
causes proteins to fold into native conformations is termed the hydrophobic effect 
(Figure 1.7c).
1.7.5 Disulphide Bonds
Protein structure can be further stabilised by the formation of disulphide 
bonds between pairs of cysteine residues (Figure 1.7d). This is an oxidative reaction 
that does not occur in the reducing environment of the cytoplasm. Almost all 
proteins with disulphide bonds are secreted to extracellular destinations, and 
formation of disulphide bonds occurs within the lumen of the endoplasmic 
reticulum. Disulphide bonds can occur between residues of the same polypeptide 
chain making the protein less susceptible to degradation. They can also occur 
between different polypeptide chains, in order to hold different subunits of a protein 
together.
1.7.6 Metal Binding
Another method by which the folded state of proteins can be stabilized is 
metal binding, in which metal ions are coordinated, usually by lone pair donation 
from oxygen or nitrogen atoms (Figure 1.7e). Metal ions have a role in a variety of 
important functions in proteins including protein folding, assembly, stability, 
conformational change, and catalysis. The presence or absence of a specific metal 
ion is crucial to the conformation or activity of over one third of all proteins (Tainer 
et al., 1992).
1.7.7 Kinetics of Protein Folding
It has been suggested that for a protein of 100 amino acids, a purely random 
conformational search would require around 1036 seconds or around 1029 years, 
(Dobson et al., 1998) and yet proteins are able to fold on a timescale of milliseconds 
to seconds. This suggests that only a small amount of conformational space is 
sampled during the folding process and this in turn implies the existence of kinetic 
folding pathways (Levinthal, 1968). The nucleation model of protein folding
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suggests that local folding of residues into small structures (for example a p-tum or a 
first turn of a-helix) begins at a number of points within the structure (Wetlaufer, 
1973). These nuclei then extend outwards forming larger secondary structures. 
Partially folded structures are then funnelled towards the final state by energy 
minimisation. This implies that there is more than one possible path from the 
unfolded peptide to the stable folded structure. The hydrophobic collapse model 
hypothesises that the native protein conformation forms by rearrangement of a 
compact collapsed structure (Dill et al., 1995). An early step in this pathway is the 
formation of a molton globule state (Ptitsyn, 1996) where the structure is compact 
and much of the secondary and tertiary folding has occurred but internalized 
hydrophobic side chains have not fully settled into the final stable packing. There is 
also evidence of folding states that fall within local energy minima, where some 
element is incorrectly folded and the folding pathway will not reach the lowest 
energy structure. In these cases cells have mechanisms to aid the folding process, for 
example, cis-trans isomerases catalyze cis-trans isomerisation of proline residues.
1.8 Proteins and Disease
1.8.1 Genetic Alterations
Genetic variation occurs when there are errors in DNA replication. Single 
nucleotide polymorphisms (SNPs) occur when nucleotides are inserted or substituted 
in the daughter DNA stand that are not complementary to the corresponding base 
pair in the template DNA strand. SNPs can occur for a number of reasons. Some 
SNPs may be spontaneous errors during replication, where the DNA polymerase 
fails to proofread the new polynucleotide chain. Other SNPs may occur because of 
exposure to Ultra Violet light, high-energy radiation or exposure to chemical 
mutagens. In addition to SNPs, errors within DNA replication can also result in the 
deletion or insertion of more than one nucleotide. Replication slippage or slipped- 
strand mispairing results in deletion or duplication of a short DNA segment and 
often occurs in DNA that contains contiguous short repeats.
Mutations do not occur randomly through genomes and are instead 
frequently seen at mutation hotspots that are prone to mutation. Examples of 
hotspots within eukaryotes include short tandem repeats and the dinucleotide 5’-CG- 
3’ where the cytosine is frequently methylated and replicated with error, changing it 
to 5’-TG-3\
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1.8.2 Frequency of Errors within Cell Replication
Although eukaryotic DNA replication results in only one error every million 
base pairs, human cells contain 6 billion base pairs of DNA material, so each cell 
replication has approximately 6000 base pair errors within the DNA material 
(Kunkel, 2004). Although this is a large number, not all of these changes are relevant 
since 98.5% of DNA is redundant and does not code for genes (International Human 
Genome Sequencing Consortium, 2004). It is estimated that there are around 20,000 
to 25,000 genes within the human genome, and even within these genes, large 
segments of DNA form introns and do not code for a protein product (International 
Human Genome Sequencing Consortium, 2004). Since only 1.5% of DNA actually 
codes for proteins, the error rate of protein sequence replication is about 90 base 
pairs per cell division. Many of these nucleotide changes will not directly alter the 
protein sequence since the genetic code can have up to six different three letter 
codons that are translated into the same amino acid. Some errors within DNA 
replication can also be corrected by mechanisms such as nucleotide excision repair, 
where enzymes make single strand nicks around the error site to remove the error 
segment which can then be repaired by DNA polymerases and DNA ligase.
Within single celled organisms such as bacteria and yeasts, all non-lethal 
mutations are inherited. Within multi-cellular organisms mutations mostly occur 
within somatic cells, so the mutation is not inherited in offspring, however where 
mutations occur within cells that are involved in reproduction they are inherited and 
can often form the basis of genetic diseases.
1.8.3 Genetic Basis of Disease
Over 50,000 genetic mutations have been found that are associated with a 
wide variety of diseases (Soussi et al., 2006). These genetic alterations most 
commonly occur as SNPs, with only 10% of variation as the result of changes such 
as insertions and deletions affecting two or more nucleotides.
The outcome of a genetic alteration is governed by the position of the 
alteration within the DNA sequence. The majority of disease-causing SNPs occur 
within the coding regions of genes where they are directly translated to produce an 
incorrect protein sequence. A SNP that causes the substitution of an amino acid 
within a protein sequence is termed a missense mutation or non-synonymous change. 
A SNP that does not change the amino acid is termed a synonymous change. If a
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SNP causes an amino acid to be substituted with a nucleotide sequence that signals 
the termination of translation, it is termed a nonsense mutation and results in a 
shortened polypeptide chain. Disease-causing SNPs can also occur in regions that do 
not code for the protein sequence such as those within intron and exon boundaries 
that cause incorrect splicing of the gene or within promoter and enhancer sequences 
affecting the transcription of the gene. Insertions or deletions within the nucleotide 
sequence can alter the reading frame of the coding sequence and change all the 
residues of the polypeptide chain on the carboxyl side of the mutation. Usually this 
type of mutation results in a premature termination codon and a shortened 
polypeptide chain.
1.8.4 The Effect of Missense Mutations within Protein Structures
Almost half of all DNA mutations that cause genetic diseases are missense 
mutations resulting from SNPs (Krawczak et al., 2000). Missense mutations within 
protein sequences can be classified as having one of two effects. Firstly the mutation 
can alter the overall structural stability of the protein causing reduced transcription, 
expression or secretion resulting in a reduced protein concentration. These are 
classified as Type I mutations. Type II mutations on the other hand change the 
functional aspects of the protein such as ligand binding, catalysis, post-translational 
modification or allosteric interactions. Here the protein is produced in normal 
amounts but it is not functioning in the same way as the wild type protein.
Evaluation of in vitro mutagenesis data predicts that the majority of disease 
associated mutations affect protein stability by 1 to 3 kcal/mol (Yue et al., 2005). A 
study of the factors that affect protein stability and function using a rule-based model 
suggests that the majority of disease-causing mutations are Type I mutations that 
affect protein stability through a variety of energy-related factors (Wang and Moult,
2001). For example, the loss of a hydrogen bond generally reduces protein stability 
by 0.48 to 1.91 kcal/mol (Voet and Voet, 1995). The replacement of a large side 
chain with a smaller side chain can create a cavity within the protein structure which 
can reduce its structural stability (Figure 1.8a). Cavity-creating mutations that 
substituted lysine residues with alanine residues within the hydrophobic core of 
phage T4 lysozyme were shown to decrease stability of the protein by different 
amounts ranging from 2.7 to 5.0 kcal/mol (Eriksson et al., 1992).
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Met133
p53 M etl33Thr/Val Cavity
(c) p53 proline backbone strain (His168Pro)
(b) p53 change in electrostatic charge 
(GI u204AI a/G ly/Ly s/Va I)
Arg156
Glu204
(d) FIX change in catalytic site (Ser365Arg)
His 168
Figure 1.8 Effects of missense mutations within the structure of the tumour 
suppressor gene p53 (Martin et al., 2002) and coagulation factor IX (Steward et 
al., 2003)
(a) The replacement of Met 133 with a smaller threonine or valine residue would 
cause a cavity within the structure of P53 (PDB code: 1TSR).
(b) The replacement of Glu204 would disrupt the ionic interactions between 
Glu204 and Argl56 within p53.
(c) The introduction of a proline residue in the place of His 168 would disrupt the 
helix since proline is conformationally restricted.
(d) The Ser365Arg mutation within coagulation Factor XI is associated with 
haemophilia A and disrupts the catalytic activity of FXI (PDB code: 1RFN).
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This decrease in stability may be due to the effect on the hydrophobic core of the 
protein but also may reduce the van der Waals interaction forces between atoms. 
Alternatively a change from a small residue side chain to larger side chain can cause 
over packing of atoms that make unavoidable short atomic contacts and destabilise 
the structure. Changes in electrostatic charges such as loss of a salt bridge (Figure 
1.8b) or introduction of a zero-accessibility electrostatically isolated charge can also 
have a destabilising effect on protein structure, as can the introduction of a charged 
group within close proximity to another charged group of the same charge. The 
substitution of a cysteine residue that participates in a disulphide bridge will 
destabilise the protein structure by breaking the disulphide bond. Experimental 
evidence from the disruption of naturally occurring disulphide bridges together with 
the insertion of novel disulphide bridges has confirmed that even though disulphide 
bridges reduce the entropy of the native state protein structure, enthalpic effects act 
to stabilise the structure (Betz, 1993). Backbone strain can be introduced in to a 
structure by mutation of a glycine residue that has phi and psi angles not normally 
favoured by the other residues. This can also happen with the introduction of a 
proline residue into a region of secondary structure that does not favour proline 
residues (Figure 1.8c). The mutation of a residue involved with a metal binding site 
can not only alter protein function but also reduce the stability of the folded 
structure. Experiments have shown that metal binding can contribute 6 to 9 kcal/mol 
to stability (Braxton et al., 1996).
The Wang and Moult (2001) study suggests that only a small number of 
residue mutations affect the function of the protein (Type II) as opposed to the 
structural stability (Type I). This may be explained due to the fact that much fewer 
residues are involved with a functional role than are involved in structural stability. 
There are a number of ways in which mutations can affect the functional activity of 
protein. Residue substitutions on the surface of proteins may change protein-protein 
or protein-ligand interaction sites, either by changing direct contact residues or 
altering the surface properties that contribute to binding such as the electrostatic 
potential, hydrophobicity or conformation. The mutated residue may also be directly 
involved in a catalytic process or reside near the catalytic site (Figure 1.8d). Even a 
small change within the catalytic binding cleft can affect substrate positioning and 
alter the functional activity of the mutant protein. Mutations involving residues that 
are involved with allosteric binding mechanisms can also drastically change the
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activity of a protein. For example the Aspl55Ala mutation within the double-ring 
chaperonin GroEL changes the allosteric binding of adenosine triphosphate from a 
concerted to a sequential action (Danziger et al., 2003). Finally mutations may effect 
a post-translational modification such as N-glycosylation. If the sequence pattern N- 
X-S/T (where X represents any residue except proline) is disrupted, the carbohydrate 
cannot bind to the correct site on the structure and functional activity or stability may 
be lost.
2 4
Chapter 2
Biochemistry of Coagulation and Complement Pathways
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2.1 Serine Protease Cascades
The two best-studied extracellular serine protease cascade pathways that 
contain multi-domain proteins are the coagulation/fibrinolysis system and the 
complement system. Both systems are activated by a small initial stimulus that is 
amplified to yield high amounts of terminal product. This amplification comes from 
a series of activation events where inactive serine protease complexes become 
activated which in turn activate further complexes. This process of activation 
propagates through a series of activation events in order to generate large amounts of 
specific proteins or complexes within a short time. Both coagulation and 
complement systems require a delicate balance between activation and regulation, 
with regulatory proteins present to control the formation of specific complexes.
Although the coagulation and complement systems can be described as 
separate entities, there is slight cross-linking between the two pathways. For 
example, plasmin is the end product of fibrinolysis but can also initiate the 
complement response. Complement is also involved in the activation of platelets.
2.2 The Coagulation System
Circulation of the blood within the cardiovascular system is essential for 
transportation of gases, nutrients, minerals, metabolic products and hormones 
between organs. The ability to stem the loss of blood at the site of injury is 
fundamental for survival. A complex series of haemodynamic, cellular and 
biochemical mechanisms interact to limit blood loss by forming a platelet-fibrin plug 
at the site of vessel injury. This process requires the effective coordinated function of 
blood vessels, platelets, coagulation factors and the fibrinolytic system. When 
activated by vessel injury, blood platelets adhere to the vessel wall at the site of 
injury and aggregate to each other forming the initial haemostatic plug. This initial 
plug is weak and will be washed away by local blood pressure unless it is stabilised 
by fibrin. In order to produce a stable fibrin plug, vascular injury also activates 
coagulation factors that interact sequentially to form thrombin, which in turn 
converts plasma soluble fibrinogen to fibrin.
The activation of coagulation factors is achieved by one of two pathways 
(Figure 2.1). The extrinsic pathway is initiated by the exposure of flowing blood to 
tissue factor (TF), which is released from subendothelial tissue on vessel injury.
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Figure 2.1 The activation cascades and regulatory proteins of the coagulation 
system.
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Alternatively, the intrinsic pathway is less important in the initiation of this pathway, 
but critical in the amplification role of generating thrombin and fibrin (Figure 2.1). 
Both pathways converge at the point of a serine protease (Factor Xa) that can cleave 
and activate prothrombin into thrombin.
The extrinsic pathway is initiated when TF that is normally inside cells 
comes into contact with blood coagulation factor VII (FVII) (Figure 2.1). FVII 
circulates in blood as an inactive zymogen, but on contact with TF and in the 
presence of Ca and phospholipids it is converted to an active form (FVIIa). Again 
in the presence of Ca and phospholipids, the active form of FVIIa complexed with 
TF (TF:FVIIa) is then able to activate the inactive zymogens factor IX (FIX) and 
factor X (FX) into FIXa and FXa respectively. The activation of the TF:FVIIa 
complex is not sufficient for producing the large amounts of thrombin needed to 
form a stable fibrin plug and the TF:FVIIa:FXa complex is rapidly inactivated by the 
TF pathway inhibitor (TFPI).
The appearance of thrombin generated in the extrinsic pathway can activate 
platelets which in the presence of either high molecular weight kininogen (HK) and 
Zn2+ or prothrombin and Ca2+ bind factor XI (FXI) (Baglia and Walsh, 2000). 
Thrombin can activate FXI bound to the platelet into the active serine protease FXIa 
(Gailani and Broze, 1991; Naito and Fujikawa, 1991). In this way the trace amounts 
of thrombin formed from the TF:FVIIa:FXa complex activate the intrinsic pathway. 
FXIa can not only augment its own activation in an autocatalytic manner (Galiani 
and Broze, 1991; Naito and Fujikawa, 1991), it also activates FIX to FIXa in the 
same way as the TF:FVIIa complex (Osterud and Rapaport, 1977). This allows the 
activation of FX that cannot be inactivated by TFPI.
In the absence of its cofactor, factor Va (FVa), FXa can only generate trace 
amounts of thrombin. However, the thrombin generated catalyses the formation of 
FVa from FV. FVa binds to FXa forming the FXa:FVa complex on activated 
platelets. This complex activates prothrombin 200,000-fold more effectively than 
solution phase FXa (Walsh, 2001). The newly formed thrombin, together with FXa 
will also activate Factor VIII (FVIII) into F Villa, which in turn forms the FIXa: Villa 
complex which can amplify the production of FXa.
FVIII circulates as an inactive complex with von Willebrand Factor (VWF). 
During the activation of FVIII by thrombin, VWF is released. VWF is important in 
the formation of a platelet plug, where adhesion of platelets is mediated by VWF
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forming links between the platelet glycoprotein Ib-IX-V and collagen fibrils. The 
platelets are then activated and release the contents of their granules, in turn 
activating other platelets. On activation the shape of the platelet changes, exposing a 
phospholipid surface, to which the coagulation factors can bind to.
Large amounts of thrombin will convert plasma soluble fibrinogen to fibrin. 
In the presence of fibrin and Ca2+ the activation of factor XIII (FXIII) to FXIIIa by 
thrombin is accelerated. FXIIIa forms cross-links between fibrin monomers and so 
converts the fibrin molecules into the stable fibrin mesh.
2.3 Regulation of the Coagulation System
While it is important for these factors to stem blood loss efficiently and 
effectively, it is also essential that these haemostatic mechanisms are controlled by 
inhibitory mechanisms in order to avoid an exaggerated platelet-fibrin plug that may 
block a blood vessel a cause a thrombosis. There are physiological inhibitors within 
plasma that serve to localize procoagulant activity to the site of injury and maintain 
haemostatic balance (Figure 2.1).
As well as the extrinsic pathway of activation that is rapidly controlled by 
TFPI, the intrinsic pathway is also tightly regulated. FXI is regulated by ai- 
proteinase inhibitor (alPI), Cl esterase inhibitor and protease nexin II (PNII). PNII 
inhibition is confined to the fluid phase and therefore platelet bound FXI is able to 
freely activate FIX and thus provide a burst of thrombin localised to the site of vessel 
injury without allowing uncontrolled fluid phase activation (Walsh, 2001).
Antithrombin is a serine protease inhibitor and in the presence of heparin acts 
as the principle inhibitor of thrombin and FXa but can also effect FIXa (Olson et al., 
1993). Antithrombin preferentially inactivates free enzymes that are not part of the 
protease complexes, in effect limiting the coagulation process to sites of vascular 
injury and protecting the circulation from liberated active enzymes.
Thrombin also has inhibitory activity itself and binds to an endothelial 
receptor, thrombomodulin. The thrombomodulimthrombin complex inhibits the 
ability of thrombin to cleave fibrinogen and activate FV, FVIII and platelets. The 
thrombomodulin:thrombin complex also activates Protein C (PC) to activated PC 
(APC) which enhances fibrinolysis and is also involved with down-regulating 
inflammatory cytokine production. APC activity is enhanced by Protein S (PS) and 
is regulated by APC inhibitors such as plasminogen activator inhibitor-3 and alPI
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(Heeb et al., 1987; Walker, 1981). The APC:PS complex can inactivate FVa and also 
degrade FVilla when the inactivated FV forms the APC:PS:FV complex (Dahlback, 
1995). The net effect of the thrombomodulin:thrombin complex is the loss of 
procoagulant function of thrombin and the inhibition of thrombogenesis which 
serves to limit clot extension.
Fibrinolysis is the mechanism by which clot formation is limited and so 
vessel re-canalisation and endothelial cell re-growth can occur. The fibrinolysis 
system, like the coagulation system, is a complex cascade involving zymogen to 
enzyme conversion, a feedback system and inhibitor interaction. When the balance 
between coagulation and fibrinolysis is achieved, an organism can maintain 
haemostasis.
2.4 Factor XI
FXI is a plasma serine protease that contributes to the amplification of 
thrombin generation on the surface of activated platelets via the intrinsic coagulation 
pathway (Figure 2.1) (Walsh, 2001). It was originally thought that the intrinsic 
pathway was initiated by assembly of contact proteins (factor XII (FXII), 
prekallikrein (PK) and HK) on negatively charged surfaces that in turn combined to 
activate FXI (Colman et al., 1989). A major problem with this view of independent 
intrinsic and extrinsic pathways arises with evidence that patients with FXI 
deficiency frequently present with abnormal bleeding complications after trauma or 
surgical operations, however patients seen with complete deficiencies of the contact 
proteins (FXII, HK, and PK) do not experience abnormal haemostasis.
The view of intrinsic and extrinsic activation was altered when two groups 
simultaneously showed that FXI could not only be activated by FXIIa but also by 
thrombin (Gailani and Broze, 1991; Naito and Fujikawa, 1991). Later studies 
indicated that thrombin is the preferred activator of FXI on platelet surfaces as 
opposed to FXIIa (Baglia and Walsh, 2000). FXIa promotes FIX activation to FIXa, 
and FIXa binding to activated platelet cells in complex with FVIIIa leads to FX 
activation co-localised on the platelet surface. In this way, platelets and FXI 
participate in the consolidation phase of coagulation, leading to the local explosive 
generation of thrombin at sites of vascular injury with resulting haemostatic 
thrombus formation (Walsh, 2001).
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The FXI protein is composed of five domains, four tandem repeat domains of 
~ 90 residues known as Apple (Ap) domains and the catalytic serine protease (SP) 
domain (Figure 2.2a and Figure 2.2b). Activation by thrombin, FXIIa or FXIa 
involves the cleavage of FXI between Arg369 and Ile370 to produce an N-terminal 
heavy chain containing the four Ap domains and a C-terminal light chain containing 
the SP domain. Uniquely among other coagulation factor serine proteases, FXI 
circulates as a dimer (Bouma and Griffin, 1977) with two monomers linked by non- 
covalent interactions between the Ap4 domains and by a Cys321-Cys321 disulfide 
bond (McMullen et al., 1991; Dorfman and Walsh, 2001; Cheng et al., 2003). The 
recent crystal structure of FXI reveals that the four Ap domains and SP domain 
assemble into a ‘cup and saucer’ architecture where Apl and Ap2 are arranged in 
tandem with Ap3 and Ap4 packed against them in an antiparallel fashion 
(Papagrigoriou et al., 2006) (Figure 2.2c). This forms a flat saucer-like structure, 
with the SP domain lying above this saucer. The two monomers pack together with 
contacts via the Ap4 domains, creating an inverted ‘V’ shape with the SP domains 
pointing away from the central axis.
FXI circulates within plasma in a non-covalent complex with HK that in the 
presence of Zn2+, promotes the binding of FXI to activated platelets (Thompson et 
al., 1977). FXI binds to the activated platelet surface via the platelet receptor 
glycoprotein Ib-IX-V (Baglia et al., 2002). HK acts as a cofactor in this process by 
docking to cell surface heparin and chondroitin sulphate-proteoglycans, indirectly 
anchoring FXI to the cell (Renne et al., 2000). The HK binding site within FXI has 
been mapped to residues Phe56-Ser86 within the Apl domain, using synthetic 
peptides expressed in prokaryotic cells (Baglia et al., 1990; Seaman et al., 1994). 
Later studies using proteins expressed in eukaryotic cells indicated that HK binding 
was dependant on Ap2, and Apl was shown not to be as relevant (Renne et al.,
2002). Since the correct folding of the synthetic peptides within prokaryotic cells can 
not be confirmed, the later studies are more convincing. Heparin binding sites have 
been mapped to both Ap3 and the SP domain (Ho et al., 1998; Badellino et al., 
2001).
The interaction of FXI with the surface of activated platelets has been 
localised to the Ap3 domain of FXI (Baglia et al., 1995; Ho et al., 2000; Baglia et al., 
2004).
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Figure 2.2 Summary of coagulation FXI (continued over page)
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Figure 2.2 Summary of coagulation FXI (continued)
(a) The schematic domain structure of FXI. The numbers represent the start and 
end of the domains and the position of the glycosylation sites that are 
represented in yellow. The N- and C- termini are represented by N and C 
respectively.
(b) Amino acid sequence of FXI (Refseq #NM_000128.2). The amino acids 
corresponding to each domain are highlighted in the relevant colour. The 
residues of the catalytic active site are highlighted in black and glycosylation 
sites are highlighted in yellow.
(c) Ribbon view of the crystal structure of the FXI monomer (PDB code: 2F83) 
coloured according to domain.
(d) Schematic view of the activity of FXI on the platelet surface. The position of 
FXI is arbitrary since it is not known whether it is cleaved when bound to the 
surface or free in the fluid phase. HK and Zn2+ could be substituted for
' j i
prothrombin and Ca respectively.
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In the presence of HK and Zn2+ binding requires Ser248, Arg250, Lys255, Phe260 
and Gln263, whereas in the absence of HK, binding requires Lys252 and Lys253 
(Baglia et al., 2004). Prothrombin together with Ca2+ has also been shown to 
promote the binding of FXI to activated platelets, in the same way as HK and Zn2+, 
which explains why deficiencies of HK do not result in bleeding disorders (Baglia 
and Walsh, 2000). Using synthetic peptides expressed in prokaryotic cells, 
prothrombin binding has been mapped to Apl of FXI (Baglia and Walsh, 1996).
The FIX substrate binding region was initially mapped to regions in the Ap2 
and Ap3 domains of FXI, however FXI-Prekallikrein chimera studies suggested only 
the Ap3 domain affected clotting activity (Baglia et al., 1991; Sun et al., 1999). 
Alanine site directed mutagenesis mapped binding to specific residues, where 
substitutions within Ilel83-Vall91, Seri95-Ile 197 and Phe260-Cys265 of Ap3 
impaired clotting activity of FXIa (Sun et al., 1999).
The Ap3 region within FXI that is involved with platelet binding appears to 
overlap with the FIX substrate binding region localised to Ap2-Ap3 of FXI (Baglia 
et al., 1991; Sun et al., 1999). A recent hypothesis suggests that binding to platelets 
occurs via the Ap3 domain of one FXI monomer in the dimer, which leaves the other 
Ap3 domain of the other FXI monomer available to bind FIX (Gailani et al., 2001) 
(Figure 2.2d). Both catalytic sites of the dimer may be required for the activation of 
FIX since it is cleaved in two places and a singly cleaved intermediate is not formed 
(Wolberg et al., 1997). Both monomers of FXI are cleaved during activation, 
supporting this hypothesis (Bouma and Griffin, 1977).
Glycosylation is important for both the correct folding and assembly of 
newly synthesised glycoproteins and the efficient transport of glycoproteins through 
the secretory pathway. FXI contains five potential N-linked glycosylation sites at 
positions Asn72, Asnl08, Asn335, Asn432 and Asn473 (Figure 2.2b). Carbohydrate 
attachment has been confirmed at four of these sites, with only one residue (Asn335) 
shown not to be glycosylated (Meijers et al., 1992b). This could be because Asn335 
resides in the Ap4 domain that is responsible for dimer formation. Mutagenesis 
studies also revealed that abolishing the site at Asn473 had no effect on the level of 
FXI secretion (McVey et al., 2005). Within the crystal structure of FXI, 
carbohydrates are seen to be attached to Asn72, Asnl08 and Asn432 (Papagrigoriou 
et al., 2006).
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The gene for FXI (FI 1) consists of 15 exons spanning 23 kb (Asakai et al., 
1987). The first exon encodes the 5’ untranslated region and the second encodes the 
signal peptide. Exons 3-4, 5-6, 7-8 and 9-10 encode for four Ap domains and exons 
11-15 contain the coding sequence for the SP domain (Asakai et al., 1987). A 
second form of FXI is found within platelets and appears to differ structurally from 
plasma FXI (Schiffman and Yeh, 1990). The mRNA of platelet FXI is identical to 
that of plasma FXI apart from the absence of exon 5, suggesting platelet FXI is an 
alternatively spliced form of plasma FXI (Hsu et al., 1998). The physiological role of 
platelet FXI in relation to plasma FXI remains unclassified; however platelet FXI has 
been detected in some individuals with severe FXI deficiency who do not display 
bleeding, whereas it was not detected in those that did bleed (Walsh, 2001). This 
might account for the fact that only -50% of patients reported with plasma FXI 
deficiency exhibit bleeding tendencies, whereas the remainder appear to be 
haemostatically normal (Walsh, 2001).
FXI shares 58% sequence identity with one of the contact factors, PK. Like 
FXI, PK also contains four tandem Ap domains and a C-terminal SP domain and 
circulates in plasma in complex with HK. Unlike the FXI:HK complex, the PK:HK 
complex cannot bind to platelets. PK:HK, unlike FXI:HK can bind to endothelial 
cells and activate them (Baird and Walsh, 2003; Zhao et al., 2001). In this way, HK 
acts to direct FXI and PK to different compartments of the vasculature. PK is 
directed to endothelial cells and FXI is directed to active platelets cells.
2.5 Vitamin K-Dependent Serine Proteases
There are five serine proteases (FVII, FIX, FX, PC and thrombin) within the 
coagulation cascade that can be grouped since they are Vitamin K dependent and 
exhibit both sequence and structural similarity (Greer, 1990). FVII, FIX, FX, and PC 
all contain a y-carboxyglutamic acid (Gla) domain, two epidermal growth-factor-like 
(EGF) domains and a catalytic SP domain (Blake et al., 1987) (Figure 2.3). 
Thrombin contains two Kringle domains instead of the EGF domains found in the 
other factors (Gojobori and Ikeo, 1994).
Within the Vitamin K dependent proteases, the Gla domain is significant in 
binding to the negatively charged phospholipid surfaces of platelets.
35
Thrombin
Gla Krlngle Krlngle
44-89
Factor VII
Gla EGF EGF
61-105 106-142 147-188
Factor IX
47-92 93-129 130-171
Factor X
Gla EGF EGF
41-85 86-122 125-165
Protein C
Gla EGF EGF
43-88 97-132 136-176
213-291
SP
213-452
227-459
SP
235-407
SP
212-450
364-618
Gla EGF EGF -C
-c
Figure 2.3 Schematic representations of the domains (drawn to scale) within 
five vitamin K-dependant coagulation serine proteases thrombin, FVII, FIX, 
FX and PC
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Both the FIXa:FVIIIa complex and the FXa:FVa complex are only active when 
bound to the phospholipid membrane. The carboxyl groups of the Gla residue bind 
one Ca2+ ion that serves as a bridge for this binding. Vitamin K is required for the 
post-translational carboxylation of glutamic acid to y-carboxyglutamic acid, and 
inhibition of this reaction by antagonists of Vitamin K results in defective calcium 
binding within the Gla domains and the loss of the ability to interact with the 
phospholipid membrane (Furie and Furie, 1992). All six proteins have a conserved 
18 residue propeptide sequence that is essential for recognition by the Vitamin In­
dependent carboxylase (Pan and Price, 1985). The EGF domains within FVII, IX, X, 
and PC are thought to be an important spacer between the Gla domain and SP 
domain (Stenflo, 1991). The Kringle domains within thrombin are found throughout 
clotting and fibrinolytic proteins and are thought to mediate binding between 
proteins and membranes, and regulate proteolytic activity (Patthy et al., 1984). The 
individual functions and substrates of the Vitamin K dependent proteases are 
summarised in Table 2.1.
There are two additional proteins (PS and Protein Z (PZ)) that are Vitamin K 
dependent but do not possess serine protease activity. PS is similar to the serine 
proteases in that it contains a Gla domain, followed by EGF domains, however the 
functional serine protease domain is replaced by two adjacent laminin domains 
(http://www.ebi.ac.uk/interpro/IEntry?ac=IPRO 12679) with unknown function. PZ 
has the same modular structure as PC, however the SP domain lacks the critical 
histidine and serine residues of the catalytic site and is enzymatically inactive 
(Ichinose et al., 1990; Sejima et al., 1990). PZ serves as a cofactor for the inhibition 
of FXa by a PZ-dependent protease inhibitor (Broze, 2001) and has been implicated 
in the occurrence of cardiovascular diseases (Sofi et al., 2004).
2.6 The Complement System
The complement system exists as a defence mechanism against infectious 
agents by forming the membrane attack complex (MAC) that is able to lyse 
membranes of infectious organisms. Complement proteins also trigger the 
opsonisation of antigens and the secretion of immunoregulatory molecules as well as 
participating in the removal of immune complexes from circulation.
It is now known that the complement system comprises over 30 proteins. 
Most of these proteins circulate in the blood in inactive forms.
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Table 2.1 Vitamin K dependent serine proteases of the coagulation pathway
Protein Activator Substrates Gene
Name
Function
Thrombin FXa FXI
FV
FVIII
Fibrinogen
F2 •  Converts fibrinogen to fibrin and activates 
FXIII that is involved in cross-linking 
fibrinogen.
•  It augments its own production by activating 
FXI, FV and FVIII.
•  Activates Platelets.
FXa FIXa:FVIIIa Prothrombin 
TF:FVIIa
F10 •  In the presence o f FVa cofactor, FXa cleaves 
prothrombin in two places which yields active 
thrombin.
FIXa FXIa
TF:FVIIa
FX F9 •  Activates FX, when in complex with cofactor 
FVIIa.
FVIIa TF FX
FIX
Prothrombin
F7 • Forms TF:FVIIa complex that activates FIX 
and FX.
• Forms TF:FVIIa:FXa complex that leads to 
initial small amount o f thrombin generation
Protein C Thrombin FVa
FVIIIa
PROTC •  Activated by thrombin:thrombomodulin 
complex to degrade FVa and FVIIIa.
• Activity is enhanced by interacting with PS.
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They are then activated through enzyme cascades that are triggered by the presence 
of pathogens or antigen-antibody (Ag:Ab) complexes (Figure 2.4). Complement can 
be initiated by three different pathways, the classical pathway, the alternative 
pathway and the mannose-binding lectin pathway. All three pathways converge at 
the point of C5 activation (Figure 2.4) (Law and Reid, 1995).
The classical pathway is triggered by the formation of soluble Ag:Ab 
complexes or with the binding of Ab to Ag on a target cell. The initial stage of the 
classical pathway involves the activation of the serine protease C l. The Cl complex 
contains one molecule of C lq, two molecules of C ls and two molecules Clr. When 
C lq  binds to an Ag:Ab complex, a conformational change occurs, which displaces 
the regulatory Cl-inibitor (Cl-INH). This conformational change also activates C lr, 
which cleaves C ls and generates an active serine protease that can cleave C4 into 
C4a and C4b and C2 into C2a and C2b. Cleaving C4 exposes the binding site on C4b 
for C2a. C4b attaches to the target surface in the vicinity of Cl and when C2a binds 
the C4b2a complex is formed which acts as the central C3 convertase. C3b bound to 
C4b2a on the surface of cells forms the classical pathway C5 convertase C4b2aC3b.
The alternative pathway, unlike the classical pathway is triggered 
spontaneously within a host organism, without the need for an initiating Ag:Ab 
complex. It is activated by the binding of C3b to surfaces devoid of certain 
carbohydrates such as sialic acid. Sialic acids are common to eukaryotic cell surfaces 
but not on the surfaces of microbes or invading pathogens. Within serum, C3 is 
cleaved spontaneously to yield C3a and C3b. This is a slow process unlike the rapid 
enzymatic cleavage of C3 by the C4b2a complex formed via the classical pathway. 
In the presence of an activating surface, the C3b fragment binds non-specifically 
where it remains active and can bind to Factor B (FB) to form a complex stabilised 
by Mg2+. When FB binds to C3b, a conformational change exposes a binding site for 
Factor D (FD). FD cleaves the C3b-bound FB, releasing a small fragment Ba that 
diffuses away and leaving the C3bBb complex. This complex has C3 convertase 
activity and is analogous to the C4b2a C3 convertase formed by the classical 
pathway. Properdin binds to this complex in order to stabilise it, extending its half- 
life. This C3 convertase can activate un-hydrolysed C3 to generate more C3b 
autocatalytically and repeat the earlier steps of FB activation. When C3b binds to the 
C3bBb complex C3bBb3b forms the alternative pathway C5 convertase.
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Figure 2.4 The activation cascades and regulatory proteins of the complement 
system
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The lectin pathway is activated when host proteins known as lectins bind to 
specific carbohydrate targets. Like the alternative pathway, this method of activation 
does not require an antigen-bound antibody. Instead it is initiated by the binding of 
mannose-binding lectin (MBL) to mannose residues on glycoproteins or 
carbohydrates on the surface of microorganisms. On binding to the surface of a cell 
or pathogen MBL also binds to MBL-associated serine proteases MASP-1 and 
MASP-2 to form a complex. This complex can cleave and activate C4 and C2. 
Analogous to the classical pathway, MASP-1 and MASP-2 have structural and 
functional similarity to C lr and Cls. This allows the formation of the C4b2a 
complex C3 convertase without the need for Cl proteins and antigen-bound 
antibodies of the classical pathway.
The three pathways converge at the initiation of the MAC by the C5 
convertase (Figure 2.4). C5 is cleaved to form C5a and C5b, and the large C5b 
complex binds to the surface of the target cell. This exposes binding sites on C5b for 
subsequent components of the MAC, C6, C7, C8 and C9. Once formed, the MAC 
complex creates a large pore (70-100 A  in diameter) within the target cell membrane. 
Since ions and small molecules can diffuse freely through this pore the cell cannot 
maintain its osmotic stability and is destroyed by an influx of water and loss of 
electrolytes.
As well as forming the MAC, complement proteins also interact in order to 
initiate an inflammatory response. Some of the smaller fragments obtained from 
cleavage of complement proteins such as C3a, C4a and C5a bind to receptors on 
mast cells and blood basophils inducing degranulation that causes the release of 
histamine and other pharmacologically active mediators. The large amounts of C3b 
formed by the C3 convertase not only initiate the MAC but also diffuse away from 
the site of activation and coat immune complexes and antigens in the process of 
opsonisation. Phagocytic cells (neutrophils, monocytes and macrophages) express 
large amounts of complement receptor type 1 (CR1). Antigen coated with C3b binds 
to cells expressing CR1 and phagocytosis is induced. Activation of phagocytic cells 
by various agents such as C5a anaphylatoxin has been shown to increase the number 
of CR1 molecules from 5000 on resting phagocytes to 50,000 on activated cells. This 
greatly facilitates the binding of C3b-coated antigens, allowing C3b to target the 
antigen directly to the phagocyte, enhancing the initiation of antigen processing and 
antibody production.
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2.7 Regulation of the Complement System
Without tight regulation, the complement system would be too destructive, 
and complement proteins in circulation would be quickly depleted. In order to 
regulate complement initiation and proliferation, a number of regulators and 
inhibitory mechanisms exist (Figure 2.4). On an overall level, complement proteins 
do not remain active for a long time, even in the absence of regulatory proteins. The 
amount of C3b and C4b bound to tissue or part of the C3 convertase is regulated by 
two processes. The first process involves the dissociation of the protease component 
of the C3 convertase (either C2a or Bb) and is known as decay accelerating activity. 
The second process, known as cofactor activity involves the degradation of C3b or 
C4b into inactive forms by the plasma serine protease Factor I that works in the 
presence of a cofactor protein. Within the classical pathway another regulatory 
process exists in the form of Cl-INH that is released from the Cl complex when it is 
activated. Cl-INH is a serine protease inhibitor and following its release it is able to 
bind across the C ls-C lr active sites and deactivate the Cl complex.
Since complement activation is highly unfavourable on host cells, they are 
protected in a number o f ways. CD59 is a protein found on many eukaryotic cells 
that binds C8 of the MAC, preventing formation of the membrane pore (Kim and 
Song, 2006). The membranes of most eukaryotic cells have high levels of sialic acid, 
which contribute to the rapid inactivation of bound C3b molecules on host cells; 
consequently the binding of C3b rarely leads to further reactions on the host cell 
membrane. Because many foreign antigenic surfaces (e.g. bacterial cell walls, yeast 
cell walls and certain viral envelopes) have only low levels of sialic acid C3b bound 
to these surfaces remains active for a longer time. Host cells also express large 
amounts of proteins that act as cofactors to the Factor I (FI) inactivation of C3b and 
C4b. These cofactor proteins form part of a protein family known as the Regulators 
of Complement Activity (RCA) family.
2.7.1 RCA Protein Family
The RCA protein family is a group of structurally, functionally and 
genetically related plasma and membrane glycoproteins that control the 
amplification step of complement at the point of C3 convertase formation (Hourcade 
et al., 1989).
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The RCA group was initially proposed based on linkage studies of allelic 
protein variants of CR1, Factor H (FH) and C4 Binding Protein (C4bp) (Holers et al., 
1985). This group of genes was then located to human chromosome 1 at site lq3.2 
(Carroll et al., 1988). The six proteins of the RCA group that are involved with 
regulation of the complement system are summarised in Table 2.2.
Figure 2.5 summarizes the regulation of the alternative pathway C3 
convertase by the serine protease FI and three members of the RCA group, FH, 
Membrane Cofactor Protein (MCP), CR1 and Decay Accelerating Factor (DAF). 
The different regulators act together to control and inhibit formation and assembly of 
the alternative pathway C3 convertase and the generation of C3b. Once the C4b2a 
and C3bBb convertase complexes are formed, they are unstable and dissociate with a 
half life of less than 5 minutes. FH, CR1, C4bp and DAF have decay-accelerating 
activity and interact with the complexes to accelerate dissociation. Once C4b and 
C3b have dissociated from the complexes, they are cleaved by FI to form C4c + C4d 
and iC3b respectively. FH, CR1, and MCP act as cofactors in the FI inactivation of 
C3b from convertase complexes. FI also inactivates newly generated surface 
deposited C3b in the presence of the same cofactors. The inactivation of surface 
bound C3b is an important mechanism of recognising self from non-self cells. 
Pathogenic cells do not contain complement regulatory proteins and favour binding 
of properdin to the C3bBb complex which stabilizes the C3bBb convertase activity. 
This allows complement to proceed on pathogenic cells, while being regulated on 
host cells.
The structural conservation within the RCA protein family is seen with a 
repeating amino acid motif/domain commonly known as the short consensus repeat 
(SCR) domain. SCR domains are the important building blocks of RCA proteins and 
are present in varying numbers of adjacent copies (Table 2.2).
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Table 2.2 Properties of six RCA Proteins
Protein
Number o f Primary Decay Cofactor
SCR domains Ligands Acceleration Activity
Distribution
FH
C4bBPa
C4bBP|3
DAF
CR2
CR1
MCP
20
4
15
30
4
C3b
C4b
C4b
C3b/C4b/ 
C3 Convertase
C3dg
C3b/C4b
C3b/C4b
Plasma
Plasma
Plasma
Membrane
Membrane
Membrane
Membrane
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Figure 2.5 Regulation of the alternative complement pathway
(a) Progression of alternative complement activation on pathogen surface and 
formation of the MAC.
(b) Protection of host cell by FI, FH, MCP and CR1.
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2.7.2 SCR domains
SCR domains, also known as complement control protein (CCP) domains or 
Sushi domains were first identified in FB (Morley and Campbell, 1984) and are the 
most abundant domain type in the complement system. SCR domains are not only 
found within complement proteins but have also been identified in Factor XHIb 
coagulation factor and various other transmembrane receptors (Soares et al., 2005). 
The experimental structures of SCR domains that have been determined using X-ray 
crystallography and nuclear magnetic resonance (NMR) are summarised in Table 
2.3. A secondary structure alignment of these domains is shown in Figure 2.6a. SCR 
domains consist of around 60 residues that form a compact globular structure 
consisting of a central framework of three two-stranded p-sheets, whose strands lie 
approximately parallel to the long axis of the domain (Figure 2.6a and Figure 2.6b). 
Additional P-strands are often seen at the N and C terminus, making up to eight P- 
strands in total. SCR domains are stabilised by two conserved disulphide bridges 
formed from four invariant cysteine residues in the pattern of Cysl-Cys3 and Cys2- 
Cys4. These disulphide bridges occur at the N and C-terminal ends of the SCR 
domain. There is also a highly conserved buried tryptophan residue (Figure 2.6). 
SCR domains are frequently N-glycosylated. The dimension of an SCR domain is 
approximately 40 A x  1 6 A x  1 2 A  (Aslam et al., 2003). The loops formed between 
p-strands vary both in terms of amino acid number and conservation. The loop 
between P2 and P3 is known as the hypervariable loop since this region of the SCR 
domain shows very low sequence conservation across different SCR domains.
RCA proteins are comprised of between four and 30 SCR domains that are 
separated by linkers variable in both sequence and length. These linkers are on 
average four residues in length but can contain between two and eight residues 
(Kirkitadze and Barlow, 2001). Evidence of flexibility between SCR modules has 
been shown in the case of MCP SCR-1 and SCR-2 (Casasnovas et al., 1999), FH 
SCR-15 and SCR-16 (Barlow et al., 1993) and the four SCR domains of Vaccinia 
virus complement control protein (VCP) (Wiles et al., 1997). The structural studies 
summarised in Table 2.3 highlight the high conformational structural variability of 
the interdomain linkers, even when the linkers are as short as three residues in 
length. Domain pairs have been shown to exist in both extended and compact folded 
back forms (p-glycoprotein I and Complement Receptor 2 (CR2) respectively).
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Table 2.3 35 solved SCR domain structures and their 45 PDB deposition codes.
Protein PDB Entry Method
CR1 SCR 16 
SCR 15-16 
SCR 16-17
1PPQ
1GKN
1GKG
NMR
NMR
NMR
CR2 SCR 1-2 1GHQ 1LY2 X-ray crystallography
DAF SCR 1-4 
SCR 2-3
10JV
10K2
1NWV
10JW
10K3
10JY
10K9
10K1
X-ray crystallography 
NMR
SCR 3-4 1H03
1UOT
1H04 1H2P 1H2Q
X-ray crystallography
MCP SCR 1-2 1CKL X-ray crystallography
VCP SCR 1-4 
SCR 2-3
1G40
1E5G
1G44 1RID 1Y8E X-ray crystallography 
NMR
SCR 3-4 IV VC 1VVD 1VVE NMR
C4BP-a SCR 1-2 2A55 NMR
Factor H SCR 5* 
SCR 15 
SCR 16 
SCR 15-16 
SCR 19-20 
SCR 19-20
1HFI
1HCC
1HFH
1G7I
2BZM
NMR 
NMR 
NMR 
NMR 
X-ray crystallography 
NMR
Clr SCR 2 
SCR 1-2
1MD7
1GPZ
1MD8 X-ray crystallography 
X-ray crystallography
C ls SCR 2 1ELV X-ray crystallography
MASP-2 SCR 2 
SCR 1-2
1Q3X
1ZJK
X-ray crystallography 
X-ray crystallography
(32 GP-I SCR 1-4 1C1Z 1QUB X-ray crystallography
GABA-B Receptor 1 SCR 2 1SS2 1SRZ NMR
Interleukin-2 Receptor SCR 1-2 1Z92 X-ray crystallography
Interleukin-15 Receptor SCR 1 2ERS NMR
*The coordinates for FH SCR-5 were kindly provided by Prof P. N. Barlow o f Edinburgh University 
(Barlow et al., 1992).
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Figure 2.6 Sequence and structure of the SCR domain (continued over page)
Figure 2.6 Sequence and structure of the SCR domain (continued)
(a) Secondary structure alignment of 37 experimentally solved SCR structures 
identified by their PDB codes. Conserved cysteine and tryptophan residues 
are highlighted in black boxes. Secondary structure is highlighted, where the 
p-strands are highlighted in grey and a-helices in green, p-strands are 
numbered P1-P8 in the order they occur in the sequence. Cysteine residues 
are numbered C1-C4 in the order they occur in the sequence. The sequences 
of both the NMR and crystal structures are shown for FH SCR-19 and SCR- 
20 (lbzm and 2g7i).
(b) SCR domain structure of FH SCR-19 from the crystal structure (PDB code: 
2G7I). All eight P-strands are shown and labelled corresponding to (a). The 
conserved tryptophan side chain is shown in blue. Disulphide bridges are 
shown in yellow and labelled corresponding to (a). The N- and C- termini are 
represented by N and C respectively.
49
SCR domains can be rotationally orientated in a wide range of conformers 
determined by the linker structure itself, and also the inter-SCR contacts between 
adjacent surface residues. It is impossible to predict these orientations through 
homology modelling since linker regions are not conserved, and the amino acid side 
chains of the SCR domains that could participate in inter-SCR contacts are variable.
2.7.3 Factor H
FH was first identified in 1965 as a piH  globulin (Nilsson and Mueller- 
Eberhard, 1965). FH is synthesised in the liver and present in plasma at a 
concentration of 110-615pg/l (Rodriguez de Cordoba et al., 2004). It is a central 
regulator o f the alternative pathway of complement activation, regulating alternative 
activation both within the fluid phase and on cellular surfaces (Figure 2.5). It has 
cofactor activity in the FI breakdown of C3b to form iC3b (Law and Reid, 1995). It 
also has decay accelerating activity in the breakdown of the C3 convertase C3bBb 
and competes with FB for binding to C3b. It is particularly important for regulating 
complement attack on host cells that lack membrane-bound complement regulators 
such as cells in the basement membranes of the kidney glomeruli. FH has been 
shown to bind to endothelial cells and protect them from complement attack 
(Jokiranta et al., 2005).
FH is a single polypeptide chain glycoprotein (155kDa) composed of 1231 
amino acids that are grouped into 20 SCR domains separated by linkers varying from 
three to eight amino acids (Figure 2.7). There have been extensive studies into the 
structure of FH and X-ray and neutron scattering of intact FH has shown FH to 
possess a folded back conformation, with the C-terminal SCR-20 exposed in solution 
(Aslam and Perkins, 2001). This work also indicated FH was present in solution in a 
monomeric form (Aslam and Perkins, 2001), however other data has been 
interpreted in terms of a dimeric form (Perkins et al., 1991). NMR studies have also 
elucidated the structures of SCR-5, SCR-15/SCR-16 and SCR-19/SCR-20 fragments 
(Barlow et al., 1992; 1993; Herbert et al., 2006). X-ray crystallography has also been 
used to analyse a SCR-19/SCR-20 fragment that appeared in a tetrameric form 
(Jokiranta et al., 2006). Both the NMR and X-ray fragments of SCR-19 and SCR-20 
appear to be extended, rather than folded back. (Herbert et al., 2006; Jokiranta et al., 
2006).
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The cofactor and decay accelerating activity site o f FH is located within the 
four N-terminal domains, SCR-1 to SCR-4, which bind to intact C3b (Sharma and 
Pangbum, 1996). Additional C3 binding sites have been identified to possess 
cofactor activity within SCR-6 to SCR-10 which binds the C3c fragment within C3b, 
and within SCR-16 to SCR-20 which binds the C3d fragment within C3b (Sharma 
and Pangbum, 1996; Jokiranta et al., 2000) (Figure 2.7). Functional assays 
demonstrated that only the first C3b site located at the N-terminus possesses decay 
accelerating activity (Sharma and Pangbum, 1996).
Although FH binds and inactivates C3b promptly in the fluid phase, the 
inactivation of C3b attached to cell surfaces is dependent on the presence of sialic 
acids and other polyanionic molecules such as glycosaminoglycans or sulphated 
polysaccharides such as heparin. Heparin binding has been used as a model for 
examining the sialic acid-binding characteristics of FH. Two heparin binding sites 
have been located in SCR-7 and SCR-20 (Blackmore et al., 1996; 1998) and a third 
heparin binding site was thought to exist at or near SCR-13 (Pangbum et al., 1991), 
but later localised to SCR-9 (Ormsby et al., 2006) (Figure 2.7). Although the three 
SCR domains involved with heparin binding do not show a high degree of sequence 
identity, they are the only three SCR domains that have short preceding linkers of 
only three amino acids. This short linker may be important for the interaction with 
heparin (Ormsby et al., 2006). The binding site at SCR-9 was also shown to enhance 
the binding at SCR-7, suggesting that multiple heparin binding sites may interact 
simultaneously (Ormsby et al., 2006).
The physiologically more relevant sialic acid binding regions of FH have also 
been localised to SCR-6/10, SCR-13 and SCR-16/20 (Koistinen, 1992, 1993; Ram et 
al., 1998). The C3b-binding and polyanion-binding sites in SCR-19 and SCR-20 
have been shown to be overlapping (Hellwage et al., 2002) and clusters of positively 
charged residues on the surface of SCR-19 to SCR-20 that are likely to be involved 
with the interaction of FH and C3b and heparin have been identified (Perkins and 
Goodship, 2002; Hellwage et al., 2002; Ganesh et al., 2004; Herbert et al., 2006). It 
is likely that the increased affinity between FH and C3b in the presence of sialic 
acids is the consequence of simultaneous recognition of both sialic acids and C3b by 
the same FH molecule. This is supported by the presence o f multiple binding sites 
for both C3b and polyanions within FH that can allow for interactions with multiple 
C3b molecules.
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Figure 2.7 Summary of complement FH structure and sequence.
Colour coding o f the domains is consistent throughout the figure.
(a) Schematic representation of the linear arrangement o f SCR domains within FH, shown with binding sites mapped to SCR 
domains. Glycosylation sites are shown in yellow. Heparin binding sites are indicated by a vertical arrow and the letter H. The 
18-residue signal peptide is represented by a grey box. The N- and C- termini are represented by N and C respectively. 
Numbers represent the start and end o f each domain, with linkers not included. CRP = C-reactive protein.
(b) Amino acid sequence o f FH (Refseq # NM 000186.1). Putative glycosylation sites are highlighted in yellow and adjacent SCR
domains are highlighted in alternating blue and green text.
Examination of four cell types (both activating cells and non-activating cells) has 
demonstrated that the SCR domains important for C3b binding and cofactor activity 
are different on each cell type, revealing a complex molecular mechanism of 
discrimination between microbes and host cells (Pangbum, 2000). Recombinant FH 
molecules with C-terminal deletions loose the ability to control alternative pathway 
activation on host-like surfaces (Pangbum, 2002). Using experimental analysis of 
monoclonal antibodies (mAbs) it was shown that the C-terminal domain of FH, 
SCR-20 was the most important SCR domain for ligand interaction, in contrast to 
other sites where mAbs only showed minor inhibitory effects (Oppermann et al., 
2006). The authors suggest that native compact FH makes the first and initial 
contact with the exposed C-terminus SCR. Upon binding, FH then unfolds and 
exposes the additional binding sites, allowing N-terminally mediated complement 
regulation (Oppermann et al., 2006). This hypothetical model is supported by the 
clustering of mutations with SCR-19 and SCR-20 of FH that are associated with 
atypical Haemolytic Uraemic Syndrome (Chapter 5).
C-reactive protein (CRP) activates the classical pathway of complement by 
interacting with C lq (Volanakis and Kaplan, 1974). During tissue damage, normally 
unexposed structures such as phospholipids, mitochondria and chromatin are 
released from injured and apoptotic cells. These structures are able to induce an 
inflammatory response through activation of the classical pathway. CRP has been 
shown to bind to these damaged cells, where it can also induce the classical pathway 
(Volanakis and Wirtz, 1979). The mechanistic detail of CRP complement activation 
is not clear since the activation only proceeds to generate C3 convertase and does not 
lead to formation of the MAC (Berman et al., 1986). CRP has also been shown to 
bind to FH, with a binding region localised to SCR-7 and a second site localised 
within SCR-8 to SCR-11 (Jarva et al., 1999). This binding to FH could explain why 
CRP does not induce complement activation further than C3 convertase formation. 
CRP-bound FH remains functionally active, which suggests CRP could act by 
binding to damaged cells and targeting the regulatory activities of FH to areas 
affected by injury in order to prevent excessive inflammatory response (Jarva et al., 
1999). It has been indicated that the heparin and CRP-binding sites within FH SCR- 
7 are overlapping (Giannakis et al., 2003).
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Additional roles for FH have been revealed. FH seems to play a role in 
adhesion for human neutrophils (DiScipio et al., 1998). FH has been shown to 
interact with the MAC-1 receptor, which is also a receptor for iC3b, and induce 
intracellular signals as it enhances the activation response of neutrophils. It has also 
been revealed that FH is relevant in the pathogenicity of microorganisms such as 
Neisseria gonorrhoeae and Streptococcus pyogenes. These pathogens bind to FH via 
surface proteins in order to evade complement attack and reduce amounts of C3b 
attached to their surface (Horstmann et al., 1988; Ram et al., 1998; Kraiczy et al., 
2004). In a similar mechanism, some tumour cells have evolved methods to evade 
complement attack by expressing FH-binding proteins on their cell surface (Fedarko 
et al., 2000). FH has also been associated with processes as diverse as diabetes 
mellitus, Alzheimer’s disease, rheumatoid arthritis or atherosclerosis (reviewed in 
Rodriguez de Cordoba et al., 2004).
The FH gene (CFH) consists of 23 exons and spans over 94kb of genomic 
DNA (Male et al., 2000). The first exon codes for the 5’ untranslated region and 
signal peptide, followed by the other exons that code for individual SCR domains, 
apart from SCR-2 that is encoded for by both exon 3 and exon 4. Exon 10 does not 
contribute to the FH transcript and is only utilised in the alternatively spliced FH 
molecule, FH like protein (FHL-1) (Estaller et al., 1991). FHL-1 is comprised of 431 
amino acids that encode for seven SCR domains that are identical to SCR-1 to SCR- 
7 of FH followed by four amino acids (Ser-Phe-Thr-Leu) at the C-terminus (Table 
2.4). FHL-1 has been shown to have FH regulatory activity and cell adhesion activity 
(Zipfel and Skerka, 1999). Like FH, FHL-1 also has a heparin binding site with 
SCR-7 and also binds M-protein expressed on the surface of S. pyogenes pathogens 
(Kotarsky et al., 1998). Both FH and FHL-1 are synthesised in the liver, but FHL-1 
is present in plasma in much lower amounts (10-50 jig/ml). Both genes are 
transcribed from the same transcription start site, however there are cases of cell type 
and stimulus-dependent differential regulation, suggesting distinct functions. The 
precise role of FHL-1 in vivo remains undetermined.
CFH is closely related with five other FH-related (FHR) genes (FHR1, 
FHR2, FHR3, FHR4, FHR5) that form a tightly linked cluster within the RCA group 
as a result of gene duplication (Zipfel et al., 1999; Rodriguez de Cordoba et al., 
2004). These proteins are summarised in Table 2.4.
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Table 2.4 FH Protein Family*
Gene Location / Function Modular Homology
FH
Plasma protein has decay accelerating activity 
acts as cofactor to serine protease FI for C3b 
inactivation 000000000@0@©0®@@@®@
FHL-1
Shown to have FH complement regulatory 
activity and cell adhesion activity. Present in 
lower amounts than FH. 000000©
FHR1
Associated with lipoprotein complexes. May 
facilitate the adhesive response of neutrophils to 
lipopolysacharides.
1 1 1 1
| 
_i
 
j
1 1 1 t 1 1 1 1 1
C
yO
FHR2 Same as above ............ 00- - ......................... 00
FHR3
Associated with lipovisicles, it is detected to 
high amounts in human chylomicrons and 
VLDL particles. Binds to C3b and heparin. ............ 00© ............................ 00
FHR4
Detected in vivo associated with complement 
deposits suggesting possible role in 
complement. Binds C3b. ............ 0 -00—  ------------(3©
*Adapted from Rodriguez de Cordoba et al., 2004.
The proteins all have much lower plasma concentrations than FH, and although close 
homology with FH suggests functional conservation, their in vivo functional 
properties are not yet fully defined. Binding of C3b has been demonstrated for 
FHR3, FHR4 and FHR5, although no cofactor activity has been measured (Hellwage 
et al., 1999; Murphy et al., 2002). In contrast to the multiple interaction sites 
identified for FH, C3b binding has been shown to interact with FHR3 and FHR4 at a 
single point and FHR3 has been shown to bind heparin at a single point (Hellwage et 
al., 1999). Since these proteins may compete with FH for C3b binding, the local 
concentration of the individual proteins at site of alternative pathway activation 
seems critical and important for C3 regulation.
2.7.4 Membrane Cofactor Protein
MCP, also known as CD46 was identified in 1985 as a C3b and C4b binding 
protein of human peripheral blood mononuclear cells (Seya et al., 1986). The gene 
(MCP) was later mapped to the RCA cluster on chromosome 1 and identified to be 
-43 kb in length containing 14 exons (Lublin et al., 1988; Liszewski et al., 1991).
MCP exists as a family of four regularly expressed isoforms that arise by 
alternative splicing (Post et al., 1991; Russell et al., 1992) (Figure 2.8). The 
polypeptide of each isoform shares four N-terminal SCR domains. This region is 
then followed by a serine, threonine and proline rich (STP) domain that is O- 
glycosylated and alternatively spliced into two forms, one containing both exon 7 
and exon 8 and the other just containing exon 8 (Figure 2.8). A small segment of 
undefined function then flanks the transmembrane domain which is followed by an 
alternatively spliced cytoplasmic tail region (Cyt-1 or Cyt-2) (Figure 2.8). Most cells 
within an individual express the same ratio of the four isoforms (Post et al., 1991), 
and this relative ratio of isoforms is inherited in an autosomal co-dominant fashion 
(Wilton et al., 1992; Seya et al., 1999). Predominance of certain types of isoform has 
been noted in the brain, kidney, salivary gland and fetal heart (Johnstone et al., 1993; 
Gorelick et al., 1995). Isoforms containing large amounts of O-glycosylation have 
been shown to be present on tumour cells (Seya et al., 1995). Other rare splice 
variants have also been described (Post et al., 1991; Purcell et al., 1991; Russell et 
al., 1992).
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Figure 2.8 Sequence and structure of complement MCP major isoforms.
(a) Schematic representation of the domains within MCP isoform A to isoform 
D.
(b) Amino acid sequences of the four MCP isoforms A to isoform D (Refseq # 
NM_002389.3) with domains coloured corresponding to (a). Splice sites 
between exons are represented in red underlined text. The numbering 
corresponds to Isoform A.
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MCP is present on most cells including lymphocytes, granulocytes, 
monocytes, platelets, endothelial cells, epithelial cells and fibroblasts (Seya et al., 
1986; Lublin et al., 1988). MCP acts as a cofactor for the plasma serine protease FI 
to cleave C3b and C4b that are deposited on host cells (Seya et al., 1986). 
Performing this role intrinsically, MCP protects the cell on which it is expressed and 
not neighbouring cells (Oglesby et al., 1992).
Structural studies of MCP are difficult since it is a membrane bound protein; 
however the X-ray crystal structure of a SCR-1 to SCR-2 construct has been 
elucidated at 3.1 A  resolution (Casasnovas et al., 1999). The structure indicates the 
architecture and structural arrangement of the glycosylated forms of an MCP SCR-1 
to SCR-2 fragment and suggests the SCR domains are not fully elongated but are 
folded back onto each other with an angle of 60° (Casasnovas et al., 1999). This 
inter-SCR junction may not however be stable in the native form of MCP and 
therefore the spatial arrangement of binding surfaces within the fragment may not be 
identical to that in the native structure. This is important to remember when 
interpreting mutagenesis data. The two N-glycans appear on the same face of the 
structure.
Using SCR deletion mutants, ligand binding and cofactor activity sites for 
C3b and C4b have been identified within MCP SCR-2 to SCR-4 domains (Adams et 
al., 1991), with SCR-2 to SCR-3 also shown to protect Chinese hamster ovary cells 
from alternative pathway mediated cytolysis and SCR-2 to SCR-3 shown to be 
essential for classical pathway regulation (Iwata et al., 1995). This suggests SCR-1 is 
not required for complement activity, and in New World primates SCR-1 is spliced 
out in somatic tissues (Hsu et al., 1999). However, later mutagenesis studies 
indicated critical residues in all four SCR domains (Liszewski et al., 2000). SCR-3 
and SCR-4 have been shown to bind C3b, but the additional presence of SCR-2 was 
required for C3b cofactor activity (Liszewski et al., 2000).
There are three N-linked glycosylation sites within MCP, one in each of the 
SCR-1, SCR-2 and SCR-4 domains (Figure 2.8). Although the N-glycans enhance 
regulatory activity, they are not required for ligand binding or cofactor activity 
(Liszewski et al; 1998) but have been shown to be important for basolateral cell 
localization (Maisner et al., 1996). The N-glycan within SCR-2 also seems to be 
structurally significant, making crystal contacts with side chains of residues within 
SCR-2 (Casasnovas et al., 1999; Herbert et al., 2002). O-glycans have been shown to
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enhance regulatory efficiency since isoforms with larger O-glycosylation domains 
have been shown to bind C4b more efficiently than isoforms which are smaller and 
less glycosylated (Liszewski et al., 1996).
As well as complement regulation, new findings have expanded the role of 
MCP in immunity and disease (Riley-Vargas et al., 2004; Liszewski et al., 2005). 
Both cytoplasmic tails of MCP contain signalling motifs which have been shown to 
be involved in the regulation of human T-cells (Marie et al., 2002). MCP is also a 
receptor for a growing list of pathogens including the measles virus (Naniche et al., 
1993; Dorig et al., 1993) and Streptococcus pyogenes (Giannakis et al., 2002). The S 
pyogenes interaction is mediated by Streptococcal M protein that exists on the 
bacterial cell surface. This protein also binds to FH SCR-7 (Sharma and Pangbum, 
1997; Blackmore et al., 1998) and the binding sites have been shown to have 
sequence and structural similarity (Giannakis et al., 2002). Binding of pathogens to 
MCP allows the FI-mediated indctivation of C3b and C4b to take place, and allows 
the pathogen to evade the complement system. There are also multiple lines of 
evidence that MCP might have an important role in reproduction and fertilisation 
(Riley-Vargas et al., 2005).
2.7.5 Factor I
FI is a soluble regulatory serine protease that cleaves three peptide bonds in 
the a-chain of C3b, and two bonds in the a-chain of C4b, inactivating the compounds 
to the iC3b opsonin and C4c + C4d respectively (Figure 2.5). FI only inactivates 
C3b and C4b in the presence of cofactors such as FH, CR1 and MCP.
FI is predominantly synthesised in the liver as a 565 residue single-chain 
precursor. Four basic amino acids (Arg336-Arg337-Lys338-Arg339), as well as an 
18 residue leader peptide sequence are excised from the precursor prior to secretion 
as a heterodimer (Figure 2.9). The secreted form of FI appears to be already active 
(i.e. it does not require proteolytic cleavage to express activity) and no natural 
inhibitors to FI have been found. The removal of the four basic amino acids forms a 
heavy chain (50kDa) composed of two low-density lipoprotein receptor (LDLR) 
domains, a cluster of differentiation (CD5) domain and a FI membrane attack 
complex (FIMAC) domain and a light chain (38kDa) composed of only a serine 
protease (SP) domain (Figure 2.9).
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Figure 2.9 Sequence and structure of complement serine protease FI.
(a) Schematic representation o f  the domains within FI. The 18 residue prepropeptide sequence is represented by a grey box. 
Glycosylation sites are highlighted in yellow. The N- and C- termini are represented by N and C respectively. Numbers 
represent the start and end o f  each domain, with linkers not included.
(b) Amino acid sequence o f  FI (Refseq # NP 000195.1). Domains are coloured with respect to (a). The glycosylation sites are 
highlighted in yellow  and the residues o f  the catalytic active site are highlighted in black.
Little is known about the specific functions of the individual domains of the light 
chain, however sequence analysis of FI sequences from other organisms show the 
domains are well conserved which suggests that they are functionally and 
structurally relevant (Terado et al., 2002). Human FI contains six N-linked occupied 
glycosylation sites with three within the light chain and the other three in the heavy 
chain (Figure 2.9) (Ritchie et al., 2002).
The interactions between FI, cofactors and substrate (C3b) have been most 
extensively studied with the FI - FH - C3b complex. It has been shown that FI 
interacts weakly with both C3b and FH, and C3b and FH also interact directly within 
the complex (Soames and Sim, 1997). FH has been shown to enhance binding of FI 
to C3b and similarly FI has shown to enhance binding of FH to C3b. This indicates 
that binding of FH to C3b may cause a conformational change within C3b that 
facilitates the binding of FI to C3b or the C3b-FH complex (Soames and Sim, 1997).
Although during natural substrate cleavage, FI forms this cofactor-substrate 
complex, it has been shown that the isolated FI SP domain has proteolytic activity in 
the absence of a cofactor, and that the SP domain is inhibited and not stimulated by 
FH (Tsiftsoglou et al., 2005). This work suggests that both the cofactor and the 
heavy chain of FI have roles in orientating the natural substrates to specific cleavage 
sites, since the isolated SP domain cleaves C3 at several sites and is less specific. 
This is supported by the presence of a Kazal-type protease inhibitor module within 
the FIMAC domain of the FI heavy chain. Kazal-type inhibitors are a diverse family 
of proteins which inhibit thrombin/trypsin like proteases (Schlott et al., 2002). It 
could be that the SP domain of FI is inhibited within the FI complex because it is in 
close proximity to the FIMAC domain (Chamberlain et al., 1998). With this model, 
the Fl-cofactor-substrate complex could cause separation of the SP and FIMAC 
domains, orientating the substrate towards the SP domain, allowing FI to cleave the 
substrate at highly specific sites (Tsiftsoglou et al., 2005).
The gene that encodes for FI (IF) is located on chromosome 4q25 and spans 
63kb (Vyse et al., 1994). It comprises 13 exons, with a strong correlation between 
exon organisation and domain structure organisation. The SP domain is encoded in 
five exons, and bears a closer resemblance to trypsin than it does to the other 
complement serine proteases (Vyse et al., 1994).
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2.8 Disorders of Coagulation and Uncontrolled Complement Activation
Disturbances of the natural balance between the procoagulation and 
anticoagulation systems or between complement activation and regulation can lead 
to a variety of disorders (Table 2.5). Although these disorders can be the result of 
acquired factors such as the development of autoantibodies, they are more frequently 
the result of genetic alterations within the genes that encode coagulation or 
complement factors. The coagulation and complement systems are linked since 
deficiencies in complement regulators often lead to disorders of haemostasis, usually 
affecting platelets. Disorders within coagulation factors can lead to bleeding 
disorders due to incorrect coagulation, or alternatively can predispose to thrombosis.
There are several bleeding disorders that are associated with coagulation 
factor deficiencies. Von Willebrand disease, haemophilia A and haemophilia B are 
the most frequent congenital bleeding disorders occurring in the general population 
with frequencies of 1 in 100, 1 in 20,000 and 1 in 100,000 respectively (Cooper and 
Tuddenham, 1994). The fourth most frequent bleeding disorder is FXI deficiency 
occurring more commonly in countries with large Jewish communities (Seligsohn, 
1978). Other rare disorders are seen with deficiencies of fibrinogen, prothrombin, 
FV, FV/FVIII combined, FVII, FX and FXIII (Peyvandi and Mannucci, 1999).
When a patient presents with a bleeding disorder it is often difficult to 
pinpoint the exact cause of the bleeding and find the factor that is deficient. There 
are two laboratory tests routinely used for evaluation of coagulation pathways. The 
activated partial thromboplastin time (APTT) evaluates the intrinsic pathway. The 
prothrombin time (PT) is the most commonly performed test in haemostasis and 
evaluates the extrinsic pathway. Disorders are confirmed with specific assays of the 
coagulation factors suspected to be involved.
Since the alternative pathway of complement is triggered spontaneously, 
efficient regulation is required in order to prevent uncontrolled complement attack 
on self cells. A deregulation of the alternative pathway results in defective 
recognition and the formation of toxic activation products on the surface of host 
tissues and structures. This is linked to coagulation disorders since overactive 
complement attack can result in platelet activation and unwanted thrombus 
formation.
At the cell surface, multiple regulators combine to coordinate the 
amplification of C3bBb convertase.
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Table 2.5 Diseases of the blood coagulation and complement systems
Disease Protein Pathway Molecular Consequence Symptoms
Haemophilia A FVIII Coagulation Deficiency of FVIII affects coagulation pathway and Bleeding into joints, muscles digestive tract 
fibrin production. Gene resides on the X-chromosome. and brain.
Haemophilia B FIX Coagulation Deficiency of FIX affects coagulation pathway and 
fibrin production. Gene resides on the X-chromosome.
Bleeding into joints, muscles digestive tract 
and brain.
Haemophilia C (FXI Deficiency) FXI Coagulation Deficiency of FXI affects propagation phase of 
coagulation.
Variable bleeding disorder after trauma. 
Particularly after dental extraction.
FX Deficiency FX Coagulation Deficiency of FX affects thrombin formation Variable bleeding disorder associated with 
nosebleeds, bleeding into joints and 
gastrointestinal blood loss
von Willebrand Disease VWF Coagulation Low levels or incorrectly functioning VWF affect 
platelet adhesion in the first stage of clot formation
Variable bleeding disorder with nose 
bleeds, easy bruising and heavy menstrual 
periods in women.
Factor V Leiden FV Coagulation FV cannot be inactivated by PC, allowing unregulated 
thrombin formation.
Increased risk of thrombosis.
Protein C deficiency PC Coagulation FV or FVIII cannot be inactivated by PC, allowing 
unregulated thrombin formation.
Increased risk of thrombosis.
atypical Haemolytic Uraemic 
Syndrome (aHUS)
FH, MCP, 
FI
Complement Defective alternative pathway control leads to 
endothelial cell activation and complement attack on 
host cells
Microangiopathic haemolytic anemia, acute 
renal failure, low platelet count 
(thrombocytopenia)
Membranoproliferative 
Glomerulonephritis (MPGNII)
FH Complement Defective alternative pathway control leads to 
endothelial cell activation and complement attack on 
host cells
Kidney failure. Dense complement 
containing deposits form in capillary cell 
walls o f kidneys
Age-related Macular 
Degeneration (AMD)
FH Complement Polymorphism in SCR-7 of FH that is associated with 
disease risk.
Vision loss due to plaques developing 
behind the retina. Plaques contain large 
amounts of FH.
Thrombotic Thrombocytopenic ADAMTS, 
Purpura (TTP) FH
Coagulation/
Complement
Incorrect cleavage of VWF leaves haemostatically 
more active multimers (ULVWF) that bind to platelets 
and activates them into forming platelet thrombi
Neurological symptoms, kidney failure, 
low platelet count
FI Deficiency FI Complement Uncontrolled alternative pathway leads to excessive 
consumption of C3 and C3 deficiency. C3 is no longer 
able to efficiently opsonize encapsulated organisms.
Increased susceptibility to recurrent 
infection from encapsulated bacteria 
Patients have also been reported with 
kidney failure.
The presence of multiple, redundantly acting regulators explains why in a normal 
situation a defect of a single regulator does not cause damage, however in high levels 
of complement activation due to stress or within specific tissues, a reduced activity 
or a defect of one single regulator can shift the sensitive balance from protection to 
damage (Zipfel et al., 2006). Several genetic disorders have been reported where 
increased C3 turnover and consumption leads to complement activation on 
endothelial cells (Table 2.5).
The main difficulty in treating these disorders is that it is initially difficult to 
identify the protein(s) at the heart of the problem. Even when this is identified, 
symptoms within patients with the same disorder can vary from mild to extremely 
severe. With the advance of automatic genetic sequencing technology it has become 
easier to identify the underlying genetic abnormality within a specific protein that 
causes the disorder. This has lead to better understanding o f the underlying 
molecular cause of the disease and may also explain the difference in symptoms seen 
within patients suffering from the same disorder. The number of different mutations 
associated with different disorders varies. For example at the time of writing around 
45 different mutations within the FX protein have been identified in patients 
suffering from FX deficiency (Uprichard and Perry, 2002), whereas over 900 
different mutations have been identified within FVII in Haemophilia A patients 
(http://europium.csc.mrc.ac.uk/WebPages/Main/main.htm).
The clinical phenotypes of the majority of bleeding disorders are frequently 
classified as being either a Type I quantitative deficiency or a Type II qualitative 
deficiency. This can be extended to complement deficiencies. Type I refers to cases 
where not only the activity of the protein is reduced, but also the level of the protein 
within patient plasma is also reduced as recognised by an Ag assay or other 
techniques. In contrast, Type II deficiencies are classified as those where patients 
have reduced activity of the protein, but the level of the protein is normal. The 
genetic cause of the disorder can be classified in this way, since mutations that 
reduce the translation, secretion or stability of the protein can be classified as Type I, 
whereas those mutations that result in mutant forms of a dysfunctional protein can be 
classified as Type II (Section 1.8.3).
Analyses of the genetics and the pathomechanisms of both coagulation and 
complement diseases are important in providing knowledge for novel methods of 
diagnosis and therapy for these diseases. In addition, understanding the different
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genetic and phenotypic outcomes can lead to a better understanding of the cascade 
systems of coagulation and alternative complement regulation.
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Chapter 3 
Bioinformatics Methods
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3.1 Data Management
3.1.1 Databases and Database Management Systems
For data to be useful it is important that it is organised and categorised in 
such a way that it is easy to find. A database is a collection of data that is organized 
so that its contents can easily be accessed, managed and updated. Databases are often 
accompanied by a database management system (DBMS) that consists of software 
specifically designed to control the storage and access of data. There are a number of 
DBMSs available that offer different features and technology (Table 3.1).
DBMSs differ in the sophistication of their features that define how secure, 
reliable and efficient data is managed and accessed concurrently. The decision of 
which DBMS to use can often be a trade-off between the cost of buying the DBMS 
software and the features the software supports. For example Microsoft SQL Server 
technology offers advanced features such as stored procedures that can be useful in 
reducing the number of times a database needs to be accessed but it is very 
expensive and platform specific and so it is not really viable for non-profit academic 
databases.
3.1.2 Database Design
The first stage in designing a database is deciding on the database schema. 
The database schema is a conceptual model of the structure of a database that defines 
the data contents and relationships. The most widely used model for designing 
databases is the relational data model. This model is based on the idea that all data is 
stored within tables known as relations that are linked by explicit relationships 
(Figure 3.1). Tables within the database are made up of attributes, where each row or 
tuple represents a database entry. Relationships between tables are described by the 
number of times data within a table are linked. For example the one-many 
relationship (1:N) between the student and student_course tables represents the fact 
that one student can be registered for one or more courses. Relationships can also be 
one-one (1:1) or many-many (N:N). In contrast to the relational model, the object 
orientated model represents objects and the relationships between objects directly, by 
controlling the way in which objects are created and accessed. Although the object- 
orientated model can be well suited to representing data with complex relationships, 
the relational model is more widely used because of its simplicity and the number of 
well-established DBMSs that support the model.
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Table 3.1 Comparison of five popular DBMSs
DBMS Speed Size Cost Portability URL
MS Access Fast Small MS office Bundle No http://office.microsofl.com
MySQL Very Fast Medium Free Yes http://www.mysql.com
PostgreSQL Slow Medium Free Yes http://www.postgresql.org/
Oracle Slow Large Expensive Yes http://www.oracle.com/index.html
MS SQL Server Very Fast Large Expensive No http://www.microsofl.com/sql/default.mspx
Student
StudentID StudentSurname Student ForeName
1 Smith John
2 Johnson Sarah
3 Brown James
Course Info
CourselD CourseTitle CourseName CourseCredits
CS11 IDP Introduction to Database Proarammina 20
CS09 INT Internet Technology 15
Figure 3.1 Example of a relational database
Three tables are shown and the relationships between those tables are represented by 
lines, where the end of a line with three prongs signifies the direction of the 1 :N 
relationship. Attribute names are shown in red text and primary keys are underlined. 
The table name is shown in the grey box.
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Within a relational database tables are linked by keys. A primary key is a 
unique identifier within a table that can be made up of one or more attributes. The 
value of a table’s primary key cannot be NULL. Primary keys are used to ensure data 
is not duplicated, and also to form relationships between tables. If a primary key of 
one table exists as an attribute of another table, it is known as a foreign key within 
that table and the two tables are linked.
A database needs to be designed efficiently so that the accessing, searching 
and updating of data is as fast as possible without anomalies. Normalisation is a 
design technique that ensures relational tables are free of redundant data and updates 
and modifications are consistent and correct. The theory is based on the concepts of 
normal forms. A relational database table is said to be a particular normal form if it 
satisfies a certain set of criteria. For example, the first normal form requires that the 
values in each attribute of a table are atomic, meaning there are no sets of values or 
composite values within a column, i.e. a name would be split into first_name and 
last_name allowing both values to be searched and ordered. A relational table is in 
second normal form if it is in first normal form and every non-key attribute is fully 
dependent upon the primary key. Third normal form ensures that every non-key 
attribute is dependent only upon the primary key. For example, the value of one 
attribute should not be linked to another attribute that is not the primary key. The 
advantage of having relational tables in third normal form is that it eliminates 
redundant data which in turn saves space and reduces data manipulation anomalies.
3.1.3 Structured Query Language (SQL)
The standard language for creating, managing and accessing a relational 
database is Structured Query Language (SQL). While SQL queries enable data to be 
retrieved and modified, developing a full database application will usually require 
programming in a language such as Perl, Java or C++ for all the non-database tasks, 
such as providing user interface or reporting. Technologies have developed to allow 
such languages to use SQL to access databases. For example, a programming 
interface known as database interface (DBI) is frequently used with Perl for database 
applications.
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3.1.4 MySQL
For the design and implementation of my databases I have opted for the 
MySQL DBMS (http://www.mysql.com). MySQL is the world's most popular open 
source database technology because of its consistent fast performance, high 
reliability and ease of use. It is used in more than 8 million installations ranging from 
large corporations to specialized embedded applications. MySQL is flexible in that it 
runs on both UNIX and Microsoft Windows operating systems. The UCL 
biochemistry web server is maintained by Apache Server (http://httpd.apache.org/), 
which has been the most popular web server on the Internet since April 1996. 
Apache server alongside MySQL and PHP, Perl or Python form the LAMP stack, 
that comprises a set of free software programs commonly used together to run 
dynamic web servers.
3.2 Web Technology
The Internet and World Wide Web technologies have revolutionised the way 
data can be stored and accessed. We now have access to the massive amounts of 
genome and protein sequence and structure data from the worldwide scientific 
community. The growth of the internet has resulted in a large number of websites 
that present diverse biological data, and accordingly specialist bioinformatics 
techniques have been developed and adapted to store and display this data.
3.2.1 HTML and CSS
Web pages contain plain text written in a mark-up language that indicates 
how the text and information should be presented by the internet browser. The most 
popular mark-up language of the web is HyperText Markup Language (HTML). 
HTML concentrates on describing The presentation of data rather than its content. 
HTML contains two types of markup. The major type is known as a tag consisting of 
a label contained between ‘<’ and ‘>’ characters for an ‘opening’ tag and between 
‘<’ and */>’ characters for a ‘closing’ tag. The second type of markup is known as 
the attribute which consists of an attribute type and value pair contained within a 
HTML opening tag. Cascading Style Sheets (CSS) provide an extension to HTML 
that can separate some of the presentation of a web page from the content. This is 
useful when redesigning a page, where only the CSS needs to be modified without
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changing the page’s content. CSS also allows aspects of presentation to be modified 
for a whole website instead of individual web pages.
3.2.2 Client-Side Scripting
Internet browsers now also support client-side scripting languages such as 
Javascript (Sun Systems) or VBScript (Microsoft). Client-side scripting is useful to 
add interactivity to HTML allowing different and changing content depending on 
user input or environmental conditions (such as the time of day) without further 
requests to the web server. JavaScript is the most popular scripting language on the 
internet, and can be interpreted by all major browsers, such as Microsoft Internet 
Explorer, Mozilla Firefox, Netscape and Opera. I have continuously used JavaScript 
within my websites to allow dynamic user input such as expanding boxes and 
checking and changing dynamic forms. The use of HTML and CSS together with 
JavaScript is known as Dynamic HTML (DHTML).
3.2.3 Server-Side Scripting
In contrast to client-side scripting such as JavaScript, server-side scripting 
can be used to produce output in HTML format based on information residing on the 
web server. Unlike client-side scripts, server-side scripts are executed by the web 
server and not the web browser. The user cannot see the source code (unless the 
author publishes the code separately), and may not even be aware that a script was 
executed. Server-side scripting is useful if access is required to information or a 
database that resides on the server, as opposed to client-side scripting that is useful 
for obtaining information that is contained on a user’s computer. Server-side scripts 
require the web server to support the specific language used to write the script 
whereas client-side scripts do not require additional software on the server but do 
require the user’s web browser to understand the script. Server-side scripts produce 
the same output regardless of the client's browser, operating system, or other system 
details.
The UCL biochemistry web server provides support for several server-side 
scripting languages such as Perl (http://www.perl.com) and PHP 
(http://www.php.net). Other popular server-side scripting languages such as ASP 
(Microsoft, http://www.asp.net) are widely used but are expensive and operating 
system dependent. For the websites discussed in this thesis, I have opted to use PHP
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server-side scripting to present data obtained from MySQL databases that reside on 
the web server. PHP has a wide installation base across the Internet and is one of the 
most popular programming languages for implementing websites with over 20 
million internet domains using PHP (Alshanetsky, 1998). One of the major reasons 
for choosing PHP over Perl was the large amount of documentation and support 
available for PHP programming due to the large number of people using it.
3.2.4 Future Directions and Web issues
One of the major issues with web design is cross-browser consistency. As 
HTML has evolved, new tags have been introduced and different web browsers have 
a different level of support for certain tags. When designing a web page it is very 
important to test the web page on different browsers since the HTML may be 
interpreted differently by different browsers and the page may be displayed 
incorrectly.
Another major issue with biological data sources on the web is concerned 
with presentation of data. A large amount of biological data stored on the web is 
presented in HTML. This is a problem for automated data processing however, since 
HTML does not syntactically tag data and it is only concerned with its presentation. 
Although the web contains a huge resource of data, it is not necessarily possible to 
automatically extract this information. A program that extracts information must deal 
with HTML code and this is particularly difficult within websites that are formatted 
in complicated tables. Furthermore, if the web sites design changes then the program 
that is automatically reading it must be updated too. For this reason standards have 
been introduced by the World Wide Web Consortium (W3C) to introduce the 
concept of semantic data tagging, extensible Markup Language (XML) was 
developed to facilitate data interchange via the web. Conceptually and syntactically 
XML is similar to HTML, however XML allows the user to define a set of tags with 
semantic meaning, providing a text-based means to describe and apply a tree-based 
structure to information or data within a web page. These tags are described in a data 
type definition (DTD). XML describes only the content of a document and does not 
describe how to display it. When XML data is to be presented through a web- 
browser extensible Stylesheet Language (XSL) can be used to describe how the data 
should be displayed.
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The use of XML has been recognised within the field of bioinformatics since 
the growth of individual biological databases has highlighted the importance and 
implications of integrating data sources together. Many efforts are underway to 
integrate data using semantic markup and ontologies to allow different databases to 
be linked (Orengo et al., 2003).
3.3 Biological Databases
Since the advent of automated DNA sequencing, protein and gene sequences 
have become abundant. If this sequence information is to be used for analysis and 
interpretation it has to be widely available in an organised format. There are 
numerous biological databases that exist to provide different sources of information, 
ranging from simple files detailing the sequence and organism of a gene or protein to 
fully annotated files detailing not only the sequence of a protein or a gene but also 
functional and structural information where present (Table 3.2).
The most common types of biological database are sequence databases. 
GenBank is the largest collection of publicly available DNA sequences (Benson et 
al., 2006). GenBank is accessible through the National Center for Biotechnology 
Information (NCBI) retrieval system, Entrez, which integrates data from the major 
DNA and protein sequence databases along with taxonomy, genome, mapping, 
protein structure and domain information, and biomedical literature via PubMed. 
GenBank contains genetic sequences obtained by submissions from individual 
laboratories as well as batch submissions from large-scale sequencing projects. 
Because of this, GenBank is redundant in the sense that it represents sequence 
information generated at different times and may represent alternative views of a 
protein sequence, a protein name or other information. Reference Sequence (RefSeq) 
is a database at the NCBI that is built from the data within GenBank and represents a 
non-redundant up-to-date view of a protein or gene (Pruitt et al., 2005). RefSeq is 
manually curated by NCBI staff and collaborators who check format and consistency 
and validate data. As Refseq provides a valid non-redundant data set, many journals 
prefer authors to use RefSeq sequence files as opposed to GenBank sequences.
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Table 3.2 Bioinformatics Databases
Database Description Size* Url Reference
GenBank DNA and amino acid sequence files submitted -54,000,000 http://www.ncbi.nlm.nih.gov/Genbank/ 
by sequencing projects. Data is redundant and records 
more than one sequence can appear for the 
same protein/gene.
Benson et al., 2006
RefSeq DNA and amino acid sequence files that are 
checked and validated by manual curation.
-2,700,000
protein
records
http://www.ncbi.nlm.nih.gov/RefSeq/ Pruitt et al., 2005
UniProt/Swiss-Highly annotated protein sequence files that 
Prot are non-redundant.
-230,000
protein
records
http://www.expasy.oig/sprot/ Wu et al., 2006
Protein Data 
Bank (PDB)
Protein and DNA structure coordinated files. 
May contain multiple structural files for the 
same protein.
-37,000
structure
files
http://www.pdb.org/pdb/Welcome.do Berman etal., 2000
Cath Hieracial classification of protein structures, 
clustering at four main levels, class, 
architecture, topology and homologous 
superfamily. Mostly uses automated methods.
-43,000
domains
http.Y/www.cathdb.info/latest/index.html Oiengo et al., 2003
Scop Hierachial classification of protein structures 
into four main classes, family, superfamily, 
fold and class. Mostly manual curation.
-26 ,000  
PDB files 
-70,000 
domains
http://scop.mrc-
lmb.cam.ac.uk/scop/intro.html
Murzinetal., 1995
Pfam Database of protein sequence families 
generated using multiple sequence 
alignments and Hidden Markov Models.
-8000 proteinhttp://www.sanger.ac.uk/Software/Pfam/ Finn et al., 2006 
families
Table 3.2 Bioinformatics Databases (continued)
Database Description Size* Uri Reference
ProDom Protein domain families automatically 
generated from the global comparison of all 
SWISS-PROT and TrEMBL sequence 
databases.
-70,000 protein 
families
http://protein.toulouse.inra.fr
/prodom/cunent/html/home.php
Bru et al., 2005
Interpro Integrates data from PROSITE, PRINTS, 
SMART, Pfam and ProDom into a database 
of protein domains and functional sites.
-13,000 entries http://www.ebi.ac.uk/interpro/ Mulder etal., 2005
DBSnp Database of variation within the human 
genome, including SNPs, microsatellite 
repeats and small insertions and deletions of 
nucleotides submitted by sequencing groups.
-7,000,000 
validated SNPs
http://www.nebi.nlm.nih.gov/projects/SNP/Sherry et al., 1999
HGVBase Highly curated database of variation within 
the human genome including phenotypic 
information.
-3,000,000
records
http://hgvbase.cgb.ki.se/cgi-
bin/maiapl?page=release_details.htm
Fredman et al., 2002
Human Gene 
Mutation 
Database 
(HGMD)
Database of genetic alterations associated 
with disease. Data collected using manual 
and automatic search procedures.
-5000 mutations http://www.hgmd.cf.ac.uk/docs 
genetic /newback.html 
alterations
Stenson et al., 2003
Online 
Mendelian 
Inheritance in 
Man (OMIM)
Database of human genes and genetic 
disorders manually maintained.
-17,000 genes http ://ww w. ncbi. nlm. nih. gov 
/entrez/query ,fcgi?db=OMIM
Hamosh et al., 2005
*at time of writing (Aug 2006)
The UniProtKB/SwissProt protein database is the most highly annotated 
protein sequence database and was established in 1986 by the Swiss Institute for 
Bioinformatics (SIB) and the European Bioinformatics Institute (EBI) (Wu et al., 
2006). UniProt provides a high level of annotation, a minimal level of redundancy 
and a high level of integration with other databases. The current release of the 
database at the time of writing (Release 50.1 of 13-Jun-06) contains over 230,000 
sequence entries. UniProt can be accessed and searched by the Expert Protein 
Analysis System (ExPASy) proteomics server of the SIB (http://www.expasy.org).
In addition to protein sequence information, there is now also a large amount 
of structural information available on large numbers of proteins from different 
organisms. When protein structures are solved they are submitted to the protein data 
bank (PDB). At the time of writing there are over 42,000 different structures of 
protein, nucleic acids and complexes within the PDB (http://www.pdb.org). A major 
resource for accessing this structural information is PDB Sum (Laskowski et al.,
1997) that provides summaries and analyses of all structures within the PDB.
There are many other useful biological databases that contain information 
and analyses building from the sequence and structural databases previously 
discussed. These are listed in Table 3.2.
The most important feature of a biological database is the ability to find the 
required information. The majority of sequence databases offer keyword searches or 
searches by standard gene or protein names. Sequence records can also be retrieved 
using sequence similarity searching where the user finds sequences that are identical 
or similar to a query sequence string. It is also useful to standardise databases so they 
can be linked with other data sources. The majority of widely used databases have 
links to other external databases, for example UniProt offers links to the protein 
entries within GenBank, PDB, ProDom, PRINTS, SMART and PubMed. The 
organisation and retrieval of data is extremely important if the huge amount of 
sequence information is to be useful.
3.4 Sequence Similarity Searching
Sequence similarity searches aim to extract sequences from a database that 
are similar to a query sequence. This can be useful when looking for homologous 
sequences for homology modelling (Section 3.6) as well as looking for conservation 
of residues that are mutated. Similarity searches work by comparing (aligning) the
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query sequence to each database sequence in turn and then ranking the database 
sequences with the highest scoring (most similar) sequences at the top.
3.4.1 Sequence Similarity Methods
Dynamic programming is a method to produce the best alignment of two 
sequences. Sequence similarity analyses commonly use two dynamic programming 
algorithms, the Needleman-Wunsch algorithm and the Smith-Waterman algorithm. 
These differ since the Needleman-Wunsch algorithm searches for global similarity 
between sequences whereas the Smith-Waterman algorithm searches for local 
similarity. Local alignments find similarity within small parts of the sequence and 
are most commonly used because real biological sequences are often not similar over 
their entire lengths, but only in local portions, such as domains within protein 
sequences. Global alignments are useful when looking for sequence similarity over 
the full length of a sequence, for example when searching for sequences of the same 
protein within different species. The best-known sequence alignment tool is the 
CLUSTALW package (Higgins et al., 1994). This software can not only perform 
pairwise alignments but also uses progressive steps of pairwise alignments to form a 
guide tree in order to find the most optimal multiple sequence alignment. DIALIGN 
is an alternative to CLUSTALW that performs multiple sequence alignments using 
local sequence alignment algorithms as opposed to the global sequence alignments 
employed by CLUSTALW (Morgenstem, 1998).
Within biological sequence databases, BLAST (Altschul et al., 1990) and 
FASTA (Pearson and Lipman, 1988) are two of the most commonly used tools for 
sequence similarity searches. Both methods work on the assumption that high- 
scoring alignments are likely to contain short stretches (words) of identical or near 
identical letters. BLAST works by looking for words of a fixed length (default of 
three amino acids for proteins) that score higher than a threshold score. These word 
matches are then extended to form high-scoring segment pairs. FASTA on the other 
hand searches for identically matching words of two amino acids. Un-gapped 
alignments that contain a high density of word matches are then aligned accurately 
using dynamic programming. PSI-BLAST is an extension of BLAST that can detect 
more distantly related sequences using an iterative search with a profile generated 
from the top scoring BLAST hits of each iterative step (Altschul et al., 1998).
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3.4.2 Database Scoring
One of the main problems with sequence similarity searches is to know when 
an identified sequence represents a real relationship (true positive) rather than a 
chance similarity between unrelated sequences (false positive). It is sometimes 
difficult to make the distinction between true positives and false positives as there is 
likely to be some overlap between the highest scoring true negatives and the lowest 
scoring true positives (Figure 3.2). In order to rank sequences in terms of most likely 
significant matches, sequence similarity methods have to develop statistical scoring 
that takes into consideration database size, sequence length and how close sequences 
align. Pairwise-sequence identity scores represent the percentage of amino acids 
within a query sequence that are identical within the matched sequence. Most 
sequence searching software also reports a p-value (probability value) that represents 
the probability that a score above a certain threshold would have been obtained by 
chance between two unrelated sequences. A related score is given by the E-value 
(expected value) that is the expected frequency of scores above a threshold that 
would be expected to have occurred by chance. Significant matches are therefore 
identified by a low p-value and low E-value.
3.5 Molecular Evolution and Homology
Molecular evolution considers how the genetic material of populations of 
organisms changes over time. Recent advances in genomic sequencing and high- 
throughput protein characterisation have lead to a dramatic increase in 
bioinformatics approaches to studying evolutionary relationships between biological 
sequences and between protein structures.
Genetic changes can identify which species are most related since more 
closely related species will have more similar genome sequences. Systematic 
analysis of genetic sequences can help reveal phylogenetic relationships between 
organisms. Furthermore, analysis of protein sequences can reveal relationships 
between proteins and even where protein sequences have changed beyond 
recognition, similarities may still be seen within protein structures. Similar proteins 
or genes can be described as homologous if they have diverged from a common 
ancestor, where the level of homology can be calculated from levels of sequence or 
structural similarity.
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Figure 3.2 Database scoring
Example normal distributions of scores that represent the output from negative input 
and the output from positive input, i.e. database entries that do not satisfy certain 
criteria and those that do.
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Homologous genes can be described as paralogs of each other if the 
homologous relationship is the result of gene duplication within the same species 
and the genes now perform different but related functions. Homology may also be 
the result of speciation where the homologous genes are described as orthologs since 
they exist in a different organism but perform the same or highly similar function.
3.6 Homology Modelling
Homology modelling can provide a reliable method of predicting a three- 
dimensional structural model of a protein. Where experimental X-ray 
crystallographic or NMR structures of a protein sequence are not available, it is 
sometimes possible to build a model of a structure using another protein of known 
sequence or structure as a template. Homology modelling is useful because it is not 
always possible to obtain X-ray crystallography or NMR data, which is both a time- 
consuming and expensive process.
The initial stage of homology modelling involves the identification of 
homologous sequences of known structure that can be used as a template structure 
from which to build a model. The accuracy of the model relies on finding the best 
template, both in terms of sequence identity and the number of amino acids that need 
to be inserted into or deleted from the template in order to build the model. Template 
structures can be found by searching the PDB using standard search tools such as 
BLAST and FASTA. When individual protein domains are being modelled, it can 
also be useful to use domain databases such as Pfam or Interpro (Table 3.2) in order 
to identify PDB structures that contain a specific domain.
The second and possibly most important stage of homology modelling is the 
alignment of the target sequence with the template sequence. The optimal alignment 
for homology modelling should be identical to the alignment achieved if both 
structures were known and structurally aligned. When the sequence identity is high 
(>70%), the alignment can be quite trivial. However, achieving the optimal 
alignment becomes difficult when the sequence identity gets lower and the number 
of sequence insertions and deletions gets larger. Automatic sequence alignments 
obtained using methods such as CLUSTALW or DALIGN do not always achieve the 
optimal sequence alignment needed for homology modelling since they are 
concerned with sequence and not structure. Most of the time sequence alignments 
need to be manually edited to consider the three dimensional fold of the protein. It is
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important that sequence insertions and deletions are restricted to structurally variable 
regions such as loops and do not occur within structurally conserved regions or 
secondary structure elements.
3.6.1 INSIGHT II Homology Module
INSIGHT II (release 98.0; Accelrys, San Diago, USA) is a suite of molecular 
graphics and computational chemistry software. The HOMOLOGY package of 
INSIGHT II allows the user to perform homology modelling using a traditional 
method of model building. This approach centres on the observation that insertions 
and deletions within protein sequences are generally confined within structures as 
small local changes in structurally variable regions. Outside of these small local 
changes, the majority of the structure remains unchanged forming structurally 
conserved regions (Greer, 1990). In order to identify structurally conserved regions it 
is useful to perform structural alignments using more than one template structure, 
and identify core parts of the structure that are the same lengths and secondary 
structure in each of the templates and the targets. Where only one template structure 
is known, it is useful to assume all secondary structural regions are conserved except 
where sequence insertions or deletions occur within loops.
With INSIGHT II, once the structurally conserved regions are identified the 
target sequence can be modelled by inheriting these regions from the template 
structure. Where amino acids are the same within the template and model sequence, 
all the coordinates for the amino acid are transferred. Where they are different, the 
backbone coordinates are transferred but the side chain atoms are automatically 
replaced.
When a residue is different in the target sequence and template structure, the 
replacement residue is aligned to the backbone and dihedral angles of the structure. 
If the model residue has more atoms that template residue, distal atoms are given an 
extended conformation. Occasionally this new predicted side chain conformation is 
not accurate because of local environment atom clashes. In these cases a 
conformational search is carried out for the affected side chains.
The prediction of the conformation of residue side chains is a complicated 
task due to the large numbers of possible conformations. However, statistical studies 
of protein structures have shown that side chains adopt only a small number of the 
many possible conformations available to them. The correct rotamer to use for a
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residue is largely dependent on local environment since side chains are generally 
closely packed. Hydrophobic interactions, hydrogen bonding and charge-interactions 
are all important in determining the side chain conformation of a residue. Although 
several libraries of rotamer frequencies have been compiled (Benedetti et al., 1983; 
Ponder and Richards, 1987) when several side chains interact with each other, there 
are still a large number of possible conformations. To avoid having to compute every 
possible conformation, a systematic search of these conformations can be performed. 
The algorithm implemented by the HOMOLOGY module of INSIGHT II uses a 
moving list cycle to find the lowest energy conformation. Those residues that can 
move are defined and the best rotamer for the first residue is found based on lowest 
energy criteria. The second residue rotamer with the lowest energy is then found and 
so on, where a cycle is defined as one complete pass through the list. The search 
stops when the energy does not change appreciably from one cycle to the next. This 
method is used because of its simplicity and speed, however it is important to realise 
the search is not exhaustive since not all possible conformations are searched.
In order to build structurally variable regions, one of two methods can be 
implemented by the HOMOLOGY module of INSIGHT II. Loop regions can be 
built using peptide segments already found within other protein structures within the 
PDB or by ab initio methods using conformation search and molecular dynamics. 
The search loop function has the advantage because all loops that are found have 
internal geometries that resemble known protein conformations. However, it may not 
always be possible to fit a known loop into the model protein framework without 
steric overlaps, and in these cases the generate loop function is preferred. Within the 
HOMOLOGY module, loop searches are carried out by searching an existing a- 
carbon distance matrix to identify proteins that have two points with similar a- 
carbon distances to the selected region of the model where the insertion takes place. 
The identified protein then also must have the same number of residues between the 
two points as the target model sequence. The ten best-fit loop structures are shown, 
as defined by the lowest root mean-squared distance (RMSD -  Section 3.7) between 
the model structure and the protein containing the loop. When the matches are 
displayed, they are superimposed onto the model structure and the user must decide 
the most appropriate loop structure. The generate loop command is used to build a 
peptide backbone between two peptide segments using randomly generated values 
for all the loop ® and T  angles. The 0  and T  angles are adjusted for a certain
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amount of iterations until the loop is closed and distance criteria are met (Shenkin et 
al., 1987). If distance criteria are met and the loop is closed, it is then rotated as a 
rigid body and superimposed onto the model structure. The geometry of the base of 
the loop is then checked for proper chirality, and those loops with opposite chirality 
are discarded. Again the ten best models are displayed and the user decides the most 
appropriate structure.
3.6.2 MODELLER
MODELLER is one of the most widely-used programs for generating protein 
models (Sali and Blundell, 1993) and can be used as a stand alone package or as an 
add-on to the INSIGHT II package. It works in a different way to traditional methods 
such as INSIGHT HOMOLOGY. The initial stages of generating an alignment are 
the same, but instead of building the model first from structurally conserved regions 
followed by structurally variable region construction, MODELLER uses molecular 
dynamics to assemble both regions in one step. Additional restraints are imposed in 
the molecular dynamics force field in the form of a probability density function that 
contains preferred inter-Ca distances that are calculated from the template 
structure(s). When there is more than one template structure, the probability density 
function is weighted so that highly conserved regions of structure have stronger 
restraints than structurally variable regions. The MODELLER approach is often 
more accurate than the INSIGHT HOMOLOGY method since it side steps the 
problem of identifying structurally conserved and structurally variable regions. It 
also deals with long loop regions better than INSIGHT HOMOLOGY.
3.6.3 Model Refinements
A model built using a method such as INSIGHT HOMOLOGY may contain 
structural artefacts such as large side chains substituted for small ones, peptide 
backbone strain or non-optimum conformation of loops. In order to overcome such 
artefacts, models are usually refined using energy minimisation (EM) and molecular 
dynamics (MD) using the DISCOVER module of INSIGHT II.
EM involves moving atoms within a structure in order to find a minimum 
energy conformation. In order to assess the energy of a system, more complex 
quantum effects are ignored and the molecules are treated as simple sets of springs 
which obey the laws of classical mechanics defined by Newton. The potential energy
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of a molecular system can be represented by the energy necessary to stretch a bond, 
the energy necessary to distort the angle between three atoms, the energy required to 
rotate atoms about their bond axis, the energy necessary to move an atom out of the 
plane defined by three atoms to which it is bonded and the energy associated with 
the attractive, repulsive and electrostatic forces between atoms that are not bonded to 
one another. This energy force field is approximated by discounting the non-bonded 
energies of atoms that are beyond a certain distance from each other since they 
would not be expected to contribute greatly to the energy of the system. Standard 
mathematical minimisation algorithms exist in order to find the energy minimum. 
The steepest descent method gradually changes coordinates of a model in order to 
decrease the energy of the system by varying the step size between energy changes. 
In particular, projecting the location of the nearest minimum along the gradient will 
always find the nearest energy minimum to the starting point and is therefore useful 
for resolving bad contacts within models. An alternative method is the conjugate 
gradient method that uses information from previous starting points to determine the 
optimum direction for a line search. This method is more likely to identify a global 
energy minimum rather than the closest minimum to the starting point. The 
limitations of EM are that it is not possible to make large movements that effectively 
explore all available conformational space.
Rather than trying to find an energy minimum, MD models the dynamics of a 
molecule either in vacuo or in the environment of a solvent. Each atom is assigned 
an initial velocity from a temperature-dependant Boltzmann distribution. Newton’s 
laws of motion are then applied iteratively to keep updating coordinates, forces, 
acceleration and velocities, thus integrating the laws of motion. As MD provides a 
dynamic simulation, it is able to move over energy barriers that are inaccessible to 
EM and can sometimes be a more effective way to attempt to find the minimum 
energy of a protein structure.
3.6.4 Limitations of Homology Modelling
There are several things that can affect the accuracy of a homology model. It 
is firstly important to realise that any NMR or X-ray experimental structure that is 
used as a template is itself a model, and therefore a model of a structure obtained 
from homology modelling is in fact a model based on another model. This is 
important since analysis of homology models is limited to offering hypotheses that
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can then be tested by experiment. The most important factor in determining the 
accuracy of a homology model is identifying the closest template structure and 
obtaining the most optimal sequence alignment between that structure and the 
template sequence. The accuracy of methods of structure prediction is measured 
every two years by the Critical Assessment of Structure Prediction (CASP) 
experiment. The second CASP experiment in 1996 (CASP2) suggested that as 
sequence identity between target and template protein drops below 40%, the model 
quality fails rapidly (Martin et al., 1997). This is largely because of the difficulty in 
identifying the optimal sequence alignment and identifying structurally conserved 
regions. However, with protein sequences where there are many possible template 
structures and regular conserved secondary structures and/or conserved disulphide 
bridges, it is possible to obtain reliable results with lower sequence identities.
The number of residues that need to be inserted and/or deleted in the model 
also affects the quality of the model, and the alignment and template sequence with 
the minimum amount of change to the parent structure should always be chosen. 
Within a homology model, the peptide backbone of the structurally conserved 
regions should be well predicted. The least accurate regions of the model will be the 
insertions and deletions within structurally variable regions since they have not been 
built directly from the template structure. Similarly since side chain rotamers may 
have changed from the model, side chain interactions within homology models 
should be analysed with caution. The quality of a model can be assessed using 
structural analysis methods described in Section 3.7.
Although there are limits to the accuracy of homology modelling, it still 
remains a useful technique to build a model structure without expensive and time 
consuming techniques such as NMR and X-ray crystallography. A homology model 
can often help in the interpretation of biochemical and mutagenesis experiments, the 
analysis of functional properties and the understanding of ligand and substrate 
binding (Greer, 1990).
3.7 Structural Analysis Tools
PROCHECK (Laskowski et al., 1993) is a suite of programs that can assess a 
PDB atomic coordinate file using stereochemical parameters derived from high- 
resolution X-ray crystal protein structures. It can also assess bond lengths and bond 
angles against values derived from a comprehensive analysis of small-molecule
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structures. The output of PROCHECK details the stereochemical quality of the 
model based on properties of individual residues, including Ramachandran plots of 
the mainchain torsion angles (Section 1.3.1). I have routinely used PROCHECK to 
validate the homology models discussed in this thesis.
Determination of the secondary structure of a modelled protein is useful 
when comparing the core structure of one protein with the core structure of another 
protein. This is useful not only in homology modelling alignments of reference 
template structures, but also in structural classification. It is important to have 
stringent definitions of secondary structures in order to identify significant conserved 
and divergent features between homologous strands and loops within domains. 
DSSP (Dictionary of Secondary Structure of Proteins) is a structural analysis 
program that classifies the secondary structure elements of a protein structure 
(Kabsch and Sander, 1983). In order to classify secondary structure, DSSP analyses 
the pattern of hydrogen bonds within the structure, the inter-Ca distances and torsion 
angles and the solvent exposure of residues and classifies each residue into one of 
eight conformational states, defined by the letters T,G,H,I,B,E,S and C. These eight 
states are defined by analysing hydrogen bonding pairs between residue i and i+1 (n- 
tums) and between residues that are not near in sequence (bridges). An isolated n- 
tum is defined as a turn (T). Two or more consecutive «-tums are defined as helices 
where n=3 represent a 3io-helix (G), n=4 represent a a-helix (H) and n=5 represent a 
7t-helix (I). Two residues that form an isolated bridge represent a (3-bridge (B), 
whereas consecutive bridges of identical type form extended P-strands (E). DSSP 
also recognises regions of high mainchain curvature known as bends (S) and 
unclassified regions are termed coil (C). DSSP has been frequently used within this 
thesis to determine the secondary structure of both X-ray and NMR structures as 
well as homology models.
The structure of a globular protein contains a hydrophobic core and a polar, 
hydrophilic surface. The term ‘accessible surface area’ is used to define the exterior 
of a protein that is in contact with solvent. The surface accessibility of a residue can 
be used to suggest whether the residue is buried or surface exposed and can be useful 
for structure validation as well as mutation and ligand binding analysis. The 
accessible surface area is calculated as the surface that is traced by the centre of a 
probe molecule as it moves over the protein making van der Waals contact (Lee and 
Richards, 1971). The sphere of radius 1.4 A is commonly used because its
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dimensions are approximate to that of a free water molecule. The relative 
accessibility of a residue is calculated as a percentage of the residue solvent 
accessibility compared to the value for maximal accessibility for that residue type. 
This is output as a value of 0-9, where 0 corresponds to 0-9% accessibility, 1 
corresponds to 10-19% accessibility, and so on. Buried residues have accessibilities 
of 0 or 1. Wherever solvent accessibilities are reported in this thesis they represent 
the relative accessibility output from either DSSP (Kabsch and Sander, 1983) or 
NACCESS (Hubbard and Thornton, 1993), where both programs are 
implementations of the Lee and Richards algorithm (Lee and Richards, 1971).
The Root Mean Square Deviation (RMSD) is the conventional measure to 
say how similar one structure is to another. If structures are superimposed, the 
RMSD can be calculated as the square root of the average squared distance between 
equivalent atoms, defined by the equation:
The RMSD is frequently used within programs where structures are compared, but it 
does have a number of problems when used to measure homology modelling 
accuracy. For example, a few poorly placed atoms within a modelled loop can 
increase the RMSD and mask the fact that the majority of atoms are aligned 
extremely well. The RMSD can be calculated from a least-squares fit 
superimposition of structures, where structures are rotated in order to find a rotation 
and translation where the two sets of 3D coordinates have the lowest RMSD. Within 
MODELLER, this is computed using the Ca atoms of the structure backbone.
3.8 Domain Classification
There are a number of resources available that classify protein structures 
according to evolutionary relationships. This has helped the functional annotation of 
many protein sequences, since proteins that are evolutionary related often inherit the 
same or similar functions. Protein family databases also provide tools to analyse 
large datasets of proteins from genomic and proteomic studies. Within homology
RMSD
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modelling, protein structure classification is useful if the target sequence of the 
unknown structure shares a family with proteins of known structure.
The earliest form of protein family classification focused on protein sequence 
comparison in order to detect evolutionary relatives. Protein motifs represent small, 
highly conserved stretches of continuous sequence, which may be associated with a 
particular structure or biological function. Sequences can be searched for these 
motifs and classified accordingly. Other classification systems use clustering 
methods to identify groups of related sequences or domains. Table 3.2 describes 
some of the current major sequence protein family databases.
Analysis of protein structural families has shown that protein structure 
appears to be more conserved than sequence (Chothia and Lesk, 1986). Despite the 
utility of sequence comparisons in classifying proteins into families, remote 
homologues (<30% identity) can only be accurately identified by protein structure 
comparison (Todd et al., 2001). With the growth in protein structures it is now 
possible to cluster evolutionary relatives into families based on structural 
comparison. This has given rise to various protein structure classification databases 
such as CATH (Orengo et al., 1997) and SCOP (Murzin et al., 1995) which rely on 
both expert classification and automatic structural comparison methods (Table 3.2).
Structural data can not only aid the recognition of remote homologues but 
also help determine the domain composition of a protein. It can sometimes be 
difficult to recognise individual domains from sequence alone and it is often more 
useful to use protein structures to assign domain start and end boundaries. Within the 
structure it is clear that there are more contacts between residues within a domain 
than those between residues in different domains, and domain cores may be 
represented by hydrophobic clusters.
3.9 Mutation Analysis
Section 1.8 discusses the effect of mutations within protein sequences. Not 
only are mutations important for evolutionary analysis, they also have important 
implications in human diseases. For this reason, a number of resources exist for the 
analysis of mutations within proteins and genes. The HGVS (Human Genome 
Variation Society) promotes the collection, documentation and free distribution of 
genomic variation information and associated clinical variations. The Human Gene 
Mutation Database (HGMD) represents an attempt to collate known (published) gene
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lesions responsible for human inherited disease (Stenson et al., 2003). For the 
HGMD, data are collected weekly by a combination of manual and computerised 
search procedures of journals reporting mutations. In order to keep data as accurate 
as possible mutations described in abstracts or unpublished form are not included in 
HGMD. For these reasons, the HGMD entry for a specific protein may not represent 
the true data known for mutations within that protein. OMIM (Online Mendelian 
Inheritance in Man) is probably the most widely used resource for obtaining 
information on human genes and genetic diseases (Hamosh et al., 2005). Each 
OMIM entry has a full-text summary of a genetically determined phenotype and/or 
gene and has numerous links to other genetic databases such as DNA and protein 
sequence databases, PubMed references and patient support groups. It is based on the 
book, Mendelian Inheritance in Man that is authored and edited by Dr. Victor A. 
McKusick and a team of science writers and editors at Johns Hopkins University, 
and has been published in 12 versions since 1966 (McKusick, 1998). The online 
version is updated daily.
dbSNP was launched in September 1998 and unlike HGMD and OMIM it 
does not focus on known disease causing mutations (Sherry et al., 1999). dbSNP 
aims to record all sources of variation within the human genome, including SNPs, 
micro satellite repeats and small insertions and deletions of nucleotides. It is useful 
to have information on SNPs in order to identify associations between a disease and 
SNPs in a population. In a similar way to dbSNP, HGVbase records information on 
sources of human genome variation (Fredman et al., 2002). HGVbase however, 
represents a non-redundant, fully annotated data set of human genome variation. The 
primary purpose of HGVbase is to facilitate genotype-phenotype association 
analyses that explore how SNPs and other common sequence variations may 
influence phenotypes such as common disease risk and drug response differences.
In recent years improvements in the techniques used for large scale 
identification of SNPs have brought a new challenge in understanding how and when 
SNPs cause disease in order to identify possible candidates for disease-association 
study. Protein sequence information and evolutionary sequence conservation can be 
powerful indicators of which mutations are likely to cause to disease. Protein 
structural and functional information can also explain how different phenotypes can 
originate from the same gene. Structural analysis of mutation data can also help
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determine residues that are crucial for specific interactions or for the formation of the 
native protein structure.
One of the first large scale analysis of genetic variation in terms of structural 
biology analysed SNP data in order to define the specific characteristics of disease 
associated mutations (Wang and Moult, 2001). Using a test set of 262 missense 
mutations within 23 proteins that are associated with disease, a model was generated 
to analyse and predict the functional affects of residue substitutions. A 2003 review 
by Steward et al. analysed the residue substitutions of missense mutations found 
within OMIM (McKusick, 2000) together with non-disease associated SNPs from 
dbSNP (http://www.ncbi.nlm.nih.gov/SNP). Interestingly arginine is the most 
commonly mutated residue in both datasets whereas glycine is the second most 
common substituted residue in the disease associated set, whereas it appears in a 
similar proportion to other residues in the dbSNP dataset.
Several specialist web servers have been developed in order to interpret the 
huge amounts of genetic variation within central databases such as dbSNP. MutDB 
provides specialist tools in order to understand the effect of amino acid substitutions 
within protein structures and is linked to dbSNP, SwissProt and PDB (Dantzer et al., 
2005). The Polyphen web server predicts the possible impact of an amino acid 
substitution on the structure and function of a human protein using a rule-based 
method considering the physical properties of protein structures and amino acid 
substitutions (Sunyaev et al., 2001). The method predicted that 10-30% of the test 
data set of SNPs that were known to cause disease phenotypes did not damage 
protein structure or function, giving an estimated false positive rate of only 9% 
(Sunyaev et al., 2001). In another automated analysis of mutations, 882 distinct non- 
synonymous SNPs within the tumour suppressor gene p53 were analysed (Martin et 
al., 2002). The study used simple assessments of the effects of residue changes 
within the p53 structure, specifically analysing the hydrogen bonds within residue 
substitutions, the steric acceptability of substitutions, whether mutations substituted 
residues to proline sidechains or from glycine sidechains and whether the mutation 
affected DNA or zinc binding. Using this analysis, only 34% of 882 mutations 
within p53 could be explained in structural terms by their predicted effects on 
protein folding or interaction. When sequence conservation was considered, the 
proportion of explained mutations increased to 57%. This highlights the difficulties 
in designing automated methods to predict the outcome of amino acid substitutions.
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It is often useful to consider protein specific factors, such as functional activity or 
stability. For example, in the case of p53 that is only marginally stable at body 
temperature (Nikolova et al., 2000), a slight structural alteration may be significant 
to destabilise the structure, whereas a protein that is more stable may be able to 
incorporate larger structural rearrangements.
Although central databases focusing on all mutations within the human 
genome are useful, they may not represent a full up to date view of what is known 
for a specific gene or disease of interest. For fields of research that focus on a disease 
or set of specific genes it is useful to have databases that are specifically designed 
with that research topic in mind. Locus-Specific Databases (LSDBs) focus on 
mutations within a gene or a set of genes of interest. For example it may be useful to 
see both published and unpublished data and patient information such as age or 
ethnic background. There are over 500 LSDBs available on the internet covering a 
wide range of genes and disease. Not only do the LSDBs differ in the genes and 
diseases they discuss, they also vary in format, with most just containing simple 
tables of mutation data that can be downloaded but not searched (Claustres et al.,
2002). There have been several reviews of LSDBs giving recommendations to 
database curators (Scriver et al., 1999; Claustres et al., 2002). These 
recommendations focus on making databases as compatible as possible with each 
other and other central mutation resources. Several generic software programs such 
as UMD (Beroud et al., 2000), MutStar (Brown and McKie, 2000) and LOVD 
(Fokkema et al., 2005) have been designed to aid the development of LSDBs without 
database and web design knowledge. These programs are useful because they store 
data in a consistent manner that can be linked to other databases. However, because 
they are generic tools they lack functionality specific to individual fields of study.
The major problem with LSDBs is the curation needed to keep the databases 
up to date. Initially creation of a database can be exciting and gratifying in terms of 
publications and collaborations, but keeping the database up to date is time 
consuming and less stimulating. A recent study of 138 LSDBs found that 40 had not 
been updated since the year 2000, and another 44 had not been updated between 
2001 and 2003 (Soussi et al., 2006). Financial issues are a major factor in 
maintaining the database and several databases such as the Asthma and Allergy gene 
database have had to close due to lack of funding (Merali and Giles, 2005).
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Table 3.3 lists some of the coagulation protein mutation databases already 
available on the world wide web. These databases provide information on mutations 
from published articles and also collaborating groups. The haemophilia A database, 
established at the Medical Research Council (MRC) clinical sciences research centre 
of the Hammersmith Hospital, London stores information on 943 FVIII mutations. It 
provides downloadable tables of mutations within various categories and summary 
tables describing the distribution of mutations within the FVIII gene (F8). There is 
no user defined search facility and the overview table was last updated in October 
2003. The FVII mutation database was also established at the MRC clinical sciences 
research centre. Within this database, the user can search for mutations by codon 
number, nucleotide number or clinical phenotype (asymptomatic, unknown, mild, 
moderate or severe). A reference list and table of all mutations is also provided in 
HTML format. The haemophilia B database at Kings College London provides 
tabular views of point mutations and short additions and deletions in the FIX gene. 
These tables are split to cover specific ranges of nucleotides. There is a reference list 
but no user defined search facility. The VWF mutation database at Sheffield 
University, UK provides tabular views of VWF mutations, as well as a reference list. 
There is a user defined search facility, where users can search by amino acid number, 
nucleotide number, exon number, VWF mutation classification or by submission 
data. None of these four databases provides structural analysis of mutations or 
statistics to allow the user to view each mutation in context.
3.10 Molecular Visualisation Tools
Molecular visualization provides interactive 3D views of molecules such as 
proteins. Atoms can be rendered and viewed in a variety of ways allowing the user to 
understand the atomic structure of the molecule. Proteins can be displayed as cartoon 
secondary structures or backbone atoms, as well as full atomic structures.
There are several programs that exist for molecular graphics visualization for 
the depiction and exploration of biological macromolecule structures, such as those 
found in the PDB. RasMol (Sayle and Milner-White, 1995) is an open source 
program that was created in 1992 and is still an important tool for molecular 
biologists. Before RasMol, visualization software could only run on expensive, rare 
graphics workstations. RasMol is open source and works on both Microsoft 
Windows and UNIX based operating systems.
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Table 3.3 Coagulation disorders mutation databases
Database
H aem ophilia A  
D atab ase
Url
http://europium .csc.m rc.ac.uk/W ebPages/M ain/m ain .htm
FVII Mutation 
D atab ase
h ttp ://193 .60 .222 .13 /
H aem ophilia B 
D atab ase
http://w w w .kcl.ac.uk/ip /petergreen/haem B database.htm l
VWF Mutation 
D atab ase
http://w w w .vw f.group.shef.ac.uk/
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For these reasons RasMol is the most popular molecular graphics program. JMol is 
also a free open source molecular graphics program that is similar to RasMol and 
incorporates RasMol scripting (http://www.jmol.org). It is written in Java and runs 
on Microsoft Windows, Apple Macintosh, Linux and UNIX systems. As well as a 
standalone application and a development tool kit that can be integrated into other 
Java applications, JMol also exists as a web applet that can be integrated into web 
pages to display molecules in a variety of ways. JMol is incorporated into web pages 
using JavaScript, with JavaScript controls that allow RasMol scripting. Molscript 
(Kraulis, 1991) together with Raster3D (Merritt and Murphy, 1994) can be used in 
order to produce high quality, detailed schematic molecular graphics images from 
molecular 3D coordinates.
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Chapter 4
Factor XI Deficiency Mutation Database
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4.1 Introduction
Factor XI (FXI) is the inactive precursor (zymogen) of a plasma serine 
protease in the intrinsic pathway of blood coagulation involved in the augmentation 
of thrombin production (Section 2.4). The FXI gene (FI 1; OMIM# 264900) is 23kb 
long and contains 15 exons and 14 introns that encode an 18-amino acid signal 
peptide and a 607-amino acid mature protein (Asakai et al., 1987). Activation 
involves the cleavage of FXI at Arg369-Ile370 to give an N-terminal heavy chain 
containing four Apple (Apl-Ap4) domains of ~80 residues each and a C-terminal 
light chain containing the serine protease (SP) domain (Figure 4.1). The Ap domains 
within FXI show sequence homology with each other and with the Ap domains of 
prekallikrein (PK) (Fujikawa et al., 1986). These Ap domains are part of a larger 
domain superfamily known as the PAN module superfamily (Brown et al., 2001). 
FXI circulates as a dimer, with two monomers linked by non-covalent interactions 
between the Ap4 domains and by a Cys321-Cys321 disulphide bond (McMullen et 
al., 1991; Dorfman and Walsh 2001; Cheng et al., 2003).
FXI is the only contact factor to play a role in physiological coagulation, as 
evidenced by the fact that deficiencies of FXII, PK and HK do not result in clinical 
bleeding. In contrast, mutations within FI 1 are associated with a variable bleeding 
disorder known as FXI deficiency, also known as Haemophilia C, plasma 
thromboplasmin antecedent (PTA) deficiency or Rosenthal’s syndrome. FXI 
deficiency is a rare bleeding disorder seen in general populations at a frequency of 1 
in a million, although this figure may be higher since deficiencies are only revealed 
after an initiating event or trauma. The condition is more common in distinct 
populations such as persons of Ashkenazi Jewish descent who have a heterozygote 
frequency of 9% and a homozygote frequency of 0.22% (Shpilberg et al., 1995).
Normal levels of FXI coagulant activity (FXI:C) range from 70 to 150 u/dl. 
Individuals who are heterozygous for a causative mutation within FI 1 have FXI:C 
levels of 20-70 u/dl and are termed partially deficient. Individuals who are 
homozygous or compound heterozygous for a causative FI 1 mutation possess levels 
of <1-20 u/dl and are termed severely deficient. The level of FXI in patient plasma 
(FXI:Ag) is measured by enzyme-linked immunosorbent assay and is most often 
seen at half normal levels in heterozygous patients, and low levels within 
homozygous patients.
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Figure 4.1 Domain structure of FXI
The five domains of FXI are shown where the zigzagged line represents the 
activation cleavage site between Arg369 and Ile370. The N and C termini of FXI are 
labeled N and C respectively. Domains are not drawn to scale.
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FXI deficiency shows variable injury-related bleeding in most severely deficient and 
in 50% of partially deficient individuals (Fujikawa et al., 1986).
Bleeding symptoms generally arise after trauma or surgery and spontaneous 
bleeding is not typical. In females, heavy menstrual bleeding and bleeding after 
pregnancy are particular features. Surgical procedures on areas of high intrinsic 
fibrinolytic activity such as the oral and nasal cavities, prostate and uterus are 
associated with increased rates of post-operative haemorrhage (Bolton-Maggs et al.,
1995). It does not seem possible to predict in advance which patients are likely to 
bleed, since not all severely deficient patients bleed excessively after surgery and a 
proportion of partially deficient patients bleed.
FXI deficiency can be treated by antifibrinolytic agents and FXI replacement 
(Bolton-Maggs, 1998). Antifibrinolytic agents have also been effective during 
surgery in areas of high fibrinolytic activity such as the mouth (Bolton-Maggs,
1998). Transexamic acid is the most frequently used agent and has the advantage that 
it can be given orally as a tablet or mouthwash, and has been used successfully 
together with fibrin glue in dental extractions (Rakocz et al 1993). FXI replacement 
is achieved by the use of fresh frozen plasma (FFP) or FXI concentrate. The 
disadvantages of using FFP are the large volume required, allergic reactions and the 
potential of infection (Bolton-Maggs, 1998).
Until recently FXI inhibitors were not considered to be of major clinical 
importance. However, a 2003 study implied that patients with low levels of FXI are 
susceptible to developing an inhibitor following plasma replacement (Salomon et al.,
2003). This implies it is important to screen patients for inhibitors before treatment 
with plasma derived products (Bolton-Maggs, 1998).
FXI deficiency is most commonly associated with four well defined 
mutations within Jewish populations, named Jewish mutations Types I-IV (Asakai et 
al., 1989; Peretz et al., 1996). The Type II mutation (Glull7X) is the most common 
mutation in Jewish FXI deficient patients. The Type III mutation (Phe283Leu) is 
also frequently seen. The Type I (a G to A transition at the donor splice site of intron 
N) and Type IV (a 14bp deletion at the exon 14/intron N splice site) both affect 
splicing of the catalytic SP domain of FXI. There are numerous other mutations 
found in more general populations. Although this nomenclature is frequently used
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when describing Jewish mutations, it should not be confused with the phenotypic 
classification of Type I and Type II mutations (Section 1.8.4).
Recently there has been an increase of reports of F l l  mutations associated 
with FXI deficiency. In order to investigate phenotype and genotype relationships 
between F l l  mutations, a database of all reported F l l  mutations was compiled for 
this thesis. Until now analyses of all known information on FXI deficiency and F ll  
mutations have not been studied. Unlike most other coagulation mutation databases 
that consist only of tabulations of known mutations, this database is designed to be 
dynamic and interactive. This new database integrates both the phenotypic and 
genetic data together with the first structural analysis of F l l  mutations. 
Experimental study of the mutant protein in a mammalian expression system is the 
gold standard for the interpretation of mutations to distinguish between disease- 
causing ones or neutral polymorphisms. However, this information is not available 
for all mutations. For many other coagulation proteins, three-dimensional structural 
models have been used in order to predict the impact of a given point mutation on 
the protein structure and its consequence for disease (Nitu-Whalley et al., 2000; 
Peyvandi et al., 2002). Up until now, this structural analysis has not been performed 
for FXI mutations.
The new database described for this thesis is available on the World Wide 
Web at the following address: (http://www.FactorXI.org). The database not only 
provides a central repository for all reported genetic alterations within F l l , it also 
allows new mutations to be analyzed. Unlike mutations associated with other 
coagulation disorders, disease associated mutations within F l l  can now be 
interpreted in the context of what is already known about the structure of FXI and in 
the context of what is known about other F l l  mutations. The interactive design of 
the database permits a more comprehensive comparative understanding of the 
genetic factors that influence FXI deficiency. Analysis of these genetic factors may 
provide insight into the activity of FXI, providing information for the design of 
therapeutic and diagnostic techniques. This work has also highlighted the need for a 
more unified approach to reporting FXI deficiency patients and mutations.
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4.2 Methods
4.2.1 FXI Structural Information
Until the first report of an experimental FXI structure in 2006 (Papagrigoriou 
et al., 2006), my homology modelling provided the only structural information on 
FXI domains (O’Connell et al., 2005, Saunders et al., 2005). This homology 
modelling is now described.
4.2.1.1 Template finding
There are four Ap domains and one SP domain within FXI (Figure 4.1). 
Suitable template protein structures for modelling the FXI Ap domains were 
obtained from PSI-BLAST (Altschul et al.,1998) searches of the PDB using the 
PredictProtein server (http://cubic.bioc.columbia.edu/predictprotein/). The Interpro 
database (Mulder et al., 2005) was also used to identify sequences belonging to the 
PAN-module superfamily (Tordai et al., 1999). Suitable templates for the SP domain 
were identified using BLAST (Altschul et al., 1998) to search the PDB.
4.2.1.2 Sequence Alignment
The template Ap structures obtained were as follows (Figure 4.2): the E. Tenella 
adhesin protein (PDB code: 1HKY), the anti-platelet toxin from H. officinalis (PDB 
code: 1I8N) and the N-terminal domains of human hepatocyte growth factor (PDB 
code: 2HGF). The sequences identified by Interpro and obtained from SwissProt 
were as follows: rat (HGF_RAT), mouse (HGF_MOUSE) and Xenopus
(HGF_XENOPUS) hepatocyte growth factor, the N-terminal domains of mouse 
(PLMN MOUSE), bovine (PLMN_BOVIN), macaque (PLMN MACMU) and 
human (PLMN_HUMAN) plasminogen, and the Ap domains of mouse 
(KALMOU SE 1 -4), rat (KAL_RATl-4) and human (KAL_HUMAN 1 -4) 
prekallikrein. For completeness, two hypothetical nematode proteins with the same 
conserved pattern of Ap cysteine residues were also included (YMP9_CAEEL, 
YSM5_CAEEL.l), as well as other PAN modules such as Microneme Antigen 
precursor (MIA_SARMU) and a rat macrophage stimulating protein precursor 
(MSP_RAT).
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Figure 4.2 Multiple sequence alignment of the Ap and PAN domain superfamily
(a) The sequences of Ap domain structural templates and the four FXI Ap 
domains are shown. The secondary structures of the three known structures (PDB 
Codes: 1HKY, 2HGF and 1I8N) are highlighted in boxes, assigned using DSSP. The 
p-strands are denoted PA-PG in the order they occur in the sequence, whereas the a- 
helix is denoted A l. Conserved cysteine residues are highlighted in black and 
labelled Cl to C6 underneath the alignment. The disulphide bridge connectivity is 
denoted as C1-C6, C2-C5 and C3-C4. Sequences are numbered with respect to 
FXI_AP1, with the linker sequences of each Ap domain added for completeness.
(b) The consensus secondary structure prediction for Apl is shown, where E 
denotes p-strand, H denotes helix and C denotes coil.
(c) The Ap and PAN sequences are shown to highlight sequence conservation 
throughout this domain family. The sequence codes are defined in Section 4.2.1.2.
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DSSP secondary structure assignments of the three template structures were included 
into the sequence alignment in order to correctly assign sequence gaps to the loop 
regions, and to conserve the location of the cysteine residues. Since the Ap domains 
of FXI were previously undefined, the secondary structure of the Apl sequence was 
predicted using the consensus result of five methods, namely GORIII (Gamier et al.,
1996), PHD (Rost et al., 1993), Jpred (Cuff et a l, 1998), PSI-PRED (McGuffin et 
al., 2000) and SAM T-99 (Karplus et al., 1997; 1999; 2004).
The template SP domain structures were identified with BLAST. A total of 
84 unique SP proteins were present in the top 500 BLAST results. These 84 unique 
matches were analysed with CLUSTALW to identify five close homologues using a 
guide tree (Figure 4.3). These five sequences were human a-thrombin (PDB code: 
1H8I), human protein C (PDB code: 1AUT), human complement C lr (PDB code: 
1GPZ), boar sperm P-acrosin (PDB code: 1FIZ) and human mast cell P-tryptase 
(PDB code: 1AOL).
Homology models of the Apl to Ap4 and SP domains were constructed using 
INSIGHT II HOMOLOGY (Accelrys, San Diego, CA), Discover and Biopolymer 
modules and the structural refinement program O (Jones et al., 1991) on Silicon 
Graphics workstations (Section 3.6.1). The HOMOLOGY module was used to 
structurally align the five structural templates for the SP domain (Figure 4.4). The 
FXI SP domain was then added to this alignment manually.
4.2.1.3 Model building
The Ap domain models were built from their closest structural template in 
terms of insertions and deletions, the E. Tenella adhesin protein (PDB code: 1HKY). 
The SP domain model was built from the closest template a-thrombin (PDB code: 
1A0L). The structure verification program PROCHECK (Laskowski et al., 1993) 
and O were used alongside the energy minimisation program of the Discover module 
and the structure idealisation program REFMAC5 of CCP4i (Murshudov et al.,
1997) in order to improve the connectivity, check bond angles and lengths and 
reduce the number of bad contacts within the five domain models.
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1 EKB_B Enteropeptidase
1 EZW_A Suppressor ofTumorgenicity 14
1QRZ_A Plasminogen
1 BUI_A Plasmin
1BML_A Plasmin
1 PYT_D Chymotrypsinogen C
1 BRU_P Elsastase
1 FON_A Procarboxypeptidase A-56 
1 BOE_A Elastase 
1 Cl M_A Porcine Elastase 
1ELT Elastase
1 M9U_A Earthworm Fibrinolytic Enzym
1 EQ9_A Chymotrypsin
1 A0L_A B-Trypsin
1 FIZ_A B-Acrosin
FXI SERINE PROTEASE
1 AUT_C Activated Protein C
1H8LH Thrombin
1 GPZ_A Complement Cl R
1 A5H_ATissue Plasminogen Activator
1 A5I_ATissue Plasminogen Activator
1 LMW_B Urokinase-Type Plasminogen Activator
Figure 4.3 CLUSTALW guide tree analysis of sequence similarity between SP 
domain structures
A sub-tree of 22 SP sequences taken from the analysis of 86 unique SP domain 
structures is shown to indicate those domains that are most similar to FXI SP domain 
in terms of sequence analysis. Those eight structures that are most similar to FXI SP 
domain are highlighted in a grey box and red text. SP domains are identified by their 
PDB codes.
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Figure 4.4 Structural alignment of the sequences of the five closest matches to 
the SP domain of factor XI
The sequences are labeled as follows: Throm, human thrombin; Prot_C, 
human Protein C; C1R, human complement C lr; B_Acro, human p-acrosin; B_Tryp, 
human p-tryptase; fXI_SP, human Factor XI. The seven most conserved cysteine 
residues and three catalytic residues (His413, Asp462, and Ser557) are highlighted in 
black. Areas of secondary structure were assigned using DSSP and highlighted in 
grey boxes. The 14 conserved P-strands are labeled from A to O and the three a- 
helices from Al to A3. The four insertions and deletions between FXI SP and its 
closest template p-tryptase are shown in red dashed boxes. Sequences are numbered 
relative to FXI.
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4.2.1.4 Experimental Structures of FXI
Within the last two years, and after the homology modelling was performed 
(O’Connell et al., 2005), several X-ray crystal structures have been reported for both 
the inactive zymogen and active serine protease of FXI (Table 4.1). These structures 
will provide a more accurate analysis of mutations.
Within the database and mutation analysis, the secondary structure of both 
the Ap and SP domains is allocated a specific nomenclature in order to define the 
structural position of mutations. This nomenclature labels the P-strands of each 
domain alphabetically in the order that they occur within the sequence. Similarly the 
a-helices and 3io-helices within the domains are labelled in the order they occur, 
where the first a-helix is denoted Al and the second A2 and so on and the first 3io- 
helix is denoted G l, and the second G2 and so on (Figure 4.2 and Figure 4.4). Using 
this nomenclature the Ap domains can be described as a five stranded P-sheet 
structure formed by P-strands pC, PE, PD, PG and PA that is sandwiched between an 
a-helix (Al) on one surface and a two stranded P-sheet formed by P-strands PB and 
PF on the other surface. The six conserved cysteine residues of the Ap domains form 
three disulphide bonds. In order to describe disulphide bonds, cysteines are 
numbered from Cl to C6 in the order they occur in the sequence. Using this 
nomenclature the disulphide bridges can be denoted as C1-C6, C2-C5 and C3-C4 
(Figure 4.2). The 14 p-strands within the SP domain are also named in a similar way 
(PA to PO) as well as the helices (A1-A3).
4.2.2 Identification of Mutations
Mutations within F l l  that cause FXI deficiency were identified by searching 
the Human Gene Mutation database
(http://archive.uwcm.ac.uk/uwcm/mg/hgmdO.html). Additional mutations were 
identified by searching the literature database PubMed 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) using the following 
search expressions: factor XI, FXI, F ll  deficiency, plasma thromboplastin 
antecedent, PTA deficiency, Rosenthal’s syndrome.
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Table 4.1 X-ray crystallographic data on FXI domains
PDB
File Domain[ Description Resolutioni Reference
1XX9 SP Complex with Ecotin M84 R 2.2 A Jin et al., 2005a
1XXD SP Complex with mutated Ecotin 2.91 A Jin et al., 2005a
1XXF SP Complex with Ecotin Mutant 2.6 A Jin et al., 2005a
1ZHM SP Complex with Benzamidine (S434A- 1.96 A Jin et al., 2005bT475A-K4 37 Mutant)
1ZHP SP Complex with Benzamidine (S434A- 2.7 A Jin et al., 2005bT475A-K505 Mutant)
1ZHR SP Complex with Benzamidine (S434A- 1.73 A Jin et al., 2005bT475A-C482S-K 437A Mutant)
1ZJD SP Complex with Kunitz Protease Inhibitor 2.6 A Navaneetham et al.,Domain of Protease Nexin II 2005
1ZLR SP Complex with boronic acid 2.5 A Lazarova et al., 2006
1ZMJ SP Complex with boronic acid 2 A Lazarova et al., 2006
1ZML SP Complex with boronic acid 2.25 A Lazarova et al., 2006
1ZMN SP Complex with boronic acid 2.05 A Lazarova et al., 2006
1ZOM SP Complex with a peptidomimetic Inhibitor 2.25 A Unpublished
1ZPB SP Complex with inhibitor with alpha- ketothiazole arginine 2.1 A Deng et al., 2006
1ZPC SP Complex with inhibitor with alpha- ketothiazole arginine 2.6 A Deng et al., 2006
1ZPZ SP Complex with a peptidomimetic Inhibitor 2.5 A Unpublished
1ZRK SP Complex with Naphthamidine inhibitor 2.3 A Unpublished
1ZSJ SP Complex with Naphthamidine inhibitor 1.9 A Unpublished
1ZSK SP Complex with Naphthamidine inhibitor 1.9 A Unpublished
1ZSL SP Factor XI complexed with a pyrimidinone 2.05 A Nagafuji et al.,inhibitor Unpublished Work
1ZTJ SP Factor XI complexed with a pyrimidinone 2.05 A Nagafuji et al.,inhibitor Unpublished Work
1ZTK SP Factor XI complexed with a pyrimidinone 2.5 A Nagafuji et al.,inhibitor Unpublished Work
1ZTL SP Factor XI complexed with a pyrimidinone 2.6 A Nagafuji et al.,inhibitor Unpublished Work
2FDA SP Complex with inhibitor with alpha- ketothiazole arginine 2 A Deng et al., 2006
2F83 ALL Intact dimeric coagulation factor XI 2.87 A Papagrigoriou et al.,2006
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Other mutations were identified by manual and automatic searches of abstracts from 
the annual meetings of the following societies: ISTH (International Society on 
Thrombosis and Haemostasis), BSH (British Society for Haematology), ASH 
(American Society of Hematology), European Haematology Association and GTH 
(German Society of Thrombosis and Haemostasis).
Reported mutations within F ll  are most frequently numbered with respect to 
the mature protein, where codon 1 represents the first amino acid after the signal 
peptide. This is in contrast to HGVS guidelines (http://www.hgvs.org/mutnomen/), 
where codon 1 represents the first amino acid from the initiation of translation codon 
ATG. In order to be consistent with the literature of FXI deficiency, mutations 
within this chapter are discussed using the mature protein numbering corresponding 
to the PDB file 2F83 and the Refseq sequence file #NM_000128.2.
4.2.3 Phenotypic Classification of Mutations
For the mutations that had been published in sufficient detail, phenotypic data 
was included in the database, namely FXI:C in most cases, and FXI:Ag and/or 
bleeding phenotype in some cases.
Phenotypic classification is useful to identify whether a patient suffers from a 
Type I quantitative or Type II qualitative disorder (Section 1.8.4 and Section 2.8). 
With FXI deficiency, Type I mutations are identified in heterozygous patients with 
half normal levels of FXI:Ag (~50 U/dl) and in homozygous patients with little or 
no FXI:Ag. Alternatively Type I mutations can be assigned when experimental 
studies indicate that FXI expression or secretion is reduced. Type II mutations are 
identified in patients with normal levels of FXI:Ag or can be assigned when 
experimental studies indicate normal expression and secretion. Difficulties arise in 
this phenotypic classification when heterozygous mutations have negative effects on 
wild type secretion by forming mutant-wild type heterodimers, or when the 
mutations are seen in compound heterozygous patients.
4.2.4 Database Design
The FXI deficiency database follows a relational database structure, 
implemented using MySQL. The database schema describing the relational tables is 
shown in Figure 4.5.
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mutation
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initRes 
mutRes 
domName 
mutType 
phenotype 
refState 
m utC om m ents 
codonKnown
patientlnfo
patID*
activity
antigen
genotype
classification
race
sex Age
bleeding
patCom m ents
ref
domain
dom Nam e*
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resolution
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templatePDB
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conserved Pos
reference
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title 
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Figure 4.5 FXI deficiency database schema
Each table within the relational database is shown in a box. The attributes of 
each table are listed. Those attributes followed by a * character are the primary keys 
of each table. The attributes that are highlighted in green text are foreign keys also 
used in other tables. The relationships between each table are indicated by black 
lines where three pronged lines represent 1 :N relationships and normal lines indicate 
1:1 relationships (Section 3.1.2).
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Every mutation is stored within the mutation table, where each record is 
identified by a unique identifier (mutID). The mutation table is linked to the 
patientMutation table that describes each patient and its associated mutation using 
the mutID data field. Each patient referenced in this table is identified with a unique 
identifier (patID), and if the patient has more than one mutation, more than one 
record is added for the same patID but a different mutID. The patientlnfo table 
describes information on the patient, and is linked to each mutation via the 
patientMutation table.
The protein sequence of FXI is stored within the FXIresidue table, with each 
record corresponding to a residue position, and detailing the amino acid, DSSP, 
position within the structure and accessibility score at that position of the sequence. 
This is linked to each missense mutation via the codon field, so information can be 
gained on the codon involved in any mutation. Residue properties are held in a small 
table, residuelnfo where each record corresponds to one of the twenty amino acids, 
and properties of that amino acid such as hydrophobicity and size are stored for 
analysis of missense mutations. Information on those residues within FXI that are 
associated with binding, dimerisation or catalytic activity is stored in the 
bindingRegion relation that can be accessed where the codon field of the mutation is 
within the start and the end range of the binding site record. This highlights whether 
the mutated residue is likely to be associated with any function.
Structural information is stored in the domain, pdbModel, homologyModel 
and missingResStructure tables. Each domain of FXI is assigned using the domain 
relation, and linked to the appropriate structure file within the pdbModel or 
homologyModel table. Those residues that are undefined within the crystal structure 
of FXI are detailed in the missingResStructure relation in order to present structural 
analysis of these residues in an appropriate manner.
Reference information is stored in the reference table. This provides 
information on those references quoted in the patientlnfo table, the model table and 
the bindingRegion table. The ref field for each reference entry provides the unique 
attribute and if this is included in the patientlnfo table, the model table or the 
bindingRegion table, reference information can be provided for each patient, model 
or binding region.
Finally the link table holds information on useful links associated with FXI 
deficiency. This link table does not contain any information held in any of the other
i l l
tables and is therefore a single entity that is not associated to any other data within 
the database.
The database is accessed using PHP and MySQL. PHP programming is used 
to dynamically create HTML output to display data from the database. The HTML 
code, together with CSS and JavaScript programming is used to display information 
and provide a dynamic user interface.
4.3 Results
4.3.1 Homology Modelling
A summary of the templates used for the homology modelling of FXI 
domains is shown in Table 4.2. The homology models of the FXI domains are shown 
in Figure 4.6.
The only structural homologues of the Ap domains available from 
experimental studies at the time of modelling were the ninth PAN module of an 
adhesin protein, EtMIC5, from the protozoa E. tenella (PDB code: 1HKY) (Brown et 
al., 2003), the N-domain of human hepatocyte growth factor (PDB code: 2HGF) 
(Zhou et al., 1998), and an anti-platelet toxin from H. officinalis (PDB code: 1I8N) 
(Huizanga et al., 2001). Even though these three structures shared low sequence 
identity of 8% to 13% with one another, and 11% to 22% sequence identity with the 
four Ap domains in FXI, they exhibit two or three conserved disulphide bridges and 
a conserved secondary structure consisting of a five-stranded P-sheet (P-strands C, E, 
D, G and A) flanked by a single a-helix on one surface and a distorted two-stranded 
P-sheet (P-strands B and F) on the other surface (Figure 4.6). The four Ap domains 
in FXI show 24% to 38% sequence identity with one another.
Although the cysteine residues Cl and C6 at the amino and carboxy termini 
of the FXI Ap domains are not conserved in all the Ap domain sequences, they are 
present in two of the structural templates, those of the E. Tenalla adhesion protein 
(PDB code: 1HKY) and the H. Officinalis anti-platelet toxin (PDB code:lI8N). The 
1HKY template had the highest sequence identity with the FXI Ap domains (15- 
22%), and modelling based on this template required only three insertions and no 
deletions, which is fewer compared with the other two structural templates.
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Table 4.2 Summary of homology modeling of FXI domains*
Domain TemplatePDBa Protein Insertions Deletions
Sequence
Identity
Apl 1HKY E. tenella adhesin 2,10,3 None 17%
Ap2 1HKY E. tenella adhesin 2, 9 ,4 None 22%
Ap3 1HKY E. tenella adhesin 2, 9 ,4 None 15%
Ap4 1HKY E. tenella adhesin 2, 9 ,4 None 22%
SP 1A0L P-tryptase 2,2 2,8 40%
*The numbers in the insertions and deletions columns indicate how many residues had to be inserted 
or deleted from the template structure in order to model the domain. More than one value separated by 
a comma indicates there are insertions or deletions at more than one place in the model. The sequence 
identity is a pairwise comparison of the sequence of the domain and the sequence of the template 
protein domain.
aThe PDB codes are as follows: 1HKY (Brown et al., 2003) and 1A0L (Pereira et al., 1998).
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,His4ir
Figure 4.6 Secondary structure cartoons of homology models of FXI domains
(3-strands are colored in green and helices are shown in red. The disulphide bridges 
within each domain are highlighted in yellow. The N and C termini are represented 
by N and C respectively.
(a) Apl Domain.
(b) Ap2 Domain.
(c) Ap3 Domain.
(d) Ap4 Domain.
(e) SP domain. The catalytic triad residues are shown in black.
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All four resulting Ap models shared a short two-residue insertion at Phel2- 
Glul3 (Apl), Metl02-Lysl03 (Ap2), Phel92-Alal93 (Ap3) and Phe283-Leu284 
(Ap4). The Apl model also has two insertions of ten residues (Ala45-Trp55) and 
three residues (Glu66-Leu68), whereas the Ap2, Ap3 and Ap4 models have an 
insertion of nine residues at Thrl33-Hisl43 (Ap2), Ser225-Gln233 (Ap3) and 
Pro316-Gly324 (Ap4) and another insertion of four residues at Glyl55-Thrl58 
(Ap2), Gly245-Ser248 (Ap3) and Gly336-Thr339 (Ap4). All three insertions were 
confined to loop regions in the 1HKY structure as desired for optimal modelling 
(Figure 4.2). The unpaired Cys321 sidechain is on the surface of the Ap4 domain as 
required in order that it can form the FXI dimer. The Cysll residue of Apl is also 
surface exposed and can form a disulphide bridge (McMullen et al., 1991). The 
putative N-glycosylation sites at Asn72 (Apl) and Asnl08 (Ap2) show varying 
degrees of solvent exposure, suggesting oligosaccharide chains can be attached. The 
four models all satisfy validation using PROCHECK.
In order to model SP domains in the coagulation proteases, classic SP 
domains such as those in chymotrypsin and trypsin have been used in previous 
studies (Schmidt et al., 2004). To improve the choice of an appropriate template, 84 
unique SP structures were identified in the PDB and five close templates were 
identified using CLUSTALW guide tree analysis (Figure 4.3). These five templates 
were used for the structural alignment with the SP domain of FXI (Figure 4.4). In 
this, the 14-stranded P-sheet secondary structure is well conserved as a double Greek 
key supersecondary motif. The closest template to the FXI SP domain in terms of 
insertions and deletions was 1A0L, this being the crystal structure of human p- 
tryptase (Pereira et al., 1998) with a high sequence identity of 40%. Interestingly, 
three of the remaining four templates corresponded to two other coagulation 
proteases (human a-thrombin and protein C) and one complement protease (human 
complement Clr). The model of the FXI SP domain built from the 1A0L template 
possessed a conserved core of 224 residues, with insertions and deletions only 
affecting 14 residues. These 14 residues corresponded to two small insertions at 
surface loop regions (Val418—Glu419 and Gly548-Gly549) and two-residue and 
eight-residue deletions at the surface loop regions between Asn512-Thr513 and 
between His534-Lys535 respectively. These changes corresponded to surface loops 
of the SP structure as desired. The putative N-glycosylation sites at Asn432 and 
Asn473 were both located on the opposite SP domain face to that of the catalytic
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triad, and either can be solvent exposed, suggesting that oligosaccharide chains can 
be attached. Glycosylation at both of these sites has been confirmed (Meijers et al., 
1992b), although within the recent crystal structure only one residue (Asn432) has a 
sugar attached (Papagrigoriou et al., 2006). The SP model was validated using 
PROCHECK.
4.3.2 Comparison of homology models with crystal structures
In the absence of a crystal structure, homology modelling was performed to 
analyse missense mutations (O’Connell et al., 2005). With the subsequent 
availability of an experimental structure for FXI, structural analysis of mutations can 
now be carried out using the crystal structure of FXI (PDB code: 2F83). The crystal 
structure is also more relevant since it presents the overall architecture of FXI and 
describes how domains form interdomain contacts. The accuracy of the analysis of 
mutations using homology models can be compared with the present analysis using 
the crystal structure of FXI.
The homology models of the Ap domains show good agreement with the 
crystal structure. The RMSD between the homology model and crystal structure 
calculated using a least-squares superposition of the Ca backbone atoms with 
MODELLER varies between 2.3 A  and 2.7 A . On a residue-by-residue basis using a 
three-state analysis (helix, strand or loop), DSSP shows that the homology and 
crystal secondary structures of the Ap domains (excluding linker regions that are not 
present in the homology structures) are in 72% agreement (Figure 4.7). The main 
differences between the model and the crystal structure are found in the length and 
position of the P-strands, where P-strands appear longer in the crystal structure. The 
presence of short three residue 3io-helices at the long loop insertion positions within 
the crystal structure also lowers the score. This may be a result of the rigid state of 
FXI within the crystal structure, compared to the NMR solution structure of the 
template adhesin protein (Brown et al., 2003) or the length of the long loop 
insertions (Figure 4.2). Although DSSP shows only 72% agreement, the five 
stranded p-sheet and a-helical arrangement has been correctly predicted in all four 
cases of the Ap homology models, and this is highlighted when the models and 
crystal structures are superimposed (Figure 4.8).
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Figure 4.7 DSSP and accessibility analysis of crystal and homology models 
(continued)
Crystal structures are identified by their PDB codes, whereas the models are 
represented by the ‘Mod’ line. Gaps correspond to regions of the sequence that are 
not represented in the structure. DSSP analysis of secondary structure is shown 
(E=P~strand, H=a-helix, G = 3io-helix and S,C,T = coil) and regions of secondary 
structure are highlighted in grey boxes. Accessibility is also shown where 0 
represents a residue with 0-9% accessibility and 1 represents a residue with 10-19% 
accessibility and so on.
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Figure 4.8 Superimposition of homology models and crystal structures
The crystal structure is shown as the cyan ribbon, and the homology model is shown 
with a red ribbon.
(a) Apl domain
(b) Ap2 domain
(c) Ap3 domain
(d) Ap4 domain
(e) The SP domain homology model (red) is shown superimposed onto both the 
crystal structure of the FXI zymogen that is shown in cyan (PDB code: 2F83) 
and the crystal structure of FXIa that is shown in green (PDB code: 1XX9).
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Superimposition of the four pairs of structures highlights that the main structural 
differences lay within the loop regions between P-strands, whereas the core of the 
structure is well predicted. This would be expected since these regions were not 
modelled directly from the structural template.
Interpreting the side chain accessibilities in a two-state analysis (using 0%- 
19% to denote buried sidechains and 20%-100% to denote exposed sidechains), the 
homology models and individual domain crystal structures of equivalent Ap domains 
show 79-85% agreement (Figure 4.7). The main differences lie within the first P- 
strand PA of each Ap domain. Many of the differences are only small, where a 
residue with an accessibility of 0 or 1 in one structure has an accessibility of 2 in the 
other structure.
The SP domain forms a 14-stranded P-sheet double Greek key 
supersecondary motif that is conserved in other serine proteases (Figure 4.4). The 
catalytic triad of His413, Asp462 and Ser557 lies on the interface between the two 
Greek key supersecondary structures. The SP homology model of FXI shows high 
agreement with the crystal structure of both the zymogen and activated FXI (Figure 
4.7). DSSP three-state analysis indicates the SP homology and zymogen crystal 
structure (PDB code: 2F83) are in 84% agreement, whereas the SP homology model 
and the activated FXI crystal structure (PDB code: 1XX9) show 94% agreement. 
The activated FXI structure is considered more relevant since the SP homology 
model was built from an active serine protease template, and so therefore represents 
the active form of FXI. The zymogen and the activated FXI SP domain crystal 
structures show 89% agreement. The least-squares superposition RMSD between the 
homology model and the activated FXI crystal Ca backbone is only 1.19 A .  
Superimposition shows that the core of the structure is well predicted, whereas 
surface loop regions vary. The zymogen and activated FXI structures also show 
strong agreement, apart from the N-terminal region that is inserted upon activation 
(Figure 4.8e). Sidechain accessibilities between the activated FXI crystal structure 
and homology model also show a strong agreement of 85% (Figure 4.7).
4.3.3 Analysis of mutation data
A total of 120 genetic alterations within F l l  are associated with FXI 
deficiency (Table 4.3). This includes 78 missense mutations, 18 nonsense mutations, 
seven introgenic splice site alterations and 11 insertions and deletions.
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Table 4.3 Disease-associated mutations within Fll
• ji dticntDomain Nucleotide Change3 Molecular Consequence D c
KCCOIuS
Promoter Region c.-54G>A Promoter region 1
Signal Peptide c.3G>T Met-18Ile 2
Signal Peptide C.440T Ser-4Leu 1
Linnker Region c.55G>T GlulX 1
Apl c.100G>C Aspl6His 0
Apl c.55T>C Val20Ala 0
Ap 1 C.1220T Pro23Leu 1
Apl c.1 2 2 0 A Pro23Gln 1
Apl C.137G>T Cys28Phe 3
Apl c.141G>C Gln29His 1
Apl c.166T>C Cys38Arg 13
Apl c.l92_193insG Frameshift and premature stop at 
codon 50
1
Apl c.227G>A Cys58Tyr 2
Apl c.227G>T Cys58Phe 1
Apl C.2590A Pro69Thr 1
Apl C.303OA Lys83Arg 1
Apl c.301 307dupAAGC 
AAT
Frameshift and premature stop 
23 residues downstream
2
Reference
Mitchell et al., 2006 
Mitchell et al., 2006 
Quelin et al., 2006 
Mitchell et al., 2006 
Pughetal., 1995 
Zivelin et al., 1999a 
Quelin et al., 2005 
Mitchell et al., 2006 
Hill et al., 2005 
Bolton-Maggs et al., 2003; Mitchell et al., 2006 
Zivelin et al., 1999b; Zivelin et al., 2002; Quelin et al., 2005 
Quelin et al., 2004
Zivelin et al., 1999a; Mitchell et al., 2006 
Mitchell et al., 2006 
Quelin et al., 2005 
Hill et al., 2005 
Ventura et al., 2000
Table 4.3 Disease-associated mutations within F ll  (continued)
Domain Nucleotide Change8 Molecular Consequence Patient
Records0
Linker C.3160T Gln88Stop 6
IntronD c.325+lG>A Changes splice site at exon 4/ 2
intro n D boundaiy
Ap2 c.325G>A Ala91Thr l
Ap2 c.328T>G Cys92Gly 2
Ap2 c.359T>C Metl20Thr l
Ap2 c.365G>A Glyl04Asp 5
Ap2 C .4 0 0 0 T Glull6X
Ap2 c.403G>T Glul 17X 33
Ap2 C.408OA Cysll8X
Ap2
Ap2
c .419G > A
C .4 3 8 0 A
Cysl22Tyr
Cysl28X
3
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Ap2
Ap2
Ap2
Ap2
C .4 4 9 0 T
c.452A>C
c.454G>C
c.454G>C
Thrl32Met
Tyrl33Ser
Tyrl33Cys
Alal34Pro
Reference
Quelin et al., 2004 
Mitchell et al., 2006
Mitchell et al., 2006 
Quelin et al., 2005 
Mitchell et al., 2006 
Alhaq et al., 2000,; Mitchell et al., 2003;
Mitchell et al., 2006 
Dossenbach-Glaninger et al., 2002; 
Dossenbach-Glaninger and Hopmeier, 2006 
Asakai et al., 1989; Hatskelzon et al., 1996; Peretz et al., 1996; 
Martincic et al., 1998; Ventura et al., 2000;
Zivelin et al., 1999a, 1999b; 2002; Zadra et al., 2004;
Solda et al, 2005; Mitchell et al., 2006; Quelin et al., 2006 
Bolton-Maggs et al., 1999; Zadra et al., 2004;
Mitchell et al., 2006 
Quelin et al., 2006 
Zacharski, 1978; Imanaka et al., 1995, Bolton-Maggs et al., 2004; 
Dai et al., 2004; Hill et al., 2005,; Mitchell et al., 2006 
Mitchell et al., 2006 
Bolton-Maggs et al., 2003; Hill et al., 2005; Mitchell et al., 2006 
Mitchell et al., 2006 
Bolton-Maggs et al., 2003; Mitchell et al., 2006
Table 4.3 Disease-associated mutations within F ll  (continued)
Domain Nucleotide Change3 Molecular Consequence1* Patient
Records0
Reference
IntronE c.485+5G>C Changes splice site at exon 5/ 
intron E boundary
0 Pugh et al., 1995
IntronE c.486-2A>G Changes splice site at intron E/ 
exon 6
3 Mitchell et al., 2003,2006; Quelin et al., 2006
Ap2 C.4840T Argl44Cys 1 Dossenbach-Glaninger et al., 2003
Ap2 c.521G>A Glyl55Glu 3 Alhaq et al., 2000; Mitchell et al., 2003; O'Connell et al 2005
Ap2 c.569T>C Leul72Pro 1 Wu et al., 2004
Intron F c.595+3A>G Change splice site of exon 6/ 
intron F boundary
3 Zivelin et al., 2002; Dossenbach-Glaninger and Hopmeier, 2006; 
Mitchell et al., 2006
Ap3 c.599G>A Cysl82Tyr 1 Bolton-Maggs et al., 2003; Mitchell et al., 2006
Ap3 c.616T>C Prol88Ser 2 Zivelin et al., 1999a; Quelin et al., 2006
Ap3 c.643 648delATCG 
AC
Deletion of residues lie 197 and 
Aspl98
1 Zadra et al., 2004
Ap3 c.644 649delTCGAC 
A
Deletion of residues lie 197 and 
Aspl98
1 Dossenbach-Glaninger and Hopmeier, 2006
Ap3 C.6820T Arg210X 1 Quelin et al., 2004
Ap3 c.688T>C Cys212Arg 2 Morishita et al., 2003; Mitchell et al., 2006
Ap3 c.716T>C Phe221Ser 1 Morishita et al., 2003
Ap3 C.7280T Ser225Phe 2 Kravtsov et al., 2005
Ap3 c.738G>C Trp228Cys 8 Alhaq et al., 1999
Ap3 c.738G>A Trp228X 2 Wu et al., 2003
Ap3 C.7510T Gln233X 1 Mitchell et al., 2006
Ap3 c.755G>T Arg234Ile 0 Bolton-Maggs et al., 2003
Ap3 c.756A>T Arg234Ser 2 Mitchell et al., 2006
Table 4.3 Disease-associated mutations within F ll  (continued)
Dom ain Nucleotide Change® M olecular Consequence*1 Patient
Records0
Ap3
Ap3
Ap3
Ap3
Ap3
Ap3
Ap3
Ap3
Ap4
c.764G>A
c.783G>C
c.788G>A
c.797G>A
C.802OT
c.809A>T
c.841C>T
c.856G>T
c.901T>C
Cys237Tyr
Glu243Asp
Gly245Glu
Sei248Asn
Arg250Cys
Lys252Ue
Gln263X
Val271Ile
Phe283Leu
3 
2 
2 
2
4 
2 
10 
1 
9
Ap4
Ap4
Ap4
Ap4
Ap4
Ap4
Ap4
Ap4
c.907delG Frameshift and premature stop at 1
codon 290
c.918delG Frameshift and premature stop at 1
codon 330
c.943G>A Glu297Lys 4
c.959T>C Leu302Pro 0
c.960delGT Frameshift and and premature 1
stop at codon 344 
c.961delTG Frameshift and and premature 1
stop at codon 344 
c.965C>T Thr304Ile 2
c.976C>T Arg308Cys 2
Ap4 c.1021G>A Glu323Lys
Reference
Zivelin et al., 199%; Zivelin et al., 2002 
Quelin et al., 2005 
Hill et al., 2005 
Martincic et al., 1998 
Bolton-Maggs et al., 2003; Mitchell et al., 2006 
Dai et al., 2004; Mitchell et al., 2006 
Sato et al., 2000; Au et al., 2003; Kawaguchi et al., 2000 
Jayandharan et al., 2005 
Martincic et al., 1998; Asakai et al., 1989; 
Dossenbach-Glaninger et al., 2001 
Zivelin et al., 2002
Hill et al., 2005
Mathonet et al., 1999; Quelin et al., 2005,2006 
Pughetal., 1995 
Quelin et al., 2006
Mitchell et al., 2006
Pugh et al., 1995; Quelin et al., 2005; Mitchell et al., 2006 
Mitchell et al., 1999, 2006
Pugh et al., 1995; Wu et al., 2004; Mitchell et al., 2006
Table 4.3 Disease-associated mutations within F ll  (continued)
Domain Nucleotide Change8 Molecular Consequenceb Recordsc
Ap4 C.1026G>T Affects splicing causing a 
frameshift and premature stop 
codon at position 330
2
Ap4 c.l026dupG Insertion between residue 324 
and 325 leading to frameshift 
and premature stop 15 residues 
downstream.
2
Intron I c. 1029-2A>G Changes splice site of intron 
I/exon 10 boundary
0
Ap4 c.1060G>A Gly336Arg 1
Ap4 c,1072delA Frameshift and premature stop at 
codon 372
1
Ap4 c.1077A>G Ile341Met 1
Ap4 c. 1084G>A Gly344Arg 1
Ap4 c.1103G>C Gly350Ala 1
Ap4 c.1103G>A Gly350Glu 0
Ap4 C.1107OA Tyr351X 3
Ap4 c.ll06A>C Tyr351Ser 1
Ap4 c.lll8T>C Leu355Ser 1
Ap4 c.1120T>C Cys356Arg 1
SP C.11320T Arg378Cys 1
Intron J C.1135+1G>A Change splice site of exon 10/ 
intron J boundary
1
Intron J C.1135+5G>A Change splice site o f exon 10/ 1
intron J boundary
Reference
Ventura et al., 2000 
Dossenbach-Glaninger et al., 2001
Pughetal., 1995
Quelin et al., 2004 
Ventura etal., 2000
Mitchell et al., 2006 
Mitchell et al., 2006 
Quelin et al., 2004 
Kravtsov et al., 2004 
Au et al., 2003 
Jayandharan et al., 2005 
Mitchell et al., 2006 
Mitchell et al., 2006 
Germanos-Haddad et al., 2003; Mitchell et al., 2006 
Hayashi et al., 1997
Mitchell et al., 2006
Table 4.3 Disease-associated mutations within F ll  (continued)
Domain Nucleotide Change3 Molecular Consequenceb Rrcords0
Intron J c. 1136-4delGTTG
SP c.1199C>T
SP c.1202G>A
SP c.1211C>A
SP c.1219A>C
SP c.!247G>A
SP c.1253G>T
SP c.1270C>T
SP c.1289C>T
Intron K c. 1305-10T>A
SP c,1378T>G
SP c.1393G>T
SP c.1432G>A
SP c,1478C>T
SP c.1489C>T
SP c.1500C>G
SP c,1531T>C
SP c.1531T>C
SP c,1545G>T
SP c.!556G>A
Change splice site of intron J/ 3
exon 11 boundary
Pro382Leu 3
Trp383X 1
Thr386Asn 3
Thr389Pro 1
Cys398Tyr 4
Gly400Val 3
Gln406X 1
Ala412Val 2
Changes splice site of Intron K/ 1
Exon 12 boundary
Phe442Val 1
Glu447X 1
Gly460Arg 9
Thr475Ile 3
Arg479X 1
Cys482Trp 1
Tyr493His 2
Tyr493His 2
Trp497Cys 1
Trp501X 1
Reference
Xie et al., 2005
Bolton-Maggs et al., 1999; Quelin et al. 2005; Mitchell et al., 2006 
Wu et al., 2003 
Wistinghausen et al., 1997 
Bolton-Maggs et al., 2003; Mitchell et al., 2006 
Gailani et al., 2001; Kravtsov et al., 2005 
Gailani et al., 2001, Kravtsov et al., 2004 
Mitchell et al., 2006 
Mitchell et al., 1999; Hill et al., 2005 
Ventura el al., 2000
Imanaka et al., 1995 
Tsukahara et al., 2003 
Alhaq et al., 2000; Mitchell et al., 2003; Bolton-Maggs et al., 2003; 
Jayandharan et al., 2005; Quelin et al., 2005; Mitchell et al., 2006 
Bolton-Maggs et al., 2003; McVey et al., 2005; Mitchell et al., 2006 
Mitchell et al., 2006 
Mitchell et al., 2006 
Zivelin et al., 2002 
Zivelin et al., 2002 
Quelin et al., 2005 
Iijima et al., 2000
Table 4.3 Disease-associated mutations within F ll  (continued)
Domain Nucleotide Change3 Molecular Consequence15 Patient
Records0
Reference
SP c.l556dupG Frameshift and premature stop at 
codon 535
2 Morishita et al., 2003 ; Tsukahara et al., 2003
SP c.1557G>C Trp501Cys 3 de Moerloose et al., 2004
SP c. 1608G>C Lys518Asn 3 Ventura et al., 2000
SP c.1613C>T Pro520Leu 6 Gailani et al., 2001; Hill et al., 2005; Quelin et al., 2005; 
Mitchell et al., 2006
SP c. 1693G>A Glu547Lys 3 Hill et al., 2005; Quelin et al., 2005
SP c.l714_1716+lldel 14bp deletion at exon 14/intron 
N junction disrupts splicing.
1 Peretz et al., 19%
Intron N C.1716+1G>A Changes splice site of intron 
N/Exon 14 boundaiy
2 Asakai et al., 1989; Mitchell et al., 2006
SP C.1718G>A Gly555Glu 2 Zivelin et al., 2003; Mitchell et al., 2006
SP C.1742G>T Cys563Phe 1 Mitchell et al., 2006
SP c,1760G>C Tip569Ser 2 Gailani et al., 2001, Kravtsov et al., 2004
SP c.1778C>T Thr575Met 7 Quelin et al., 2004; Gemanos-Haddad et al., 2005; 
Mitchell et al., 2006
SP c.1782C>A Ser576Arg 3 Mitchell et al., 1999; O’Connell et al., 2005; Mitchell et al., 2006
SP C.1797T>A Cys581X 2 Quelin et al., 2004
SP C.18240A Tyr590X 2 Bolton-Maggs et al., 2003; Hill et al., 2005; Mitchell et al., 2006
SP C.1849T>G Trp599Arg 1 Takamiya et al., 2005
SP c.1853T>C Ile600Ser 3 Bolton-Maggs et al., 2003; Hill et al., 2005; Mitchell et al., 2006
acDNA numbering is taken from RefSeq # NM 000128.2, where +1 corresponds to the A of the ATG translation initiation codon.
For mutations occurring in intragenic regions, sequences are taken from GenBank #AY191837.1.
b Amino acid numbering follows traditional nomenclature, where residues are numbered with respect to the mature peptide as in the FXI structure file (PDB code: 2F83). 
c0 patient records refer to mutations that are only reported with genotypic information.
Table 4.4 Polymorphisms within Fll reported in the literature
Nucleotide Change* MolecularConsequence** Gene Region Domain No Of Alleles
Frequency Of Minor 
Allele(s) Reference
c.-2+120G>A Change in Intron In. A - 2 n.r Quelinetal., 2004
c.-l-231T>C Change in Intron In. A - 2 32-47% Peretz et al., 1997, Quelin et al., 2004
c.-l-198T>G Change in Intron In. A - 2 n.r Quelin et al., 2004
c.-l-138C>A Change in Intron In. A - 2 42% Ventura et al., 2000, Quelin et al., 
2004
c.56-1209dupCA*** Change in CA 
repeat of intron
In. B - 4 <2%, 37-42%, 16- 
23%
Bodfish et al., 1991, Peretz et al., 1997
C.1970T Pro48Leu Ex. 3 Apl 2 <5% Cargill et al., 1999
c.218+126A>G Change in Intron In. C - 2 Quelin et al., 2004
c.429C>T Aspl25Asp Ex. 5 Ap2 2 5-15% Martinic et al., 1998, Cargill et al., 
1999, Ventura et al., 2000
c.485+23G>C Change in Intron In. E - 2 n.r Cargill et al., 1999
c.486-431G>A Change in Intron In. E - 2 39-45% Butler & Parsons 1990, Peretz et al., 
1997, Bolton-Maggs et al., 2004
c.486-361C>T Change in Intron In. E - 2 n.r Bolton-Maggs et al., 2004
c.731A>G Gln226Arg Ex. 7 Ap3 2 <5% Cargill et al., 1999
c.801A>G Thr249Thr Ex. 8 Ap3 2 >15-20% Martinic et al., 1998, Cargill et al., 
1999,Ventura et al., 2000
C.8610T Ile269Ile Ex. 8 Ap3 2 n.r Cargill et al., 1999
c.922A>T Ile290Phe Ex. 9 Ap4 2 <5% Cargill et al., 1999
C.1016G>T Cys321Phe Ex. 9 Ap4 2 n.r Cargill et al., 1999, 
Zivelin et al., 2002
c.1191T>C Gly379Gly Ex. 11 SP 2 >15-50% Martinic et al., 1998, 
Cargill et al., 1999
c.l574-93dupAT**** Change in AT 
repeat of Intron
In M - 4 <1%, 13-38%, 4-20% Peretz et al., 1997
c.1704C>T Asp550Asp Ex. 14 SP 2 <5% Cargill et al., 1999
C.1717-48A>G Change in Intron In. N - 2 n.r Cargill et al., 1999
C.1812G>T Arg586Arg Ex. 15 SP 2 <5% Cargill et al., 1999, Zivelin et al., 2002
c,1839G>A Glu595Glu Ex. 15 SP 2 <5% Cargill et al., 1999, Zivelin et al., 2002
*cDNA numbering is taken from RefSeq # NM 000128.2, where +1 corresponds to the A of the ATG translation initiation codon. Where mutations occur in introgenic regions, 
sequences are taken from GenBank #AY191837.1.
**Amino acid numbering follows traditional nomenclature, where residues are numbered with respect to the mature peptide.
***The numbering is given for the start of the (CA)11 repeat in intron B.
****This The numbering is given for the start of the (AT)10 repeat in intron M 
nr = not reported, In = intron, Ex. = exon.
These mutations are distributed equally along the whole length of FXI (Figure 4.9). 
This number has almost doubled since Version 1 of the database, which had held 
records on 65 F l l  mutations (Saunders et al., 2005). Several FI 1 polymorphisms 
that are not thought to have any affect on protein structure or function and are 
therefore not associated with FXI deficiency have also been discussed in the 
literature (Table 4.4). From this point onwards, all mutations are analysed in terms of 
the crystal structure, unless stated otherwise.
4.3.3.1 Missense Mutations
The 78 missense mutations within F l l  are distributed in all five domains of 
FXI, with only one residue alteration (Val371Ile) lying within the linker regions 
between the domains (Figure 4.9). The structural analysis of these mutations is 
described in Table 4.5 and shown in detail in Figure 4.10 and Figure 4.11. Of the 45 
missense mutations that can be phenotypically classified, the majority (39) are Type
I and only six mutations are assigned Type II phenotypes. The majority of the Type
II functional mutations (four out of six) reside in the catalytic SP domain.
Mutations are spread evenly throughout the domains, although fewer 
mutations involve surface residues and clustering is seen towards the central core of 
each domain (Figure 4.10 and Figure 4.12). All of the Type II mutations are exposed 
at or near the surface of the FXI molecule.
4.3.3.2 Missense Mutations in the Signal Peptide
Within the signal peptide, two missense mutations (Met-18Ile and Ser-4Leu) 
occur that have been assigned Type I phenotypes since FXI:Ag levels in patients are 
low. The Met-18Ile mutation abolishes the ATG initiation codon and the Ser-4Leu 
mutation occurs near the binding site of the Signal Recognition Particle, which 
targets proteins to the endoplasmic reticulum (Quelin et al., 2006).
4.3.3.3 Type I Missense Mutations in the Ap Domains
Mutations that are classified as Type I most commonly replace residues that 
are buried within the structural core. Of the 22 Type I missense mutations within the 
Ap domains of FXI, ten of these can be explained in terms of disruption of the 
conserved Ap disulphide bridges.
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Met-ISIIe
Ser-4Leu
Ala91Thr
Cys92Gly
Metl02Thr
Glyl 04Asp
Glu116X
Glull7X
Cys118X
Cys122Tyr
Cysl28X
Thrl 32Met
Tyrl 33Cys/Ser
Alal34Pro
c48S+5G>C
c486-2A>G
Argl44Cys
GlylSSGIu
Leu172Pro
c59S+3A>G
Phe283Leu Arg378Cys
c.907delG C.1135+1G>A
c918delG C.1135+5G>A
cGlu297Lys c.1136-4_l 136delGTTG
Leu 302 Pro Pro382Leu
c.960_961delGT Trp383X
c961_962delTG Thr386Asn
Thr304lle Thr389Pro
Arg308Cys Cys398Tyr
Glu323Lys Gly400Val
C.1026G>T Gln406X
c1026dupG Ala412Val
C.1029-2A>G C.1305-10T>A
Gly336Arg Phe442Val
c1072delA Glu447X
Ile341 Met Gly460Arg
Gly344Arg Thr475lle
Gly350Ala/Glu Atg479X
Tyr3S1/Ser/X Cys482Trp
Leu355Ser Tyr493His
Cys356Arg Trp497Cys
N   Ap1 -  Ap2 Ap3 Ap4
86^91
I Gln88X
GlulX c325+1G>A
Asp16His 
Val20Ala 
Pro23Gln/Leu 
Cys28Phe 
Gln29His 
Cys38Arg 
c.192_193insG 
CysS8Phe/Tyr 
Pro69Thr 
Lys83Arg
c.301_307dupAAGCAAT
SP l - c
Cysl82Tyr c.lS56dupG
Prol88Ser Lys518Asn
c643_648delATCGAC ProS20Leu
c644_649delTCGACA Glu547Lys
Arg210X c!714_1716+11del
Cys212Arg Cl716+1G>A
Phe221Ser GlySSSGIu
Ser225Phe CysS63Phe
Trp228Cys TrpS69Ser
Trp228X Thr575Met
Gln233X SerS76Arg
Arg234lle Cys581X
Cys327Tyr Tyr590X
Glu243Asp Trp599Arg
Gly24SGIu lle600Ser
Ser248Asn
Arg250Cys
Lys252lle
Gln263X
Val271 lie
Figure 4.9 The distribution of 117 nucleotide changes within F l l  that are 
associated with FXI deficiency
Domains are drawn to scale. The numbering underneath the domains indicates the 
range of amino acids from the start to the end of the domain. Linkers are not 
included. N and C indicate the N-terminus and C-terminus respectively.
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Table 4.5 Structural analysis of 73 missense mutations in the crystal structure 
of FXI
Domain Mutation DSSP Position Accessibility* Phenoly
Signal Peptide Met-18Ile - - - I
Signal Peptide Ser-4Leu - - - I
Apl Aspl6His E PC Exposed (9) I
Apl Val20Ala E PC Exposed (2) U
Apl Pro23 Gln/Leu C PC - a-helix Loop Buried (0) I
Apl Cys28Phe H a-helix Buried (0) I
Apl Gln29His H a-helix Buried (1) I
Apl Cys38Arg C a-helix - PD Loop Buried (0) I
Apl Cys58Phe/Tyr E pE Buried (0) U/U
Apl Pro69Thr C PE - PF Loop Exposed (8) u
Apl Lys83Arg C PG - C4 Loop Buried (1) u
Ap2 Ala91Thr C Linker Buried (1) u
Ap2 Cys92Gly C Cl Buried (1) I
Ap2 Metl02Thr E PB Buried (0) I
Ap2 Glyl04Asp C PB - PC Loop Buried (0) u
Ap2 Cysl22Tyr H a-helix Buried (0) u
Ap2 Thrl32Met E PD Buried (0) u
Ap2 Tyrl33Cys/Ser E PD Buried (0) U/U
Ap2 Alal34Pro E PD Buried (0) u
Ap2 Argl44Cys C PD -  PE Loop Exposed (7) u
Ap2 Glyl55Glu C PE - PF Loop Buried (1) II
Ap2 Leul72Pro C PG - C4 Loop Buried (1) u
Ap3 Cysl82Tyr C Cl Buried (1) u
Ap3 Prol88Ser E PA Exposed (7) u
Ap3 Cys212Arg H a-helix Buried (0) u
Ap3 Phe221Ser E PD Buried (0) I
Ap3 Ser225Phe C PD - PE Loop Buried (1) I
Ap3 Trp228Cys C PD - PE Loop Buried (0) I
Ap3 Arg234Ile/Ser C PD - pE Loop Exposed (9) U/U
Ap3 Cys237Tyr E PE Buried (0) I
Ap3 Glu243Asp C PE - PF Loop Exposed (9) I
Ap3 Gly245Glu C pE - pF Loop Buried (0) I
Ap3
Ap3
Ser248Asn
Arg250Cys
C
C
PE - PF Loop 
PE - PF Loop
Exposed (6) 
Exposed (9)
II
Ap3
Linker
Lys252Ile
Val271Ile
E
C
PF
Linker
Exposed (9) 
Buried (0)
I
Ap4 Phe283Leu E PB Buried (0) I
Ap4 Glu297Lys C PC - PD Loop Exposed (9) I
Ap4 Leu302Pro H a-helix Exposed (6) I
Ap4 Thr304Ile H a-helix Exposed (3) I
Ap4 Arg308Cys C a-helix - PD Loop Exposed (3) I
Ap4 Glu323Lys C PD - pE Loop Exposed (9) I
Ap4 Gly336Arg C PE - PF Loop Buried (1) I
Ap4 Ile341Met E pF Exposed (4) u
Ap4 Gly344Arg C pF - PG Loop Exposed (3) u
Ap4 Gly350Ala/Glu E pG Buried (0) I/U
Ap4 Tyr351Ser E PG Buried (1) u
Ap4 Leu355Ser C PG - C4 Loop Exposed (4) u
Ap4 Cys356Arg G C4 - G-helix 3 Exposed (3) u
SP Arg378Cys C Loop to PB Exposed (9) II
SP Pro382Leu C Loop to PB Buried (0) I
SP Thr386Asn E PB Buried (0) I
SP Thr389Pro E PB Buried (0) u
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Table 4.5 Structural analysis of 73 missense mutations in the crystal structure 
of FXI (continued)
Domain Mutation DSSP Position Accessibility Phenotype
SP Cys398Tyr E pc Buried (0) I
SP Gly400Val E pc Buried (0) I
SP Ala412Val G G1 Buried (0) I
SP Phe442Val C PF - G2 Loop Exposed (6) I
SP Gly460Arg C PG - PH Loop Buried (0) I
SP Thr475Ile C PH - Al Loop Exposed (5) I
SP Cys482Trp C PH - Al Loop Buried (0) U
SP Tyr493His C Al - pJ Loop Exposed (2) U
SP Trp497Cys E PJ Exposed (5) I
SP Trp501Cys C PJ - pK Loop Buried (0) I
SP Lys518 Asn E pK Exposed (9) I
SP Pro520Leu C PK - A2 Loop Exposed (9) II
SP Glu547Lys C A2 - pM Loop I
SP Gly555Glu C A2 - PM Loop Buried (0) II
SP Cys563Phe E PM Buried (0) U
SP Trp569Ser E pN Exposed (2) I
SP Thr575Met E PN Exposed (2) II
SP Ser576Arg E PN Buried (0) U
SP Trp599Arg H A3 Exposed (2) I
SP Ile600Ser H A3 Buried (0) I
* Accessibility is described as either buried or exposed, with the relative side chain 
accessibility score calculated using DSSP shown alongside in brackets. Scores of 0 
or 1 represent buried residues, whereas scores of 2 or higher represent exposed 
residues.
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Catalytic Site
I
180
Catalytic Site
Figure 4.10 Front and back structural views of the distribution of 78 missense 
mutations within FXI (continued over page)
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Figure 4.10 Front and back structural views of the distribution of 78 missense 
mutations within the crystal structure of FXI (continued)
The backbone of the FXI crystal structur is shown in ribbon format, coloured 
according to domain where Apl is dark blue, Ap2 is light blue, Ap3 is cyan, Ap4 is 
green, SP is magenta and the linker regions are pink. The Ca atoms of those residues 
involved in mutations are shown as spheres, coloured according to phenotype where 
red corresponds to Type I mutations, green corresponds to Type II mutations, yellow 
corresponds to mutations with unknown phenotype and grey corresponds to non­
disease associated polymorphisms. The side chains of the catalytic residues within 
the SP domain are shown and coloured in cyan.
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FXI_SEQ |lF L Y Q W H F IL F lfv S G
FXI_D SSP ...............................................
FXI_ACCESS ...............................................
A pl 10 2 0  30 4 0  5 0  60  70 80 90
FXI_SEQ E VTQLLKDTCFEGGDITTVFTPSAKY Q W  TYHPR L L F T FT A E S |SE D P T R W F T  V LK D SV TETLPRVN RTA AISGYSF*Q SHQIS
FX I_D SSP ---------E EEEEE -  -  -  E E EEEE -  - - HHHHHHHHHH--------- E E E E E ------------------------- E EE E E --  - GGG - - - E E E E E E E E E E E -------------------
FXI_ACCESS 6959  5 3 9 4 1 1 0 9 2 3 9 4 6 6 2 4  0 0 2 0 9 4  0 1 3 2 0 0  54 4 50 0 0 0 1 0 2 2  81954 5 9 9 9 3 1 2 0 1 0 0 1 1 9 9 9 5 2  8 9 5 9 8 8 1 0 3 0 0 2 0 5 1 7 1 8 9 4 3 9
A B C a-helix D E G2 F G
10 0  11 0  1 20  130 1 40  1 5 0  16 0  170 180
  I i----------------- 1 :_ —-1—  I 1—- I
FXI_SEQ A NXDIYVDLDMRGINYNSSVAKSAQE QER TDDVH HFFTYATRQFPSLEHBNI LLK H TQ TtjfTPTRITK LD K W SG FSLK S ALSNL
FXI_D SSP ------------E E EEEE E - EEEEEEE - - -HHHHHHHHH------------ E E E E E -------------------------E E E E E E --------------- E E E E E E E E E E E E ---------------------
FXI_ACCESS 1 1 2 9 7 6 2 9 3 1 3 0 9 0 9 9 6 6 8 4 9 0 9 2 2 9 3 0 1 9 7 0 0 5 3 5 2 0 2 0 0 0 0 0 3  9 9 2 9 3 9 9 9 7 3 2 0 3 0 0 5 1 9 7 1 1 0 5 9 0 7 8 6 9 7 0 0 0 0 0 1 1 1 1 2 2 3 0 7 4
A B C a-helix D E F G
Ap3 1 9 0  2 0 0  2 1 0  2 2 0  2 3 0  2 4 0  2 5 0  2 6 0  2 7 0
 - - 1   -------------1--------------- | - - ------------ 1— .............. | .................. - | ------------ - 1 - r ------------1 I -
F X I_ S E Q  a S i r d i f p n t v f a d s n i d s v m a p d a f v  g r i  t h h p g  l f f t f f s J e w p k e s q r n l  LLK T SE SG L PST R IK K SK A L SG FSL Q S R H S I P f  
FX I_ D S S P  -E E E E E  - - - E E EEEE E - - - HHHHHHHHH------------------------- E E E E E ------------GGG -  - E E E E E E  E E E E E E E E E E  -  - GGG-----------
F X I_A C C E SS  6 1 5 4  9 8 7 7 6 2 1 1 6 3 7 8 6 7 5 1 3 0 2 3 2 9 0 0 1 4 3 0 0 5 4 4 1 0 1 0 0 0 1 1 1 5 9 0 8 9 9 8 5 9 0 2 0 3 0 0 3 0 9 9 0 9 2 6 6 9 7 9 9 6 7 0 3 0 0 2 1 3 2 1 0 4 4  0 2 3 0  
A B C a-heiix D G1 E F G G3
Ap4
2 8 0  2 9 0  3 0 0  3 1 0  3 2 0  3 3 0  3 4 0  3 5 0  3 6 0
. . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . I - - —  I - - -  - - I . . . . . . . . . . . . . . . . . . . — - I - - - - - - - - - - - - - - - - - - I - - - - - - - - - - - - - - | - - - - - - - - - - - - - - - - - - - - - I - - . . . . . . . . . . . . . . . . . I - . . . . . . . . . . . . . . . . . . . . .
F X I_ S E Q  F  h s s f y h d t d ? l g e e l d | v a a k s h e a  q k l  t n a v r  q f f t y t p a q a s | n* g k g k  Y LK LSSN G SPT K ILH G RG G ISG Y TLR L KMDNECTTKIKPR
FX I_ D S  S P  -EE  -  -  EE  - -  E E E E E E E E --------------------- HHHHHHHH----------E E E E E ---------------------- E E E E E E E ---------------E E -------------E E E E ---------GGG-----------------------
F X I_A C C E S S  2 2 1 7 4  6 2 9 6  0 1 0 6 2 9 9 5 8 7 4 7 1 9 5 2 9 3 0 1 9 6 0 3 9 2 1 3 0 1 0 0 0 1 4  6 2 9 7 9 9 8 9 2 9 0 8 0 6 0 1 0 0 8 7 1 0 7 6 0 4 2 9 3 9 3 0 0 0 0 1 0 5 3 4 3 7 1 0 5 3 1 1 5 9 5 9 9 6  
A B C a - h e l i x  D E F  G G3
SP*** 3 7 0  3 8 0  3 9 0  4 0 0  4 1 0  4 2 0  4 3 0  4 4 0  4 5 0  4 6 0
I  I- — — - - I --------------- | --------------- I - - -  I --------------- I ---------------- I --------------- I ---------------- I
F X I_ S E Q  IV G G TA SV iG EjPW Q V TL H TTSPTQ RH LCG G SX IG N Q W ILTA A SCFY G yESPK ILRV Y SG ILN Q SEIK ED TS FFG V Q EIIIH D Q Y K M A ESP
F X I_ D S S P  ------------------------------E E E E E E ---------- E E E E E E E E -------- EEEE-G G G G---------- G G G EEEEE-------- GGG---------------E E E E E E E E ----------------------
FX I_A C C E SS  9 9 4 5 4  6 0 4 9 1 2 1 0 0 0 0 0 0 1 0 5 6 9 9 7 9 2 4 0 0 0 0 0 3 1 7 5 2 0 0 0 0 0 4 0 1 9 5 3 9 4  3 9 4  0 7 0 0 1 1 2 2 4 2 7 5 2 9 9 9 3 9 6 2 1 0 9 9 4 1 6 2 9 9 4  9 9 1 6 6 0  
B C D G1 F G2 G
4 7 0  4 8 0  4 9 0  5 0 0  5 1 0  5 2 0  5 3 0  5 4 0  5 5 0
  I  I  I  I  I  I - - - - - - - - - - - - - - I . . . . . . . . . . — ' I - - - - - - - - - - - - - - I
F X I_ S E Q  Y J i ALLKLETTVNYJDSQRPI(8LPSK(SDRNVIXTDCW VTGKGYRKLRDKIQNTLQKAKI§LVT1IEECQKRYRGHKITHKMICAGYR|GGK
F X I_ D S S P  - -  -E E E E E ------------------------------------- GGG-------------- E E E -------- -------------  E E -------- HHHHH------------------------------------------------
FX I_A C C E SS  6 0 0 0 0 0 6 0 9 8 6 0 9 5 5 9 2 3 2 0 0 0 3 0 0 1 0 0 9 9 3 9 2 9 4 0 5 2 0 0 0 3 ............... 9 5 7 5 4 0 7 0 3 9 4 9 5 3 9 6 9 8 0 6 9 4 0 9 7 7 9 1 3 9 4 0 2 0 1 ....................
H A l  J  K A2
5 6 0  5 7 0  5 8 0  5 9 0  6 0 0- - - - - - 1-------- |------- - | ---------|---------I-------
F X I_ S E Q  DACKgD §GGPLSCKHN 5VW HLVGlf WGEGCAQRERPGVYTNWEYVDWILEKTQAV
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Figure 4.11 DSSP and accessibility analysis of residues and m utations in the 
crystal structure of FXI
The sequence of FXI is shown with the secondary structure assignments highlighted 
in grey boxes. DSSP output is shown where E represents P-strands, H represents a- 
helices and G represents 3io-helices. P-strands are labeled and assigned in 
alphabetical order in the order they occur in each domain sequence. Helices are 
denoted as either G1-G3 or A1-A3 in the order they occur in the sequence. 
Conserved cysteine residues within the Ap domains are shown in yellow text. The N- 
glycosylation residues are highlighted in yellow boxes. The positions of 78 missense 
mutations are highlighted in boxes, where 37 red boxes denote Type I mutations, 6 
green boxes denote Type II mutations, 27 orange boxes denote those mutations with 
unknown phenotype and five purple boxes denote non-disease associated 
polymorphisms.
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Figure 4.12 Structural views of residues involved in missense mutations within 
FXI (continued over page)
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Figure 4.12 Structural views of residues involved in missense mutations within 
FXI (continued over page)
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Figure 4.12 Structural views of residues involved in missense mutations within 
FXI (continued)
Secondary structure cartoons of the five domains within the crystal structure of FXI 
with the side chains of residues that are involved within mutations highlighted and 
colored with respect to phenotypic classification, where red denotes Type I, green 
denotes Type II and orange denotes unknown phenotype. Domains are orientated in 
relation to the best position that shows all mutations and functional residues.
(a) Mutations within Apl are shown. The Ca atom of Glu66 is shown as a sphere 
and colored magenta to represent the region within Apl that is important for 
thrombin binding (Papagrigoriou et al., 2006).
(b) Mutations within Ap2 are shown.
(c) Mutations within Ap3 are shown. The Ca atoms of those residues implicated 
in platelet binding are shown as spheres and colored magenta. The region of 
secondary structure and coil corresponding to the FIX binding region is also 
colored magenta.
(d) Mutations within Ap4 are shown. The Ca atoms of those residues implicated 
in the formation of the FXI dimer are shown as spheres and colored magenta.
(e) Mutations within the SP domain are shown. The Ca atoms of the residues 
involved in cleavage and activation of the SP domain (Arg369 and Ile370) 
are shown as spheres and colored magenta. The side chains of the catalytic 
residues (His413, Asp462 and Ser557) are also shown and colored magenta.
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Since the Ap domain is a small P-sheet structure, cysteine residues participating in 
disulphide bonds are expected to provide strong stabilizing affects on the domain 
(Creighton, 1993). Four Type I mutations (Cys28Phe, Cys38Arg, Cys92Gly and 
Cys237Tyr) are directly involved, where the substitution of a conserved cysteine 
residue would break the disulphide bridge and in turn reduce the structural stability 
of the domain. For example, Cys38Arg in the Apl domain breaks the disulphide 
bridge between Cys38 and Cys32 and introduces a large bulky arginine side chain 
(Figure 4.13). This would be expected to disrupt the structural stability of FXI. 
Phenotypic data supports this, demonstrating that there is a significant intracellular 
accumulation of the FXI protein but negligible secretion (Zivelin et al 2002). Energy 
minimisation of mutant FXI-Arg38 using homology modelling also suggested that 
the introduction of Arg38 would break the a-helix of Apl (O’Connell et al., 2005), 
however energy minimisation using a FXI-Arg38 mutant derived from the crystal 
structure was less conclusive and did not show the a-helix to be broken.
The disulphide bridges of the Ap domains also appear to be indirectly 
affected by a further four Type I mutations (Pro23Leu, Gln29His, Leu302Pro and 
Thr304Ile). Within Apl, Pro23 is on the end of the a-helix and alteration of this part 
of structure could affect the disulphide bridge between Cys28 and Cys59. Gln29His 
also occurs next to Cys28 in the Apl domain. Within Ap4, the Leu302Pro mutant 
introduces a proline into the centre of the Ap domain a-helix, in close proximity to 
two disulphide bridges (Cys299-Cys328 and Cys303-Cys309). In Ap3, Thr304Ile 
replaces a hydrophilic side chain with a bulky hydrophobic side chain in close 
proximity to the Cys212-Cys218 disulphide bridge.
In addition, two more Type I missense mutations (Trp228Cys and 
Arg308Cys) are implicated in disulphide bridge disruption since they introduce 
cysteine residues. The Trp228Cys substitution introduces a cysteine in close 
proximity to the Cys208-Cys237 bridge of the Ap3 domain and the Arg308Cys 
substitution introduces a cysteine residue adjacent to the Cys303-Cys309 bridge of 
the Ap4 domain. In both cases the correct disulphide pairing within FXI may not be 
formed due to the introduction of additional cysteine residues, and the structure 
could be disrupted.
Four Type I missense mutations appear to affect the dimerisation of FXI.
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Figure 4.13 Cys38Arg mutation
(a) The wild-type FXI crystal structure is shown with disulphide bridges 
highlighted in yellow, and the side chain of Cys38 highlighted in red. 
Disulphide bridges are labeled C1-C6, C2-C3 and C4-C5 where each 
cysteine is numbered in the order it occurs in the sequence of FXI.
(b) FXI is shown where the arginine has been substituted for Cys38 within the 
crystal structure of FXI and the C3-C4 disulphide bridge is broken.
FXI circulates as a dimer that is formed from non-covalent interactions 
within two FXI Ap4 domains, with the following residues being of particular 
relevance: Leu284, Glu286, Asp289, Glu287, Ile290, Thr315, Gln318, Cys321, 
Asn322, Lys327, Tyr329, Lys331, Ile341 and Arg345 (Papagrigoriou et al., 2006). 
Two Type I mutations (Phe283Leu and Gly350Ala) have been shown by 
experimental analysis to affect the dimerisation of FXI (Meijers et al., 1992a; 
Kravtsov et al., 2005). These mutations lie in close proximity to the residues 
implicated in dimerisation (Figure 4.12d). Phe283 is buried on pD of Ap4 on the 
interface between Ap3 and Ap4 and is part of a buried group of hydrophobic 
residues including Pro203, Tyr278, Phe311 and Tyr351. The substitution of a 
smaller hydrophobic residue into this cluster may affect the conformation of this 
region and indirectly change the positions of residues that make dimer contacts. 
Likewise, Gly350 occurs within the five-stranded P-sheet, and is buried on PG. The 
small change from a glycine to an alanine may cause a slight rearrangement of those 
residues that are involved in dimerisation. In addition to these two mutations where 
defective secretion has been confirmed, an additional Type I mutation, Gly232Lys 
may also affect the dimerisation of FXI since it lies adjacent to Cys321. The surface 
charge reversal caused by the Glu323Lys substitution within this region may perturb 
the association of two FXI molecules (Figure 4.12d). Finally, the Arg308Cys Type I 
mutation may also be relevant to dimerisation since it resides on the same face of the 
FXI surface as the dimerisation residues (Figure 4.12d).
Type I missense mutations most commonly replace residues that are buried 
within the structural core, of which 14 have been discussed so far. Four more Type I 
mutations within Ap3 and Ap4 (Phe221Ser, Ser225Phe, Gly245Glu and Gly336Arg) 
occur at positions with accessibility scores of 0 or 1. Phe221Ser is buried on PD 
sandwiched between the a-helix and PG strand of Ap3. The replacement of a large 
phenylalanine side chain with a smaller serine sidechain will create a void in the 
structure (Figure 4.14a). Ser225Phe lies in close proximity to Phe221 on a loop 
between pD and PE. This has the opposite affect of Phe221Ser, where a small serine 
sidechain is substituted for a large phenylalanine side chain in a densely packed 
region. This is likely to cause clashes with Lys555 and Glu227 (Figure 4.14b). 
Gly245Glu also occurs in a densely packed region of Ap3 on the loop between pE 
and PF. Again, the substitution of a large bulky side chain in place of glycine would 
cause atom clashes with Hisl27, Vall26 and Leu219.
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(a)
(b)
Figure 4.14 Buried mutations (Phe221Ser and Ser225Phe) within the crystal 
structure of the Ap3 domain in FXI
(a) The sidechain of Phe221 is shown in red, with surrounding residue side 
chains shown in cyan and rendered in cpk. The secondary structure cartoon 
of surrounding FXI residues is also shown. The substitution of serine in place 
phenylalanine would create a void.
(b) The side chain of Ser225 is highlighted in red, whereas the side chains of 
Glu227 and Arg255 are colored blue. The backbone is shown as a blue 
ribbon. The introduction of a phenylalanine side chain in the place of serine 
would cause atom clashes.
Phe221
Glu227
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Although Gly336Arg lies within Ap4, it is not implicated in dimerisation as it lies on 
the interface between Ap3 and Ap4 (Figure 4.12d). The introduction of a large 
arginine side chain in this region could cause atom clashes.
The structural consequences of the remaining four Type I mutations of the 
Ap domains (Aspl6His, Glu243Asp, Lys252Ile, Gly297Lys) are less clear. 
Aspl6His is surface exposed within Apl. It could be suggested that this mutation is 
not structurally relevant and is more likely to be implicated in the functional aspects 
of Apl such as thrombin or HK binding, however this does not explain why 
experimental analysis has shown that the amount of mutant protein secreted from 
cells in vitro is reduced (Pugh et al., 1995). Glu243Asp also occurs on a surface 
exposed loop, and involves the substitution of a negatively charged amino acid with 
another negatively charged amino acid, which causes no immediately obvious 
structural effects. A third mutation, Lys252Ue in Ap3 is distant from any disulphide 
bridge, does not participate in interdomain contacts and lies fully exposed on PF. 
Although expression of FXI-Lys252Ile was shown to be reduced when transfected 
into cells, it was present in cell lysates in similar amounts to wild type, suggesting 
that the mutant protein was synthesized as normal, but secretion was reduced (Dai et 
al., 2004). It is possible that the introduction of a surface hydrophobic isoleucine 
sidechain at the protein surface adjacent to the exposed Ile251 sidechain may affect 
the solubility of FXI. Lys252 also resides within a positively charged region of the 
surface. The introduction of isoleucine at this position would reduce the surface 
charge and may affect FXI solubility or secretion. Finally the Glu297Lys mutation 
lies within Ap4 and is surface exposed but not in close proximity to the dimerisation 
residues (Figure 4.12d). This mutation substitutes an exposed negatively charged 
residue with a positively charged residue. It is not clear how this could affect the 
structure of FXI, but FXI:Ag levels suggest the mutant protein is not present in 
plasma so further comment is not possible (Quelin et al., 2005; 2006).
4.3.3.4 Type I Missense Mutations in the SP domain
Most of the Type I mutations in the SP domain (Pro382Leu, Thr386Asn, 
Gly400Val, Phe442Val, Ala412Val, Gly460Arg, Trp501Cys, Trp569Ser, Trp599Arg 
and Ile600Ser) show low solvent accessibility and appear to relate to protein packing 
or the folding pathway. For example, Gly460Arg is close to the catalytic triad
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His413-Asp462-Ser557, however phenotype data shows that it is a Type I mutation 
(Bolton-Maggs et al., 2003; Quelin et al., 2005). Energy minimisation for the 
Gly460Arg mutation using the FXI crystal structure supported this analysis, 
demonstrating that the introduction of a large arginine side chain changes the 
conformation of the mutant SP domain core. Ala412Val also lies close to the active 
site residues (Figure 4.12e). However, the replacement of a valine residue for an 
alanine would be likely to cause atom clashes with Tyr454 and clashes with the 
backbone at position Ile463.
The SP domain is stabilized by four disulphide bonds at positions Cys362- 
Cys482, Cys398-Cys414, Cys496-Cys563, and Cys527-Cys542. In parallel to the Ap 
domains, Type I mutations within the SP domain also affect disulphide bridges. 
Cys398Tyr breaks the disulphide bridge between Cys398 and Cys414. Trp501Cys 
and Trp497Cys introduce an additional cysteine residue. This may perturb the 
correct disulphide bridge formation during the folding of the SP domain supporting 
the Type I classification.
Two Type I mutations (Thr475Ile and Lys518Asn) involve surface exposed 
residues. With Thr475Ile, the substitution of an exposed polar residue with a 
hydrophobic residue is likely to affect the stability of FXI. Lys518Asn involves the 
loss of a negative charge that disrupts a salt bridge between Lys518 and Asp495 
(Figure 4.15).
The structural interpretation of the remaining two SP Type I mutations, 
Phe442Val and Gly547Lys is less clear. Phe442Val occurs at the end of a surface 
exposed P-strand (PF) and before a 3io-helix (G2). This mutation occurs far from the 
active site and on the opposite face of the SP domain from the Arg369-Ile370 
activation region. Since it resides next to another hydrophobic residue (Phe443) the 
mutation would change the surface properties of the SP domain, but it is unknown 
how relevant this is for the secretion or function of FXI. Glu547Lys also lies on a 
surface exposed loop. Within the zymogen FXI crystal structure, this loop is 
disordered, whereas in the crystal structure of activated FXI it is ordered and close to 
the N-terminal Ile370 sidechain that is inserted into the SP domain on activation of 
FXI (Figure 4.16). Since no likely structural consequences can be inferred from this 
mutation, it could be that Glu547 is important for the activation of FXI, however, 
phenotypic data suggests the mutation is Type I.
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Figure 4.15 The disruption of a salt-bridge by Lys518Asn in the FXI crystal 
structure
The sidechains of Lys518 and Asp495 form an ionic interaction within the SP 
domain of FXI.
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Figure 4.16 Residues within the SP domain that are implicated in the activation 
of FXI
The crystal structure of the zymogen and activated FXI are superimposed. The 
backbone is shown as a ribbon, where the blue ribbon represents the zymogen of FXI 
and the cyan ribbon represents FXIa. The side chain of the SP domain N-terminal 
residue Ile370 that is cleaved during activation of FXI is shown in red. The 
sidechains of mutated residues at Pro520 and Glu547 are also highlighted, and 
colored by phenotype classification where Pro520 is green to represent its Type II 
classification and Glu547 is orange to represent its unknown classification.
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4.3.3.5 Type II Missense Mutations
Only two Type II mutations were identified in the Ap domains (Glyl55Glu, 
Ser248Asn), where the phenotypic data gives evidence of a functionally defective 
protein. The Glyl55Glu mutation in the Ap2 domain occurs at an exposed position 
on a loop between J3E and (3F. Functional studies have shown this region could be 
involved with FIX binding (Baglia et al., 1991). Energy minimisation using the 
crystal structure of FXI with Glyl55 replaced by glutamic acid compared to energy 
minimisation of the wild type crystal structure suggests that the localised loop 
conformation changes in the mutant structure, altering the sidechain orientation of 
residues such as Thrl54 (Figure 4.17). The Ser248Asn mutation in the Ap3 domain 
occurs on the corresponding substrate binding loop by analogy with the Ap2 domain. 
This is also associated with Factor IX binding and implicated in platelet binding 
(Baglia et al., 1995; Gailani et al., 2001; Sun et al., 1999; Ho et al., 2000). Ser248 is 
functionally important for platelet binding (Baglia et al., 1995; Ho et al., 2000) and 
substitution is presumed to affect the conformation of the substrate binding loop. 
Expression studies confirm a decreased affinity of FXI-Asn248 for platelet binding 
and impaired activation by thrombin in the presence of activated platelets (Sun et al., 
2001).
Four Type II mutations are localized to the SP domain (Arg378Cys, 
Pro520Leu, Gly555Glu and Thr575Met). Two of these mutations (Gly555Glu and 
Thr575Met) correspond to instances where partially buried small side chains are 
replaced by large bulkier side chains. Both of these mutations are located near to the 
catalytic triad, and are seen to protrude into the active site cleft (Figure 4.18). For 
Gly555Glu, Schmidt and coworkers showed that the mutant glutamic acid sidechain 
may impair substrate accessibility within the active site cleft (Schmidt et al., 2004).
For the other two Type II mutations (Arg378Cys and Pro520Leu), this 
interpretation was not possible because they are distant from the catalytic triad 
(Figure 4.12e). Within the zymogen structure, Arg378 is fully exposed, in close 
proximity to the SP activation region between Arg369 and Ile370 (Figure 4.12e). 
Since phenotypic data suggest Arg378Cys is a functional mutation, Arg378 may be 
important for activation of FXI, and form interactions with FXI activators such as 
thrombin. Pro520 also occurs in close proximity to Ile370 at the N-terminus, which 
is inserted into the SP domain during activation (Figure 4.16).
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Gln153
Thrl54
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Figure 4.17 Energy minimization of the GIyl55Glu mutation
The backbone of the wild type and mutant FXI structures are superimposed, 
where the wild type is shown in magenta ribbon and the mutant FXI structure is 
shown in blue ribbon. The side chains of residues on the exposed loop that changes 
conformation during energy minimisation are also highlighted.
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Figure 4.18 Mutations within the SP domain of the FXI crystal structure that 
block the active site
The side chains of the catalytic residues are shown in magenta within the zymogen 
structure. The side chains of Thr575 (green), Gly555 (green) and Ser576 (orange) are 
shown.
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Since Pro520 defines the rim of the pocket into which Ile370 is inserted during 
activation, it is suggested that this mutation may block the development of catalytic 
activity in FXI.
4.3.3.6 Missense Mutations with unknown phenotype
The lack of FXI:Ag data or conflicting FXI:Ag levels means that a large 
number of missense mutations (40%) cannot be assigned as Type I or Type II 
mutations. However, the phenotypic outcome of eight of these mutations (Cys58Phe, 
Cys58Tyr, Cysl22Tyr, Cysl82Tyr, Cys212Arg, Cys356Arg, Cys483Trp and 
Cys563Phe) can be predicted to be Type I since they disrupt disulphide bonds. 
Disruption of these disulphide bonds is likely to reduce protein stability and cause 
the protein to misfold resulting in Type I phenotypes as seen in four classified Type I 
mutations (Cys28Phe, Cys38Arg, Cys92Gly and Cys237Tyr).
A further two mutations are likely to indirectly affect the formation of 
disulphide bridges. The Val20Ala mutation that resides on buried (3C of Apl is in 
close proximity to the Cys28-Cys58 disulphide bridge and the Ala91Thr mutation 
within Ap2 is buried and lies adjacent to Cys92 of the Cys92-Cysl75 disulphide 
bridge (Figure 4.12b).
Several other unclassified missense mutations lie buried within the core of 
the structure and are likely to either cause atom clashes or create voids. For example, 
Metl02Thr lies buried on 0B of Ap2. The replacement of the large Met residue with 
the smaller threonine residue could create a void. Additionally Thrl32Met, 
Tyrl33Ser, Tyrl33Cys and Alal34Pro all reside on (3D of Ap3, where their side 
chains are buried into the core of the structure (Table 4.5). Within the catalytic SP 
domain, Thr389Pro is buried on PB and does not lie in close proximity to the 
catalytic triad. It also resides close to other buried Type I mutated residues (Figure 
4.12e).
The structural affects of a further two unclassified mutations (Lys83Arg and 
Leul72Pro) can be predicted within Apl and Ap2. Lys83Arg lies buried on a surface 
exposed loop and may participate in a salt bridge with Arg354. Disruption of this salt 
bridge with the addition of a positively charged residue is likely to affect the 
structural stability of FXI. The Leul72Pro within Ap2 resides on the interface 
between other Ap domains and is likely to exert structural affects due to the addition 
of a proline residue into a conformationally restricted loop.
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Within Ap4, four mutations cannot be classified and do not affect cysteine 
residues. Since Ap4 is involved in dimerisation, mutations in this domain can not 
only affect the structural stability or function of FXI, but also perturb residues 
involved in dimerisation. Ile341Met and Gly344Arg lie in close proximity to the 
residues involved in dimerisation and may alter the structural conformation of this 
region (Figure 4.12d). Tyr351Ser is buried on |3G and is likely to create a void. 
Leu355Ser lies on the opposite face to the dimer residues near the domain interface 
with Apl (Figure 4.12d). This mutation could affect interdomain contacts, reducing 
the stability of FXI. The Gly350Glu mutation resides at the same position as 
Gly350Ala that is associated with defective dimerisation (Kravtsov et al., 2005). 
Gly350Glu could also affect dimer formation, however since the replacement of a 
large bulky glutamic acid residue would cause several atomic clashes; it is more 
likely that this mutation would affect the correct folding of the Ap4 domain, 
reducing the stability of FXI.
Several mutations could have functional affects on FXI, but further 
experiment would be required to clarify this. For example, the Pro69Thr mutation 
within Apl lies in close proximity to Glu66 (Figure 4.12a) that is strongly implicated 
in thrombin binding (Baglia and Walsh, 1996; Papagrigoriou et al., 2006). 
Ser576Arg partially projects into the substrate binding cleft formed between the two 
subdomains of the SP domain (Figure 4.18). The replacement with an arginine 
residue is expected to block the binding of substrate to the cleft. FXI:Ag levels range 
from 22-71 Ud/1 for patients that are heterozygous for this mutation (Mitchell et al., 
1999; 2006; O’Connell et al., 2005), so it is not clear whether this mutation can be 
classified as a Type I or Type II phenotype, although energy minimization does 
suggest FXI can incorporate this mutation without large rearrangements to the FXI 
structure. Tyr493His is in close proximity to Pro520Leu near the N-terminus of the 
SP domain, and may have a similar effect as the Pro520 mutation (Figure 4.12e and 
Figure 4.16). However, reduced secretion and intracellular level of the Tyr493His 
construct in expression studies implies that there is also a structural element to this 
mutation.
The structural prediction of five mutations (Glyl04Asp, Argl44Cys, 
Arg250Cys, Arg234Ser and Arg234Ile) is not clear. Glyl04Asp resides in a buried 
position on a surface exposed loop in Ap2. The addition of a longer side chain here 
would cause atom clashes but since this mutation is near the surface, it is not known
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whether the mutation would disrupt the stability of the domain or alter the surface 
properties that are essential to FIX binding. Also within Ap2, Argl44Cys is surface 
exposed near the proposed FIX binding region, however assignment of Type II is not 
straightforward since it is unknown whether the addition of a cysteine residue could 
interfere with the disulphide bridges of FXI. Similarly, within Ap3 Arg250Cys lies 
very close to the platelet binding region within Ap3 (Figure 4.12c), but also involves 
the addition of a cysteine residue. Both the Arg234Ile and Arg234Ser mutations 
could disrupt formation of 3io-helix within Ap3, but since this 3io-helix is part of a 
surface loop it is not certain whether disruption here would cause the whole protein 
to misfold, or whether the surface properties would change, disrupting either the 
platelet or FIX binding site. In a similar situation, the Prol88Ser within Ap3 changes 
a surface exposed proline residue to serine residue that is located on a p-strand. This 
alteration could feasibly disrupt the surface properties, or propagate and disturb the 
rest of the domain structure.
4.3.3.7 Nonsense Mutations
A total of eighteen nonsense mutations (GlulX, Glu88X, Glull6X, 
Glull7X, Cysll8X, Cysl28X, Arg210X, Trp228X, Gln233X, Gln263X, Tyr351X, 
Trp383X, Gln406X, Glu447X, Arg479X, Trp501X, Cys581X and Tyr590X) have 
been identified in FXI deficient patients. Most of these mutations (GlulX, Gln88X, 
Glull6X, Cysll8X, Cysl28X, Arg210X, Gln233X, Gln263X, Glu447X and 
Trp501X) show low patient FXI:Ag levels, suggesting that the truncated mutant 
protein is not secreted. The G lull7X  mutation is frequently seen in Jewish 
populations. Within the database, there are 33 patient records corresponding to this 
mutation. These 33 patient records show varying FXI:Ag levels, ranging from 33-88 
U/dl for the heterozygous patients, and 3-14 U/dl for the compound heterozygous 
and homozygous patients. These levels suggest that the mutation reduces levels of 
plasma FXI; however there is not a complete loss of FXI in patient plasma, which 
may indicate the presence of small amounts of truncated protein. This is similar to 
the Cys518X mutation that has been reported in a homozygous patient with FXI:Ag 
levels of 20 U/dl. There is no FXI:Ag data for the remaining nonsense mutations 
(Trp228X, Tyr351X, Trp383X, Gln406X, Arg479X and Tyr590X) so further 
comment is not possible.
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4.3.3.8 Other Mutations
The remaining 20 disease causing mutations are split into four categories; 
insertion of nucleotides, deletion of nucleotides, alterations in splice sites and 
nucleotide changes within the promoter region of FI 1.
Four mutations (c.l92_193insG, c.301_307dupAAGCAAT, c.l026dupG and 
c.l556dupG) involve the introduction of nucleotides that shift the reading frame of 
F l l  and lead to premature stop codons and truncated peptides (Table 4.3). FXI:Ag 
patient levels confirm that three of these truncated proteins (c.l92_193insG, 
c.301_307dupAAGCAAT and c.l556dupG) are not secreted into plasma.
In addition to insertion of nucleotides, a further eight mutations 
(c.643_648delATCGAC, c.644_649delTCGACA, c.907delG, c.918delG, 
c.960_961delGT, c.961_962delTG, c.ll36-4delGTTG and c.l714_1716+lldel) 
involve the deletion of nucleotides (Table 4.3). The c.643_648delATCGAC and 
c.644_649delTCGACA deletions both translate to the deletion of two amino acids 
lie 197 and Asp 198. Although the reading frame of F l l  is preserved, both of these 
mutant proteins are not present in plasma (Zadra et al., 2004; Dossenbach-Glaninger 
and Hopmeier, 2006). Two deletion mutations (c.ll36-4delGTTG and 
c. 1714_1716+1 ldel) disrupt splice sites and lead to an incorrectly spliced peptide. 
The remaining deletions alter the reading frame of F l l  and result in truncated 
peptides that are not expected to be present in plasma.
There are seven alterations of nucleotides within introgenic regions of F l l  
(c.325+lG>A, c.485+5G>C, c.486-2A>G, c.595+3A>G, c.1029-2A>G,
c.1135+1G>A and c.1135+5G>A) that were found in FXI deficient patients (Table 
4.3). Although these mutations lie in introgenic regions, they are expected to be 
significant since they alter the splice sites at exon/intron boundaries. For example, 
c.1029-2A>G abolishes the 3’ AG site of intron N. This could lead to a premature 
stop codon and truncated protein or the abnormal mRNA might not be transported 
into the cytoplasm and so not be translated (Pugh et al., 1995).
The c.-54G>A mutation occurs within the promoter region of F l l  and is 
likely to affect initiation of transcription.
4.3.3.9 Non-Disease Causing Polymorphisms
Five non-synonymous, frequently occurring polymorphisms have been 
identified in F l l  (Table 4.4 and Table 4.6).
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Table 4.6 Structural analysis of five non-synonymous SNPs within the crystal 
structure of FXI
Domain Mutation dbSNP ID DSSP Position Accessibility
Apl Pro48Leu rs5968 C PD -  PE Loop 9
Ap3 Gln226Arg rs5969 C PD -  G1 Loop 5
Ap4 Ile290Phe rs5972 E pc 7
Ap4 Cys321Phe rs5967 C PD -  PE Loop 9
SP Trp381Arg rsl 800439 C Loop to PB 1
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Since these residue changes are present in the normal population, it is useful to 
compare them to those mutations that are associated with FXI deficiency.
Four of these polymorphisms (Pro48Leu, Gln226Arg, Ile290Phe and 
Cys321Phe) are present in the Ap domains. All four residues are surface exposed and 
are not expected to cause any structural rearrangements within Ap domains. Within 
the FXI structure, all four polymorphisms do not reside close to any Type II 
mutations; therefore the polymorphisms are not expected to affect FXI activity 
(Figure 4.10). Although Cys321 forms a disulphide link between the two FXI 
monomers within the FXI dimer, it is not required for dimerisation (McMullen et al., 
1991; Dorfman and Walsh, 2001; Cheng et al., 2003). The remaining polymorphism 
(Trp381Arg) occurs in the SP domain, and interestingly involves a buried residue in 
the same subdomain as the catalytic active site residues (Figure 4.10). Since the 
mutation involves the substitution of a large bulky side chain with another large 
bulky side chain it is not expected to cause atom clashes or form a void in the 
structure, and since Trp381 is not in close proximity to the catalytic residues it would 
not be expected to affect the activity of FXI. However, since the substitution of an 
arginine side chain would introduce an unpaired charged group into the hydrophobic 
core of the SP domain, it is not clear how the alteration could be accommodated into 
FXI without any structural effects. Since the polymorphism is only referenced in 
dbSNP (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp), it 
could be a sequencing artefact or represent a disease associated mutation that has not 
been reported in a patient.
4.3.4 FXI Web Database
The FXI deficiency database is available at http://www.FactorXI.org 
and maintained and updated on the Department of Biochemistry and Molecular 
Biology server at UCL. The data was first published on the website in November 
2004 with Version 1 of the database. In November 2006, the database was updated to 
Version 2, to include mutation analysis within the crystal structure of FXI, as 
opposed to the homology models. The web pages are fully interactive and easily 
navigated using a static menu on the left hand side of the screen (Figure 4.19). This 
menu provides the main subjects, with a pull down menu under the mutation heading 
providing search and analysis pages. The site map is shown in Figure 4.20.
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F XI Deficiency Mutation Database'-'
New!!! Version 2 November 2006
The FXI deficiency database has been updated to incorporate the new FXI crystal structure
(2ES2), providing more accurate analysis of mutations than the homology models previously 
used.
We have also redesigned the site in order to display information more clearly. Please let us 
know what you think of the new design.
Have you or someone you know been diagnosed with FXI Deficiency?
The information contained on this web site is provided for scientific research purposes only. We
do not give medical advice or recommend any particular treatment for specific individuals. Click 
here for patient information.
Quick Search
Codon: I
Mutation Analysis
Enter Codon No : | |
Mutated Residue : | ' ’
FXI Mutations
There are currently 122 disease causing mutations in the FXI gene compiled within this 
database corresponding to 271 FXI deficient patients reported in literature. Mutations are 
characterized with a Type I or Type II phenotype.
Type I and Type II Phenotypes
° Type I (CRM') is characterized by both low FXI coagulant activity (FXI:C) and low antigen 
(FXI.Ag). This indicates that the mutant protein is either present in lower amounts or 
absent in plasma suggesting that the mutation has a structural effect on the mutant 
protein - ie reducing translation, secretion or stabililty of FXI. 
o Type II (CRM+) is characterized by low FXI:C with normal FXI:Ag. This indicates that the 
mutant protein is present in normal amounts in plasma but has reduced or absent activity, 
suggesting that the mutation has a functional effect on the protein e.g. affecting 
substrate binding.
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Figure 4.19 Screen shot of the FXI deficiency database home page
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each other are coloured to make the links between pages more clear.
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4.3.4.1 Database Searches
A choice of three search forms is available (quick, basic and advanced) that 
can be adapted to perform specific requirements. Mutations can be retrieved using a 
number of search criteria such as the codon number, FXI domain, phenotype, 
genotype or bleeding classification. The results of all searches can be downloaded 
and displayed in Microsoft EXCEL (http://www.microsoft.com) format for further 
analysis. The search results describe the following fields of information: phenotype 
(Type I, Type II, unknown or none), genotype (heterozygous, homozygous or 
compound heterozygous), FXI:C level, FXI:Ag level, deficiency classification (mild 
or severe), bleeding symptoms, patient history, patient age and sex, ethnic origin, a 
reference to the original paper describing the mutation and patient, and any extra 
comments about either the mutation (such as expression data) or the patient (such as 
compound heterozygosity). An additional search tool in the form of a mutation map 
displays mutations in terms of a manually updated figure representing the 
distribution of mutations, and also in terms of an automatic sequence map displaying 
the sequence while highlighting the positions of each mutation.
4.3.4.2 Database structural analysis
An interactive three-dimensional view of each missense mutation within the 
FXI crystal structure (PDB code: 2F83) is provided using the newly developed Java 
Applet JMol version 10 (http://jmol.sourceforge.net/). JMol is used interactively and 
allows for user input with various display options (Figure 4.21). Firstly, the mutation 
can be viewed in terms of the whole structure or its associated domain. Either the 
missense mutation on its own can be highlighted, or this can be done simultaneously 
together with all the other known mutations in the domain in order to place the single 
mutation in context. The position of each mutation in the crystal structure in terms of 
DSSP is also described in the results table. Structural information such as the known 
binding regions of FXI and amino acid properties such as hydrophobicity and charge 
are also stored in the database, and can be queried as required. This approach uses 
information from the database to predict a flexible yet powerful analysis of any user- 
defined substitution of a FXI residue. Figure 4.21 shows an example of the output for 
a hypothetical substitution.
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Figure 4.21 Screen shot of analysis of a hypothetical mutation
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This tool can also be used to predict whether a novel mutation may perturb structural 
stability (Type I) or biological function (Type II), or alternatively may be a non­
disease-causing polymorphism, using information such as residue position and 
conservation of residue properties.
4.3.4.3 Database Statistical Analysis
The information within the database is used to automatically generate 
statistics on F ll  mutations. The website displays these in graphs showing the 
distribution of mutations within domains, the distribution of mutation type, the 
distribution of phenotype and the patient information coverage. This is useful since it 
provides an up to date analysis of what is known about mutations associated with 
FXI deficiency.
4.3.4.4 Miscellaneous Tools
New mutations are entered into the database via an electronic submission 
form. In order to maintain the database entries in a reliable and structured format, the 
database curator checks all new mutations. In particular, the database will accept and 
flag mutations and patients that have not been published in peer-reviewed articles, or 
those that have only been published in abstract form. This enables the source of each 
mutation to be identified.
The website also provides a reference library for FXI, with each reference 
quoted in full and linked to the abstract via the PubMed database at 
http://www.ncbi.nlm.nih.gov/. The user is also able to browse information pages 
providing a summary of both FXI protein structure and function and FXI deficiency. 
The website also provides numerous links associated with FXI, FXI deficiency and 
F ll  mutations, in particular those FXI patients who find the website are forwarded 
to health organization fact sheets.
4.4 Discussion
Improvements in sequencing methods have increased our understanding of 
the molecular basis of genetic disease. As more and more disease associated 
mutations become known, it becomes increasingly important to understand how this 
genetic variation affects the function and expression of genes and proteins. Using 
structural and sequence information to predict the phenotypic outcome of genetic
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mutations is extremely useful for molecular diagnostics, predicting the effects of in 
vitro and in vivo mutagenesis experiments and identifying candidate SNPs for 
inheritance studies. The integration of clinical, sequence and structural information 
into the FXI database provides a knowledge bank to power such predictions. In this 
study, sequence and structural information has been used to explain the phenotypic 
outcome of 40 classified missense mutations and predict the phenotypic outcome of 
24 unclassified mutations. However, the structural effects of 12 mutations were 
unclear, highlighting the importance of combining experimental, sequence and 
structural information together.
4.4.1 Effectiveness of Homology Modelling
The 2004 study of FXI missense mutations resulted in the first detailed 
homology models for the structure of the FXI domains based on the then recently- 
determined crystal and NMR structures of an E. Tenalla adhesin protein and human 
P-tryptase. Initially the accuracy of the Ap domain models was demonstrated by 
DSSP analyses that showed all the major secondary structure elements seen in the 
NMR structure of an E. Tenalla adhesion (PDB code: 1HKY) were present in the 
four Ap models after extensive energy refinement. There was also general agreement 
between the DSSP secondary structure assignments and the consensus secondary 
structure predictions (Figure 4.2b). Although sequence identities between the Ap 
domains of FXI and template structures are low (Table 4.2), they are as expected for 
small homologous P-sheet proteins (Lesk and Chothia, 1982). This is illustrated by 
the low sequence identities (8% to 12%) between the known structures that are 
shown to exhibit strong structural conservation (Figure 4.2a). For all five domain 
models, the cores of these models were expected to be well predicted, while their 
accuracy was expected to diminish in the regions of insertions and deletions in loops 
at the protein surfaces. This was sufficient to locate the positions of individual amino 
acids involved in mutations, while the positions of residue sidechains was not well 
determined, and so analysed accordingly. Furthermore it was not possible to predict 
with certainty the effect of mutations on the interactions between domains.
The homology models provided the first structural analysis of mutations and 
residues implicated in the binding of substrates and ligands. Previously, models for 
the four Ap domains had been presented using an ab initio molecular dynamics and 
energy minimisation techniques (Baglia et al., 1991; 1993; 1995; 1996). As our
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models were based on experimentally solved homologous structures, they were 
significantly more accurate (O’Connell et al., 2005). The major difference from the 
ab initio predictions and the homology models was that the earlier ab initio models 
had predicted that three anti-parallel (3-strands formed a continuous binding surface, 
with binding regions mapped to this area. In distinction, the new models predicted 
that this same region also contained three |3-strands E, F and G, but only two of these 
(E and G) participate in the five-stranded P-sheet. Part of this p-sheet is buried, while 
the remainder contributes to two large surface exposed loops with two distorted p- 
strands B and F beneath the five-stranded P-sheet. The homology structures were 
confirmed with the recent crystal structure of intact FXI.
Table 4.7 represents my structural analysis from 2005, where 42 missense 
mutations were analysed within homology models of FXI domains. It is useful to 
compare this with the crystal structure analysis of mutations to provide an insight 
into the accuracy of these earlier predictions (Table 4.5). Of the 28 missense 
mutations with known phenotypic data, 26 show identical DSSP assignment of helix, 
strand or coil compared to the assignments using the crystal structure. Only two 
mutations were incorrectly assigned, where Phe283Leu was assigned as being in a 
coil instead of P-strand and Gly350Ala was assigned as p-strand instead of coil. Both 
of these mutations lie within Ap4 and are implicated in dimerisation. Both mutations 
have been incorrectly predicted since the p-strands of the homology models are 
shorter than the P-strands of the crystal structure (Figure 4.7). However, this 
incorrect assignment did not affect the outcome of the analysis of the mutations. In 
the homology study, surface accessibility was assigned using NACCESS (Hubbard 
and Thornton, 1992). Directly comparing the DSSP accessibility scores from the 
model and crystal structure (Figure 4.7) only three mutations have side chain 
accessibility incorrectly predicted (i.e. defined as buried instead of accessible or vice 
versa). Since side chain accessibility scores were interpreted with caution, the 
incorrect assignment did not affect the analysis of the mutations within the homology 
structures (O’Connell et al., 2005).
In conclusion, although crystal structures provide a more accurate analysis of 
side chain conformations, it is clear that homology models can give an informative 
analysis of the structural affects of mutations, and can act as an accurate alternative 
when an experimental structure is not available.
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Table 4.7 Structural analysis of 28 missense mutations using homology
modelling
Domain Mutation DSSP Accessibility Type Predicted Effect
Apple 1 Cys38Arg C 0 I Structural; Disrupts disulphide 
bridge
Apple 2 Glyl55Glu C 4 II Functional; Disturbs proposed 
FIXa binding loop
Apple 3 Phe221Ser E 1 I Structural; Buried residue
Gln226Arg* C 6 CH Polymorphism
Cys237Tyr E 0 I Structural; Disrupts disulphide 
bridge
Ser248Asn* C 1 II Functional; Replaces platelet 
binding site
Lys252Ile E 7 CH Structural: May affect solubility
Apple 4 Phe283Leu C 0 I Functional/Structural; May 
prevent dimerisation
Leu302Pro H 4 I Structural; Disrupts helix 
formation and disulphide bridge
Thr304Ile H 7 I Structural; Disrupts disulphide 
bridge
Arg308Cys C 9 I Structural; Disrupts disulphide 
bridge
Glu323Lys B 4 I Functional/Structural; May 
prevent dimerisation
Gly336Arg S 9 CH Structural; May prevent 
dimerisation
Gly350Ala C 1 CH Structural; Buried residue; may 
affect dimerisation
SP Thr386Asn E 0 I Structural; Buried residue
Cys398Tyr E 0 I Structural; Disrupts disulphide 
bridge
Gly400Val E 0 I Structural; Buried residue
Ala412Val G 0 I Structural; Disrupts secondary 
structure
Phe442Val S 2 I Structural; Disrupts correct folding 
pathway
Gly460Arg S 0 I Structural; Buried residue
Tyr493His c 9 CH Functional; At surface near N- 
terminal Ile370
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Table 4.7 Structural analysis of 28 missense mutations using homology
modeling (continued)
Domain Mutation DSSP Accessibility Type Predicted Effect
Trp501Cys S 0 I Structural; Buried residue; Extra 
Cys residue
Lys518 Asn E 5 CH Functional; At surface near N- 
terminal Ile370
Pro520Leu C 2 II Functional; At surface near N- 
terminal Ile370
Gly555Glu T 2 II Functional; Perturbs active site
Trp569Ser E 2 I Structural; Disrupts correct folding 
pathway
Thr575Met E 0 CH/II Functional; Perturbs active site
Ser576Arg E 0 II Functional; Perturbs active site
CH Compound Heterozygosity.
* Index patient compound heterozygous for these two mutations
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The RMSD between the five homology domain models and the crystal 
structure ranged from 1.19 A  to 2.7 A . This can be considered accurate since the 
average RMSD between homology models of known structured within the CASP6 
experiment ranged from 2.6 A  to 29.5 A  (Tress et al., 2005).
4.4.2 Effectiveness of Mutation Analysis using Crystal Structures
The final crystal structural analysis of the mutations in the four Ap domains 
of FXI has given insight into the effects governing both Type I and Type II 
mutations. With Type I mutations, the crystal structure showed that either Ap 
domain folding, substrate binding or dimerisation is altered, whereas Type II 
mutations affect substrate binding regions on the surface of the Ap domains.
Since the Ap domains share homology with each other it is interesting to 
view the distribution of all Ap mutations in terms of a single consensus Ap domain 
structure in order to identify positions of structural relevance. Figure 4.22 shows the 
conservation of the Ap domain structure and positions of the mutations within each 
domain. The majority of mutations mapped to the Ap domains are classified as Type 
I, where phenotypic data shows a low concordant FXI:C and FXI:Ag implying a 
problem with expression or secretion of FXI, or rapid degradation. The majority of 
these Type I mutations within the Ap domains disrupt one of the three conserved 
disulphide bridges. It is not surprising these mutations have Type I phenotypes since 
each Ap domain comprises a small cysteine-rich structure whose fold is primarily 
stabilised by its disulphide bridges (Creighton, 1993). This makes it susceptible to 
protein misfolding if these disulphide bridges are disrupted. The relatively frequent 
occurrence of mutations that affect the C3-C4 bridge indicates the importance of this 
disulphide bridge for the overall fold of the Ap domain (Figure 4.22).
Of the type II mutations affecting the Ap domains, only Ser248Asn has been 
previously well defined (Martincic et al., 1998; Sun et al., 2001; Gailani et al., 2001). 
In the case of Glyl55Glu, there is a discrepancy in reported FXI:Ag levels. Two 
patients appear to have a Type I disorder with concordant FXI:C/FXI:Ag levels 
(Mitchell et al., 2003; Alhaq et al., 2000) while a third has a higher FXI:Ag (64 U/dl) 
than FXI:C (N. M. O’Connell, personal communication). The homology model was 
initially used to investigate this mutant, and energy minimisation suggested that the 
putative FIX substrate binding loop within Ap2 could be disrupted supporting a Type 
II functional assignment (O’Connell et al., 2005). However, Glyl55Glu occurs at
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one of several positions within the Ap domain that correspond to more than one 
mutation. Three mutations (Glyl55Glu, Gly245Glu and Gly366Arg) occur at this 
position (number 66) (Figure 4.22). This position is interesting since Glyl55Glu has 
been assigned a Type II phenotype, whereas Gly245Glu and Gly336Arg are both 
Type I mutations at the same position. Since the replacement of this conserved 
glycine residue in both Ap2 and Ap3 causes a Type I phenotype and reduces the 
amount of FXI in plasma, it would be expected that the replacement of Glyl55 
would also cause a Type I phenotype. Although the FXI:Ag level within one study 
points towards a Type II mutation since the patient is heterozygous for the mutation 
and the FXI:Ag level is above half of normal levels, together with the conservation 
of Type I mutations at this position in Ap3 and Ap4 and the fact that the FXI:Ag 
level is reduced, Glyl55Glu is more likely to be correctly assigned as a Type I 
phenotype. Although initial studies of the FIX substrate binding region within FXI 
pointed towards binding regions within both Ap2 and Ap3, Type I phenotypic 
assignment of Glyl55Glu is supported by later experiments that suggested only 
alterations within the Ap3 domain affected clotting activity (Baglia et al., 1991; Sun 
et al., 1999). Within the FXI crystal structure, this loop is exposed towards the 
interface between the Ap2 and Ap3 domains, suggesting that substrate binding may 
not be possible within this loop due to interdomain and dimer contacts (Figure 4.17). 
Further experimental study is needed to confirm the functional aspects of this 
mutation and the Ap2 domain.
Within the Ap domain, mutations tend to cluster in regions such as P-strand 
C that has seven mutations, and the loop between pD and PE that contains five 
mutations (Figure 4.22). Three of the four polymorphisms also reside in this loop 
between pD and PE suggesting residue substitutions can be accommodated into this 
loop without affecting FXI structure or function.
The formation of FXI dimers occurs due to covalent and non-covalent 
interactions between the Ap4 domains (Meijers et al., 1992a; Gailani et al., 2001; 
Dorfman et al., 2001; Cheng et al., 2003; Papagrigoriou et al., 2006). The structural 
analysis has implicated that four mutations (Gly232Lys, Phe283Leu, Arg308Cys and 
Gly350Ala) are in the region of Ap4 where more extensive interactions between 
monomers may occur. Although two of these residues (Phe283 and Gly350) are not 
surface exposed, they lie on the same face as the residues implicated in dimer 
contacts, and substitution of either Phe283 or Gly350 is likely to alter the surface of 
Ap4.
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Figure 4.22 Distribution of mutations within aligned Ap domain sequences
The sequences of the four Ap domains within FXI are shown, with regions of 
secondary structure highlighted in grey. The positions of missense mutations are 
highlighted as ellipses that are colored according to phenotype, where red represents 
Type I mutations, green represents Type II, orange represents unknown phenotypes 
and purple represents the position of non-disease associated polymorphisms. The 
consensus DSSP assignment of secondary structure is written below the alignment, 
where E represents p-strand, H represents helix and gaps represent regions of coil 
within the structure.
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Of these two mutations, Phe283Leu is one of the most frequent mutations linked to 
FXI deficiency in the Jewish community (Asakai et al., 1991; Shpilberg et al., 1995). 
The structural interpretation of Phe283Leu is supported by expression studies that 
indicated a reduction in secretion of the mutant Leu283 (approximately 8% of WT 
FXI) and an intracellular accumulation of mutant FXI monomers (Meijers et al., 
1992a 1992b). Gly350 occurs at a highly conserved position (80) within the Ap 
domain structure (Figure 4.22). The relatively slight change of this glycine to an 
alanine has effects on the dimerisation of FXI but also seems to be structurally 
relevant for Apl, Ap2 and Ap3 since it is conserved throughout the Ap domains of 
FXI and PK that do not form dimers (Figure 4.2).
It is interesting that a non-disease associated polymorphism (Cys321Phe) that 
is seen frequently in normal populations occurs at the Cys321 residue responsible for 
the disulphide link between two FXI monomers. Within the FXI dimer structure, 
although covalent interactions between the Cys321 residues on each FXI monomer 
are significant in dimer formation, Cys321 is not required for dimerisation (Meijers 
et al., 1992a). This implies that non-covalent interactions with other exposed 
residues are more critical to dimer formation than the disulphide bond formed at 
Cys321.
Two type II mutations (Gly555Glu and Thr575Met) within the SP domain 
have been shown to affect the function of FXI by blocking access to catalytic site 
residues. The initial study using homology models suggested a mechanism for the 
functional defect produced by a third Type II mutation, Pro520Leu (O’Connell et al., 
2005). This can now be confirmed with analysis of the crystal structure. Pro520 is 
conserved in Factor X and Factor VII, and the mutation of Pro520 in both these other 
proteins also causes Type II phenotypes (James et al., 1991; Wulff and Hermann, 
2000; Peyvandi et al., 2000). Since Pro520 lies within the region where Ile370 is 
inserted during activation of FXI it is proposed this mutation affects the activation of 
FXI. On cleavage of the Arg369-Ile370 bond, the free N-terminus of the SP domain 
inserts into the activation pocket of FXIa, generating the oxyanion hole (Friedrich et 
al., 2003) (Figure 4.16). The introduction of a leucine side chain may block this hole, 
and block activation of FXIa. It is also suggested that the Arg308Cys mutation may 
be relevant for FXI activation since it lies in close proximity to the Arg369-Ile370 
cleavage site within the zymogen structure.
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4.4.3 Web Database
The structure and content of the FXI deficiency database corresponds to the 
recommendations of the Human Variation Society (HGVS) for locus-specific 
databases (Claustres et al., 2002). There have been over 2000 hits since December 
2004 and feedback from the scientific community has been positive. The mutation 
and patient data within the database are also available in XML format.
4.4.4 Phenotypic Classification and Prediction from Structures
Without phenotypic information, structural interpretation can be limited. 
Using the mutation data within this database, the structural effects of 64 mutations 
can be explained. However, the consequences of 12 missense mutations are unclear 
and require further experimental study to establish the cause of phenotypic outcome. 
For example the effect of Arg234Ile/Ser cannot be predicted, since it may disrupt the 
Ap3 domain and affect platelet binding or structural stability of FXI. Likewise, 
structural interpretation of the Lys252Ile mutation in Ap3 initially pointed in the 
direction of a Type II mutation, since Lys252 is a surface exposed residue strongly 
implicated in platelet binding. However, experimental analysis shows that protein 
expression is reduced (Dai et al., 2004).
To complicate matters further, even with Type I and Type II 
classification/prediction of mutations it is still not possible to predict the clinical 
phenotype. For example, patients that are heterozygous for a Type II mutation appear 
no more severely affected clinically than patients heterozygous for the deletion of the 
entire F ll  gene (Mitchell et al., 2006).
It is also difficult to predict the effect of heterozygous mutations. As FXI is 
secreted as a dimer, heterozygous mutations can exert dominant-negative effects on 
either the secretion or function of FXI since the mutated monomer of FXI can form a 
dimer with either itself or with a wild-type FXI monomer. A recent study proposed a 
classification of Type I mutations as being those that reduce or prevent polypeptide 
synthesis, those that fail to form intracellular dimers and are retained in cells and 
those mutations that form dimers that are not secreted (Kravtsov et al., 2005). The 
latter category involves those mutations that will have a greater affect on FXI:C due 
to the trapping of wild type monomers.
The analysis of non-synonymous polymorphisms in the context of what is 
known about disease causing mutations is also useful to highlight the difficulties in
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assigning causality to mutations. For example, initially Gln226Arg was highlighted 
as a disease causing mutation, since it was not present in a normal population of 100 
alleles (Martincic et al., 1998). Gln226 is also conserved across species, suggesting 
an important role for the Gin residue at this position. Homology modelling first 
showed that Gln226 is located on a large surface loop insertion that is present in all 
FXI Ap domains. It is also fully solvent exposed in the crystal structure where the 
loop is remote from the FIX or platelet binding region. Substitution with arginine is 
not predicted to result in structural or functional disruption. Compound 
heterozygosity for Gln226Arg and Ser248Asn was confirmed in an index patient, but 
FXI:C was consistent with only a partial deficiency of FXI (Martincic et al., 1998). 
Expression of recombinant FXI-Arg226 was similar to recombinant wild-type FXI 
while the catalytic efficiency of FXIa-Arg266 was also similar to wild-type FXI (Sun 
et al., 2001). This suggests that Gln266Arg is a non-disease-causing polymorphism. 
This assignment highlights the importance of structural analysis and expression 
studies in terms of assigning whether a mutation is disease-causing or a benign 
polymorphism.
In order to analyse the clinical outcome of mutations further, the clinical 
phenotypes of patients need to be better classified so that they can be directly 
compared with each other. At present, it is only possible to interpret the comments 
made in publications that describe patient information in varying amounts of detail 
and from the point of view of different consultants (Figure 4.23). For this reason, 
working with Dr D J Perry (Addenbrookes Hospital, Cambridge, UK) I have 
proposed a classification of clinical outcome on the submission form for new 
mutations within the web database. This comprises a set of multiple choice questions 
to define symptom descriptions more clearly. Unfortunately as yet, no direct 
submissions of mutations have been sent to the database so this classification has not 
been applied. As the database increases in size and popularity, more groups may be 
encouraged to submit mutations.
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Figure 4.23 The coverage of 271 patient records with respect to different 
data fields.
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4.5 Conclusions
The FXI Deficiency database is a comprehensive web-based database of all 
reported F ll  mutations. It allows rapid access to the entire listing of published 
mutations in F ll  including splice site mutations, point mutations and insertions and 
deletions. To our knowledge there is no other up-to-date interactive locus-specific 
database recording all the mutations and genetic alterations in the F ll  gene. Unlike 
other static databases of coagulation protein mutations, this information is stored in a 
relational database that can be queried and searched at the user’s discretion. Using 
these interactive searches and structural prediction analysis, it becomes possible to 
view each mutation in the full context of what has been previously elucidated for 
other F ll  mutations. New FXI disease-causing mutations can also be structurally 
characterised to complement phenotypic data. Expression studies can be designed to 
verify the molecular basis of each deficiency. If widely accepted, this database of 
patient data should lead to a more rational evaluation of phenotype and bleeding risk.
The initial version of the website provided analysis using homology models 
which have been confirmed by the recent crystal structure of FXI. In the absence of a 
crystal structure, the homology models were of use to investigators seeking to 
predict the effect of new FXI mutations.
As new database submissions are via an electronic form, new data in the 
database will be automatically organized in the required structured and complete 
manner necessary to improve and maintain the utility of the database. In time, the 
accumulated collection of structured mutation and patient data will enable a more 
comprehensive understanding of genotype-phenotype relationship in FXI deficiency.
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Chapter 5
Complement Factor H Mutation Database
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5.1 Introduction
Abnormal regulation of complement attack on host cells is associated with a 
number of diseases.
Haemolytic uraemic syndrome (HUS) is characterized by a phenotype of 
microangiopathic haemolytic anaemia (loss of blood cells), thrombocytopenia (lack 
of platelets) and acute renal failure in affected individuals (Perkins and Goodship,
2002). Thrombotic microangiopathy (blockage of capillary loops of the glomeruli of 
the kidney) is unique to this syndrome and causes vessel wall thickening with 
swelling and detachment of endothelial cells from the basement membrane of the 
kidney (Zipfel et al., 1999).
The majority of childhood HUS cases are caused by toxic Escherichia coli 
bacteria and are associated with diarrhoea (D+HUS). This typical D+HUS form is 
generally non-recurring and although patients show acute renal failure, renal 
function usually recovers and the overall prognosis is good. A second form of HUS, 
known as atypical HUS (aHUS) is not associated with E. coli infection or diarrhoea 
(D'HUS) and has a poorer prognosis. aHUS is rare and can present sporadically from 
a number of predisposing factors such as pregnancy, drugs (e.g. chemotherapy or 
immunosuppressive agents) or other diseases such as systemic lupus erythematosus 
and anti-phospholipid syndrome (Kavanagh et al., 2006). Patients suffering from 
aHUS often develop end stage renal disease requiring renal transplantation therapy.
aHUS is associated with reduced plasma levels of protein C3 and defective 
complement control. In 1998 genetic analysis revealed that aHUS segregated with a 
hot spot of mutations within the RCA gene cluster (Warwicker et al., 1998). 
Subsequently, various studies reported mutations within the FH gene of aHUS 
patients (Sanchez-Corral et al., 2000; Richards et al., 2001; Caprioli et al., 2001; 
2003; Neumann et al., 2003; Dragon-Durey et al., 2004) and two other complement 
regulatory proteins, MCP and FI were also implicated to have a role in aHUS 
(Richards et al., 2003; Esparza-Gordillo et al., 2005; Caprioli et al., 2006; Fremeaux- 
Bacchi et al., 2006). All three proteins control the regulation of the alternative 
pathway of complement activation, and in particular regulate the C3 convertase 
enzyme, C3bBb
Autoantibodies against FH of the Immunoglobulin G subtype have also been 
identified in the plasma of three patients with recurrent aHUS. These antibodies 
affect the function of FH and cause reduced FH regulatory activity (Dragon-Durey et
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al., 2005). Recently mutations within C3 and FB have also been linked to aHUS 
patients, further complicating the genetic aspects of this disease (Fremeaux-Bacchi et 
al., 2006; Goicoehea de Jorge et al., 2007).
Mutations within CFH, MCP or IF  allele have been identified in 50% of aHUS 
patients (Kavanagh et al., 2006). The majority of these aHUS patients are 
heterozygous for mutations, having one normal functioning copy of the gene. 
Suboptimal activity of the protein as a result of one wild type allele is sufficient to 
maintain the integrity of cells under normal conditions, since other regulators can 
compensate. However, upon insult (during infection and/or inflammation) the release 
of inflammatory mediators can cause the retraction of activated endothelial lining 
cells and result in the exposure of the subendothelial extracellular matrix. In 
particular the glomerular and subendothelial membranes of the kidney lacks 
endogenous complement regulators such as CR1 and DAF. Without proper 
complement regulation, there is enhanced tissue damage and destruction. Thrombin- 
induced platelet aggregation is enhanced by presence of C3 (Polley and Nachman, 
1979). On activation, platelets release FH from their a-granules in order to protect 
them from complement activation and regulate C3b levels (Devine and Rosse, 1987; 
Karpman et al., 2006). Where complement activation cannot be efficiently 
controlled, more platelets aggregate and pathological events can lead to small blood 
clots.
Membranoproliferative glomerulonephritis type II (MPGN II) is a rare 
disease which is characterised by complement protein containing dense deposits that 
form within the basement membrane of the glomerular capillary wall of the kidney. 
This is followed by capillary wall thickening, growth in number of mesangial cells 
and the formation of glomerular scar tissue (Appel et al., 2005). MPGN II has been 
reported for homozygous patients that completely lack FH in plasma or only possess 
dysfunctional FH (Dragon-Durey et al., 2004; Licht et al., 2006). These patients 
usually suffer kidney damage early in life. MPGN II is also linked to the presence of 
an autoantibody against the C3bBb convertase (C3NeF) that acts to stabilise the 
convertase and increase its half life. C3NeF is however present in patients showing 
no signs of MPGN II (Licht et al., 2006). The absence of functional FH in plasma 
allows uncontrolled complement activation at the glomerular membrane, which in 
contrast to tissue cells, lack endogenous complement regulators such as MCP.
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Complement activation here results in membrane thickening and the inhibition of 
kidney function.
Recent genetic linkage studies have also revealed a role of FH in age-related 
macular degeneration (AMD). AMD is the most common cause of blindness in the 
western world and is a disorder of the macular area of the retina characterised by 
small deposits called drusen that form under the retina. Although the disease 
mechanism is still unknown, various lifestyle and genetic factors have been shown to 
increase the risk. A common polymorphism of FH, Tyr402His within SCR-7, was 
identified as a major risk factor for developing AMD (Klein et al., 2005; Haines et 
al., 2005; Edwards et al., 2005; Hageman et al., 2005). The histidine variant was 
present significantly more in diseased individuals (94%) than in controls (46%). It is 
unknown how this polymorphism within FH could alter the function of FH and how 
this functional alteration could be a risk factor to AMD.
Interpreting the molecular basis of aHUS, MPGN II and AMD can lead to a 
better understanding of the factors that combine in order to regulate complement 
activity on host cells. For example, identifying that a mutation within FH could have 
the same glomerular disease outcome as a mutation within MCP suggests that both 
proteins work together during glomerular C3 activation (Zipfel et al., 2006). It is 
important to understand the molecular basis of complement disorders in order to 
interpret possible therapeutic and diagnostic alternatives. Knowledge of complement 
regulation is relevant for a number of therapies, particularly transplantation 
autoimmune rejection. In terms of aHUS treatment it has now become evident that 
kidney transplants have been shown to correct MCP dysfunction (Richards et al.,
2003) whereas patients with mutations in either FH or FI suffer recurrent aHUS after 
kidney transplantation. This is readily understood as MCP is a membrane protein and 
hence is transplanted with the kidney. Since FH and FI are produced in the liver, a 
combined kidney and liver transplant would be expected to reduce the disease 
occurrence however this is a risky procedure and none of the three initial reports had 
a favourable outcome (Remuzzi et al. 2002; 2005; Cheong et al., 2004). However a 
recent report documented a successful combined liver-kidney transplant alongside 
plasma replacement in aHUS patient that was compound heterozygous for CFH 
mutations (Saland et al., 2006). Plasma containing FH could also represent 
therapeutic prospects but any studies need to be followed carefully since the initial 
trigger of aHUS remains unclear. A number of patients with genetic defects do not
177
develop the disease until a later period in their lives indicating that additional 
triggers and environmental factors are relevant. It has also been suggested that 
complement activation could be modulated using complement inhibitors such as 
monoclonal antibodies or recombinant regulators (Mollnes and Kirschfmk, 2006; 
Zipfel et al., 2006). The clinical heterogeneity of disease outcomes depending upon 
the nature of the underlying genetic defect highlights the potential utility for 
comprehensive genetic analysis of aHUS, MPGN II and AMD patients.
Within this chapter I will describe the compilation of a comprehensive web- 
based database of all reported CFH mutations and the insights into the classification 
and molecular consequences of aHUS that have been gained from this. MCP and IF 
mutations associated with aHUS as well as CFH mutations associated with MPGN II 
and AMD are also incorporated into the database. This database integrates genetic 
and phenotypic information together with structural analysis of these mutations in 
order to provide a central resource on alternative pathway complement mutations 
and disease. The use of such an interactive and contextual database alongside 
structural analysis will enable the significance of new mutations to be more easily 
understood, leading to a molecular interpretation of FH function and its mutants and 
providing further insight into the role of the complement proteins in aHUS, MPGN 
II and AMD diseases.
5.2 Methods
5.2.1 Identification of Mutations
Mutations within FH, MCP and FI were identified by searching the HGMD 
(http://archive.uwcm.ac.uk/uwcm/mg/hgmdO.html) at the locus sites of CFH, MCP 
and FI. Additional mutations were identified searching the literature database 
PubMed (http://www.ncbi.nih.gov/entrez/query.fcgi) with the following search 
terms: FH mutation, factor H mutation, CFH mutation, HUS mutation, MCP 
mutation, CD46 mutation, aHUS mutation, Factor I mutation, IF mutation. Novel 
mutations were also submitted to the database from eight European collaborating 
groups as follows: Prof G Remuzzi at the Mario Negri Institute for Pharmacological 
Research Villa Camozzi in Italy; Prof T H J Goodship at the Department of 
Nephrology, University of Newcastle upon Tyne, UK; Dr V Fremeaux-Bacchi at the 
Service d'Immunologie Biologique, Hopital Europeen Georges Pompidou, France; 
Prof P F Zipfel at the Department of Infection Biology, Hans Knoll Institute for
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Natural Products Research, Germany; Prof S Rodriguez de Cordoba at the 
Departamento de Inmunologia, Centro de Investigaciones Biologicas (CSIC), Spain; 
Dr M Lopez-Trascasa at the Unidad de Inmunologia, Hospital Universitario La Paz, 
Madrid, Spain.
SNPs are defined as point mutations that occur in over 1% of the general 
population. To avoid confusion, I will refer to SNPs that are not associated with 
disease as non-disease causing polymorphisms both within the database and this 
thesis. There are several SNPs that are associated with a disease risk such as the 
His402Tyr SNP within FH that is associated with AMD and the c.l-332C>T, 
c.2016A>G (Gln672Gln) and c.2808G>T (Glu936Asp) SNPs within FH that are 
associated with aHUS. These SNPs are referred to as disease-associated 
polymorphisms. Genetic alterations that are extremely rare within populations and 
are thought to be the major cause of disease or deficiency are referred to as disease- 
associated mutations.
SNPs were identified by searching dbSNP using the NCBI Entrez search 
tool (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=snp). The 
gene symbols CFH, MCP and IF  were used to search for SNP records relating to 
each of the gene loci. An automatic parsing tool was written to analyse the results of 
each search using the XML output format returned by dbSNP. This tool identifies 
the 21 nucleotides within the 5’ and 3’ sequences before and after the SNP by 
finding the appropriate XML label within the result. These sequences are then split 
into 6 blocks of seven that are then matched to the nucleotide DNA sequence of the 
gene the SNP refers to. The matches are then ordered and a score is given when 
more than three blocks in the right order match the nucleotide sequence. The 
majority of SNP matches match the gene sequence identically; however those that do 
not are labelled for manual inspection. Some SNP records refer to the reverse 
translation of the gene, and to accommodate this, the SNP finder tool reverse 
translates the 3’ and 5’ sequences and searches for the reverse translation also. Using 
the position of the SNP within the gene sequence, and constant information such as 
intron/exon boundary numbers, the tool can automatically generate the correct 
HGVS nomenclature (http://www.hgvs.org/mutnomen/) for each SNP. This tool is 
incorporated into the management system of the database.
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5.2.2 Phenotypic Classification of Mutations
It is useful to identify whether a patient suffers from a Type I or a Type II 
disorder (Section 1.8.3). Type I disorders occur when the protein level is low and 
indicate defective transcription, defective translation, abnormal secretion or rapid 
degradation, while Type II disorders arise when the protein level is normal but its 
functional activity is reduced. This scheme is commonly used with coagulation 
protease mutations (Chapter 4).
Problems arise for the classification of FH aHUS mutations as there is a large 
variation of FH protein levels in plasma. Even with unaffected individuals, FH levels 
can range between 235 -  810 mg/1 (Neumann et al., 2003) or 350 -  650 mg/1 
(Caprioli et al., 2001), and FH levels have been shown to be significantly lower in 
neonates and infants than in adults (Ault, 2000). This makes it increasingly difficult 
to assign whether the FH level of a patient that is within the normal range accounts 
for one or two alleles (Figure 5.1). For example, the majority of aHUS patients are 
heterozygous, having one intact and one defective allele. If the mutated allele has a 
defective protein secretion the FH plasma level would be about 50 % of the normal 
value. However as the ‘normal’ values cover such a large range it is difficult to say 
whether this is Type I. Within the database, those mutations with FH levels that fall 
within ambiguous ranges are classified with an unknown phenotype unless the 
structural models can aid interpretation and classification in order to assign a Type I 
or Type II phenotype.
5.2.3 Structural Analysis
Experimentally solved NMR structures are available for SCR-5, SCR-15, 
SCR-16 (Barlow et al., 1992; Barlow et al., 1993) and SCR-19 and SCR-20 of 
human FH (Herbert et al., 2006; Jokiranta et al., 2006) (Table 1.3). In order to 
perform structural analysis within the remaining 15 SCR domains of FH, homology 
models were constructed from close structural templates using MODELLER v7 
(http://salilab.org/modeller/FAQ.html). In addition to FH SCR structural templates, 
PSI-BLAST (Altschul and Koonin, 1998) searches of the PDB together with 
searches of the PFAM database (Finn et al., 2006) identified 35 different SCR 
structural templates in 45 different protein structure files (Table 2.3).
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Figure 5.1 Serum concentrations of FH and C3 for 56 patients
The reported FH serum concentration as a function of the C3 serum concentration is 
shown for 56 patients carrying a mutant FH allele, where this information is 
available in the literature. Note that a given FH mutation can occur more than once. 
The colour coding indicates which SCR is affected. The dashed lines indicate the 
upper and lower levels of the normal range described in the Caprioli et al., 2001 
study. The solid line represents the mid point of this range.
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From these possible templates, the closest template for each SCR sequence within 
FH in terms of sequence identity and minimum insertions and deletions was 
identified using CLUSTALW alignments (Higgins et al., 1994) (Figure 5.2, Table 
5.1).
Experimentally-solved NMR structures are available for SCR-1 and SCR-2 
of MCP (Casasnovas et al., 1999) (Table 2.3). Homology models of the remaining 
two SCR domains in MCP were again constructed using MODELLER v7. The 35 
structural SCR templates were used to identify the closest template using manual 
sequence alignment (Figure 5.3, Table 5.1).
There are no experimentally determined coordinates available for FI, 
although the individual domains do have closely related templates available in the 
PDB (Table 5.2). These were identified using PSI-BLAST and aligned using 
CLUSTALW (Figure 5.4). The PSI-BLAST search for the FI SP domain sequence 
within the PDB returned 11 unique serine proteases within the first 50 hits. All of 
these matches had over 32% sequence identity.
The conserved disulphide bridges were maintained in the majority of 
homology models with two exceptions: (i) The FI CD5 domain has a disulphide 
bridge alteration. The Cys31-Cys95 (corresponding to Cysl41 and Met204 of FI) 
disulphide bridge within the CD5 template domain of MAC-2 Binding Protein is not 
conserved in the FI CD5 sequence (Figure 5.4b). There is however, a cysteine 
residue (Cysl81) within the FI CD5 domain that is aligned with Leu70 of the MAC- 
2 Binding Protein. Leu70 lies in close proximity to Cys31 (the distance between the 
CA atoms of Leu70 and Cys31 is 6.37A) in the CD5 domain of the MAC-2 Binding 
Protein, so the disulphide bridge connectivity could be maintained within the 
modelled structure (Figure 5.5a). (ii) The FI LDLR-1 domain loses a disulphide 
bridge at the position corresponding to that between Cys5 and Cysl7 in the LDL 
Receptor domain (Figure 5.4c and Figure 5.5b). The bond lengths and bond angles 
within all modelled domains were verified using PROCHECK (Laskowski et al., 
1993).
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1G4 0 _3  jQSPPSISNGRHNGYEDFYTDGSWTYSgNSGYSLIGNSGVLgSGGEjsDPPTS
1 0 0 0  1 0 1 0  1 0 2 0  1 0 3 0  1 0 4 0
SCR_17 HLSLPSFENAIPMGEKKDVYKAGEQVTYTfflATYYKMDGASNVTffllNSRfflTGRPTH
1G4 o_3 | q s p p s i s n g r h n g y - e d f y t d g s w t y s | n s g y s l i g n s g v i J s g g e § s d p p t |
1 0 6 0  1 0 7 0  1 0 8 0  1 0 9 0  1 1 0 0
SCR_18 BvNPPTVQNAYIVSRQMSKYPSGERVRYQfflRSPYEMFGDEEVMHLNGNfflTEPPQH 
1G4 0_3 gQSPPSISNGRHNGY-EDFYTDGSWTYSgNSGYSLIGNSGVLgSGGEjsDPPTfl
Figure 5.2 Alignments of FH SCR domains with templates
The sequences of 15 FH SCR domains of unknown structure are shown aligned with 
their template SCR domain sequences, identified by their PDB codes. The P-strand 
secondary structure is assigned using DSSP and highlighted in grey boxes and 
labelled from pi to p8 when present (according to Figure 2.6). Conserved cysteine 
and tryptophan residues are highlighted in black. Residue numbering corresponds to 
the FH protein sequence detailed in RefSeq #NM_000186.1 where +1 corresponds to 
the A of the ATG initiation codon.
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Table 5.1 Summary of homology modelling of 15 domains in FH, two domains 
in MCP and five domains in FI*
SCR TemplatePDBa Protein Insertions Deletions
Sequence
Identity
FH 1 1HFI Human FH 3 None 25%
FH 2 1QUB 1 Human (32-Glycoprotein I; 1 None 28%
FH 3 1QUB 3 Human 02-Glycoprotein I; 1 None 18%
FH 4 1HCC Human FH None 1 32%
FH 6 1G40-1 VCP None 1 16%
FH 7 SCR5b Human FH None None 33%
FH 8 1HFI Human FH 3 2 27%
FH 9 SCR5 Human FH 2 None 23%
FH 10 1HCC Human FH 1 None 31%
FH 11 1HCC Human FH 1 None 33%
FH 12 1HCC Human FH None None 33%
FH 13 1HCC Human FH None 3 19%
FH 14 1G40-3 VCP None None 30%
FH 17 1G40-3 VCP 1 None 40%
FH18 1G40-3 VCP 1 None 35%
FH 19 1G40 3 VCP 1 None 40%
FH 20 1G40-1 VCP 1,1 1 18%
MCP 3 1GPZ 1 Complement Protease C1R None 1 19%
MCP 4 1G40 1 VCP None None 39%
FI FIMAC 1LR7 Follistatin 2 6, 2,1 23%
FI CD5 1BY2 MAC-2 Binding Protein 2,1 2 25%
FI LDLR-1 1AJJ LDL Receptor Module None None 40%
FI LDLR-2 1AJJ LDL Receptor Module None None 45%
FI SP 1YBW Hepatocyte Growth Factor 2,2,1 2,1,2,4,1 32%
*The numbers in the insertions and deletions columns indicate how many residues had to be inserted 
or deleted from the template structure in order to model the domain. More than one value separated by 
a comma indicates there are insertions or deletions at more than one place in the model. The sequence 
identity is a pairwise comparison of the sequence of the domain and the sequence of the template 
protein domain.
^he PDB codes are as follows: 1HFI, 1HCC (Barlow et al., 1993); 1QUB (Bouma et al., 1999); 
1G40 (Murthy et al., 2001); 1GPZ (Budayova-Spano et al., 2002); 1LR7 (Innis et al., 2003); 1BY2 
(Hohenester et al., 1999); 1AJJ (Fass et al., 1997); lybw (Shia et al., 2005).
bSCR5 is not deposited in the PDB, however PDB coordinates were kindly provided by Prof P.N. 
Barlow of Edinburgh University (Barlow et al., 1992).
VCP, Vaccinia virus complement control protein
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(a)
MCP_SCR3 
1GPZ 1
(b)
MCP_SCR4 
1G 40 4
17 0  1 8 0  1 9 0  2 0 0  2 1 0  2 2 0
PPPK IK N G K HTFSEVEVFEYLDAVTYSiDP-APGPDPFSLIGESTIYfiGDNSVlSRAAPEl
G p k t l d e f t i i q n l q p q y q f r d y f i a t h k q g y q l i e g n q v l h s f t a v h q d d g t ^ h r a m p  
P2 P4 P5 P6 +
2 3 0  2 4 0  2 5 0  2 6 0  2 7 0  2 8 0
-feFPW ENGKQISGFGKKFYYKATVM FEBDKGFYLDGSDTIvHDSNSlfflDPPVPKffl- 
-gPH PTISN G YLSSG FKR SY SY ND N V D FIflK Y G YK LSG SSSS'lSsPG N lflK PELPK H - 
+ +
P2 p4 p6 p7
Figure 5.3. Multiple sequence alignments of MCP domains with closely related 
templates
The sequences of the SCR-3 and SCR-4 domains are shown aligned with their 
template SCR domain sequences, identified by their PDB codes. The p-strand 
secondary structure is highlighted in grey boxes and labelled from pi to P8 when 
present, and conserved cysteine and tryptophan residues are highlighted in black. 
The cysteine pairs that form disulphide bridges have the same symbols. Residue 
numbering corresponds to the MCP protein sequence detailed in RefSeq # 
NM 002389.3 file, where numbering starts from +1 at the A of the ATG initiating 
codon.
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Table 5.2 Structural templates for FI domains
Domain PDB Entry Protein
1LR7 Follistatin
1BMO BM-40
FIMAC 1PCE PEC-60
10MT Ovomucoid
1BUS Proteinase Inhibitor IIA
CD5 1BY2 MAC Binding Protein
1N7D LDL receptor
1D2L Complement-Like repeat 3 (CR3)
LDLR-1 1J8E Low-Density lipoprotein receptor related protein 1
LDLR-2 1V9U Viral coat protein VP1
1CR8 Lipoprotein receptor-related protein complement repeat 8
1JRF Viral Receptor Domain of Tva
SP* 1A5I Plasminogen Activator
105 A Serine Protease Hepsin
1YBW Hepatocyte Growth Factor
1SGF Nerve Growth Factor
1NPM Neuropsin
1XX9 Coagulation Factor XI
1EAW Suppressor Of Tumorigenicity
1RFN Coagulation Factor IX
1AUT Activated Protein C
1BRU Elastase
1FIW (3-Acrosin Heavy Chain
*Only the 11 unique structures from the top 50 PSI-BLAST results are shown.
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Figure 5.4 Multiple sequence alignments of FI domains with closely related 
templates (continued over)
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Figure 5.4 Multiple sequence alignments of FI domains with closely related 
templates (continued)
The sequences of all six FI domains are shown aligned with the template 
domain sequences identified by their PDB codes. The secondary structure is assigned 
using DSSP and highlighted in grey boxes, with conserved cysteine residues are 
highlighted in black. Residue numbering corresponds to the FI protein sequence 
starting from the initiating ATG codon at the beginning of the 18-residue signal 
peptide (RefSeq #NM_000204.1).
(a) The FI FIMAC (FI membrane attack complex) domain.
(b) The FI CD5 (cluster of differentiation 5) domain.
(c) The FI LDLR (low-density lipoprotein receptor) domain.
(d) The FI SP (Serine Protease) domain.
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Cys141-Cys180 (FI)
M et204 (FI)
Pro222 Tyr235
Cys4-Cys16/ 
(LDLR M odule)
Figure 5.5 Secondary structure ribbon models of FI CD5 domain and LDLR- 
1 domain disulphide alterations
(a) The CD5 domain homology model is shown in blue superimposed onto 
the MAC-2 binding protein template structure (PDB code: 1BY2) shown in 
red. The disulphide bridge between Cys31 and Cys95 of the MAC-2 template 
is shown in yellow. The side chain of the Met204 residue in FI that replaces 
Cys95 and breaks the disulphide bridge is shown in red. The alternative 
disulphide bridge between Cysl41 and Cysl80 of FI is shown in green.
(b) The LDLR-1 domain homology model is shown in blue superimposed 
onto the LDL receptor module template structure (PDB code: 1AJJ) shown in 
red. The disulphide bridge between Cys4 and Cysl6 of the LDL receptor 
module that is missing within the FI LDLR-1 sequence is highlighted in 
yellow. The sidechains of the residues that align with this disulphide bridge 
are shown in green.
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5.2.4 Database Design
The FH-HUS database follows the same relational database design as the 
Factor XI database described in Chapter 4, however it is adapted to include more 
than one protein. This was achieved by adding a protein identifier field to the 
following tables: mutationTable, sequenceTable, domainTable and
bindingRegionTable. Additional tables were added to include information on assay 
techniques and normal control FH and C3 levels as well as alternative syntax and 
association mutations in other species and SNP information. The database design is 
described in Figure 5.6.
5.3 Results
5.3.1 Homology Modelling
Although the sequence identity between the SCR domain structural templates 
is quite low (10-51% between themselves), they generally possess an eight-stranded 
(PI to (38) antiparallel P-sheet SCR structure that is subdivided into three pairs of p- 
strands, with p2-p4-p6 forming a central p-sheet stabilised by two disulphide bridges 
C1-C3 and C2-C4 at the two ends of the domain (Section 2.7.2, Figure 2.6). This 
was maintained throughout the homology models. Sequence identity was higher 
between the FI domain and template sequences (23-45%) and the secondary 
structure was fully conserved in all alignments, with residue insertions and deletions 
confined only to the loop regions. As all homology models inherited the secondary 
structure of their templates, the cores of the protein domain models are expected to 
be well predicted. Since insertions and deletions were confined to loop regions, 
accuracy is expected to diminish in these regions at the protein surfaces. This is 
sufficient to locate the positions of individual amino acids, whether buried within the 
core or exposed on the surface however the positions of residue sidechains may not 
be as well determined. Therefore all accessibility scores for any side chain within a 
homology model must be interpreted with caution. This limitation does not apply if 
accessibility scores are taken from NMR or X-ray crystallography structures.
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Figure 5.6 FH-HUS database schema
Each table within the relational database is shown in a box. The attributes of each 
table are listed. Those attributes followed by a * character are the primary keys of 
each table. The attributes that are highlighted in green text are foreign keys also 
used in other tables. The relationships between each table are indicated by black 
lines where a three pronged lines represent 1:N relationships and normal lines 
indicate 1:1 relationships (Section 3.1.2).
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5.3.2 Database Overview
At the time of writing three versions of the database have been released 
(Table 5.3). A total of 54 disease-predisposing mutations were classified within CFH 
in the original version 1 description of the database, released in November 2004 
(Saunders et al., 2006). Since that time 22, 25 and 16 more unique disease- 
predisposing mutations have been identified in CFH, MCP and FI, respectively in 
the version 2 release of June 2006 (Figure 5.7a). The version 2.1 release of October 
2006 included dbSNP records and a total of 776 genetic alterations.
The majority (89%) of disease associated mutations have been identified 
within aHUS patients; however the database does contain a small number of MPGN 
II patients (Figure 5.7b). Each mutation and patient record has been manually 
entered with the aim of registering every individual aHUS patient described with a 
CFH, MCP or FI mutation. At present the database records correspond to a total of 
109 patients. Varying amounts of data are available for each mutation and patient, 
with only eight mutations having no available patient information. Figure 5.7c 
highlights the variation on the amount of reported data for each of the 109 patients. 
This variation shows the inconsistency of the published mutation reports to date, and 
highlights areas where information is lacking, such as the clinical history of the 
patient.
5.3.3 FH Mutations
The Version 2.1 update of the database contains over 300 genetic alterations 
within CFH as of October 2006. 338 of these are SNPs automatically extracted from 
dbSNP. The majority of these SNPs are nucleotide conversions within introgenic 
regions (Figure 5.8a and Figure 5.8b).
5.3.3.1 FH Mutations Overview
There are 76 rare genetic alterations within CFH that have been identified in 
aHUS, MPGN II and FH deficient patients that are thought to be the major cause of 
disease since they are not found in control populations (Table 5.4 and Figure 5.8a 
and Figure 5.8b). The majority (82%) of the CFH nucleotide changes are point 
substitutions in the sequence that lead to missense and nonsense mutations, although 
there are a small number of insertions and deletions and splice site mutations (Figure 
5.8c, Table 5.4).
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Table 5.3 FH-HUS version history
Version FirstOnline Data Updates Reference
1 Nov
2004
54 CFH
genetic
alterations
-First Release Saunders et al., 
2006
2 June
2006
167 genetic 
alterations: 
100 CFH 
A3 MCP 
24 IF
-Updated structural 
analysis for SCR19 and 
SCR-20 X-ray structures 
-Added MCP and FI 
mutations
-Added MCP and FI 
structural models and 
analysis
-Added disease-associated 
polymorphisms
Saunders et al., 
2007
2.1 Oct
2006
776 genetic 
alterations: 
423 CFH 
138 MCP 
215 IF
-Added dbSNP data for 
CFH, MCP and IF  loci
None
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FI 14%
( b )
FH Deficiency 1%
FI Deficiency 4% Glom erulonephritis  1 
MPGN 4%
aH U S89%
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Protein 
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Figure 5.7 Statistics of mutations and patients within the FH-HUS database
(a) Pie chart of 117 disease-associated mutations to show the distribution of 
mutations within the three genes.
(b) Pie chart of 117 reported disease associated nucleotide changes to show the 
distribution of mutations that are involved with each disease.
(c) The coverage of 109 patient records with respect to different data fields.
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(a)
c.-1917C>T 
C.-1747T>G 
c.-1542T>C 
Exon 1 1
Exon 2 
Exon 3 
Exon 4
Exon 5 
Exon 6 -
Exon 7 ■
Exon 8 -  
Exon 9
c.58+204T>A
C.58+239T>A
C.58+580C>T
c.58+587A>G
c.58+736A>G
C.58+1035OT
c.58+1059T>C
c.58+1319T>C
c.S8+1596C>A
c.58+2032C>T
C.58+2655A>G
c.58+2777G>T
C.58+4440G>A
c.58+4692A>G
C.58+5498G>T
c.58+5798C>T
c.58+6890A>T
C.58+7961C>T
C.58+8131G>A
c.58+8199G>A
C.58+10305A>C
c.59-9983A>G
c.59-9642A>G
c.59-9407A>G
c.59-8506T>A
c.59-7645A>T
c.59-7602A>G
c.59-7569C>T
c.59-7509G>A
c.59-7289C>T
c.59-7167C>G
c.59-7006G>A
c.59-6430C>T
c.59-6356G>A
c.59-6337G>A
c.59-4276C>T
c.59-3439A>T
c.59-2696A>T
c.59-205K>T
c.59-1792T>C
c.59-1513A>C
c.59-853A>G
c.59-36G>A
C.244+240T>C
-c.350+291G>A
C.620-140C>T
c.620-239A>G
c.427+392A>G
c.428-430T>G
c.428-345G>A
c.428-219T>C
c.428-44A>T
c.790+1509C>T
c.790+1546T>A
c.791-1360C>T
c.791-2363C>T
c.791-2450A>G
c.1159+161 A>G
c.964+1240T>A
c.964+1346T>C
c.964+1376A>C
c.964+1838T>A
C.964+475T>C
c.964+913G>C
c.965-1136A>G
c.965-1486G>T
c.965-14A>T
C.965-1575->A
c.965-1968T>C
c.965-271C>T
c.965-529A>G
c.965-53T>G
C.965-895C>T
Figure 5.8 Distribution of nucleotide changes within CFH (continued over page)
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(b)
C..1478C>G
Exon 10'
Exon 11
Exon 12 
Exon 13 
Exon 14
Exon 15
Exon 16 “ 
Exon 17"
Exon 18' 
Exon 19l
Exon 20 * 
Exon 2 1 1
Exon 22
c.1336+892A>G
C.1336+1095A>G
c.1336+1244A>T
c.1336+1360C>T
C.1336+1364C>T
C.1336+1626T>A
c.1336+1812A>G
c.1336+2136C>G
C.1336+2169A>T
C.1336+2244G>T
C.1336+2654C>T
c.1336+2658C>T
c.1336+2662C>T
c.1336+3090C>T
c.1336+3252A>G
C.1336+3647G>A
C.1336+3678C>T
C.1336+4152T>A
C.1336+4485C>T
C.1336+4544T>C 
c.1336+4713A>G 
C.1336+4740G>C 
c.1336+4886G>T 
c.1336+5113C>T 
c.1336+5136T>C 
c.1336+5207A>C 
c.1336+5282C>T 
c1336+5424T>G 
c.1336+5672A>G 
Cl 336+5839A>G 
c.1336+6282A>C 
c.1336+7154G>A 
C.1336+7424C>A 
C.1336+7719A>T 
C.1336+7883A>T 
C.1336+8059T>A 
c.1336+8360A>T 
c.1336+8918C>T
c.1336+8950T>A 
C.1336+10212C>T 
C.1336+10609C>T 
C.1336+10612A>C 
C.1336+10638C>G 
c.1336+11388C>T 
C.1336+11470A>G 
Cl 337-11747A>G 
C.1337-11648A>G 
C.1337-10956C>T 
C.1337-10884T>C 
c.1337-10879G>A 
c.1337-10480G>A 
C.1337-10411A>G 
C.1337-10392C>T 
c.1337-10174T>C 
c.1337-9435G>T 
C.1337-9063C>T 
C.1337-8872C>A
C.1337-8595T>C 
C.1337-8151T>A 
Cl337-7948T>C 
Cl337-7883A>G 
C.1337-7686G>C 
C.1337-7509G>A 
C.1337-7294A>G 
Cl 337-7185A>G 
C.1337-7004A>G 
C.1337-6762G>C 
C.1337-6760T>A 
c.1337-6362T>C 
c.1337-5930A>T 
C.1337-5702C>A 
C.1337-5580C>G 
c1337-5576A>G 
C.1337-5562A>C 
C.1337-5556C>T 
C.1337-5529C>T
C.1337-5497C>T 
Cl 337-5491 G>T 
C.1337-5475G>T 
C.1337-5023A>G 
C.1337-4967A>T 
C.1337-4920C>A 
C.1337-4856T>C 
c.1337-4433G>C 
c.1337-4260A>G 
c.1337-3775T>A 
C.1337-3773G>A 
C.1337-3753T>A 
C.1337-3686C>G 
C.1337-3684C>G 
C.1337-3678A>C 
C.1337-3670C>A 
C.1337-3629G>T 
C.1337-3599T>C 
c.1337-3551 G>C
C1337- 
C.1337 
Cl 337 
c.1337 
C.1337- 
C1337- 
Cl 337 
C.1337 
C.1337 
C.1337 
C.1337 
c.1337 
C.1337 
C.1337 
c.1337
3410A>C
2938A>C
2279A>G
■2253A>C
2250C>T
2194A>G
2155C>T
2152A>G
2144A>T
2051T>C
1864G>T
1490T>C
706A>G
■519A>G
347C>A
C.1519+743G>T c1519+749G>T c.1520-410A>C c.1520-98T>G 
C.1519+745G>T c.1519+751 G>T C.1520-331 G>T 
C.1519+747G>T c1520-563G>A c.1520-148A>G
c.1696+490C>G c.1696+2432A>T c.1696+4165T>C C.1697-4001 A>C C.1697-1873T>C c.1697-544T>C
C.1696+516A>G c.1696+2618G>A c.1696+4415T>C C.1697-3131T>A c.1697-1842G>T
C.1696+1012C>T c.1696+2833A>G c.1696+4492G>A c.1697-2787A>G c.1697-1781C>A
C.1696+1079A>C c.1696+3005T>C c.1697-4454G>A C.1697-2626A>C C.1697-1579G>A
c.1696+1755A>T c.1696+3184G>A c.1697-4257C>A C1697-2238C>T c.1697-1127C>G
c.1696+2021 A>G c.1696+3586A>C c.1697-4020C>T C.1697-2103C>T C.1697-800G>A
Cl 873+268A>G C.1874-439C>T
c.2211C>A
c.2339G>T
C.2236+8A>T c.2237-603T>G
c.2236+64A>G C.2237-545G>A 
C.2236+667T>C c2237-188T>C
C2413+620G>A c.2413+1394G>T c.2413+3823A>T c.2414-2247G>A c.2414-939C>A
C.2413+632T>C c.2413+2672C>G c.2413+3919T>C C.2414-1750A>G c.2414-787T>C
C.2413+813A>G c.2413+3141G>A c.2414-3429T>C c.2414-1511G>A c.2414-434T>C
C.2413+1001 A>T c.2413+3264A>G c.2414-3144T>C C.2414-1395T>C c.2414-300C>A
c.2413+1039T>C c.2413+3401 G>C c.2414-2589G>A c.2414-1322A>C c.2414-68T>G
c.2413+1061T>G c.2413+3478G>C c.2414-2316A>G C.2414-957T>C c.2414-28C>A
C.2413+1295G>T c.2413+3634C>T c.2414-2269T>C C.2414-945T>C
c.2596+64T>C c.2596+83C>T
C.2782+76A>G C.2782+1382T>C C.2783-1054OA
c.2782+225T>C C.2783-1294A>G c.2783-989T>C
C.2782+895T>C c.2783-1109G>A c.2783-858G>T
C.2782+1378C>A c.2783-1089C>A c.2783-526T>A
c.2956+235C>T
c.2957-215T>G
C.2957-89C>T
C.2957-88G>A
c.2990A>C
C.3028A>G C.3134-543G>A c.3134-466G>A c.3134-325A>G 
C.3134-480T>A c.3134-446T>A C.3134-5C>T
c3178C>G
- c.3427G>C
C.3310+117T>C 
C.3310+181T>C 
C.3310+296T>A 
C.3310+508T>C
C.3311-916A>T 
c.3311-889G>T 
C.3311-887C>T 
c.3311-883C>T
C.3311-784C>G 
c.3311-518T>A 
C.3311-347A>C 
C.3311-277A>T
C.3493+174G>A
C.3493+480C>A
C.3494-192C>A c.3494-134T>C 
C.3494-191G>A c.3494-125T>C
c.3493+537C>G c.3494-163T>C c.3494-116J>C_
Jc .3620G > T
C.*17G>A c.*181T>A C.*639G>A c.*676G>A
' ~ '-------- C.*25C>T c.*462C>G c.*658T>C c.*693A>T
C.*58T>C c.*490C>A c.*668G>A
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c.79_82delAGAA
Arg53Cys
Val62Ile*
Arg78Gly
I
Glul89X
I
Ala307Ala*
I
Gln400Lys
His402Tyr*
Cys431Ser/Tyr
I
Thr519Ala
Cys536Arg
SCR 1
Cys630Trp
Cys673Ser/Tyr
I
SCR 2 SCR 3 SCR 4 SCR 5 SCR 6 SCR 7 SCR 8 SCR 9 SCR 10
c.2303_2304dupA
Arg780Ile
Ile881Leu Thr987Ala
Ser890Ile Asn997Thr
His893Arg Vall007Cys
c.2686_2700del c.3032delG
Tyr899Stop UalOlGThr
Cys915Ser Tyrl021Phe
Gln925X
1
Cysl043Arg
1
|M 8  21-80
c.l-332C>T*
SCR 11 U SCR 12 U SCR 13 H SCR 14
85-141 146-205 210-262 267-320 325-385 389-442
I I
c.351delG Lys224Del
c.371_397del Pro258Leu
Argl27Leu
SCR 15 SCR 16
A splll9G ly
Valll34Gly
Tyrll42Asp/Cys
Trpll57Arg
c.3486delA
Cysll63Trp
c.3493+lG>A
SCR 17 H SCR 18 SCR 19 H SCR 20 - 0
I
His332Tyr
448-505 509-564 569-623 630-684 691 -744
I I I
Ala473Ala* Pro621Thr Ser714X
Arg493Thr
c.l494delA
753-803 811 -864 870-926 931 -984 989-1043 1048-1102 1109-1163 1167-1228 1231
I I I I
Val835Leu Glu936Asp* Asnl050Tyr Glull72X
Glu850Lys Gln950His Vall060Ala eu A rgll82Ser
Tyr951His Glnl076Glu c.3546_3581dup36
Thr956Met Trpll83Arg/Leu/X
Cys959Tyr Thrll84Arg
Ile970Val Leull89Arg/Phe
Cys973Tyr Serll91Leu/Trp
Trp978Cys Glyll94Asp
Vail 197 Ala
Glu 1198Ala/Lys/X
P hell99Ser
Glyl204Glu
Leul207Arg
Argl210Cys
Serl211Pro
Argl215Gly/Gln
Thrl216Del
[c.3674A>T;
c.3675_3699del]
Prol226Ser
c.3695 3698del
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Figure 5.8 Distribution of nucleotide changes within CFH (continued)
(a) The distribution of common non-disease associated SNPs within the CFH 
gene (exons 1 to exon 9). Exons are shown in blue and drawn to scale.
(b) The distribution of common non-disease associated SNPs within the CFH 
gene (intron 9 to C-terminal). Exons are shown in blue and drawn to scale. 
Those SNPs within coding regions are shown in red.
(c) The distribution of disease-associated mutations within individual domains of 
FH. Mutations are written above and below their respective domains. 
Domains are drawn to scale. The grey box indicates the coding segment for 
the signal peptide. The numbering underneath the domains indicates the 
range of amino acids from the start to the end of the domain. Linkers are not 
included. N and C indicate the N-terminus and C-terminus respectively. 
Mutations followed by a * character represent disease-associated 
polymorphisms. Mutations in grey text are not associated with disease but 
represent non-synonymous SNPs
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Table 5.4 Disease-Associated Mutations within CFH
SCR Nucleotide Change* Molecular Consequenceb Condition Patient
Records0
Reference
1 c.79_82delAGAA Frameshift resulting in 
premature stop at codon 14
aHUS 1 Warwicker et al., 1998
1 c.158G>A Arg53His aHUS 0 Zipfel, Unpublished
1 c.232A>G Arg78Gly aHUS 1 Caprioli et al., 2003
2 c.351delG Frameshift resulting in 
premature stop at codon 121
aHUS 0 Rodriguez de Cordoba, in preparation
2 c.371_397del Frameshift resulting in 
premature stop at codon 133
aHUS 1 Dragon-Durey et al., 2004
2 c.380G>T Argl27Leu MPGN II 1 Dragon-Durey et al., 2004
3 c.565G>T Glul89X aHUS 1 Sanchez-Corral et al., 2000
4 c.670 672delAAG Lys224Del MPGN II 2 Licht et al., 2006
4 C .7730G Pro258Leu aHUS 1 Sanchez-Corral, in preparation
7 C .11980A Gln400Lys aHUS 1 Dragon-Durey et al., 2004
7 c.l292G>C Cys431Ser MPGN II Dragon-Durey et al., 2004
7 C.1292G>A Cys43 lTyr Glomerulonephritis 1 Rodriguez de Cordoba, in preparation
8 c.l494delA Frameshift resulting in 
premature stop at codon 503
aHUS 1 Caprioli et al., 2001
9 c,1606T>C Cys536Arg FH Deficiency 1 Ault et al., 1997
10 C .18610A Pro621Thr aHUS 1 Vaziri-Sani et al., 2006
11 C.1890T>G Cys630Trp aHUS 1 Neumann et al., 2003
11 c.2017T>A Cys673Ser MPGN II 1 Dragon-Durey et al., 2004
11 c.2018G>A Cys673Tyr aHUS 1 Dragon-Durey et al., 2004
12 C .21410G Ser714X aHUS 1 Neumann et al 2003
13 c.2303_2304dupA Frameshift resulting in aHUS 1 Dragon-Durey et al., 2004premature stop at codon 756
14 c.2503G>C Val835Leu aHUS 0 Zipfel, Unpublished
14 c.2548G>A Glu850Lys aHUS 1 Neumann et al., 2003
15 c.2641A>C Ile881Leu aHUS 0 Zipfel, Unpublished
15 c.2669G>T Ser890Ile aHUS 3 Goodship, Unpublished; Noris et al., 2005; Caprioli et al., 2006
Table 5.4 Disease-Associated Mutations within CFH (continued)
SCR Nucleotide Change3 Molecular Consequenceb Condition
15 c.2678A>G His893Arg aHUS
15 c.2686 2700del Deletion of 15 base pairs aHUS
15 c.2697T>A Tyr899X aHUS
15 c.2743T>A Cys915Ser aHUS
15 C.27730T Gln925X aHUS
16 c.2850G>T§ Gln950His aHUS
16 c.2851I>C Tyr951His aHUS
16 C.28670T Thr956Met aHUS
16 c.2876G>A Cys959Tyr aHUS
16 c.2908A>G Ile970Val aHUS
16 c.2918G>A Cys973Tyr aHUS
16 c.2934G>T Trp978Cys aHUS
16-17 c.2959A>G Tyr987Ala aHUS
17 c.3019G>T Vall007Cys aHUS
17 c.3032delG Frameshift resulting in 
premature stop at codon 1014
aHUS
17 c.3062A>T Tyrl021Phe aHUS
17 c.3127T>C Cysl043Arg aHUS
18 c.3179T>C Val 1060Ala aHUS
18 c.3226C>G Glnl076Glu aHUS
19 c.3356A>G Asplll9Gly aHUS
19 c.3401T>G Valll34Gly aHUS
19 c.3424T>G Tyrl 142Asp aHUS
19 c.3425A>G Tyrll42Cys aHUS
19 c.3469T>C Trpll57Arg aHUS
19 c.3486delA Frameshift resulting in 
premature stop at codon 1150
aHUS
19 c.3489C>G Cysll63Trp aHUS
19 c.3493+lG>A Splice Site alteration between 
Exon 21 and Intron 22
aHUS
20 c.3514G>T Glul 172X aHUS
20 c.3546G>C Argil82Ser aHUS
20 c.3546 3581dup36 Insertion of 12 additional amino 
acids after codon 1176
aHUS
Patient
Records^ Reference
Dragon-Durey et al., 2004 
Caprioli et al., 2006
Dragon-Durey et al., 2004; Licht et al., 2006;
Caprioli et al., 2006; Zipfel Unpublished
Dragon-Durey et al., 2004
Dragon-Durey et al., 2004
Caprioli et al., 2003
Caprioli et al., 2003
Perez-Caballero et al., 2001
Ault et al., 1997
Caprioli et al., 2006
Goodship, Unpublished; Saland et al., 2006 
Neumann et al., 2003 
Zipfel, Unpublished 
Goodship, Unpublished 
Caprioli et al., 2006
Neumann et al., 2003; Zipfel Unpublished 
Neumann et al., 2003 
Guigonis et al., 2005
Richards et al., 2001; Neumann et al., 2003
Richards et al., 2001
Neumann et al., 2003
Neumann et al., 2003
Sanchez-Corral, in preparation
Neumann et al., 2003
Richards et al., 2001
Caprioli et al., 2003 
Neumann et al., 2003
2 Caprioli et al., 2003; Manuelian et al., 2003
0 Zipfel, Unpublished
2 Filler etal., 2004
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Table 5.4 Disease-Associated Mutations within CFH (continued)
SCR Nucleotide Change3 . Molecular Consequenceb Condition PatientRecords0 Reference
20 c.3547T>A Trpll83Arg aHUS 2 Sanchez-Conal et al., 2002; Remuzzi et al., 2002
20 c.3548G>T Trpll83Leu aHUS 3 Perez-Caballero et al., 2001, Dragon-Durey et al., 2004; 
Esparza-Go rdillo et al„ 2005
20 c.3549G>A Trpll83X aHUS 1 Noris, unpublished
20 c.3551C>G Thrll84Arg aHUS 1 Richards et al., 2001
20 c. 3562 3 564del A AG Lysl 188Del aHUS 1 Edey et al., In Preparation
20 c.3565C>T Leull89Phe aHUS 1 Rodriguez de Cordoba et al., 2004
20 c.3566T>G Leull89Arg aHUS 1 Perez-Caballero et al., 2001
20 c.3572C>T Seri 191Leu aHUS 4 Richards et al., 2001; Noris Unpublished
20 c.3572C>G Seri 191Trp aHUS 1 Rodriguez de Cordoba et al., 2004
20 c.3581G>A Glyll94Asp aHUS 2 Caprioli et al., 2003; Castelletti et al., 2006
20 c.3590T>C Vail 197 Ala aHUS 6 Caprioli et al., 2001; Perez-Caballero et al., 2001; Richards et 
al., 2001; Caprioli et al 2006; Saland et al., 2006
20 c.3592G>T Glull98X aHUS 0 Zipfel, Unpublished
20 c.3592G>A Glull98Lys aHUS 1 Vaziri-Sani et al., 2006
20 c.3593A>C GIul 198Ala aHUS 1 Caprioli et al., 2003
20 c.3596T>C Phell99Ser aHUS 1 Dragon-Durey et al., 2004
20 c.3611G>A Glyl204Glu aHUS 0 Goodship, unpublished
20 c.3628C>T Argl210Cys aHUS 9 Caprioli et al., 2001; Sanchez-Corral et al., 2002; Neumann et 
al., 2003; Castelletti et al., 2006,
Caprioli et al„ 2006; Noris Unpublished
20 c.3643C>G Argl215Gly aHUS 2 Warwicker et al., 1998; Richands et al., 2001; 
Noris Unpublished
20 c.3644G>A Argl215Gln aHUS 1 Caprioli etal., 2001
20 c.3646 3648delACA Thrl216Del aHUS 1 Neumann et al., 2003
20 (c.3674A>T;
c.3675_3699del]
A to T trans\'ersion followed by 
24bp deletion causing frameshift 
and premature stop at codon 1227
aHUS 2 Buddies et al., 2000; Caprioli et al., 2001
20 c.3676C>T Prol226Ser aHUS 1 Neumann et al., 2003
20 c.3695 3698delAGA 
A
Deletes terminal codon after 
Argl231
aHUS 1 Neumann et al., 2003
acDNA numbering is taken form RefSeq # NM 000186.1 where +1 corresponds to the A of the ATG initiation codon.
'’Residues are numbered starting from the initiating methionine residue at +1. 
c0 patient records refer to mutations that are only reported with genotypic information.
Mutations referred to as ‘unpublished’ are submitted to the database by collaborating labs but do not have a formal publication reporting the mutation and
patient.
5.3.3.2 FH Missense Mutations
There are 54 point nucleotide substitutions within CFH that result in single 
amino acid substitutions that are associated with disease. These missense mutations 
are distributed throughout the length of FH with 49 mutations associated with aHUS 
patients, 3 associated with MPGN II patients, one reported in a patient described as 
FH deficient and one mutation reported in a patient described as suffering from 
Glomerulonephritis (Table 5.4 and Figure 5.8c). Structural analysis of these 
mutations using experimental structures or the homology models of individual SCR 
domains provides further insight into phenotypic classification and structural 
perturbation (Table 5.5).
The position of each mutation with phenotypic classification is highlighted 
within the relevant SCR model in Figure 5.9. Phenotypic classification was only 
possible for 31 of these mutations, with the remaining 22 not having sufficient data 
to assign a Type I or Type II phenotype. The majority of classified mutations have a 
Type II phenotype (56%) with the remaining mutations classified as Type I (44%).
5.3.3.3 FH Type I Missense Mutations
Of the 11 missense mutations with Type I phenotypic classification, seven 
mutations (Cys431Ser, Cys536Arg, Cys673Ser, Cys673Tyr, Cys915Ser, Cys959Tyr 
and Cys973Tyr) involve the substitution of either the second or third conserved 
cysteine residue of the SCR domain. This is expected to alter the stability of the SCR 
domain leading to reduced amounts of plasma FH. Two other Type I mutations 
(Pro258Leu and Pro621Thr) involve the substitution of proline residues. Pro258 and 
Pro621 lie on the loop after (37 strand just before the fourth cysteine residue within 
SCR-4 and SCR-10 respectively (Figure 5.2). Sequence analysis of other SCR 
domains shows this proline to be well conserved (Figure 2.6), implying that this is 
important for correct protein folding. The remaining three Type I mutations seem to 
have different effects on SCR stability. Argl27Leu mutation involves a substitution 
within the buried central 06 strand that is close to the conserved cysteine residue at 
position Cysl29 within SCR-2 while the His893Arg within SCR-15 involves the 
substitution of a residue on the 02-04 loop in close proximity to the linker region 
between SCR-14 and SCR-15. It could be that the His893Arg mutation has an effect 
on the inter-domain contacts between SCR-14 and SCR-15 and reduces the stability 
ofFH.
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Table 5.5 Structural analysis of 54 missense mutations in FH
SCR Mutation DSSP Position Accessibility ConsensusNumbering* Phenoly
1 Arg53His C P4 - {36 Loop 9 27 U
1 Arg78Gly C P7 - C4 Loop 1 47 u
2 Argl27Leu E P6 8 37 I
4 Pro258Leu C P7 - C4 Loop 5 47 I
7 Gln400Lys C P2 - P4 Loop 9 12 u
7 Cys431Tyr E P6, C3 0 39 u
9 Cys536Arg C C2 2 26 I
10 Pro621Thr C P6 - C4 Loop 0 47 I
11 Cys630Trp C Cl 3 1 u
11 Cys673Ser/Tyr E P6, C3 1 39 I/I
14 Val835Leu E P4 0 22 u
14 Glu850Lys C P4 - P6 Loop 5 38 II
15 Ile881Leu E p2 2 12 u
15 Ser890Ile C P2 - P4 Loop 6 15 II
15 His893Arg C P2 - P4 Loop 8 18 I
15 Cys915Ser E P6, C3 0 39 I
16 Gln950His C P2 - P4 Loop 7 17 u
16 Tyr951His C P2 - p4 Loop 7 18 u
16 Thr956Met E P4 7 23 II
16 Cys959Tyr C P4 - P6 Loop, C2 5 26 I
16 Ile970Val E P6 4 38 II
16 Cys973Tyr C P6 - C4 Loop, C3 0 39 I
16 Trp978Cys C P6 - C4 Loop 0 43 u
Linker Tyr987Ala - - - - u
17 Vall007Leu c P2 - p4 Loop 6 15 II
17 Tyrl021Phe c P4 - P6 Loop 9 29 u
17 Cysl043Arg c C4 4 49 u
18 Vail 060Ala c P2 - P4 Loop 4 13 u
18 Glnl076Glu E P4 8 25 u
19 Aspl 119Gly E p2 9 11 II
19 V alll34G ly E p4 0 22 II
19 Tyrl 142Asp/Cys C P4 - P5 Loop 5 30 II/II
19 Trpl 157Arg E P7 4 43 II
19 Cysl 163Trp E P8,C4 1 49 u
20 Argl 182Ser C p2 - p3 Loop 9 13 u
20 Trpl 183Arg/Leu C P2 - P3 Loop 9 13 II/II
20 Thrl 184Arg C P2 - P3 Loop 9 13 II
20 Leul 189Arg/Phe C pi - P3 Loop 8 14 II/U
20 Seri 191Leu/Trp E P3 0 15 u/u
20 Gly 1194 Asp C P3 - P4 Loop 4 19 u
20 Vail 197 Ala E p4 0 22 II
20 Glul 198Ala/Lys E P4 5 23 U/II
20 P hell99Ser E P4 0 24 I
20 G lyl204Glu C P4 - P5 Loop 5 29 II
20 Argl210Cys C P5 - P6 Loop 9 34 II
20 Argl215Gly/Gln E p6 9 36 II/II
20 Prol226Ser C P6 - P8 Loop 0 47 II
* Consensus numbering refers to the position o f the mutation in a consensus sequence o f 124 human 
complement protein SCR domains that is numbered from 1-49 (Figure 5.19).
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SCR-4 SCR-6
Cys431
Gln400
His332
SCR-7 SCR-8
Thr519
Cys536
SCR-9 SCR-10
Figure 5.9 Positions of 54 missense mutations and 12 non-synonymous 
polymorphisms within FH domain models (continued over page)
Arg493
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Figure 5.9 Positions of 54 missense mutations and 12 non-synonymous 
polymorphisms within FH domain models (continued over page)
Figure 5.9 Positions of 54 missense mutations and 12 non-synonymous 
polymorphisms within FH domain models (continued)
The backbone of the SCR domains of FH are shown in blue ribbons with the p- 
strands highlighted and labelled in green and the a-helix of SCR-20 is coloured cyan. 
Only the side chains of missense mutation residues or those involved in non- 
synonymous polymorphisms are shown. Residues where the mutations have 
phenotypic classification are coloured red for Type I and green for Type II. Those 
residues where mutations do not have phenotypic classification are coloured orange. 
The non-synonymous polymorphic residues are coloured in grey. Only structures for 
domains with mutations or polymorphisms present are shown. N and C indicate the 
N-terminus and C-terminus respectively. The hypervariable loop between P2 and P3 
is highlighted in purple. Each model of a single SCR domain is shown in the same 
view across the y-axis.
207
Although there are 18 missense mutations within SCR20, only one (Phel 199Ser) can 
be assigned a Type I phenotype. Phel 199 is buried within the structure of SCR-20 
on P4. The substitution of a large phenylalanine side chain with a small serine would 
be expected to create a void in the structure and reduce the stability of SCR-20 
leading to a Type I phenotype.
5.3.3.4 FH Type II Missense Mutations
The majority (20) of classified FH missense mutations show Type II 
phenotypes. Five of these mutations (Glu850Lys, Ser890Ile, Thr956Met, Ile970Val 
and Vall007Leu) occur between SCR-14 to SCR-18 (Figure 5.8c). All of these 
residues are exposed and are expected to affect the function of FH by changing the 
surface properties associated with either C3b or heparin binding. For example, 
Ile970Val replaces a large hydrophobic residue within the conserved P4 strand of 
SCR-16 with a smaller hydrophobic residue. SCR-16 is implicated in C3d binding 
(Sharma and Pangbum, 1996) and disruption of this surface exposed region may 
affect binding directly or indirectly. The remaining mutations are split between SCR- 
19 and SCR-20, with five (Aspl 119Gly, Vail 134Gly, Tyrl 142Asp, Tyrl 142Cys and 
Trpll57Arg) located within SCR-19 and 11 (Trpll83Arg, Trpll83Leu, 
Thrll84Arg, Leull89Arg, Valll97Ala, Glull98Lys, Glyl204Glu, Argl210Cys, 
Argl215Gly, Argl215Gln and Prol226Ser) located within SCR-20 (Figure 5.9). 
Since these residue alterations are expected to reduce alternative pathway control 
and result in aHUS symptoms, it is likely they are either directly or indirectly 
implicated in either the host cell recognition functions of FH or the binding of C3b 
cofactor activity.
Within SCR-19, Aspl 119Gly is exposed on the surface of p2. This region of 
FH is associated with heparin and C3d binding (Jozsi et al., 2006) and a change in 
surface charge with the removal of this negatively charged aspartic acid side chain 
could affect binding. The V all34G ly mutation is interesting since it involves a 
buried residue within the core of the SCR domain structure. This would be expected 
to disrupt the stability of the domain and present a Type I phenotype. However the 
change from a small valine side chain to a glycine does not seem to affect the 
stability since the patient plasma levels of FH are normal (Neumann et al., 2003). It 
is more likely that the substitution causes structural rearrangements and alters the 
positions of surface residues involved in binding. The remaining mutation
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(Tyrll42Asp) within SCR-19 is located near the junction between SCR-19 and 
SCR-20 and could affect interdomain interactions, altering the conformation of the 
two domains.
Within SCR-20, four Type II mutations (Trpll83Arg, Trpll83Leu, 
Thrll84Arg, and Leull89Arg) involve surface exposed residues that lie within the 
hypervariable loop (Figure 5.9). The clustering of Type II mutations within this loop 
highlights the functional significance of this region within SCR-20. The Val 197Ala 
and Glull98Lys mutations are similar to the V alll34Gly mutation within SCR-19 
and lie on the buried p4 strand within SCR-20. Vail 197Ala involves the replacement 
of a small valine side chain with a smaller alanine whereas Glul 198Lys involves the 
replacement of a large negative glutamic acid side chain with a similar sized positive 
lysine side chain. Like the Valll34Gly mutation, these mutations could cause 
structural rearrangements on P4 and indirectly alter the positions of surface residues 
involved in binding. Both these residues (Vail 198 and Vail 134) are part of a cluster 
of residues implicated in C3d binding (Jokiranta et al., 2006) but are also affected by 
heparin binding (Herbert et al., 2006). Another Type II mutation, Glyl204Glu 
involves the replacement of a surface exposed glycine with a large negatively 
charged residue on the loop between p4 and p5. This surface charge alteration could 
affect heparin binding since Glyl204 is in close proximity to Lysl202 and Argl203 
that are possible heparin binding residues (Herbert et al., 2006). It is also likely that 
the Argl215Gly and Argl215Gln mutations also affect heparin binding since 
Argl215 is also a putative heparin binding residue (Herbert et al., 2006). The 
Argl210Cys mutation is interesting since although Argl210 is a surface exposed 
positive residue within SCR-20 it is not implicated in heparin binding, and is not in 
close proximity to any of the other heparin binding residues. It is possible the 
introduction of another cysteine residue into SCR-20 could change the disulphide 
bond pairings and cause structural rearrangements within SCR-20. However, it is 
more likely that the change in surface charge will affect either heparin or C3b 
interactions with FH SCR-20. Finally the Prol226Ser Type II mutation involves a 
buried proline side chain on the loop between P6 and p8. This lies on the same face 
as the Argl210Cys mutation (Figure 5.9) and is also likely to affect surface 
interactions with heparin and C3b.
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5.3.3.5 FH Unassigned Missense Mutations
Patient serum levels do not distinguish between a Type I or Type II 
phenotype in the remaining 22 mutations (Arg53His, Arg78Gly, Gln400Lys, 
Cys431Tyr, Cys630Trp, Val835Leu, Ile881Leu, Gln950His, Tyr951His, Trp978Cys, 
Thr987Ala, Tyrl021Phe, Cysl043Arg, Vall060Ala, Glnl076Glu, Cysll63Trp, 
Argll82Ser, Leull89Phe, Serll91Leu, Serll91Trp, Glull94Asp and 
Glull98Ala). Interestingly the Cys431Tyr mutation occurs at the same topological 
position within the SCR domain as five other mutations within CFH (Cys431 Ser, 
Cys673Ser/Tyr, Cys915Ser and Cys973Tyr). These mutations replace the third 
conserved cysteine residue and are expected to result in an unstable SCR domain 
structure and a Type I phenotype. The Cys630Trp, Cysl043Arg and Cysll63Trp 
mutations also occur at conserved cysteine residue positions but do not coincide with 
any of the other cysteine Type I mutations. However, since the replacement of either 
Cl (as in the case of Cys630Trp) or C4 (as in the case of Cysl043Arg and 
Cysl 163Trp) would break the disulphide bridge scaffolding of the SCR domain, it is 
expected these residues would also result in a Type I phenotype and reduced FH 
levels. The Thr987Ala mutation occurs between SCR-16 and SCR-17 and is the only 
mutation within a linker region of FH. Without structural analysis not much can be 
said about this mutation, however sequence analysis of FH sequences from five 
different species indicated this threonine residue is well conserved (Figure 5.10), 
which suggests it is structurally or functionally relevant for the FH molecule. 
Another interesting mutation without phenotypic classification is V ail060Ala that 
occurs on a surface exposed loop between P2 and p3 of SCR-18. Although SCR-16 
to SCR-20 has been implicated in C3d binding (Sharma and Pangbum, 1996), it is 
not clear what effect this mutation could have. This mutation is referenced twice 
within dbSNP (rs 17434860 and rs410232), and since the alanine allele frequency is 
3% in the control population it is not certain whether this mutation is disease- 
associated or a commonly occurring SNP.
The majority (76%) of missense mutations within FH that are associated with 
disease occur at residues that are well conserved across species (Figure 5.10). This is 
expected since conserved residues are likely to be structurally or functionally 
relevant and the substitution of these residues will have a negative effect on FH. Of 
the 13 mutations that do not correspond to 100% conserved positions, nine do not 
involve conservative changes.
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SCR-1
SCR-2
SCR-3
SCR-4
CFAH_HUMAN 
Q 8M I72_PIG  
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG  
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q 8M I72_PIG  
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG  
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG 
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG 
SCR-5 Q91 YB6_RAT
Q3MHF3_BOVIN 
CFAH MOUSE
SCR-6
SCR-7
CFA H_H UM AN  
Q8M I72_PIG 
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG  
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
10
M R L L A K IIC L M L W A IC V A  
M R CPAKFVW LILW TVC VA  
M R L S A R IIW L IL W T V C V A  
M R FPAKIVW LVLW TVC VA  
M R L SA R IIW L IL W T V C A A
20 30 40 50 60 70 80_|  |  |  |  | ------|  | ----- |  |----- | | ----- |  | ----
EDCNELPPRRNTEILTGSWSDQTYPEGTQAIYKCRPGYRSLGNflMVCRKGEWVALNPUlKCQKRP
EDCREPPPRKETEIVSGSWTEQTYPEGTQATYKCRPGYRTLGSIVMVCKDGKWVSLHPSRICRKKP
EDCKGPPPRENSEILSGSWSEQLYSEGTQATYKCRPGYRTLGTIVKVCKNGEWVPSNPSRICRKRP
EDCKEPPPRKETEILSGSWTEQTYQEGTQATYKCRPGYRTLGSIVMMCRGGKWVSLHPSRICRKKP
EDCKGPPPRENSEILSGSWSEQLYPEGTQATYKCRPGYRTLGTIVKVCKNGKWVASNPSRICRKKP
14090 100 110 120 130
I-------| --------| -------- | --------| ------- | -------- | ---------| --------| -------- | ------- | -------- | --------- |
CGHPGDTPFGTFTLTGGNVFEYGVKAVYTCNEGYQLLGEINYRECDTDGWTNDIPICEVVK 
CGH PG DTS FGS FHLAVGTQFEYGAKWYTC DEGYQMLGEINFRECDTNGWTNNIPLCEVVK 
CGHPGDTPFGSFRLAVGSEFEFGAKWYTCDEGYQLLGEIDYRECDADGWTNDIPICEWK 
CAHPGDTPFGSFHLAEGTQFEYGAKWYTCDEGYQMVGEMNFRECDTNGWTNDIPICEVVK 
CGHPGDTPFGSFRLAVGSQFEFGAKWYTCDDGYQLLGEIDYRECGADGWINDIPLCEWK
150 200160 170 180 190
-------I --------| -------- | --------| -------- | ------- | -------- | ------- | --------| -------- | --------- | -------- | -------
CLPVTAPENGKIVSSAMEPDREYHFGQAVRFVCNSGYKIEGDEEMHCSDDGFWSKEKPKCVEIS
CLPVTEPENGRIVSGALEPDQEYTYGQWQFQCNAGYSLDGPKQIHCSAGGVWSGDKPKCVGIS
CLPVTELENGRIVSGAAEPDQEYYFGQWRFECNSGFKIEGQKEMHCSENGLWSNEKPQCVEIS
CLPVTEPENGKIFSDALEPDQEYTYGQVVQFECNSGYMLDGPKQIHCSAGGVWSAETPKCVEIF
CLPVTELENGRIVSGAAETDQEYYFGQWRFECNSGFKIEGHKEIHCSENGLWSNEKPRCVEIL
210 220  230  240 250 260
CKSPDVINGSPISQKIIYKENERFQYKCNMGYEYSERGDAVCTESGWRJLPSCEEKS 
CTPPNILNGYPIISKEIYKANERVQYKCSAGFEYSERGETICTASGWAPVPSCVEIT  
CLPPRVENGDGIYLKPVYKENERFQYKCKQGFVYKERGDAVCTGSGWNPQPSCEEMT 
CKTPVILNGQAVLPKATYKANERVQYRCAAGFEYGQRGDTICTKSGWTPAPTCIEIT 
CTPPRVENGDGINVKPVYKENERYHYKCKHGYVPKERGDAVCTGSGWSSQPFCEEKR
270 280 290 300  310 320
 I 1 I 1 I 1------ 1-------1------- I-------I-------1-------
CDNPYIPNGDYSPLRIKHRTGDEITYQCRNGFYPATRGNTAKCTSTGWIPAPRCTLKP
CDPPHIPNGFYTPESNRYRTGDRITYHCKEGFYPEIQGNVARCTGNHWSPAPRCTLKP
CLTPYIPNGIYTPHRIKHRIDDEIRYECKNGLYPATRSPVSKCTITGWIPAPRCSLKP
CDPPRIPNGVYRPELSKYRGQDKITYECKKGFFPEIRGTDATCTRDGWVPVPRCAWKP
CSPPYILNGIYTPHRIIHRSDDEIRYECNYGFYPVTGSTVSKCTPTGWIPVPRCTLKP
330  340 350 360  370  380
,  1 1 1 1 1 1 1 ,  1 1 ,  1---------
CDYPDIK|GGLYHENMRRPYFPVAVGKYYSYYCDEHFETPSGSYWDHIHCTQDGWSPAVPCLRK 
CSRPVIKHGKLYYD— YRGYFPANVGQYFYYYCDHNFVTPSRRSGDYLTCKRNGWSAEVPCLRQ 
CDFPQFKHGRLYYEESRRPYFPVPIGKEYSYYCDNGFTTPSQSYWDYLRCTVNGWEPEVPCLRQ 
CSYPVIKHGRLYYS— YRGYFPARVNQQFVYSCDHHFVPPSQRSWDHLTCTAEGWSPEEPCLRQ 
CEFPQFKYGRLYYEESLRPNFPVSIGNKYSYKCDNGFSPPSGYSWDYLRCTAQGWEPEVPCVRK
390 400 410 420 430 440
_ l ------- 1--------| -------- | -------- | -------- , -------- 1-------- | -------- , ------- , -------- 1---------1 —
CYFPYLENGYNgN§GRKFVQGKSIDVACHPGYALPKAQTTVTCMENGWSPTPRCIRVKT 
CIFDYLEHGHNSYSAKKYLQGETVRVQCYPGYSLPDNQDTLLCTENGWSPPPKCILVKT 
CIFHYVEYGESLYWQRRYIEGQSAKVQCHSGYSLPNGQDTILCTENGWSPPPKCVRIKT 
CIFNYLENGHTPYREEKYLQGETVRVRCYEGYSLQNDQNTMTCTESGWSPPPRCIRVKT 
CVFHYVENGDSAYWEKVYVQGQSLKVQCYNGYS LQNGQDTMTCTENGWS PPPKCIRIKT
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SCR-8
450  460 470 480 490 500
CFAH_HUMAN CSKSSIDIENGFISESQYTYALKEKAKYQCKLGYVTADGETSGSlJCGKDGWSAQPTCIKS
Q8M I72_PIG CAKSDIEIENGFFSENIFTYPLNKQTQYKCKPGYVTADGATSGLITCLQSGWSARPVCIKS
Q91YB6_RAT CSVSDIEIENGFFSESDYTYALNRKTRYRCKQGYVTNTGEISGIITCLQDGWSPRPSCIKS
Q3MHF3_BOVIN CSKSNXRIENGFLSESTFTYPLNKQTEYKCKPGYVTADGKTSGLITCLKNGWSAQPVCIKS
CFAH_MOUSE CSASDIHIDNGFLSESSSIYALNRETSYRCKQGYVTNTGEISGSITCLQNGWSPQPSCIKS
CFAH_HUMAN 
Q8M I72_PIG 
SCR-9 Q91YB6_RAT
Q3MHF3_BOVIN 
CFAH MOUSE
510 520 530 540 550 560
_ |  |  |  |  |  |  |  |  |  |  |  | -----
CDIPVFMNAR|KNDFTWFKLNDTLDYEgHDGYESNTGSTTGSIVCGYNGWSDLPICYERE
CDAPLPENARIKSDGTWFKLNDTVDYECQQGFESRNGDTAGSIVCGEDGWSDKPACYERE
CDMPVFENAMTKNNNTWFKLNDKLDYECH1GYENEYKHTKGSITCTYDGWSSTPSCYERE
CDRPVFEKARVKSDGTWFRLNDRLDYECVDGYENRDGRTTGSIVCGQDGWSDKAACYERE
CDMPVFENSITKNTRTWFKLNDKLDYECLVGFENEYKHTKGSITCTYYGWSDTPSCYERE
SCR-10
CFAH_HUMAN 
Q8M I72_PIG 
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUM AN  
Q8M I72_PIG 
SCR-11 Q91 YB6_RAT
Q3MHF3_BOVIN 
CFAH MOUSE
570 580 590 600 610 620
CELPKIDVHLVPDRKKDQYKVGEVLKFSCKPGFTIVGPNSVQCYHFGLSPDLPICK-EQVQS
CITPGIKSYLDAEPKHNKFKVGGVLKFHCRERRVMLGADSVQCYHFGWSPNLPTCKAGQVKS
CSIPLLHQDLWFPREVKYKVGDSLSFSCRSG-HRVGADLVQCYHFGWSPNFPTCE-GQVKS
CSIPEMDPYLNAYPRKETYKVGDVLKFSCSQGRIMVGADSVQCYHFGWSPKLPTCKVKKVKS
CSVPTLDRKLVVSPRKEKYRVGDLLEFSCHSG-HRVGPDSVQCYHFGWSPGFPTCK-GQVAS
630 640 650 660 670 680 690
|  |  ,  |  |  1 |  |  |  |  ,  |  |
CGPPPELLNGNVKEKTKEEYGHSEWEYYCNPRFLMKGPNKIQCVDGEWTTLPVCIVEEST 
CAPPPQLLNGEVKETQKGEYQHSEVVEYVCNPRFLMKGSHKIQCVDGEWTTLPVCIEEERT 
CDQPLEIPNGEIKGTKKVEYSHGDVVEYDCKPRFLLKGPNKIQCVDGKWTTLPICVEYERT 
CALPPELPNGKRKEIHKEEYAHNEWEYACNPRFLMKGSHKIQCVDGEWTALPVCIEEERT 
CAPPLEILNGEINGAKKVEYSHGEWKYDCKPRFLLKGPNKIQCVDGNWTTLPVCIEEERT
CFAH_HUMAN 
Q8MI72_PIG 
SCR-12 Q91YB6 RAT
Q3MHF3_BOVIN 
CFAH MOUSE
SCR-13
SCR-14
CFAH_HUMAN 
Q8M I72_PIG 
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG 
Q91YB6_RAT 
Q3MHF3_BOVIN 
CFAH MOUSE
CFAH_HUMAN 
Q8M I72_PIG 
SCR-15 Q91YB6_RAT
Q3MHF3_BOVIN 
CFAH MOUSE
700 710 720 730 740 750
CGDIPELEHGWAQLSSPPYYYGDSVEFNCSESFTMIGHRSITCIHGVWTQLPQCVAIDKLKK 
CGDIPDLDHGYVRHSAPPYHHGDSVEFGCNASFSLVGPRSITCISGKWTQLPQCFATDKLKK 
CGDLPELEHGSVKLSVPPYHHGDSVEFTCTETFTMIGHAWFCISGRWTELPQCVATDQLEK 
CGNIPDLDHGDVKPSVPPYHHGDSVEFSCREAFTMIGPRF1TC1SGEWTQPPQCIATDELRK 
CGDIPELEHGSAKCSVPPYHHGDSVEFICEENFTMIGHGSVSCISGKWTQLPKCVATDQLEK
760 770 780 790 800 810
— I  I  I I  I  I  I  I  I  I  i  I
CKSSNLIILEEHLKNKKEFDHNSNIRY|CRGKEGWIHTVCINGRWDPEVNCSMAQ-IQL 
CKASKIFASEGNLLDKTEFDHNTNQSYKCRGKSESKYSVCINGVWDPRVSCKEEV-LNS 
CKAPKSTGIDAIHPNKNEFNHNFSVSYRCRQKQEYEHSICINGRWDPEPNCTRNE-KRF 
CKGSTLFPPEGRQAHKIEYDHNTNKSYQCRGKSEHKHSICINGEWDPKVDCNEEAKIQL 
CRVLKSTGIEAIKPKLTEFTHNSTMDYKCRDKQEYERSICINGKWDPEPNCTS KTS
850 860820 830 840
-------I-------- | -------- | -------- | ------- | ---------| ------- | -------- | -------- | -------- | ------- | --------
CPPPPQIPNSHNMTTTLNYRDGEKVSVLCQENYLIQEGEEITCKDGRWQSIPLCVEKIP
cppppq ipn a q d m t tt v n y k d g e k T s il c q e n y iiq d g e e iv c k d g r w q s v p r c v e k ip
CPPPPQIPNAQVIETTVKYLDGEKVSVLCQDGYLTQGPEEMVCKHGRWQSLPRCTEKIP
CPPPPQVPNACDMTTTVNYQDGEKISILCKENYLIQDAEEIVCKDGRWQSIPRCIEKIG
CPPPPQIPNTQVIETTVKYLDGEKLSVLCQDNYLTQDSEEMVCKDGRWQSLPRCIEKIP
870 880 890 900 910 920 930
CSQPPQIEHGTINSSRSSQES--------------- YAHGTKLSYTCEGGFRISEENETTCYMGKWSSPPQCEGLP
CSEPPEIDHGtT qS PGSAEERREMFE PKKYAHGTRLS YTCEDGFEISEK-E11CHMGKWSS LPQCVGRP 
CSQPPKIEHGSIKSPRSSEER-DLIESSSYEHGTTFSYVCDDGFRISEENRVTCNMGKWSSLPRCVGIP 
CSQPPQIDHGTISSSSSAEERREIHEQRLYAHGTKLSYTCEEGFEISENNVIICHMGKWSSPPQCVGLP 
CSQPPTIEHGSINLPRSSEERRDSIESSSHEHGTTFSYVCDDGFRIPEENRITCYMGKWSTPPRCVGLP
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SCR-16
940 950 960 970 980 1 ] 1 | | | | | 1 1 1---
CFAH_HUMAN CKS P P j l  SHGWAHMSDS YJgYGEE VTYKCFEGFGIDGPAIAKCLGEKWS H P PSCIKTD
Q8M I72_PIG CAPPPEIQNGAVAQEKDSYLYGEEVTYSCDEGFGIDGPASIRCLGEKWSHPPECINTD
Q91YB6_RAT CGPPPSIPLGIVSHELESYQYGEEVTYNCSEGFGIDGPAFIKCVGGQWSEPPKCXKTD
Q3MHF3_BOVIN CGLPPYVQNGWSHKKDRYQYGEEVTYDCDEGFGTDGPASIRCLGGEWSRPQDCISTN
CFAH MOUSE CGPPPSIPLGTVSLELESYQHGEEVTYHCSTGFGIDGPAFIICEGGKWSDPPKCIKTD
SCR-17
990 1000 1010 1020 1030 1040
_ l ------------| -------------- 1 ------------ | -------------- | ------------ , -------------- 1 ------------ , -------------- 1 ------------ | -------------- 1 ------------
CFAH_HUMAN CLSLPSFE§AIPMGEKKDVYK§GEQVTYTCATTYKMDGASNVTCINSRWTGRPTCRDTS
Q8M I72_PIG CFDLPTFNDAWIGPKKPSYKSGEQVTFKCLQYFQLEGPNTIRCIKSRWIGKPACRDVS
Q91YB6_RAT CDNLPTFEIAKPTEKKKKSYRSGEQVTFRCPPPYRMDGSDIVTCVNTKWIGQPVCKDNS
Q3MHF3_BOVIN CVNLPTFEDAVLTDREKDFYRSGEQVAFKCLSYYQLDGSNTIQCIKSKWIGRPACRDVS
CFAH MOUSE CDVLPTVKNAIIRGKSKKSYRTGEQVTFRCQSPYQMNGSDTVTCVNSRWIGQPVCKDNS
SCR-18
1050 1060 1070 1080 1090 1100
—  I------- | -------- | ------- | -------- 1------- 1-------- | ------| ---------- | ------- | -------- 1------- | ------
CFAH_HUMAN CVjPPTVQNAYIVSRQMSKYPSGERVRYJCRSPYEMFG-DEEVMCLNGNWTEPPQCKDSTGK
Q8M I72_PIG CVNPPSVENAVILD-KRSRYQPGERARYECIEPYALYG-DVEVMCFNGSWTKPPQCKDSKGK
Q91YB6_RAT CVNPPHVPNATILTRHKTKYPSGDKVRYDCNKPFELFWGSGSDVPKTGFWTEPPKCKDSTGK
Q3MHF3_BOVIN CGNPPQVENAIIHN-QKSKYQSEERARYECIGNYDLFG-EMEWCLNGTWTEPPQCKDSQGK
CFAH_MOUSE CVDPPHVPNATIVTRTKNKYLHGDRVRYECNKPLELFG-QVEVMCENGIWTEKPKCRDSTGK
SCR-19
1110 1120 1130 1140 1150 1160
CFAH_HUMAN CGPPPPIDNGOITSFPLSVYAPASSVEYQCQNLTQLEGNKRITCRNGCgSEPPKCLHP
Q8M I72_PIG CGPPPPIDNGDTTSFPLPVYPPGTVVEYQCQSYYELEGSSSIKCENGQWSEPPKCLDA
Q91YB6_RAT CGPPPPIDNGDITSLSLPVYAPLSSVEYQCQNYYLLKGNKIVTCRNGKWSQPPTCLHA
Q3MHF3_BOVIN CGPPPPIDNGDITSLLQSVYPPGMIVEYRCQAYYELRGNKNWCRNGEWSQLPKCLEA
CFAH MOUSE CGPPPPIDNGDITSLSLPVYEPLSSVEYQCQKYYLLKGKKTITCTNGKWSEPPTCLHA
SCR-20
1170 1180 1190 1200 1210 1220 1231
 ,  |  |  1 1 1 |  1 |  |  1 |  |_
CFAH_HUMAN CVISREIMENYNIALWfTAKQKLYSRTGESVBTVCKRGYPfSSB|HTLRTTCWDGKLEYPTCAKR
Q8MI72_PIG CWSEEMMRKHNIELKWRPDKKLYSRTDDTIEFRCRQGYYRRTPLHTFRATCQQGKVAYPTCG—
Q91YB6_RAT CVIPEDIMEKHNIVLRWRENAKIYSQSGENIEFMCKPGYRKFRGSPPFRTKCIEGHINYPTCV—
Q 3MH F 3_BOVIN CVISEETMRKHHIQLRWKHDKKIYSKTEDTIEFMCQHGYRQLTPKHTFRATCREGKVVYPRCG—
CFAH MOUSE CVIPENIMESHNIILKWRHTEKIYSHSGEDIEFGCKYGYYKARDSPPFRTKCINGTINYPTCV—
Figure 5.10 Multiple sequence alignment of FH from five different species
CLUSTALW alignment of human, cow, rat, mouse and pig FH sequences taken 
from SwissProt. The signal peptide and each SCR domain are shown broken up 
into one segment, with the linker between the SCR domains shown in red text. 
The residues within the human sequence that are involved with mutations are 
highlighted in bold and coloured yellow and those that are polymorphic residues 
are highlighted in green.
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It is interesting how residues at the following positions Pro258, Ser890, Gln950, 
Ile970, Vall007, Tyrl021, Vall060, G lyll90 and Argl210 within FH appear to be 
structurally or functionally important since substitutions at these positions change 
phenotype and lead to disease, but are not conserved within mouse, pig, rat or bovine 
FH (Figure 5.10).
5.3.3.6 FH Nonsense Mutations
In addition to the missense mutations, seven nonsense mutations cause 
truncated FH polypeptide products. Low patient plasma FH levels indicate that three 
of these mutant peptides (Glul89X, Tyr899X and Gln925X) are not present in 
plasma suggesting that they are either incorrectly secreted or rapidly degraded. In 
contrast, a truncated form of FH, G lull72X  was purified from patient plasma and 
showed reduced binding to heparin, C3b/C3d and endothelial cells (Manuelian et al., 
2003). The fact that the shorter polypeptides appear to be unstable and are not 
present in plasma, whereas the longer polypeptide truncated by only 59 residues 
appears to be present in normal amounts suggests there may be a minimum length of 
FH protein that can exist before it is degraded or incorrectly secreted, or that later C- 
terminal SCR domains are more fundamental to the stability of the protein. FH levels 
were undefined for the remaining nonsense mutations (Ser714X, Trpll83X  and 
Glul 198X) and further comment was not possible.
5 3 3 .1  FH Deletion Mutations
Of the 12 deletion mutations, nine (c.79_82delAGAA, c.351delG, 
c.371_397del, c.l494delA, c.2686_2700del, c.3032delG, c.3486delA, [c.3674A>T; 
c.3675_3699del] and c.3695_3698delAGAA) disrupt the reading frame of CFH and 
result in a truncated FH polypeptide chain. Three other deletion mutations 
(c.670_672delAAG, c.3562_3564delAAG and c.3646_3648delACA) involve the 
removal of three nucleotides, translating to the deletion of a single amino acid 
without disrupting downstream translation of FH mRNA. This type of mutation was 
identified within SCR-4 involving the deletion of Lys224 and within SCR-20 
involving the deletion of Lysl 188 and the deletion of Thrl216 (Figure 5.11).
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Asn257
Lys224
Thrl 216
Arg1215
A rg l2 0 3
HV Loop
Figure 5.11 Mutations involving deletions of amino acids within FH
(a) The backbone of SCR-4 is shown as a blue ribbon with (3-sheets highlighted 
green. Only the side chain of the deleted residue Lys224 and the putative N- 
linked glycosylation site Asn257 are shown. N and C indicate the N- 
terminus and C-terminus respectively. The C3b binding regions identified by 
peptide spot analysis are shown in red (Licht et al., 2006). HV loop = 
hypervariable loop.
(b) The backbone of SCR-20 is shown as a blue ribbon with P-sheets highlighted 
green and the a-helix highlighted cyan. The a-carbons of the missense 
mutation residues are shown as spheres and coloured red for Type I, green 
for Type II and orange for unclassified. The side chains of the residues 
associated with heparin binding (Herbert et al., 2006) are shown and 
coloured blue where they do not have an associated mutation, and green 
where they do. The sidechains of Lysl881 and Thrl216 are shown in purple.
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Analysis of MPGN II patient plasma indicates the Lys224Del mutant form of 
FH is expressed and is present in normal amounts, suggesting a deletion at this 
position within the FH SCR domain can be incorporated into a stable protein product 
(Licht et al., 2006). This is also the case for both the Lysll88Del and Thrl216Del 
mutants, where patient FH plasma levels are normal (Neumann et al., 2003; Edey et 
al., In preparation). Interestingly, both Lys224 and Lysll88 occur on the 
hypervariable loop region of the SCR domain between P2 and p3 (Figure 5.11). The 
deletion of a residue here would not be expected to cause any structural instability 
since the length of this loop varies within FH from three residues in SCR-7 and 
SCR-9 to ten residues in SCR-20. It is more likely that the deletion of these residues 
has either a direct or indirect effect on the function of FH.
Functional studies indicate the Lys224Del mutation affects the regulatory 
function of FH without affecting the recognition and cell-binding activity (Licht et 
al., 2006). This is demonstrated by normal heparin, C3d and cell-binding activities 
but weak binding to C3b. Peptide spot analysis also identifies three distinct linear 
C3b binding regions located between residues 103-124, 166-184 and 223-238 within 
SCR2, SCR3 and SCR4 respectively. Interestingly the Lys224 residue lies within 
one of these C3b binding region of SCR4 on the surface exposed hypervariable loop 
(Figure 5.11a). The loss of Lys224 is likely to change the orientation and folding of 
this C3b binding region and lead to defective C3b binding. The putative N-linked 
glycosylation site at Asn217 within SCR-4 lies on the opposite face to the C3b 
binding region (Figure 5.11a) so any sugar attached at this position would not be 
expected to affect substrate binding, however carbohydrate staining suggests this site 
is not glycosylated (Aslam and Perkins, 2001).
The Lysll88Del mutation at the same position within SCR-20 would not be 
expected to affect decay accelerating activity since the C-terminal region of FH is 
only associated with cofactor activity (Sharma and Pangbum, 1996). Figure 5.11b 
highlights the positions of 19 residue substitutions within FH that are associated with 
aHUS. Chemical shift mapping has indicated that Lysll88 is one of eight residues 
involved in heparin binding (Herbert et al., 2006). Several mutations reside close to 
the heparin binding residues, with two mutations (Argl 182Ser and Argl215Gly/Gln) 
corresponding to the substitution of these residues. It is likely that these mutations 
together with the Lysll88Del mutation affect the ability of FH to bind to host cell 
surfaces.
216
The third deletion mutation of Thrl216 is also likely to affect the function of 
FH since patient plasma levels are normal. Thrl216 resides next to Argl215 that is 
also a heparin binding residue (Figure 5.11b). The deletion of Thrl216 could 
significantly alter the position of Argl215 and affect its heparin binding properties 
whilst maintaining a stable SCR domain structure.
5.3.3.8 Other FH Mutations
Only two of the disease associated genetic alterations within CFH involve the 
insertion of nucleotides. The c.2303_2304dupA mutation within exon 15 involves 
the introduction of one nucleotide that disrupts the reading frame at Lys768 and 
introduces a premature stop codon six amino acids downstream. The other mutation, 
c.3546_3581dup36 mutation was identified in an aHUS patient and involves the 
duplication of A rgll82-G lyll94 within SCR-20 of FH (Filler et al., 2004). The 
patient plasma levels are normal, suggesting that the mutant protein is secreted. The 
X-ray structure of SCR-20 shows that Argl 182-Glyl 194 forms a large loop on the 
surface of SCR-20 (Figure 5.9). The introduction of 12 amino acids here may extend 
the loop structure which could either directly or indirectly perturb the predicted C3d 
binding site (Jokiranta et al., 2006) while maintaining a stable FH structure.
The remaining disease causing mutation within FH is a splice site mutation 
(c.3493+lG>A) within intron 21, that changes the splice site and causes abnormal 
translation of CFH. This has been identified in a heterozygous patient with normal 
FH plasma levels (Neumann et al., 2003).
5.3.3.9 FH Polymorphisms
There are several SNPs that occur within the coding regions of CFH where 
linkage analysis has associated a predominant allele to a disease group. These are 
described in Table 5.6. Since these polymorphisms are quite common and are seen in 
general populations without phenotype, the change with CFH translation or 
transcription or within the protein structure cannot be as significant as a disease 
causing mutation. Of the polymorphisms that are in coding regions, three act as 
synonymous changes (Ala307Ala, Ala473Ala and Gln672Gln) and are not expected 
to alter the protein in any way.
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Table 5.6 Commonly occurring disease-associated SNPs within FH
SNPID Nucleotide Change* Molecular Consequence** Comments Reference
rs3753394 c.l-332C>T Change in promoter region -Allele frequencies of the T allele were much 
higher in aHUS patients (40%) than in 
controls (26%)
-Allele frequencies were also higher in aHUS 
patients with a CFH mutation (47%) than 
aHUS patients without CFH mutation (38%)
Caprioli et al., 2003
rs800292 C.184G>A Val62Ile -The valine variant was present more often in 
MPGNII patients (95%) than controls (77%)
- The valine variant was present more often in 
AMD patients (91%) than controls (78%)
Hageman et al., 2005; 
Abrera-Abeleda et al., 2006
rsl061147 c.921C>A Ala307Ala -The A allele is much more frequent in AMD 
patients (59%) than in controls (34%)
Hageman et al., 2005
rsl061170 C.1204OT His402Tyr -The histidine variant was present 
significantly more in individuals suffering 
from AMD (94%) than in controls (46%). 
-The histidine variant was also present more 
often in MPGN II patients (64%) than 
controls (34%)
Edwards et al., 2005; Klein et al., 2005; 
Haines et al., 2005; Hageman et al., 2005
rs2274700 c.!419G>A Ala473Ala -The G allele is present more often in MPGN 
II patients (91%) than in controls (54%)
-The G allele is present more often in AMD 
patients (80%) than in controls (54%)
Hageman et al., 2005 
Abrera-Abeleda et al., 2006
Table 5.6 Commonly occurring disease-associated SNPs within CFH (continued)
SNPID Nucleotide Change^ Molecular Consequence^ Comments Reference
rs3753396 c.2016A>G Gln672Gln -Allele frequencies of the G allele were much 
higher in aHUS patients (36%) than in 
controls (17%)
-Allele fiequencies were also higher in aHUS 
patients with a CFH mutation (38%) than 
aHUS patients without CFH mutation (35%)
Caprioli et al., 2003
rs!065489 c.2808G>T Glu936Asp -Allele fiequencies of the T allele were much 
higher in aHUS patients (37%) than in 
controls (18%)
-Allele frequencies were also higher in aHUS 
patients within CFH mutation (47%) than 
aHUS patients without CFH mutation (34%)
Caprioli et al., 2003
*cDNA numbering is taken form RefSeq # NM 000186.1 where +1 corresponds to the A of the ATG initiation codon. 
♦♦Residues are numbered starting from the initiating Methionine residue at +1.
It could be that these SNPs are associated with other more relevant changes that 
predispose to aHUS or AMD rather than being the significant alteration. This was 
seen with the c.-332C>T, Gln672Gln and Glu936Asp polymorphisms, where two or 
three of these polymorphisms led to a higher risk of aHUS than a single one 
(Caprioli et al., 2003). Four of the SNPs associated with disease result in amino acid 
substitutions within FH SCR domains. Val62Ile is associated with both AMD and 
MPGN II, but no link has so far been identified with aHUS (Hageman et al., 2005; 
Abrera-Abeleda et al., 2006). This substitution involves the N-terminal region of FH, 
which is associated with both cofactor and decay accelerating activity. It could be 
that a reduction in the decay accelerating activity of FH is more important in MPGN 
II and the progression of AMD than it is in aHUS. This is evidenced by the 
clustering of aHUS mutations within the C-terminal domains, with fewer missense 
mutations occurring earlier on in the sequence (Table 5.5). His402Tyr is strongly 
associated with AMD and resides on the hypervariable loop between p2 and P3 of 
SCR-7. It is a surface exposed residue where substitution would not be expected to 
cause structural alterations. This residue could be functionally relevant since SCR-7 
is associated with heparin binding, and C3c binding has been mapped to SCR-6 to 
SCR-10 (Sharma and Pangbum, 1996; Jokiranta et al., 2000). Similarly Gly936Asp 
also lies on a surface exposed loop of SCR-16 and would not be expected to cause 
structural changes but could be implicated in C3d binding since this has been 
mapped to SCR-16 to SCR-20 (Sharma and Pangbum, 1996; Jokiranta et al., 2000).
The structural models can also provide insight on the location of the FH 
polymorphisms that are not associated with any disease and have no effect on the 
stability or function of FH (Table 5.7). There are eight nonsynonymous, non-disease 
associated polymorphisms (His332Tyr, Arg493Thr, Thr519Ala, Arg780Ile, 
Asn997Thr, AlalOlOTyr, Asnl050Tyr, Leul207Arg and Serl211Pro) distributed 
along the length of FH. All of these mutations correspond to exposed residues on the 
surface of the SCR structures as is expected if the residue substitutions do not have 
any effect on the stability of the structure (Figure 5.9). All but three are on surface 
exposed variable loops between conserved P-strands, apart from Arg493Thr, 
Thr519Ala and Leul207Arg.
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Table 5.7 Structural analysis of non-synonymous polymorphisms in FH
SCR Mutation DSSP Position Accessibility ConsensusNumbering*
1 Val62Ile C P4 - (36 Loop 6 44
6 His332Tyr C Cl - (32 Loop 9 8
7 His402Tyr C |32 - (34 Loop 9 13
8 Arg493Thr E (36 9 38
9 Thr519Ala E P2 2 11
13 Arg780Ile C (34 - (36 Loop 9 25
16 Glu936Asp C Cl - (32 Loop 9 6
17 Asn997Thr C Cl - (32 Loop 9 9
17 Alai 01 OThr C P2 - (34 Loop 5 18
18 Asnl050Tyr C Cl - (32 Loop 8 3
20 Leul207Arg E P5 8 32
20 Serl21 IPro C P5 - P6 Loop 3 34
■"Consensus numbering refers to the position of the mutation in a consensus sequence of 124 human 
complement protein SCR domains that is numbered from 1-49 (Figure 5.19).
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Although these three residues lie on P-strands their sidechains are exposed and the 
substitutions are not expected to have an effect on the overall SCR domain structure. 
The majority of these residues occur in variant positions within the FH sequence 
alignment of five species (Figure 5.10). The only well conserved residues are His332 
and Asnl050. His332 is not 100% conserved and a tyrosine is found within the 
mouse sequence at the same position. Asnl050 is well conserved with the only 
change being an aspartic acid within the mouse sequence. Analysis of more 
sequences could show more variation at these positions. Of interest are the two 
polymorphisms (Leul207Arg and Serl21 IPro) within the SCR-20 domain since this 
domain is highly relevant for the function of FH. Both of these residues are surface 
exposed but reside on the same loop region as other Type II missense mutations 
(Argl210Cys and Argl215Gly/Gln) (Figure 5.9). This loop is implicated in heparin 
and C3 binding (Jozsi et al., 2006). Interestingly this region of the FH sequence 
(residues Leul207-Thrl213) does not show strong conservation between species 
(Figure 5.10), however the Type II mutation at Argl210 does suggest it is 
functionally significant.
5.3.4 MCP Mutations
A total of 138 genetic alterations were found within MCP. This includes 104 
non-disease predisposing polymorphisms, five disease-associated polymorphisms, 
and 25 disease causing mutations (Figure 5.12, Table 5.8). The 25 disease- 
predisposing mutations are distributed within the four N-terminal SCR domains, 
with one mutation falling within the transmembrane domain (Figure 5.12b).
5.3.4.1 MCP Missense Mutations
Structural analysis was possible for nearly half (11) of the disease causing 
mutations (Table 5.9, Figure 5.13). Of these missense mutations, three can be 
classified with Type I phenotypes (Cys35Tyr, Cys99Arg and Prol65Ser), and five 
with Type II phenotypes (Argl03Trp, Glul79Gln, Ser206Pro, Phe242Cys and 
Ala353Val). Two of the Type I mutations (Cys35Tyr and Cys99Arg) involve the 
replacement of the first conserved cysteine residue (Cl) of the SCR domain and 
would disrupt the disulphide bond and reduce the structural stability of the SCR 
domain. The Type I mutation Prol65Ser is on a surface loop near the N-terminal of 
SCR-3 (Figure 5.13).
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(a)
Exon 1
Exon 2 
Exon 3
Exon 4i 
Exon 5
Exon 6 
Exon 7 h 
Exon 8
Exon 9-
c.796A>G
C.857-99A>T
c.857-36A>G
C.-1494A>G c.-652C>G
C-1289A>G c-366A>G
c.389+188T>G 
c.389+541 A>T 
C.389+700A>G 
c.389+926G>A 
C.390-367G>T
c.97+908A>G
c.98-1724C>G
C.98-1019A>G
c.98-363A>G
c.98-330A>G
c.98-192A>T
c.98-156A>G
•c.417A>G
c.475+204C>G
c.475+250->A
C.475+509G>T
C.475+580C>T
c.476-313C>T
c.476-296C>T
c.476-136C>T
c.476-107C>A
C.673+1312A>G
c.673+1672C>T
c.673+1700C>G
c.673+2092C>T
c.673+2095C>T
c.673+2269A>G
c.673+2510->T
c.673+58A>G
c.673+915G>A 
C.674-2746A>G 
c.674-2464C>T 
c.674-2130C>T 
c.674-2122C>T 
c.674-1870A>G 
c.674-1649A>C 
c.674-723C>G
c.674-616C>T
c.674-312T>G
c.906A>G
C.946+23T>G 
c.946+371 A>G 
c.946+5 73C>T 
C.946+759A>G 
c.947-1014A>C 
c.947-554C>T 
c947-508C>T 
c.947-488A>G
c.989+366C>T c.989+5311T>C c.990-1298A>G 
c.989+408A>G c.989+5976T>C c.990-813A>C 
c.989+935G>T c.990-6146C>T c.990-678C>T 
c.989+1147C>T c.990-5890C>T c.990-579A>G 
c.989+1253C>T c.990-5123A>G c.990-498A>G 
c.989+1969A>T c.990-4098A>G c.990-496A>G 
c.989+2006C>T c.990-3945G>T c.990-207A>G 
c.989+2166A>G C.990-3784A>G c.990-77G>A 
C.989+2264A>G c.990-3392C>T 
c.989+2793T>C c.990-3336A>T 
c.989+4771C>A c.990-3310A>G______________
Exon 10.
Exon 11. 
Exon 12-
Exon 13-
Exon 1 4 ^
= 1-
c.1028-861C>T
c.1028-322C>G
c.*527C>T c.*3684A>G c.*4099A>G c.*5112T>C
c.*1476C>G c.*3975G>T c.*4549C>T c*5131 A>C 
C*1786A>G c.*3993C>G c.*4616A>G 
c.*2752A>G c.*4078C>T C*5056T>G__________
C .1127+44C>T 
c.1127+211A>G 
c.1127+238A>G 
c.1127+599G>T 
c.1127+639A>G 
c.1127+1078G>T 
c.1127+1359C>T 
c.1127+1682C>T 
c.1127+2032A>G 
C.1128-1962G>A 
c.1128-1907T>G 
c.1128-1327A>G 
c.1128-618C>T
Figure 5.12 Distribution of nucleotide changes within MCP (continued over 
page)
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(b)
Cys99Arg
Argl03Trp
c.389-lG>C
I
N SCR 1 SCR 2 SCR 3
Ser240Pro
Phe242Cys
Tyr248X Ala353Val
c.747_751delAGCAA
C.799_801delAC c.946-78G>A* c.2337T>C*
 i  i r i
STPI------ |TM|— |Cy-CSCR 4
1-33 34-95 98 -158
I
c.95-lG>C
Cys35Tyr
Arg 59X
[c.192T>C;
c.l93_198del]
c.286+lG>C
c.286+2T>G
c.287-2A>G
161 -224 227-284 301-329 344-366 377-392
I I I
Prol65Ser c.800_820del c.1127+638G>A*
Glul79Gln c.811_818delGACAGT 
Aspl85Asn [c.815_829del;c.832C>T]
Tyrl89Asp c.899-2A>G 
Glyl96Arg
Figure 5.12 Distribution of nucleotide changes within MCP
(a) The distribution of common non-disease associated SNPs within the MCP 
gene. Exons are shown in blue and drawn to scale. Those SNPs within coding 
regions are shown in red.
(b) The distribution of disease-associated mutations within individual domains of 
MCP. Mutations are written above and below their respective domains. 
Domains are drawn to scale. The grey box indicates the coding segment for 
the signal peptide. The numbering underneath the domains indicates the 
range of amino acids from the start to the end of the domain. Linkers are not 
included. N and C indicate the N-terminus and C-terminus respectively. 
Mutations followed by a * character represent disease-associated 
polymorphisms. STP = serine/threonine/proline rich region. TM = 
Transmembrane helix region. Cy = Cytoplasmic region.
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Table 5.8 aHUS-associated mutations within MCP *
Domain Nucleotide Change Molecular Consequence Patient
Records
Reference
Intron 1 c.95-lG>C Splice Site alteration between Intron 1 and Exon
7
2 Caprioli el al., 2006
SCR-1 c,104G>A
z
Cys35Tyr 3 Castelletti et al., 2006
SCR-1 c.175C>T Arg59X 5 Castelletti et al., 2006, 
Fremeaux-Bacchi et al., 2006
SCR-1 fc. 192'T>C;c. 193 198del] Frameshift resulting in premature stop 39 amino 
acids downstream
1 Caprioli et al, 2006
Intron 2 c.286+lG>C Splice Site alteration between Exon 2 and Intron 1 Esparza-Gordillo et al., 2005
Intron 2 c.286+2T>G
/,
Splice Site alteration between Exon 2 and Intron 1 Fremeaux-Bacchi et al., 2006
Intron 2 c.287-2A>G
z
Splice Site alteration between Intron 2 and Exon 
3
2 Caprioli et al., 2006; 
Fremeaux-Bacchi et al., 2006
SCR-2 c.295T>C Cys99Arg 1 Caprioli et al., 2006
SCR-2 c.307C>T Argl03Trp 1 Esparza-Gordillo et al., 2005
Intron 3 c.389-lG>C Change in Splice site 1 Rodriguez de Cbrdoba, in preparation
SCR-3 c.493C>T Prol65Ser 2 Esparza-Gordillo et al., 2005
SCR-3 c.535G>C Glul79Gln 1 Fremeaux-Bacchi et al., 2006
SCR-3 c.553G>A Aspl85Asn 1 Fremeaux-Bacchi el al., 2006
SCR-3 c.565T>G Tyrl 89 Asp 2 Fremeaux-Bacchi et al., 2006
SCR-3 c.586G>?** Glyl96Arg 1 Fremeaux-Bacchi et al., 2006
SCR-4 c.718C>T Ser240Pro 2 Richards et al., 2003
SCR-4 c.725T>G Phe242Cys 2 Castelletti et al., 2006
SCR-4 c.744C>? Tyr248X 1 Fremeaux-Bacchi et al., 2006
SCR-4 c.747 751delAGCAA Deletion of 5bp at codon 249 1 Esparza-Gordillo et al., 2005
SCR-4 c.799_801delAC Frameshift resulting in premature stop at codon 
271
Frameshift resulting in premature stop at codon 
271
Deletion of amino acids D271 and S272
1 Noris et al., 2003
SCR-4 c.800_820delCA 3 Rodriguez de C6rdoba, in preparation
SCR-4 c.811 815delGACAGT 1 Richards et al., 2003
SCR-4 [c.815 829del;c.8320TJ Deletion of five amino acids 1 Caprioli et al., 2006
Intron 7 c.899-2A>G Splice Site alteration between Intron 7 and Exon 1 Fremeaux-Bacchi et al., 2006
*cDNA numbering is taken form RefSeq # NM 002389.3 where +1 corresponds to the A of the ATG initiation codon 
Residues are numbered starting from the initiating methionine residue at +1.
**The ? character represents an unknown nucleotide change
Table 5.9 Structural analysis of 11 missense mutations in MCP
Domain Mutation DSSP Position Accessibility ConsensusNumbering* Phenot
SCR 1 Cys35Tyr C Cl 0 1 I
SCR 2 Cys99Arg C Cl 0 1 I
SCR 2 Argl03Trp C Cl - 132 Loop 9 5 II
SCR 3 Prol65Ser C Cl - (32 Loop 5 4 I
SCR 3 Glul79Gln C P2 - P4 Loop 9 14 II
SCR 3 Aspl85Asn C P2 - P4 Loop 5 20 U
SCR 3 Tyrl 89 Asp E P4 2 24 U
SCR 3 Glyl96Arg E P5 0 31 U
SCR 4 Ser240Pro C P2 - P4 Loop 5 13 II
SCR 4 Phe242Cys C P2 - P4 Loop 9 13 II
TM Ala353Val - - - - II
♦Consensus numbering refers to the position of the mutation in a consensus sequence of 124 human 
complement protein SCR domains that is numbered from 1-49 (Figure 5.19).
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Cys35
Ser24Q
Asp266
Pro 165
Phe242
SCR-4
Figure 5.13 Positions of 11 missense mutations and one non-synonymous 
polymorphism within 4 MCP domain models
The backbone of the SCR domains of MCP are shown in blue ribbons with the p- 
strands highlighted and labelled in green. Only the side chains o f missense 
mutation residues or those involved in non-synonymous polymorphisms are 
shown. Residues where the mutations have phenotypic classification are coloured 
red for Type I and green for Type II. Those residues where mutations do not have 
phenotypic classification are coloured orange. The non-synonymous polymorphic 
residues are coloured in grey. N and C indicate the N-terminus and C-terminus 
respectively.
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Pro 165 is adjacent to Pro 166 and the backbone is conformationally more restricted in 
this area due to the cyclic nature of proline sidechains. Substitution of one of these 
proline residues with a small serine residue may change the backbone conformation 
to destabilise the domain. This would result in a predicted Type I phenotype as 
observed.
Four of the Type II mutations (Argl03Trp, Glul79Gln, Ser240Pro and 
Phe242Cys) involved surface exposed residues within SCR domains. Argl03 resides 
on a surface-exposed loop within SCR-2 (Figure 5.13). This could be functionally 
significant since mutational studies have mapped several residues on the surface of 
SCR-2 that are associated with cofactor activity (Christiansen et al., 2000). Glul79 
resides on a surface exposed loop within SCR-3 that could be significant since SCR- 
3 has surface exposed residues associated with both C3b and C4b binding 
(Liszewski et al., 2000) (Figure 5.13). Both Ser240 and Phe242 reside on a surface 
exposed loop between p2 and P4 of SCR-4 that is also associated with C3b and C4b 
binding and cofactor activity (Liszewski et al., 2000) (Figure 5.13). The remaining 
Type II missense mutation (Ala353Val) occurs within the transmembrane region of 
MCP and may affect the hydrophobocity of this region and interaction with the 
membrane without affecting expression of MCP (Caprioli et al., 2006).
There are three missense mutations found within SCR-3 that have 
undetermined phenotypes. One of these mutations (Aspl85Asn) is found on a 
surface exposed loop within SCR-3 whereas the other two mutations (Tyrl89Asp 
and Glyl96Arg) are found on conserved p-strands (Figure 5.13). Disruption here 
could affect the structural stability of the SCR domain or indirectly alter the position 
of surface exposed residues.
5.3.4.2 Other MCP Mutations
The remaining 14 mutations all result in truncated polypeptides that are not 
expected to be present on host cell membranes. Six mutations alter the exon/intron 
boundary and splice sites of Intron 1 (c.95-lG>C), Intron 2 (c.286+lG>C, 
c.286+2T>G, and c.287-2A>G), Intron 3 (c.389-lG>C) and Intron 7 (c.899-2A>G). 
A further six mutations ([c.l92T>C;c.l93_198del], c.747_751delAGCAA, 
c.799_801delAC, c.800_820del, c.81 l_815delGACAGT and
[c.815_829del;c.832C>T]) involve deletion of nucleotides and truncated peptides. 
Finally two nonsense mutations Arg59X and Tyr248X cause premature termination
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of the MCP peptide with the transmembrane domain deleted. Therefore, MCP is not 
expected to be present in normal amounts on cell membranes.
5.3.4.3 MCP Polymorphisms
There are five SNPs within MCP that are associated with aHUS, functional 
analyses have demonstrated that SNPs C.-625G and C.-366G decrease transcription 
from the MCP promoter (Esparza-Gordillo et al., 2005). These MCP SNPs are in 
strong linkage disequilibrium organizing an SNP haplotype block denominated 
MCPggaac. Replication studies in three different aHUS cohorts have shown that 
MCPggaac is an important aHUS risk factor (Esparza-Gordillo et al., 2005; 
Fremeaux-Bacchi et al., 2006).
There is one non-synonymous SNP within MCP (Asp266Asn) that is not 
associated with disease. Asp266 is exposed on the loop between P4 and p6 of SCR-4 
(Figure 5.13). The only other missense mutations within SCR-4 that are associated 
with a functional defect both reside on the loop between p2 and p4 which is on the 
other face of the SCR domain. It is likely this region has functional significance and 
the surface of the p4 to P6 loop does not.
5.3.5 FI Mutations
The database contains a total of 215 genetic alterations within IF. This 
includes seven missense mutations, three nonsense mutations, two insertions, two 
deletions and two splice site alterations, together with 193 non-disease causing SNPs 
(Figure 5.14 and Table 5.10). Figure 5.14b highlights that the majority of IF 
mutations are within the SP domain, and other missense mutations are found in the 
two LDLR domains, suggesting that both are important for function, but no missense 
mutations have been so far identified in the FIMAC or CD5 domains.
5.3.5.1 FI Missense Mutations
Structural analysis of the seven missense mutations using the homology 
models of FI is shown in Figure 5.15 and Table 5.11. Of the seven missense 
mutations only two (Cys247Gly and His418Leu) can be assigned as showing Type I 
phenotypes, where the residue alteration affects the stability, secretion or synthesis 
of the FI protein, and patients have reduced amounts of FI in their serum.
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(a)
Exon 1 ■  
Exon 2 -
Exon 3
;xon 4 - 
_xon 5 -
Exon 6-
Exon 7
Exon 8" 
Exon 9 
Exon 10“
Exon 11 - 
Exon 12'
c.804A>G
c.71+54G>A c71+5233G>A
C.71+185G>A c71+5368T>A 
c.71+566T>C o71+5493G>A
C.71+1593C>A o71+5828T>C 
c.71+2013T>C C.71+6053T>G 
C.71+2080T>A c71+6164G>A 
c.71+2483T>G c71+6173T>A 
C.71+2550T>C c.71+6184G>A 
c.71+3395T>A c.71+6427T>G 
c.71+3537G>A c.71+6468G>A 
C.71+3612G>A C.71+6574G>A 
C.71+3698T>C C.71+6604T>C 
C.71+3907T>C C71+6664G>A 
c.71+4150T>C C.71+6711T>A 
C.71+4207T>G c.71+7019T>G 
c.71+4341G>A c71+7598G>A
c.71+9107T>C
c.71+9218G>A
C.71+9468T>G
c.71+9539T>C
C.71+9588G>A
C.71+16435G>A
c71+16540G>A
c71+16619T>C
c.71+16732T>C
c71+16824G>T
c.71+11448G>A c71+16847G>A 
C.71+11990T>C c.71+16863T>G 
c.71+12085T>C c.71+17342T>C 
c.71+12347G>A c.72-16268A>T 
C.71+12895A>C c.72-16268A>T 
C.71+12964T>C c72-16227A>G 
C .7 1 + 1 3037A>G c.72-161S2G>A 
o71+13192C>T c.72-16152G>A 
C.71+13778T>C c72-156S8G>A 
c.71+14435T>C o72-15083T>C 
C.71+14441G>A c.72-15080T>C
C.71+4371T>C C.71+7612T>C>A c.71+14498C>T c72-14676T>C
c.71+4616G>A c.71 +8259G>A c.71+14554G>T c.72-14000T>A
c.71+4759T>G C.71+9008C>A C.71+14938T>C c72-12327T>C
c.71+5103T>C C.71 +9050G>A c.71+15502T>G c.72-11859T>C
c.72-11110G>A
C .7 2 -1 0973C>T
072-10029G>A
c.72-10148T>C
C .7 2 -1 0595G>A
c.72-10626G>A
c72-9675T>C
c.72-9489G>A
c72-9247T>C
072-9065G>C
c.72-8931G>A
C.72-8245G>A
0 7 2 - 7 7 7 1  T>C
c.72-7610T>C
c.72-6987G>A
c.72-5960T>C
c.72-5843T>G
c.72-5589T>C
c.72-5555T>C
c.72-5470G>A
c.72-4888T>G 
c.72~4251T>C 
C.72-4003C>A 
c.72-2991G>A 
c.72-2679A>T 
c.72-2656T>A 
c.72-2606G>C 
c.72-2275C>A 
c.72-2155T>C 
C.72-2148G>C 
C.72-197ST>C 
c.72-1968G> A 
C.72-191 SG>A 
C.72-1790G>A 
c.72-1577C>A 
C.72-1164G>A 
c.72-1143G>A 
c.72-1107T>G
c.328+440T>C
c.328+660G>A
c.328+750G>C
0329-931G>C o329-239T>C 
c.329-568T>A c.329-209T>G 
c.329-351G>A c.329-156T>C
c.482+591G>A c.483-964C>A 
C.482+597G>A c.483-899A>G 
c.482+949G>A c.483-806C>A 
C.482+1298G>A c.483-702A>G 
„C,4S2t139?0>A_____________
c.483-693T>A
c.483-606T>C
c.483-290C>A
o483-105T>C
c.904+2476T>C
C.90S-2483T >G
c.905-2259G>C
c.905-1697G>A
C.905-1389T>G
c.905-1359T>G
c.905-1342G>A
c.905-1214T>G
o905-1185T>G
^.905-1156T>G
c.905-628G>A
c.905-451G>A
C.905-294G>C
c.883+1048T>G
c.883+169T>C
c.883+286T>G
c.883+305T>C
c.883+433G>A
c.883+755T>C
c.884-1108T>C 
c.884-723T>C 
c.884-63C>A 
C.884-634T >G 
c.884-587T>A
c.1044+12T>G
c.1044+47G>A
C.940+1339T>C
c.940+1340G>A
c.940+854T>C
c.941-943G>A
c.941-678T>C
c.941-145G>A
c.941-49G>C
o l 429+33G>A
C.1429+947G>A
01429+1051G>A
c.1429+1086T>C
c.1429+1207T>A
c.1430-1730G>A
o1430-1046T>G
c.1430-879G>A
c.1430-288C>A
c.1430-246G>A
c.1148+522G>A 
c.1148+574T>C 
o l 148+1113T>A 
o1149-1322G>C 
c.1149-1242T>C 
ol149-993T>C 
o l  149-871T>C 
C .1 149-670T>C
Exon 12 -I
C .1534+137T>C 
c.1534+206G>A
c.*115A>G
Figure 5.14 The distribution of nucleotide changes within IF  (continued over 
page)
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Figure 5.14 The distribution of nucleotide changes within IF
(a) The distribution of common non-disease associated SNPs within the IF  gene. 
Exons are shown in blue and are drawn to scale. Those SNPs within coding 
regions are shown in red.
(b) The distribution of disease-associated mutations within individual domains 
of FI. Mutations are written above and below their respective domains. 
Domains are drawn to scale. The grey box indicates the coding segment for 
the signal peptide. The numbering underneath the domains indicates the 
range of amino acids from the start to the end of the domain. Linkers are not 
included. N and C indicate the N-terminus and C-terminus respectively. 
Mutations followed by a * character represent disease-associated 
polymorphisms. FIMAC = FI membrane attack complex. CD5 = cluster of 
differentiation 5. LDLR = low-density lipoprotein receptor.
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Table 5.10 Disease-associated mutations within IF
Domain NucleotideChange8 Molecular Consequence15 Condition
Patient
Records
Reference
CD5 c.435G>A Trpl45X aHUS 1 Kavanagh et al., 2005
LDLR-1 C.7190G Ala240Gly aHUS 2 Caprioli et a l, 2006
LDLR-1 c.739T>G Cys247Gly FI Deficiency 1 Ponce et al., in preparation
Intron 5 c.772G>A Splice Site alteration between Exon 5 and Intron 5 FI Deficiency 1 Vyse et al., 1996;
Ponce et al., in preparation
LDLR-2 c.893delC Frameshift resulting in premature stop at codon 308 FI Deficiency 1 Kavanagh et al., 2005
Linker [c.907G>A; Alteration of two amino acids in the linker region FI Deficiency 1 Morley et al., 1998
c.913G>T] between the light and heavy chain
Linker C.9490T Arg317Trp aHUS 1 Caprioli et al., 2006
SP c.1190 1191InsAT Frameshift resulting in premature stop at codon 402 FI Deficiency 1 Baracho et al., 2003
SP C.1253A>T His418Leu FI Deficiency 2 Vyse etal., 1996
SP C.1420OT Arg474X aHUS 2 Fremeaux-Bacchi et al., 2004
SP c. 1446 1450delTT 
CAC
Frameshift resulting in premature stop at codon 483 aHUS 1 Caprioli et al., 2006
Intron 12 C.1534+5G>T Splice Site alteration between Exon 12 and Intron 12 aHUS 1 Caprioli et al., 2006
SP C.1555G>A Asp519Asn aHUS 1 Caprioli et al., 2006
SP C.1571A>T Asp524Val aHUS 1 Fremeaux-Bacchi et al, 2004
SP c.1610 1611insAT Frameshift resulting in premature stop at codon 538 aHUS 2 Esparza-Gordillo et al., 2006
SP C.1637G>A Trp546X aHUS 1 Fremeaux-Bacchi et a l, 2004
®cDNA numbering is taken form RefSeq # NM 000204.1 where +1 corresponds to the A of the ATG initiation codon. 
Residues are numbered starting from the initiating methionine residue at +1.
Cys247
Ala240
LDLR-1
Lys441
Arg406
His418
Asp524
SP
Figure 5.15 Positions of five missense mutations and four non-synonymous 
polymorphisms within FI domain models
The backbone of the LDLR-1 and SP domains of FI are shown in blue ribbons with 
the P-strands highlighted in green and a-helices highlighted in cyan. Only the side 
chains of missense mutation residues or those involved in non-synonymous 
polymorphisms are shown. Residues where the mutations have phenotypic 
classification are coloured red for Type I and green for Type II. Those residues 
where mutations do not have phenotypic classification are coloured orange. The non- 
synonymous polymorphic residues are coloured in grey.
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Table 5.11 Structural analysis of six missense mutations in FI
Domain Mutation_______ DSSP Position___________Accessibility Phenotype
LDLR-1 Ala240Gly C al Loop 3 II
LDLR-1 Cys247Gly C al Loop 0 I
Linker Arg317Trp Linker region 
before SP domain
“ II
SP His418Leu C PG - PH Loop 1 I
SP Asp519Asn C PL - PM Loop 0 u
SP Asp524Val C PL - PM Loop 0 II
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The Cys247Gly missense mutation involves the substitution of one of the conserved 
cysteine residues of the LDLR1 domain that may perturb its correct folding. 
Similarly, replacement of His418 within a buried p-strand of the SP domain may 
interfere with protein folding.
There are three missense mutations (Ala240Gly, Arg317Trp and Asp524Val) 
that can be assigned a Type II functional alteration, where FI plasma levels are 
normal or higher than normal in heterozygous patients. Ala240 lies within the 
LDLR-1 domain of FI. LDLR domains are cysteine-rich domains of 40-50 residues 
that occur within several complement component proteins.
Although LDLR domains are well characterised (Dolmer and Gettins, 2005), 
very little work has been carried out classifying these domains within FI and it is not 
clear how an alteration within this domain could affect FI function. X-ray and 
neutron scattering work on serum-derived FI predicted that the FIMAC, CD5 and 
LDLR-1 domains form a compact triangular arrangement within the FI structure 
(Chamberlain et al., 1998). This model postulates that the SP, CD5 and LDLR-1 
domains constitute exposed surfaces of FI that may interact separately with its 
substrates C3b and C4b and with cofactor proteins. The Ala240Gly mutation could 
affect these surface exposed regions.
Arg317 lies within the 40-residue connecting region between the light and 
heavy chains, 17 residues downstream of the cleavage site between the light and 
heavy chains. Replacement of Arg317 with a hydrophobic tryptophan residue would 
reduce the positive surface charge in this region and may alter the activation of FI. 
The Asp524Val mutation involves the substitution of a residue that lies next to 
Ser525 which is part of the catalytic triad (His380-Asp429-Ser525). The homology 
model of the FI SP domain indicates this residue side chain points away from the 
catalytic triad. A residue substitution in such close proximity may cause a sufficient 
rearrangement of the catalytic triad to perturb function, while not affecting the 
overall stability of the protein.
The remaining missense mutation (Asp519Asn) cannot be phenotypically 
classified as patient serum levels of FI are inconclusive. Asp519 lays seven residues 
downstream of Ser525 in the catalytic triad and may affect the functional activity of 
FI, however it could equally affect structural stability, since the homology model 
shows that it is not in close proximity to the active site but lies within a buried part 
of the structure (Figure 5.15).
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5.3.5.2 Other FI Mutations
Of the remaining ten disease causing mutations, six are readily explained by 
the occurrence of truncated polypeptides, with three nonsense mutations (Trpl45X, 
Arg474X and Trp546X) and three nucleotide changes (c.893delC, 
c.ll90_1191insAT, and c.l610_1611insAT) that cause a shift in the reading frame 
of IF  and result in a premature stop codon. A further two mutations also result in 
absent FI and involve a splice site change within the 5’ donor site of Intron 5 
(c.772G>A) leading to an incorrectly spliced protein and the alteration of two 
nucleotides ([c.907G>A;c.913G>T]) within the linker region connecting the light 
and heavy chains. The [c.907G>A;c.913G>T] mutation involves the substitution of 
Glu303Lys followed by the change from Glu305 to a premature stop codon. This 
produces a truncated polypeptide without the SP domain that is not detected in 
patient plasma (Morley et al., 1998).
Another splice site mutation (c.1534+5G>T) is seen at the donor site of 
Intron 12 and is likely to lead to an alternatively spliced FI molecule that is present 
in normal amounts but is not functioning correctly. Finally, the 
c.l446_1450delTTCAC deletion results in a truncated polypeptide which would be 
expected to be unstable, however the patient FI serum level is 77% of normal, and 
since the patient is heterozygous it is difficult to say whether the levels result from 
the wild type or mutant IF  allele (Caprioli et al., 2006).
Of the 16 genetic alterations reported to predispose to disease, six changes 
(Cys247Gly, c.772G>A, c.893delC, [c.907G>A;9.13G>T], c.ll90_1191insAT and 
His418Leu) result in FI deficiency as opposed to aHUS (Table 5.10). All of these 
mutations are reported in homozygosity or compound heterozygosity and result in 
the complete absence of FI in plasma. FI deficiency, like aHUS results in incorrect 
regulation of the alternative pathway, so there is consumptive depletion of C3, Factor 
B and FH. The clinical outcome results in recurrent pyogenic infections, usually 
beginning in early childhood. A distinction between aHUS and FI deficiency can be 
made since FI deficiency invariably involves the absence of FI, whereas aHUS 
involves patients that are heterozygous for IF  mutations, having one normal copy of 
the IF  allele.
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5.3.5.3 FI Polymorphisms
There are five nonsynonymous polymorphisms within IF  (Ala300Thr, 
Arg406His, Lys441Arg, Glu548Gln and Tyr571Ser) that cause substitution of amino 
acid residues but do not alter phenotype (Table 5.12). Unlike the polymorphisms 
within FH and MCP, linkage analysis of polymorphisms within FI has not been 
studied. The homology models of the FI domains indicate that, with the exception of 
Ala300Thr, all the residues involved with the non-synonymous polymorphisms are 
on surface exposed loops. Residue alterations in these exposed areas are not 
expected to cause damaging structural effects, and it is unlikely that they are 
associated with the function of FI. Ala300Thr lies within the connecting region 
between the light and heavy chains of FI. Although another mutation within this 
region (Arg317Trp) is seen to have a functional affect on FI activation, it is not 
expected that the Ala300Thr mutation would have any structural or functional 
affects.
5.3.6 FH-HUS Web Database
The FH-HUS mutation database is available at http://www.FH-HUS.org. It is 
maintained and updated on the server of the Department of Biochemistry and 
Molecular Biology at UCL. The database was constructed using mySQL 
(http://www.mysql.com) and is displayed and navigated on the web via PHP 
(http://www.php.com), Javascript and HTML programming. The data was first 
published on the website in November 2004.
The FH-HUS web database is fully interactive with a user-friendly graphical 
interface. Page navigation follows the same design as the Factor XI web database 
described in Chapter 4, however additional pages are present for navigation through 
three proteins as opposed to one. The site map is shown in Figure 5.16. Like the 
Factor XI web database, the FH database also has the same four main functionalities 
of search, structural analysis, mutation submission and statistical analysis. The 
mutation and patient data within the database are also available in XML format.
5.3.6.1 FH-HUS Web Database Searches
A choice of quick, basic and advanced searches can be carried out for CFH, 
MCP and IF  mutations (Figure 5.17a).
237
Table 5.12 Structural analysis of five non-disease associated polymorphisms in 
FI
Domain Mutation_______ DSSP Position___________Accessibility
Linker Ala300Thr " Linker region 
before SP domain
-
SP Arg406His C PF - PG Loop 9
SP Lys441Arg C PH - pj Loop 9
SP Glu548Gln c PN - po Loop 9
SP Tyr571Ser H Helix 3 9
238
H o m e -
r  In fo  ------------ HUS
MPGN 
AM D  
Factor H 
Factor I 
MCP
-  M u ta tio n s  —  Info
Basic Search —r  Search Results 
Adv Search —
New M u ta tio n  - 
Stats
M u ta tio n  Maps 
Full List FH 
Full List FI 
Full List MCP -
—  Factor H 
Factor I 
MCP
-  M odels
P rin t Results 
Excel Results
In D ep th  Analysis
-  References
-  Links
-  S ub m it
-  C on tac t 
- H e lp
C o llabora to rs
Figure 5.16 Site map of www.FH-HUS.org
The links between in page are shown with a line. The lines that cross over each 
other are coloured to make the links between pages more clear.
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Figure 5.17 Screen shots o fwww.FH-HUS.org (continued over page)
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Figure 5.17 Screen shots of www.FH-HUS.org (continued over page)
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Figure 5.17 Screen shots o fwww.FH-HUS.org (continued over page)
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Figure 5.17 Screen shots o fwww.FH-HUS.org (continued)
(a) Advanced Search Page
(b) Search Results Page
(c) Structural analysis of a hypothetical mutation
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These search forms can be adapted to perform specific requirements, for example the 
user can search for all mutations over a range of SCR domains within FH, and also 
retrieve all the missense mutations within the SP domain of FI that have a specific 
phenotype (Figure 5.17a). The results of all the searches can be downloaded in 
Microsoft EXCEL (http://www.microsoft.com) format for further analysis or 
retrieved in a printer friendly format. The following fields of information are 
returned for each mutation record that fit the search criteria: nucleotide alteration, 
codon number, initial and mutated residue (where applicable), phenotype (classified 
as Type I, Type II, unknown or none), reference, mutation type (e.g. insertion or 
deletion), domain, secondary structural position (taken from consensus DSSP 
assignments), sequence (to highlight the mutation within a short sequence of the 
protein), comments and reference state (whether it is an abstract or a full citation) 
(Figure 5.17b). The nucleotide alteration is described in terms of the HGVS 
guidelines for mutation nomenclature (http://www.hgvs.org/mutnomen/) with the 
reference nucleotide sequence taken from the RefSeq database (accession numbers 
#NM_000186.1, #NM_002389.3 and #NM_000204.1 for FH, MCP and FI 
respectively).
Past reports of FH mutations have used conflicting protein numbering, with 
some groups choosing to include the 18-residue signal peptide and others numbering 
with respect to the mature peptide. Additionally groups have also used different 
schemes for nucleotide numbering, together with different mRNA source sequences. 
To avoid confusion, although all mutations within the database are written to comply 
with HGVS guidelines, the original published format of the mutation is also included 
for easy reference. These alternative syntaxes link straight to the PubMed abstract 
they refer to. The residue number with reference to the mature FH protein (following 
PDB code: 1HAQ) is also given within brackets alongside the correct codon number.
Within the search results users can choose to display information on the 
patients that have been identified with given mutations (Figure 5.17b). The following 
fields of information are displayed when this option is selected: FH and C3 levels 
(given as low, normal or high depending on control values used in the original 
reference), genotype, clinical history, inheritance (sporadic/familial) and any 
comments regarding the patient. Data is available describing the FH and C3 assays 
used in each study and can be viewed in the context of the results via JavaScript 
hover box to allow comparison between different data sets.
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Following feedback from the aHUS research community, the second release 
of the database incorporates mutation maps based on both the protein and nucleotide 
sequence of FH, MCP and FI. These maps are automatically generated from the 
mutation data within the database and show the position of each mutation in terms of 
nucleotide and protein sequence.
5.3.6.2 FH-HUS Web Database Structural Analysis
The website also offers users a second major functionality by performing a 
structural analysis in addition to searching and displaying what is already known 
about FH, MCP and FI mutations. A structural analysis can be performed for any 
possible missense mutation within FH, MCP or FI domain structures (Figure 5.17c). 
The homology or experimental domain structures are used to highlight the positions 
of mutations within the structure and interactive views are provided by the newly 
developed Java Applet JMol version 10 (http://jmol.sourceforge.net/). Structural 
analysis of a mutation provides the user with structural information such as the 
DSSP secondary structure assignment and side chain surface accessibility (Kabsch 
and Sander, 1983) that are calculated from the homology or experimental domain 
structures. This analysis also highlights whether the mutation occurs within a known 
binding region of the protein and provides the appropriate reference. A comparison 
of amino acid properties such as hydrophobicity and charge is also shown for 
analysis of missense mutations. This approach can use information contained within 
the database to predict an analysis of any new user-defined substitution at any 
position in FH, MCP or FI (Figure 5.17c). This flexible, yet powerful tool can be 
used to assess whether a novel point mutation may perturb structural stability (Type 
I) or biological function (Type II), or alternatively may be a non-disease-causing 
polymorphism.
5.3.6.3 FH-HUS Web Database Mutation Submission
The third functionality involves interactions with collaborators and 
researchers who are encouraged to submit new mutations to the database via an 
electronic submission form. In order to maintain the database entries in a reliable and 
structured format all new mutations that are submitted are sent via email to be 
checked and manually entered. In addition the database will not only accept 
mutations that have been published in peer-reviewed articles, but will also accept
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and flag mutations and patients that have not been published in peer-reviewed 
articles, or those that have only been published in abstract form. The refState data 
field of the mutation table describes whether each mutation is reported in full, in 
abstract or not at all so that users can choose to omit unpublished mutations from 
their searches via the advanced search form. The reference field of the unpublished 
mutations and patients will contain the name of the depositor responsible for the 
submission.
Unfortunately to date only two mutations have been submitted by the online 
submission forms. These mutations were subsequently published in full length 
articles so would have been incorporated into the database without the need for 
manual submission. To encourage groups to deposit mutation data, the database has 
been publicised at four international conferences (British Society of Immunology 
Annual Congress, December 2004, Harrogate, UK; Second International Workshop
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on Thrombotic Microangiopathies, May 2005, Jena, Germany; XXI International 
Complement Workshop, October 2006, Beijing, China; 2nd Bergamo Workshop on 
Hemolytic Uremic Syndrome, November 2006, Bergamo, Italy). As the database 
attracts more visitors, groups may be more willing to support its growth and submit 
mutations. This will permit the development of a larger, more up-to-date data set, 
while also enabling the source of each mutation to be identified. A mailing list 
function is also available to alert users when a new mutation is submitted, although 
we have not had anybody sign up for this function to date. The most effective way of 
gathering new mutations was to offer co-authorship on a new paper (Saunders et al., 
2007).
5.3.6.4 FH-HUS Web Database Statistical Analysis
In addition to the search, structural analysis and submission functionality of 
the website, statistics for all the mutations and proteins within the database are 
displayed graphically. These are useful to show the distribution of the mutations over 
different SCR domains and different phenotypes, as well as to compare mutations 
within CFH, MCP and IF.
The website also provides information pages, associated links and a reference 
library for FH, MCP, FI and aHUS with each reference linked to the abstract via the 
PubMed database (http://www.ncbi.nlm.nih.gov). The homology models of the FH 
and MCP SCR domains, together with the models of the FI domains constructed
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during this study are available for download in PDB format from the website 
(http://www.FH-HUS.org/models.php), and links are provided for experimentally 
solved structures that are deposited in the PDB.
5.4 Discussion
5.4.1 Mutation Classification
Although the phenotypic classification of mutations at first seems simple, it 
should be noted that different groups use different methods for protein assays and the 
serum values of FH in particular depend highly on the type of standard used and vary 
from individual to individual (Figure 5.1). An improved classification scheme would 
denote Type I as either complete with no observed protein secretion (homozygous) 
or partial (heterozygous). In order to avoid ambiguous phenotypic assignments, 
published phenotypic data for the FH, FI and C3 levels are indicated in the database 
as high, normal, low or very low according to the assignments in the literature. 
Details such as the method of assay and the range of values in the normal controls 
are stored in the database and can be displayed for comparison between patients 
from different studies. For future database submissions, details of the assays and 
ranges will be included to facilitate interpretation of FH levels in patients.
The nine mutations in SCR-7, SCR-9, SCR-11 (two), SCR-15, SCR-16 
(two), SCR-17 and SCR-19 within CFH that involve substitution of cysteine 
residues (Table 5.5) provide a good example of ambiguity with phenotypic 
assignment. For small (3-sheet Cys-rich domains such as the SCR domain, and others 
such as the epidermal growth factor domain found in the first component of 
complement and the thrombospondin repeat Type I domain found in properdin and 
the late complement components, a Cys substitution may result in the loss of the 
disulphide bridge. This would be predicted to cause incorrect folding, given that 
these small domains are largely stabilised by these Cys-Cys bridges (Creighton,
1993). However, only six of these nine mutations show low FH levels in patient 
plasma, and surprisingly two mutations (Cys630Trp and Cysl043Arg) show levels 
falling within the normal control range. At first glance this suggests that breakage of 
either the C1-C3 bond of SCR-11 (Cys630Trp) or the C2-C4 bond of SCR-17 
(Cysl043Arg) does not necessarily lead to the misfolding and degradation of the FH 
protein. Unfortunately, it is difficult to establish whether the FH level in plasma is 
the consequence of only the wild type allele or from both the wild type and mutant
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alleles of a heterozygous patient, and as a result they are assigned as “unknown” 
within the database.
Another example of ambiguity can be seen with the analysis of five nonsense 
mutations within CFH (Table 5.5). Three of these mutations (Glul89X, Tyr899X 
and Gln924X) can be defined as Type I, where the mutant allele produces an 
unstable FH molecule and there is a lower amount of FH in patient plasma. 
However, one nonsense mutation (Ser714X) is seen in a patient with normal FH 
levels, and again the problem arises whether this is due to a truncated protein in the 
plasma, or the result of one wild type allele. Manuelian and co-workers carried out 
functional studies on three mutations within FH, of which one was a nonsense 
mutation (Glull72X). Here the truncated protein was purified from patient plasma 
and shown to have reduced binding to heparin, C3b/C3d and endothelial cells, 
leading to its assignment as Type II (Manuelian et al., 2003).
In short, it is not straightforward to predict the effect of a given mutation 
within a protein structure using serum protein levels alone, and each mutation will 
require experimental and structural characterisation in order to fully appreciate its 
effect on protein structure and function.
5.4.2 Mutations within SCR Domains
The SCR domain is the most abundant domain type in the complement 
system. Building on the sequence analysis technique used in Section 4.4.2 to analyse 
the distribution of mutations within Ap domains, there are now a sufficient number 
of known SCR mutations to permit a joint analysis of the location of mutations 
within a typical consensus SCR domain. SCR domains generally contain six to eight 
P-strands numbered pi to P8 with a hypervariable sequence loop between strands P2 
and P3 (Figure 2.6). Several reports focusing on SCR domains have numbered these 
P-strands differently (Aslam et al., 2003; Soares and Barlow, 2005; Saunders et al., 
2006). To clarify the literature, the different nomenclatures used in the original P- 
strand predictions (Perkins et al., 1988) and the DSSP summaries of experimental 
structures (Aslam et al., 2003; Saunders et al., 2006, Soares and Barlow, 2005) is 
summarised in Figure 5.18.
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Seq:
XRAY DSSP:
k|g p p p p i d n g d i t s f p l s v y a p a s s v e y q|q n l y q l e g n k r i t|r n g q w s e p p k|l
-----------EEE------------- EEEEEE---- EEE----EEEEE—  EE----EEE
Robson 1998: --------------------- EEEE— EEEEEE----EEEE-EEEEEE E EE
Chou Fas 1988:  EEEE---- EEE— EEEEEE--- EEE EEEEE— E------- E
Consensus DSSP: EE------ EEEE------- EE---- EEEEEE---EEEE---EEEEE— EE---- EE-
2 0 0 3 : PI P2 P3 p4 P5 P6
2 0 0 6 : PI P2 P3 P4 P5 P6
Nomenclature: PI p2 P3 P4 P5 P6 P7 p8
Figure 5.18 Secondary structure nomenclatures of SCR domains
The different P-strand nomenclatures for SCR domains starting from their first 
definition in 1988 (Perkins et al., 1988) are compared with those determined from 
DSSP analyses in 2003 and 2006 (Aslam et al., 2003; Saunders et al., 2006) and 
the nomenclature used in NMR studies (Soares and Barlow, 2005). The 
consensus DSSP refers to the common P-sheet assignments seen in 37 
experimentally solved SCR domain structures. The sequence of FH SCR-19 is 
used as reference. The eight-stranded nomenclature is suggested for future 
publications and references. Not all the p-strands are necessarily observed in any 
given structure.
249
In order to define an SCR sequence to map the mutations to, the consensus 
sequence of 120 SCR sequences found in human complement proteins and 4 SCR 
sequences from VCP was computed (Figure 5.19a). The 120 SCR sequences were 
taken from the following human complement proteins (FH, FHR-1, FHR-2, FHR-3, 
FHR-4, FHR-5, CR1, CR2, DAF, C4bp, C l, MASP-1, MASP-2, C6, MCP, FB and 
C7). These sequences were automatically aligned using CLUSTALW (Higgins et al.,
1994) and the consensus sequence was taken as the most commonly occurring 
residue at each position. Where gaps appeared more often than residues, a gap was 
placed in the consensus sequence. This resulted in a sequence of 49 amino acids, 
with short loops between the conserved p-strands (Figure 5.19a).
In order to analyse the structural position of these mutations, the 35 SCR 
structures within 45 PDB files described in Section 5.2.3 were used as templates 
(Table 2.3). When superimposed, these structures show high secondary structural 
conservation, with the highest amount of variation confined to surface loops between 
P-strands. From 27 of these structures (PDB codes: 1CKL, 1ELV, 1G40, 1GKG, 
1GKN, 1GPZ, 1H03, 1HCC, 1HFI, 1LY2, 10JV, 1Q3X, 1QUB and 1SRZ -  see 
Table 2.3) an averaged structure of the consensus SCR sequence was modelled using 
MODELLER (Figure 5.19b). The six central p-strands (P2-P7) are present within 
this structure; however the N-terminal strand (pi) and the C-terminal strand (P8) are 
missing because there are no residues preceding the first and last cysteine of the SCR 
domain. The averaged sidechain accessibility of the 27 experimental SCR structures 
aligned to the consensus sequence is also shown on Figure 5.19a.
Since CLUSTALW aligns sequences globally with small negative penalties 
for gaps as opposed to larger positive scores for conserved residues, sequences that 
are less conserved will always be aligned with a lot of gaps in order to match any 
residues that are the same. This does not always allow an accurate representation of 
structural conservation, and in the case of the SCR sequences, the hypervariable loop 
region is poorly aligned with gap regions occurring in different places within the 124 
SCR sequences. This resulted in a number of positions being assigned as gaps, 
whereas if they were aligned manually would have been assigned as a residue that 
was not conserved.
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Figure 5.19 Location of 63 aHUS mutations in terms of a consensus SCR 
domain
The FH and MCP missense mutations are highlighted in terms of a consensus 
sequence and structure for a SCR domain.
(a) Consensus sequence from a CLUSTALW alignment of 124 SCR domain 
sequences from human complement proteins. The mutations are mapped 
to their positions (boxed) within the consensus sequence. Where 
mutations align with insertion regions that have not been modelled in the 
consensus structure, the mutation is mapped to the position before the 
insertion. Red text denotes Type I mutations, green denotes Type II 
mutations, and orange indicates mutations where the phenotype cannot 
be defined. Six of the eight P-strands are shown in yellow and labelled in 
blue underneath. The averaged consensus accessibilities for 27 SCR 
structures are defined.
251
Figure 5.19 Location of 63 aHUS mutations in terms of a consensus SCR 
domain (continued)
(b) Front and back view of a secondary structure cartoon derived from the 
averaged structural model of 27 different experimental template SCR 
structures. The numbers within the spheres correspond to the residue position 
in the consensus sequence. Mutations are highlighted as coloured spheres to 
follow the colours defined in (a). The size of the individual spheres indicates 
the number of mutations found at that position, ranging from one to six.
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For this reason, the consensus sequence presented in Figure 5.19a, and thus the 
consensus structure of Figure 5.19b would be improved if a direct comparison of the 
hypervariable loop had been carried out to find the average length of the 
hypervariable loop. This is difficult since the boundaries of the P2 and p3 strands are 
not defined in those sequences without structural information.
The proposal of a consensus SCR structure permits a unified discussion of 
the known aHUS mutations within SCR domains. This has considerable advantages 
in that the distribution of mutations within different regions of the SCR domain can 
be analysed and phenotypic conservation can be studied. Although information 
regarding contacts between adjacent SCR domains is neglected in this analysis, the 
distribution of mutations within the consensus SCR domain can be used to 
understand structural and functional properties of the SCR domain.
A total of 63 missense mutations within the SCR domains of CFH and MCP 
were identified from the database for analysis within the consensus SCR model 
(Figure 5.19). Overall the mutations are fairly uniformly distributed in the central 
region of the SCR consensus sequence, with not much clustering of the Type I or 
Type II mutations (Figure 5.19b). Frequently mutations are seen at the same 
structural position in different SCR domains, indicated by the larger spheres.
The consensus SCR structure shows that phenotype is regularly conserved 
when more than one mutation occurs at the same consensus residue position. Type I 
mutations frequently involve buried residues, and these predominate at residue 
positions 1,4, 18, 24, 26, 37, 39 and 47. These include the two Cys residues (C2 and 
C3) that occur within the middle of the four Cys residues in the SCR domain (Figure 
5.19a). This suggests that the correct folding of the SCR disulphide bridges is central 
to protein expression levels. Type II mutations frequently occur at surface exposed 
residues, and these predominate at residue positions 5, 11, 13, 14, 15, 22, 23, 29, 30, 
34, 36, 38 and 43. Surprisingly one of these positions (22) is buried. Since Type II 
positions include residues located in all six p-strands P2 to P7 of the consensus SCR 
domain and one of these positions is buried, it is suggested that both the amino acid 
conservation at a surface exposed loop conformation and the correct sidechain 
arrangement within the central p-sheet framework of the SCR domain are central to 
function.
It is possible that a given position within the consensus SCR structure can 
show both phenotypes. Only one case was seen at position 47. Two mutations at this
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position present Type I mutations (Pro258Leu, Pro621Thr) whereas one mutation 
within SCR-20 at this position (Prol226Ser) presents a Type II phenotype. These 
mutations involve conserved proline residues that occur near the last Cys residue of 
the SCR domain. It would be expected that this proline residue is structurally 
significant since it is conserved and in close proximity to the last Cys residue of the 
SCR domain (Figure 2.6). The reason this change can be accommodated into SCR- 
20 and not into SCR-4 or SCR-10 while maintaining a stable FH structure is not 
clear. It is possible that the proline residue at position 47 is generally important for 
SCR-SCR linker contacts, and this becomes unimportant for SCR-20 as this is the C- 
terminal domain with no following linker. This varied distribution of mutation 
phenotypes shows that the structural outcomes of mutations may not be 
straightforward to predict, even with previous examples of similar mutations and 
homologous proteins.
The consensus SCR structure can also be used to analyse the 12 non- 
synonymous SNPs within CFH (Table 5.7). Their positions within the consensus 
sequence are varied. There are four polymorphisms (Glu936Asp at position 6, 
Tyr402His at position 13, Val62Ile at position 35 and Argl93Thr at position 38) that 
are associated with high frequencies in disease patients and are expected to have a 
mild effect on protein function that does not affect healthy individuals but can 
predispose a risk to a disease. Two of these polymorphisms (Glu936Asp and 
Val62Ile) correspond to surface-exposed positions 6 and 35 where disease-associated 
mutations are not seen. The Arg493Thr polymorphism in SCR-8 corresponds to a 
surface position where two Type II mutations are seen in SCR-14 (Glu850Lys) and 
SCR-16 (Ile970Val). The AMD-associated polymorphism at Tyr402His corresponds 
to the most frequently occurring surface-exposed Type II position 13 in the 
consensus SCR (Figure 5.19b).
There are seven nonsynonymous, non-disease causing polymorphisms 
(His332Tyr, Thr519Ala, Arg780Ile, Asn997Thr, AlalOlOTyr, Asnl050Tyr, 
Leul207Arg and Serl211Pro) distributed along the length of FH. Only four 
polymorphisms (His332Tyr at position 8, Asn997Thr at position 9, Asnl050Tyr at 
position 3 and Leul207Arg at position 32) correspond to surface-exposed positions 
where disease-associated mutations are not seen. Two others correspond to Type II 
locations in the consensus SCR domain (Thr519Ala at position 11 and Seri21 IPro at 
position 34). The remaining polymorphisms correspond to an exposed position with
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unknown phenotype (Arg780Ile at position 25) and an exposed position where one 
Type I mutation and one unclassified mutation are seen (AlalOlOTyr at position 18). 
All 12 polymorphisms are predicted to result in a stable folded FH protein, as 
expected, as none of them involve Cys residues in the disulphide bridges at positions 
1, 26, 39 or 49, or correspond to buried Type I locations at positions 4, 24, 26, 37 or 
47.
The concept of a consensus structure considerably simplifies the 
interpretation of aHUS mutations and other genetic alterations such as 
polymorphisms. From this we learn what is common within SCR domains and what 
is not. The conservation of phenotype at residue positions is of great interest; 
however there are a few cases where the outcome of a residue substitution on protein 
function or stability is not clear. The accumulation of more mutation data from other 
SCR domains may define the residue positions within the consensus structure that 
are more likely to result in Type I, Type II or no phenotypes.
5.4.3 MPGN II Mutations
Although the majority of FH mutations are associated with aHUS patients 
several MPGN II patients have been identified with mutations within FH (Table 5.4). 
MPGN II is observed in patients with a complete FH deficiency (compound 
heterozygous or homozygous) where there is little or no functioning FH in plasma, 
as opposed to partial FH deficient aHUS patients. Whereas aHUS patients show a 
wide range of FH plasma levels and have heterozygous mutations, with the majority 
(37%) of mutations showing Type II phenotypes, all but one of the patients reported 
with MPGN II showed very low FH plasma levels and Type I phenotypes.
In MPGN II, the lack of functioning plasma FH leads to disregulation of the 
complement alternative pathway, resulting in inflammation of the capillary loops 
within the kidney glomeruli. In contrast, the FH missense mutations seen in the 
majority of aHUS patients rarely resulted in a lack of FH, and lead to either reduced 
(half of normal) levels of plasma FH or dysfunctional FH protein present in normal 
amounts in plasma. This mirrors the situation with FI mutations, where heterozygous 
patients frequently suffer from aHUS, whereas those patients who have little or no FI 
present in plasma suffer from FI Deficiency (Table 5.10). Interestingly a mutation at 
the same position (Cys673) is seen in aHUS patient heterozygous for the Cys673Tyr
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mutation and a MPGN II patient homozygous for the Cys673Ser mutation (Dragon- 
Durey et al., 2004).
Two mutations have also been reported in a Norwegian Yorkshire breed of 
pig with MPGN II symptoms (Hegasy et al., 2002). Leu493Val and Ilell66Arg 
(numbered with respect to porcine FH: GenBank accession no: AJ278470) occur in 
SCR-9 and SCR-20 respectively. The Leu493Val substitution most likely represents 
a polymorphism since a valine is seen at this position (Val513) in human FH and is a 
conservative substitution (Figure 5.10). The Ilell66Arg substitution corresponds to 
Ilel 179Arg in human FH that is conserved within five species (Figure 5.10). lie 1179 
resides on p-strand pi of SCR-20. The substitution of a large polar arginine residue 
for the smaller hydrophobic isoleucine residue may affect side chain packing around 
the p-strand and destabilise the SCR-20 domain to prevent the secretion of FH.
The first and only case of an MPGN II patient with normal levels of plasma 
FH was identified in two sisters from Germany (Licht et al., 2006). Although the 
patients were homozygous for a Lys224 deletion they had normal FH levels. 
Functional and structural analysis of this mutant identified defective complement 
regulatory activity. The residual complement regulatory activity of the mutant FH 
protein may explain the abnormal disease progression, and why at 11 and 6 years of 
age these two patients are much older than FH deficient patients who normally 
develop MPGN II much earlier in life (Licht et al., 2006).
It is possible that the difference between MPGN II and aHUS relates to the 
point at which a deficient FH serum level becomes effective in a patient. The 
situation where a patient has little or no functioning FH in plasma early in life may 
result in the onset of MPGN II, while aHUS may result from an immunological 
insult due to infection or stress that destabilises a prevailing balance of mutant and 
normal serum FH in the heterozygous patient.
5.4.4 Age-related Macular Degeneration (AMD)
FH has been associated with AMD of the eye retina, the leading cause of 
blindness in the western world, through the observation of a Tyr402His 
polymorphism in SCR-7 in affected patients (Klein et al., 2005; Haines et al., 2005; 
Hageman et al., 2005; Edwards et al., 2005). This polymorphism has also been 
previously identified in aHUS patients, but was not associated with the disease as it 
was seen in both patients and controls (Neumann et al., 2003). The homology model
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of SCR-7 shows His402 to be on the surface exposed hypervariable loop in close 
proximity to positively charged exposed residues Arg404 and Lys405 (Figure 5.9). 
FH constructs in which both Arg404 and Lys405 are replaced with uncharged 
alanine residues showed reduced binding to heparin, C-reactive protein (CRP) and M 
protein, indicating these residues are important for binding (Giannakis et al., 2003). 
The change between tyrosine and histidine in close proximity to these residues could 
inhibit heparin binding slightly and lead to FH molecule that is not functioning at its 
optimum. It is interesting that the presence of histidine at this position might lead to 
a dysfunctional FH and cause AMD, but not cause aHUS.
FH has been shown to be a significant constituent of drusen and co-localises 
with C3b/iC3b in amyloid-containing substructural elements within drusen 
(Hageman et al., 2005). Complement components of the MAC also co-distribute 
within the retina implying that the FH protein encoded by the at-risk CFH haplotype 
may have increased complement inhibitory function (Hageman et al., 2005). 
Analytical ultracentrifugation analysis of FH SCR-6 to SCR-8 constructs of both 
His402 and Tyr402 allotypes suggests that the His402 allotype may promote self­
association. This could suggest that the risk factor with this allele is that FH His402 
has a greater propensity to form dimeric structures and accumulate within the retina 
and form drusen (Fernando et al., 2007).
5.4.5 Linker Regions
It is notable that the database only contains one nucleotide change 
(Thr987Ala) in the inter-SCR linker regions, even though 88 residues in FH (7% of 
the total) are found within these linkers. The linker regions between SCR domains 
show a large sequence and length variability, in which the length can range between 
two to eight residues. Both the length and inter-SCR contacts of adjacent SCR 
domains determine the relative orientation of domain pairs. Experimental structures 
show that SCR domain pairs can be either completely extended (P2-glycoprotein I) 
or folded back (CR2) (Perkins et al., 2002). Sequence analysis of five FH SwissProt 
protein sequences (CFAHHUMAN, CFAH_MOUSE, Q3MHF3_BOVIN, 
Q91YB6_RAT, Q8MI72_PIG) shows that the sequence conservation of the linker 
regions is not significantly different to that of residues within the first and last Cys 
residues that define the SCR domain (Figure 5.10). It is also known that the linker 
regions in FH and in complement receptor types 1 and 2 lead to a significant degree
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of flexibility in their overall 20, 15 and 30-SCR domain structures (Aslam and 
Perkins, 2001; Gilbert et al., 2006; Furtado et al., 2006). The absence of disease- 
predisposing mutations in the linker regions suggests that SCR proteins are formed 
as a series of structurally well-defined functionally-active globular domains that are 
connected by conformationally disordered linkers with little functional importance 
apart from their flexibility. However, some residues within linker regions can be 
functionally important such as the Leu-Arg-Lys linker between SCR-6 and SCR-7 
which is associated with heparin binding (Fernando et al., 2007).
5.4.6 Analysis of SCR-19 and SCR-20 Experimental Structures
The initial Version 1 of the FH-HUS database included homology models for 
FH SCR-19 and SCR-20 since at time of release no experimental structures were 
available. The Version 2 update coincided with the publication of two experimental 
structures for FH SCR-19 and SCR-20 (PDB codes: 2BZM and 2G7I) (Herbert et al., 
2006; Jokiranta et al., 2006). These experimental three-dimensional coordinates for 
SCR-19 and SCR-20 enable mutations to be analysed based on more accurate side 
chain accessibilities and loop regions. They also permit structural comparisons of 
three different structural determination techniques (X-ray crystallography, NMR and 
homology modelling).
Comparison of the NMR and crystal structures showed the following. The 
angle between SCR-19 and SCR-20 are 165° and 150° in the NMR and crystal 
structures respectively. This angle is defined in Gilbert et al. (2005) as the angle 
between the long axis of each SCR domain. The long axis is calculated as the vector 
between the average Ca positions of each disulphide bond, so that one end of the 
vector is the average Ca position of the C 1 and C3 residues and the other end is the 
average Ca position between the C2 and C4 residues. This difference indicates some 
possible flexibility between the domains. Least-squares superimposition of the SCR- 
19 and SCR-20 NMR and crystal a-carbon atoms gave an RMSD of 3.3 A, with the 
greatest differences occurring at surface loop regions, possibly indicating flexibility 
in these (Figure 5.20a). On a residue-by-residue basis using a three-state analysis 
(helix, strand or loop), DSSP analysis showed that the NMR and crystal secondary 
structures of SCR-19 and SCR-20 (excluding the linker) are in 87% and 90% 
agreement respectively (Figure 5.20b). The same comparison of the crystal structure 
with the homology model gave more varied agreements of 80% and 58%.
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Figure 5.20 Comparison of the crystal, NMR and homology models of FH SCR- 
19 and SCR-20 (continued over page)
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Figure 5.20 Comparison of the crystal, NMR and homology models of FH
SCR-19 and SCR-20 (continued)
(a) The DSSP secondary structures and sidechain solvent accessibilities of the 
NMR and crystal structures are compared with the previous homology model 
of SCR-19 and SCR-20. a-Helix and P-strand residues are denoted by H and 
E respectively, with the eight p-strands labelled as pi to P8. The sidechain 
accessibilities in these structures are numbered, where 0 denotes 0-9% 
accessibility, 1 denotes 10-19% accessibility, and so on up to 9. Residues with 
accessibilities up to 19% are considered to be buried.
(b) The experimentally-determined crystal structure (red ribbon), NMR structure 
(blue ribbon) and homology model (yellow ribbon) are compared with each 
other in two views rotated by 180°. The NMR structure of the SCR-19 and 
SCR-20 domains were separated and superimposed individually onto the 
crystal structure using the backbone atoms of the four conserved cysteine 
residues of each domain. The homology domains were also superimposed 
onto the crystal structure individually using the backbone atoms of the 
cysteine residues.
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When accessibilities were considered in a two-state analysis (using 0%-19% 
to denote buried sidechains and 20%-100% to denote exposed sidechains), both the 
NMR and crystal structures of SCR-19 and SCR-20 (excluding the linker) showed 
85% agreement (Figure 5.20b). The main differences are seen in the region before 
the p2-strand region of SCR-20. The experimental models of SCR-20 revealed an a- 
helix between pi and P2 that is unique to any previously defined SCR domain 
structure. Since this a-helix was not seen in any of the experimental structural 
templates of SCR domains (Figure 2.6) it could not be inferred in the homology 
model. It is not clear why FH SCR-20 has this unique attribute, however within the 
SCR domain structural templates, FH SCR-20 has the longest hypervariable loop 
region after p2 (Figure 2.6).
Most of the sidechains in the new NMR and crystal structures were located in 
similar positions. The most notable exception was the sidechain of Leull89 
(exposed in the crystal structure; buried in the NMR structure), which is an aHUS 
mutation site, followed by more marginal differences for Vail 134 and Seri 191. 
Comparison of side chain accessibilities within the crystal structure and the 
homology model gave agreements of 87% for SCR-19 and 81% for SCR-20. The 
reduced accuracies for the SCR-20 homology model compared to that for the SCR- 
19 homology model are attributed to introduction of the a-helix immediately before 
the P3 P-strand. The quantitative sidechain accessibilities for 15 of the 18 aHUS 
mutation sites were correctly predicted when the crystal structure was compared to 
earlier homology models (Perkins and Goodship, 2002; Saunders et al., 2006). One 
of the three exceptions is Seri 191, this being attributed to an unusual bridge formed 
between its sidechain that was re-orientated inside the SCR domain to form a contact 
with a buried water molecule (Jokiranta et al., 2006). The other two exceptions at 
Cys 1163 and Phel 199 are marginally incorrect.
When the structures were elucidated, both the NMR and crystallography 
groups analysed missense mutations within FH SCR-19 and SCR-20. Neither did so 
using the classification of Type I or Type II phenotypes. The crystallographic study 
proposed that nine aHUS mutations in SCR-19 and SCR-20 resulted in structural 
disruptions, implying that these caused Type I phenotypes (Jokiranta et al., 2006). In 
conflict with this reasoning, the quantitative accessibilities for two of these 
(Tyrll42Asp, Trpll57Arg) show that they are surface-exposed (Figure 5.20), not 
buried as stated, and the clinically-observed phenotypes for four of these
261
(Valll34Gly, Tyrll42Asp, Trpll57Arg, Valll97Ala) corresponded to Type II 
mutations (Table 5.5). The NMR study also implied that Glyll94Asp, Valll97Ala, 
Phell99Ser and Prol226Ser are associated with Type I defects (Herbert et al., 
2006), even though the observed phenotypes are Type II for Vail 197Ala and 
Prol226Ser. For those mutations with buried accessibilities but with observed Type 
II phenotypes, it would appear that internal rearrangements inside the SCR domain 
have resulted in surface alterations to result in a dysfunctional protein. This applies 
to both Valll34Gly and Vail 197Ala which occupy the same SCR consensus 
position 22 (Figure 5.19). The NMR study also provided evidence from the lack of 
spectral changes in two mutants W1183L and R1215G that supports their Type II 
phenotype assignments (Herbert et al., 2006). In distinction, the Type I/Type II 
classification structure scheme leads to a clearer understanding of the effect of the 
mutation, as opposed to focusing consideration onto only the structural position of 
the mutations.
5.4.7 Distribution of Missense Mutations within FH
Although disease-causing missense mutations are distributed throughout the 
SCR domains of FH, they cluster towards the C-terminal domains, with nearly half 
(48%) of the total mutations occurring in SCR-19 and SCR-20, and a quarter 
occurring in SCR-15 to SCR-18 (Figure 5.21). This is surprising since both cofactor 
and decay accelerating activity has been identified within SCR-1 to SCR-4 and SCR- 
6 to SCR-10 (Sharma and Pangbum, 1996; Jokiranta et al., 2000). Where classified 
the C-terminal mutations predominantly show Type II phenotypes (72%), reflecting 
the functional significance of these domains. The remaining 12 mutations in SCR-1 
to SCR-15 predominantly show Type I phenotypes (50%) which suggests the 
structure of these earlier domains is more significant than the function (Figure 5.21).
The clustering of mutations within SCR-19 and SCR-20 could suggest that, 
of the three heparin binding sites and three C3b binding sites within FH, the C- 
terminal SCR domains are functionally the most important. It has been demonstrated 
that mutant FH lacking SCR-20 (Glull72X) showed impaired binding to heparin 
and failed to bind endothelial cells (Jokiranta et al., 2005). It has also been shown 
that three mutant forms of FH (Trpll83Leu, Valll97Ala and Argl210Cys) isolated 
from patient sera showed severe reduction in binding to immobilised C3b even 
though N-terminal binding sites were unperturbed (Sanchez-Corral et al., 2002).
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| Pro258Leu Val1007Cys
Tyr1021Phe
Cys1043Arg
Arg53His
Arg78Gly
Thr987AlaCys630Trp
Cys673Ser
Cys673Tyr
Val835LeuGln400Lys
Cys431Tyr
lle881Leu
Ser890lle
His893Arg
Cys915Ser
Gln950His
Tyr951His
Thr956Met
Cys959Tyr
lle970Val
Cys973Tyr
Trp978Cys
Val1007Cys
Gln1076Glu
Asp1119Gly
Val1134Gly
Tyr1142Asp/Cys
Trp1157Arg
Cys1163Trp
Arg1182Ser
Trp1183Arg
Trp1183Leu
Thr1184Arg
Leu1189Arg
Leu1189Phe
Ser1191Leu
Ser1191Trp
Gly1194Asp
Van 197 Ala
Glu1198Ala
Gtu1198Lys
Phe1199Ser
Gly1204Glu
Arg1210Cys
Arg1215Gly
Arg1215Gln
Pro1226Ser
Glu850Lys
Arg127Leu
Pro621Thr
Figure 5.21 The type distribution of 63 aHUS and MPGN missense mutations in 
the SCR domains of FH
Mutations associated with aHUS within FH are identified, above and below the 
corresponding SCR domain. Type I mutations are highlighted in red. Type II 
mutations are highlighted in green. Unclassified mutations are un-shaded. The SCR 
domains involved in C3b binding are highlighted in orange with red borders, and the 
SCR domains involved with heparin binding are indicated with red arrows.
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This demonstrated that the C-terminal domains may form the major binding site for 
C3b. In a third study monoclonal antibodies that bind to SCR-20 were shown to 
completely block interaction of FH with heparin, C3b, C3d and binding to 
endothelial cells (Oppermann et al., 2006). In contrast monoclonal antibodies to the 
N-terminal and middle SCR domains showed no inhibitory affects. This 
experimental evidence and clustering of aHUS missense mutations within the C- 
terminal SCR domains suggests that FH could make initial contact with ligands at 
the C-terminus. This binding could then cause conformational changes which would 
in turn allow other ligand binding sites within the N-terminal domain to become 
exposed. This model explains the presence of multiple and overlapping binding 
regions.
Since SCR-19 and SCR-20 are primarily relevant for aHUS mutations, it is 
useful to look at these domains in more depth. Peptide spot analysis of FH SCR-19 
and SCR-20 identified four linear regions that interact with both heparin and C3b 
(Figure 2.22) (Jozsi et al., 2006). Region I is 10 residues long (Glul 145 to Asnl 154) 
and binds weakly compared to the other three Regions (II-IV) in SCR-20 (Asnl 178- 
G lnll87, Argl202 to Argl215 and Alal229 to Argl231). The residues within 
Regions II-IV form a continuous surface within SCR-20. Although NMR and X-ray 
structures reveal the conformation of the SCR-19 to SCR-20 to be straight, it could 
be that within intact FH or on binding, this SCR pair adopts a V-shaped structure, 
making a continuous surface between Region I to Region IV. The identification of 
four separate binding peptides accounts for the discrepancies in previous 
localisations of heparin binding sites within SCR-20. Theoretical homology 
modelling based on the crystal structures of heparin and growth factor complexes 
with 12 aHUS mutations strongly implicated four basic residues (Argl 182, Lysl 186, 
Lysll88 and Argl 192) on the hypervariable loop and near the interface between 
SCR-19 and SCR-20 with heparin binding (Perkins and Goodship, 2002). Two of 
these residues (Argl 182 and Lysl 186) occur within region II, and the other two 
follow immediately after.
Another earlier prediction of the specific residues involved in heparin binding 
suggested that heparin interacted with both the tip and side of SCR-20 on the basis of 
manual docking and energy minimisation simulations and suggested that Lysl 108 in 
SCR-19 and Lysl202, Argl206, Argl210, Lysl222, Lysl230 and Argl231 in SCR- 
20 interact with heparin (Hellwage et al., 2002).
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NHeparin
Figure 5.22 Mutations in SCR-19 and SCR-20 compared to C3d and heparin
The crystal structure of C3d (Nagar et al., 1998) is shown as a blue ribbon. The 
crystal structure for SCR-19 and SCR-20 of FH is also shown as a blue ribbon. A 
heparin model (Mulloy et al., 1993) is shown and coloured according to atom 
type. All structures are to scale. The type II mutations within FH are highlighted 
as green spheres and the side chains of putative heparin binding sites are shown in 
purple. The ribbon is coloured red to correspond to the four regions of heparin 
and C3d binding residues implicated by peptide spot analysis. The N and C- 
termini of the C3d and FH models are denoted by N and C respectively. The 
position of C3d and heparin with respect to FH is arbitrary.
£  Leu1202
Region II
Region I
Argl215
Pro 1226 Argl 210
A rgl203 
Gly1204
A^|1230 
Region IV FH
A rgl206
Region III
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The role of Lysl202, A rgl206, Argl220, Lysl230 and A rgl231 is supported by the 
peptide spot analysis, however other residues do not agree. In a third study, the 
crystal structure of the vaccinia virus complement protein (VCP) with heparin was 
used as a close analogue of the interaction between SCR-20 of FH and heparin 
(Ganesh et al., 2004). This showed that heparin interacts with a small region on only 
the C-terminal domain of VCP. An overlay of the heparin binding residues of VCP 
SCR-4 with a model of FH SCR-20 suggested seven heparin binding residues, of 
which five correspond to Region III (Lysl202, A rgl203, A rgl206, A rgl210 and 
Argl215) and two correspond to Region IV (Lys 1230 and Argl231). The heparin 
binding site within Regions I-IV is further supported by recent NMR chemical shift 
mapping that implicates R1182, K1186 and K1188 as heparin binding residues 
(Figure 5.22) (Herbert et al., 2006).
Less studies have focused on mapping the exact C3b and C3d binding 
residues within FH, although the peptide spot analysis indicated that regions within 
FH that are involved with heparin binding overlap with C3b and C3d binding sites 
(Jozsi et al., 2006). There was also a previous report that showed competition 
between C3b binding and heparin binding within SCR-20 fragments, suggesting the 
binding sites maybe overlapping (Hellwage et al., 2002).
The distribution of Type II mutations is not localised to any one specific 
region of SCR-19 and SCR-20 (Figure 2.22). It is useful to separate the mutations 
into those that involve buried residues (Valll34Gly, Vail 197Ala and Prol226Ser) 
and those that involve surface exposed residues (Tyrll42Asp, Trpll57Arg, 
Trpl 183 Arg/Leu, Thrl 184Arg, Leul 189Arg, Glul 198Lys, Gly1204Glu, 
Argl215Gly/Gln). Interestingly, the study of six of these mutant proteins 
(Trpll57Arg, Trpll83Leu, Vail 197 Ala, Argl210Cys, Argl215Gly and 
Prol226Ser) indicated those mutations involving buried side chains have more of an 
effect on both heparin binding and C3d/C3b binding, than the exposed residues 
(Jozsi et al., 2006). This can be explained by the large structural rearrangements 
caused by substitution of buried side chains as opposed to a simple substitution of a 
surface exposed residue that has no wider structural implications.
This evidence for a heparin binding site localised to SCR-20 makes it less 
easy to account directly for the role of the nine Type II missense mutations across 
SCR-16 to SCR-19 that cause aHUS (Figure 5.21). A single SCR domain is 36 ± 2 A 
in length (Aslam et al., 2003). If FH were to be a straight molecule, its overall length
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is expected to be in the region of 730 A .  Instead, FH is observed to possess a folded- 
back SCR structure of maximal length 430 A  by solution scattering (Aslam and 
Perkins, 2001). The heparin binding region of SCR-20 is required to be solvent- 
exposed and unhindered by the rest of the FH structure in order that it can bind to an 
anionic polysaccharide on a cell surface. It is possible that a residue mutation within 
SCR-15 to SCR-20 may affect the folded-back inter-SCR arrangement in FH to the 
extent that SCR-20 is less able to interact with heparin. This interpretation may be 
supported by the observed conformation change of the C-terminal SCR domain 
relative to the other three SCR domains in the crystal structures of VCP with and 
without heparin bound (Ganesh et al., 2004). As an alternative explanation, if the 
correct association of C3b with FH is important for the avoidance of aHUS, it may 
be the case that these Type II residue substitutions perturb residues that either 
interacts directly with C3b or with the inter-SCR arrangement that is necessary for 
the C-terminal domains to interact with C3b. The approximate dimensions of C3b 
are 180 A  x 20 A  x 100 A  (Perkins and Sim, 1986), hence C3b is large enough to 
present difficulty in forming contacts with FH if its folded back structure has been 
altered to offer steric hindrance to C3b binding (Figure 2.22).
Another putative docking model of the SCR-20 complex with heparin or C3d 
has not been presented in this thesis, given that possibilities have already been 
discussed in the literature. However, the orientation of mutations and functional 
studies of FH mutants (Table 5.13) suggests that many of the aHUS mutations are 
associated with the heparin binding region, while it is likely that others may be 
associated with C3b and/or C3d binding. It still remains unclear as to whether aHUS 
results as a direct consequence of mutant FH not binding to endothelial cells or as a 
result in the reduction of C3b binding and cofactor activity, or whether it is a 
combination of these factors that predispose to aHUS.
5.4.8 The European Working Party on the Genetics of aHUS
In the past few years, experimental and patient analysis has provided us with 
further insight into the susceptibility factors for the development of aHUS, and has 
gathered information together for future investigations of aHUS. For these reasons, 
“The European Working Party on the Genetics of HUS" has been set up, for which 
the FH-HUS web database will provide a focal point of its activities. Its membership 
is listed on the website under “Collaborators”.
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Table 5.13 Functional studies of FH mutants
Domain Mutant C3b/d binding HeparinBinding* Reference
SCR-19 Trpll57Arg Reduced Reduced Jozsi et al., 2006
SCR-20 Glull72Stop Reduced Reduced Jokiranta et al., 2005; 
Manuelian et al., 2003
SCR-20 Argl 182 Ala Reduced Normal Jokiranta et al., 2006
SCR-20 Trpll83Leu Reduced Reduced Joszi et al., 2006; 
Sanchez-Corral et al., 2002, 2004; 
Jokiranta et al., 2006
SCR-20 Lysl 186 Ala Normal Normal Jokiranta et al., 2006
SCR-20 Seri 191 Leu ND Normal Heinen et al., 2006
SCR-20 Serll91Leu/ 
Vail 197 Ala
Reduced Normal Heinen et al., 2006
SCR-20 Vail 197 Ala Reduced Reduced Jozsi et al., 2006; 
Sanchez-Corral et al., 2002; 2004; 
Heinen et al., 2006
SCR-20 Glul 198Ala Reduced Increased Jokiranta et al., 2006
SCR-20 Argl210Cys Reduced Reduced Jozsi et al., 2006; 
Manuelian et al., 2003
SCR-20 Argl215Gly Reduced Reduced Jozsi et al., 2006; 
Manuelian et al., 2003
SCR-20 Prol226Gly Reduced Reduced Jozsi et al., 2006;
*Contradictory results indicate Trpl 183Leu, Vail 197Ala and Argl210Cys have normal affinity for 
heparin, however other studies indicate reduced heparin binding.
ND = Not determined.
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Together with the submission tool within the web database, this large group of 
people working together will provide clearer definitions of the various forms of 
aHUS and mutations that are associated with them. This will help in defining 
treatment strategies and determining whether transplantation should be performed.
5.5 Conclusions
The FH-HUS database provides a central complete resource of information 
regarding aHUS patients and mutations. I have summarised the number of known 
CFH disease associated mutations (including novel ones) which have nearly doubled 
from 54 in November 2004 to 96 in June 2006. This CFH database has also 
benefited from recent NMR and crystal structures for FH SCR-19 and SCR-20 that 
permit more accurate predictions of the consequence of a residue change in these 
domains. The proposal of a consensus SCR structure (Figure 5.19) will facilitate 
future aHUS mutation interpretations and mutations in other SCR containing 
proteins, allowing individual SCR mutations to be viewed in the context of other 
SCR mutations. There are now a sufficient number of available SCR mutations to 
suggest that Type I phenotypes may mostly result from mutations in their cysteine 
residues or at buried positions, while Type II phenotypes may often result from 
alterations in the central p-sheet structural core and loops at surface-exposed 
positions. The incorporation of polymorphism data suggests that their locations often 
correspond with sites consistent with Type II phenotypes, while there is an almost 
complete absence of aHUS mutations in the inter-SCR linker sequences. Within the 
crystal structure of MCP SCR-1 and SCR-2 three missense mutations have been 
structurally analysed and classified. Homology modelling of the SCR-3 and SCR-4 
domains of MCP allows a further seven MCP missense mutations to be structurally 
analysed and phenotypically classified. The availability of 24 IF genetic alterations, 
together with the FI homology models provide the first structural view of the effect 
of mutations on FI function. The updated database will enable the clinician to easily 
cross-correlate mutations between these three different proteins for a given patient. 
In the case of AMD, the database highlights the risk factors associated with 
associated polymorphisms, and whether or not there are any links with aHUS. It is 
interesting that the AMD-associated Tyr402His polymorphism occurs at the most 
frequently occupied aHUS Type II mutation position 13 within the consensus SCR
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structure that represents the hypervariable loop between p-strands p2 and p3 (Figure 
5.19).
The discrepancies between the different analysis and modelling of SCR-20 
ligand interactions show that, in general, predictions of the effect of aHUS- 
associated mutations from structures require experimental verifications, such as 
those described in Table 5.13. This is frequently seen with other proteins and 
diseases as emphasized by the p53 tumour suppressor gene which with 14,000 
mutations has the most known mutations for a human protein, yet only 34.4% of 882 
distinct mutations could be explained in simple structural terms using the p53 crystal 
structure (Martin et al., 2002). This highlights the need to bring phenotypic, 
structural, sequence and functional analysis together in order to understand the 
molecular consequences of disease associated mutations.
The structure and content of the FH-HUS database corresponds to the 
recommendations of the HGVS for LSDBs (Claustres et al 2002). Since the database 
was first online in November 2004, there have been over 2500 visitors.
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Chapter 6
Coagulation Serine Protease Mutation Database
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6.1 Introduction
The coagulation pathway is made up of a number of serine proteases and 
cofactors that combine sequentially to activate or inactivate each other in order to 
yield a stable blood clot. Of these proteins, five particular serine proteases (FVII, 
FIX, FX, PC and thrombin, also known as FII) exhibit strong structural and sequence 
conservation and all require Vitamin K to function correctly (Greer, 1990). FVII, 
FIX, FX, and PC all contain a Gla (y-carboxyglutamic acid) domain, two epidermal 
growth-factor-like (EGF) domains, denoted EGF where they do not bind calcium and 
EGF_CA where they do bind calcium, and a catalytic serine protease (SP) domain 
(Blake et al., 1987) (Section 2.5, Figure 2.3). Thrombin contains two Kringle 
domains instead of the EGF domains found in the other factors (Gojobori and Ikeo, 
1994). Within these proteins the sequences of each domain show strong sequence 
conservation (Figure 6.1).
Mutations within the genes of the coagulation serine proteases are frequently 
associated with either abnormal bleeding or increased susceptibility to the formation 
of blood clots. Mutations within FIX and FX are associated with Haemophilia B and 
FX deficiency respectively. Mutations within Protein C have been shown to increase 
the risk of developing blood clots and dangerous thrombosis.
In Chapters 4 and 5, I have described the compilation of two web databases 
for complement FH and coagulation FXI mutations. This involved the manual 
collection of data on mutations and patients from full-length papers and abstracts 
identified using information retrieval tools such as PubMed. Extending LSDBs to 
include mutation information from a variety of related proteins can provide useful 
analysis of patterns of missense mutations and conservation within conserved 
regions of related proteins and domains. This was shown by the proposal of a 
consensus SCR domain that aided understanding of mutations involved in aHUS, 
AMD and MPGN II (Chapter 5). This approach can potentially aid the structural 
interpretation of other mutational data; so that mutations can be deciphered between 
non-disease causing polymorphisms or disease-associated mutations that affect the 
structure or function of the protein.
Compiling larger datasets of mutations obviously involves a greater amount 
of data interpretation and collection which can be time consuming and difficult to 
maintain. For example, the FXI mutation database discussed in Chapter 4 held 65 
mutations from around 40 publications within the first version.
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Figure 6.1 Sequence conservation of domains within the five Vitamin K 
dependant coagulation proteases (continued over page)
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(e) Serine P rotease Domain
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Figure 6.1 Sequence conservation of domains within the five Vitamin K 
dependant coagulation proteases
The sequences of the domains within the proteins are shown, where fully 
conserved residues are highlighted in black.
(a) The sequences of the Gla domain of FII (thrombin), FVII, FIX, FX and PC 
are shown. Numbering corresponds to FII.
(b) The sequences of the calcium binding EGF domain of FVII, FIX, FX and PC 
are shown. Numbering corresponds to FVII.
(c) The sequences of the non calcium binding EGF domain of FVII, FIX, FX and 
PC are shown. Numbering corresponds to FVII.
(d) The sequences of the Kringle domains within FII are shown. Numbering 
corresponds to the first Kringle domain within FII.
(e) The sequences of the SP domain of FII, FVII, FIX, FX and PC are shown. 
Numbering corresponds to FII.
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However, the current version (2004) of the coagulation FIX mutation database 
contains data from 222 publications describing roughly 900 mutations 
(http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html). In order to compile a 
database of coagulation serine protease mutations, several hundred publications have 
to be processed.
Text mining involves the automatic extraction of information from free- 
format text. Information retrieval (IR) tools, such as Internet search engines, PubMed 
and Medline focus on finding pages/articles specific to a user-defined search term. 
Although this is useful, it still requires a large amount of reading in order to gain the 
requisite information, and those articles returned might not necessarily be relevant. 
Information extraction (IE) tools take IR further and extract information about 
predefined classes of entities and relationships. IE tools are used to populate 
structured information repositories (databases) from unstructured or free text 
information sources. With the growth of electronically available publications, the 
ability to access and navigate biomedical information sources in an efficient manner 
is becoming increasingly important. However, scientific publications are written in 
natural language, which is extremely difficult to process automatically for a number 
of reasons. Firstly, natural language is ambiguous, where a single word can have 
many meanings. Secondly, natural language is flexible, where there are many ways 
of describing the same thing. Thirdly, natural language is dynamic, since new words 
constantly appear, or the meaning of words changes.
There are various computational methods that focus on solving the problem 
of natural language processing. On a simple level, regular expressions can be 
exploited to define patterns of words and phrases to aid processing. A regular 
expression is simply a string of text that describes or matches a set of strings, 
according to certain syntax rules. More sophisticated technology using part of speech 
tagging, semantic parsing based on sentence structure and machine learning have 
also been implemented. In terms of biological data mining, a variety of tools have 
been designed to look at a number of biological questions. These include SUISEKI, 
a text mining tool that can identify protein-protein interactions from the text of 
publications (Blaschke and Valencia, 2001) and PASTA, a system that performs 
automatic extraction of information relating to roles of specific amino acid residues 
in protein active sites from online articles (Gaizauskas et al., 2003). In addition, text 
mining procedures have also been applied to Medline abstracts and cross validated
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with OMIM in order to identify amino acid substitutions involved with disease 
causing mutations (Rebholz-Schuhmann et al., 2004).
In order to analyse the structural consequences of mutations in terms of 
protein sequence and protein structure conservation, a database of Vitamin K 
dependent coagulation serine protease mutations was compiled using automatic text 
mining procedures. Until now, mutations within the coagulation serine proteases 
have only been analysed in terms of single proteins, and there have been no analysis 
of mutations in the context of what is known about other serine protease mutations. 
This database provides information to analyse mutations in terms of frequency and 
phenotypic conservation in relation to sequence and structural conservation within 
the coagulation serine protease family. The data for this database was extracted by 
exploring automatic text processing methods for the identification of mutations in 
both abstracts and full length articles. The text mining methods used within this 
database can be extended to automatically extract mutations within other proteins 
and diseases.
6.2 Methods
6.2.1 Database Design
The design of the SP database is described in Figure 6.2. It follows a similar 
relational database design as the FH-HUS database described in Chapter 5, however 
since the data coverage is larger, it does not include information on individual patient 
history. In order to incorporate automatic methods of mutation extraction, additional 
tables were added to include information on reference processing (refState and 
reflnfo). Additional tables were also added to describe the conservation of domain 
structures and mutations using a consensus numbering scheme based on the 
consensus domain models (conservedDomain).
6.2.2 Automatic Mutation Extraction
Populating the Vitamin K dependent serine protease mutation database with 
mutations from full length references requires three major processes. Firstly 
references have to be identified that are likely to contain relevant mutations, 
secondly those references have to be downloaded and thirdly those references have 
to be processed/read to extract the mutations. In order to automate the procedure, the 
complete process is split into several discrete steps (Figure 6.3).
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Figure 6.2 The Vitamin K dependent serine protease database schema
Each table within the relational database is shown in a box. The attributes of 
each table are listed. Those attributes followed by a * character are the primary keys 
of each table. The attributes that are highlighted in green text are foreign keys also 
used in other tables. The relationships between each table are indicated by black 
lines where three pronged lines represent 1:N relationships and the normal lines 
indicate 1:1 relationships (Section 3.1.2).
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PubMed
i Identify possible references 
using keyword searches
Score references with a threshold 
to elimate irrelevant ones
X ZI
Collect PDFs of relevant references ■H Covert PDF reference to free text
Extract content, omitting section listing references
Find all occurrences of numbers within a sentence, 
omitting dates, measurements, ranges etc
Find all occurrences of amino acids within a sentence 
omitting parts of words
Extract amino number pairs and possible lists
Analyse combinations of amino number elements 
to compose list o f mutations within a sentence
Check possible mutation against relevant sequence 
and compute nucleotide change
Check numbering including 
signal peptide
Display text with mutations highlighted and 
allow user to input into database
Split text into sentences
SP Database
Figure 6.3 Automated mutation extraction pipeline
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6.2.2.1 Identification of References
The eUtils system at the NCBI
(http://eutils.ncbi.nlm.nih.gov/entrez/query/static/eutils_help.html) was used to 
search the PubMed and Medline literature database using keyword phrases. Keyword 
phrases were generated using official Entrez Gene names 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=gene), as well 
as alternative names and diseases from the OMIM database
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=omim). The 
keyword phrases used for each serine protease are detailed in Table 6.1.
6.2.2.2 Publication relevancy scoring
In order to avoid downloading all of the 11792 references returned as a result 
of PubMed searches (Table 6.1), the XML records of each PubMed reference were 
analysed and weighted to prioritise the references most likely to contain mutations. 
In order to generate a scoring system, the frequency of words within all the abstracts 
from the 11792 references was calculated using PHP scripts. After omitting noise 
words such as ‘the’ and ‘o f , a list of the most commonly occurring words was used 
to define a keyword scoring mechanism. These keywords are listed in Table 6.2. The 
distribution of scores using three different scoring systems is shown in Figure 6.4. 
Firstly the score for each abstract or reference was generated by counting the 
occurrence of keywords (Figure 6.4a). This system was tested for a random set of 50 
known true positive abstracts that related to references that contained mutations and 
a random set of 50 true negative abstracts that were irrelevant and did not contain 
mutations. Analysing the scoring of these true positives and true negatives did not 
define a suitable threshold score since the scores of both sets overlapped (Figure 
6.4a). In respect of this, the scoring was adjusted so that the occurrence of the same 
word did not contribute as much to the score as the occurrence of different words 
and the occurrence of key words within the title was weighted more positively than 
the occurrence of words within the abstract. This changed the distribution of scores, 
and lead to a clearer definition of the true positive and true negative set (Figure 
6.4b). The sophistication of the scoring system was enhanced further by weighting 
keywords that were more distinct, with ambiguous keywords (Table 6.2) 
contributing less to the score. This defined a clear threshold score to define the 
references most likely to contain mutations (Figure 6.4c).
279
Table 6.1 PubMed searches
Protein OMIM Gene
Symbol
Search Phrase No O f References
FII 176930 F2 f2+deficiency 228
fii+mutation 92
fii+deficiency 36
hypothrombinemia+mutation 0
dysprothrombinemia+mutation 14
prothrombin+mutation 1491
thrombin+mutation 955
prothrombin+deficiency 986
thrombin+deficiency 1106
factor+ii+mutation 1518
factor+ii+deficiency 969
f2+mutation 659
Unique matches for FII 5518
FIX 306900 F9 hemophilia+b+mutation 455
haemophilia+b+mutation 455
factor+xi+mutation 612
factor+xi+deficiency 2675
f9+mutation 234
f9+deficiency 34
fix+mutation 391
fix+deficiency 119
ptc+deficiency 2645
Unique matches for FIX 3586
FVII 227500 F7 hypoproconvertinemia 742
factor+vii+deficiency 800
factor+vii+mutation 327
f7+mutation 53
f7+deficiency 23
fvii+mutation 117
fvii+deficiency 170
Unique matches for FVII 1549
FX 227600 F10 fx+deficiency 95
factor+x+deficiency 370
factor+x+mutation 404
flO+mutation 50
fl 0+deficiency 22
stuart+prower+mutation 0
stuart+prower+deficiency 332
Unique matches for FX 826
Protein C 176860 PROC pc+deficiency 229
protein+c+deficiency 1412
coagulation+protein+c+mutation 731
Unique matches for Protein C 2192
All Unique matches for all 11792
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Table 6.2 Keyword phrases used in scoring abstracts and titles*
_______ Keyword(s)_______
mutation
mutant
mutations
deficiency
deficient
bleeding disorder 
Factor ix 
fix 
f9
Christmas disease 
Christmas factor 
ptc deficiency 
haemophilia 
factor 9 
factor x 
fx 
f10
stuart prower 
factor xa 
fxa 
fixa
factor ixa
prothrombin
thrombin
fii
factor ii
f2
hypothrombinemia
dysprothrombinemia
hyperthrombinemia
protein c
procc
p ro d
thrombophilia
factor vii
factor viia
fvii
fviia
f7
hypoconvertinemia
*Those keywords written in red are ambiguous so do not score as well as the other keywords. Words 
are written in order, with the most commonly occurring words within the returned records are at the 
top.
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Figure 6.4 The frequency of scores for PubMed entries using different scoring 
methods
(a) The distribution of the score for all records where score was calculated by 
adding keyword occurrences. This is compared to the distribution of scores 
for a test set of true positive abstracts and true negative abstracts using this 
scoring method.
(b) The distribution of the score for all records where score was calculated with a 
lower weight assigned to words mentioned more than once, and a higher 
weight to words within the title. This is compared to the distribution of 
scores for a test set of true positive abstracts and true negative abstracts using 
this scoring method.
(c) The distribution of the score for all records where score was calculated as 
above but also with ambiguous terms scoring less. This is compared to the 
distribution of scores for a test set of true positive abstracts and true negative 
abstracts using this scoring method.
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Several PubMed records did not contain abstract text, so the abstract could not be 
analysed to give a score. In these cases, the title only was analysed, and in a similar 
manner to the abstracts, a set of true positive and true negative titles were analysed to 
give a threshold score.
6.2.2.3 Collection of PDF Documents
The XML PubMed records that scored above the threshold score were sorted 
by journal name, and numerically by volume, issue and page number using a PHP 
sorting function. These references were then downloaded as portable document 
format (PDF) or plain text by either using the PubMed document object information 
(doi) identification (http://www.doi.org) from the XML records, the NCBI eUtils 
LinkOut records (http://www.ncbi.nlm.nih.gov/entrez/query/static/elink_help.html) 
or manually using the UCL library databases. When UCL did not have journal 
subscriptions, or full text was not available electronically for several references, 
these were flagged within the database as ‘nosubscription’ within the refState table 
(Figure 6.2). All PDF or text references were saved with the PubMed ID as an 
identifier.
6.2.2.4 PDF Automatic Analysis
The extraction of information from natural language texts is extremely 
difficult and error prone. Although it is important to generate quick and automatic 
methods to detect mutations, it is equally important that the database contains 
accurate data. Since automatically extracting mutations from text without manual 
interpretation could provide inaccurate data, the system was designed to allow 
manual inspection, while requiring as little human processing as possible.
In order to automatically extract mutations from full length PDF references, 
whilst also allowing manual checking, an interactive web tool was designed as part 
of the database administration system. This tool was written using PHP, JavaScript 
and HTML programming, with the database implemented using MySQL (Section 
3.1.4). This web tool highlights the occurrence of mutations within text and 
generates the SQL statements required to input the mutations into the database. The 
only user input required is the click of a button for the input of mutation or reference 
information where appropriate. Using this tool, the user can scan a PDF where
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mutations and other relevant information are already highlighted, without the need to 
read the whole paper (Figure 6.5).
The user is required to upload a PDF or text document containing the 
reference. The PDF or text document is named by the PubMed ID, allowing the 
PubMed database to be queried using eUtils. This query generates the XML 
describing the reference information which is parsed to obtain the title of the 
reference, the name of the main author, the year of publication and the journal 
citation which can be automatically inputted into the SP database.
The tool displays the PDF reference text in a large text area, with various 
elements highlighted. For example the reference title is highlighted, and the assigned 
protein is highlighted for the user to check mutations correspond to the correct 
protein. Each mutation is highlighted within the text, where mutations are coloured 
according to classification, where blue denotes mutations already in the database, 
green denotes likely mutations, orange denotes probable mutations and red denotes 
unlikely mutations (Figure 6.5). This scoring system is described in Section 6.2.2.9. 
There are JavaScript check boxes to choose whether to highlight specific mutations 
or not, which dynamically change the reference text highlighting according to user 
input.
Both reference information and mutation information is displayed so that the 
user can decide whether to input this information into the database or not. Each 
mutation can be displayed and submitted in turn. The tool automatically generates 
the SQL database input according to the user’s choices, and automatically inputs the 
data into the database in the correct syntax. Any database changes (i.e. SQL 
statements) are stored in a log file, and also displayed to the user (Figure 6.5a).
When each reference is processed, the reference state field within the 
database is changed to ‘processed’ so the user can be informed of how many 
references are still to be processed or downloaded. This also ensures that the same 
reference is not processed twice.
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match represents the correct numbering with regards 
to HGVS guidelines.
SUBMIT T O  DB
Figure 6.5 Screen shots of the mining tool
(a) An example of a reference is shown, with the reference title highlighted 
in grey, the protein name highlighted in purple and mutations highlighted 
in blue, red and yellow, depending on classification scheme. The 
reference information is displayed and on clicking the ‘SUBMIT TO DB’ 
button is entered into the database, and the warning box is displayed to 
show the SQL statement that has just computed within the database. The 
highlight options on the right hand side allow the user to display or ignore 
certain mutations. These mutations are also coloured according to 
classification scheme.
(b) An example of mutation data is shown, with a description of the scoring 
system found within the comments box. Mutations are highlighted within 
the text in yellow, and the protein name is highlighted in purple.
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6.2.2.5 PDF Conversion to Text
In order to analyse PDF content, it must be first converted into machine- 
readable text. Of the several software solutions to this problem, pdftotext (Glyph and 
Cog, LLC, http://www.foolabs.com/xpdf/download.html) was chosen since it can be 
executed on the UNIX web server. It also offers the advantage of being free and 
extremely easy to use, with several command line options.
6.2.2.6 Sentence and Reference Section Recognition
The output text from pdftotext is unformatted. For this to be processed, it 
must be first split into sentences. This was achieved using PHP regular expressions 
to define sentences endings, such as
' / (  [ a - z O - 9 ] \ . ) * ( [ A - Z ] ) / '
This example defines an alphanumeric character followed by a full stop and white 
space, followed by a capital letter character.
In order to avoid picking up mutations within the References section of a 
paper, PHP regular expressions were also used to recognise citations and likely 
references. These regular expressions were made up of journal titles and common 
patterns of citations and numbering systems, such as
' /  ( [ 0 - 9 ] { 1 , 4 } )  { 0 , 1 }  \  ( [ 1 2 ]  [ 9 0 ]  [ 0 - 9 ]  [ 0 - 9 ] \ )  { 0 , 1 }  ( [ 0 - 9 ] + ) / '
This example defines a number followed by a year followed by another number. If 
the web tool finds a likely reference section, it will omit it from the text that is 
processed for mutation occurrences. This allows the correct referencing of mutations 
in the database, so that if a more in-depth look at a mutation is required, the 
references that discuss that mutation are easily found, without assigning mutations to 
a text that only mentions them in the Reference Section.
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622 .1  Identification of Mutations
On a simple level, the descriptions of missense mutations are made up of two 
amino acids and a number (Figure 6.6). The order and position of these elements 
may be different, but essentially all three elements must appear in the mutation 
description. Nonsense mutations are also described in a similar way, except that the 
second amino acid is replaced by a word describing the stop or termination of the 
peptide chain.
Regular expressions were initially used to recognise the occurrence of 
mutations, where several likely patterns such as an amino acid and a number 
followed by another amino acid were defined. However, due to the large variation in 
natural language and the large number of ways that an amino acid substitution can be 
described this was not considered suitable to find all mutations (Figure 6.6).
Instead of scanning the text for numerous possible patterns of amino acids 
and numbers, the program stores the occurrence of numbers and amino acids within 
a sentence, defining the position of each match within that sentence. This is achieved 
using regular expressions for both numbers and amino acids, such as
'/alanine|ala|arginine|arg|asparagine|asn/'
This defines amino acid names in full syntax or three letter code. The number 
matches are then processed to omit dates, measurements, fractions, percentages, 
decimals and ranges, as well as those numbers that are part of reference citations or 
figure and table citations. The amino acid matches are also processed to omit those 
matches that form part of words such as ‘produce’ and ‘this’.
The next stage of the procedure processes the amino acids and numbers 
within a sentence in the order they occur in the text. Initially likely common syntax 
is flagged, such as amino acid-number-amino acid triples that occur in close 
proximity to each other (such as Glul 17Asp) and amino acid-number pairs (such as 
Glul 17 and Asp 118). Secondly those amino acid and number matches that appear to 
be linked are flagged or omitted. For example, Figure 6.6b and Figure 6.6c highlight 
occasions where an amino acid represents an alternative to another amino acid, or 
where an amino acid is described in a negative context. Regular expressions and 
string parsing are used to assign these alternative or negative occurrences.
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(a) Standard descriptions
-In the catalytic domain of factor X the following substitutions 
can be seen,Glu304-toLys, Asp322-to-Asn, Arg326-to-Cys, Ser334-to-Pro, Ser334-to-Pro, 
and Pro343-to-Ser, respectively (18-23).
-Glyll4 in the second EGF-like domain to Arg (GGG7AGG)
-Arg306 replaced by Cys
-Ser(AGT) 11 Arg(AGG)
-Arg306 in the catalytic domain was changed to TGT, coding for Cys 
-Arg306 has been replaced with Cys 
-Met (ATG) at position -40 to Val (GTG)
-valine is substituted at position 309 in place of alanine 
-Serine for Proline at Position 343
-serine (TCC) in place of proline (CCC) at amino acid position 343 
-glycine substitution for -carboxylated glutamic acid at position 7 
-position 57 from that for Asn (AAC) to that for Thr (ACC)
-codon -20 results in the substitution of an arginine (AGG) for a glycine (GGG)
(b) Alternative descriptions
- substitutions can be seen,Glu304-toLys, Ser334-to-Pro or Thr, and Pro343-to-Ser,
respectively (18-22).
- Glal4 in the fX Gla domain. Substitution with glycine, fXKetchikan (21),
or lysine, fXVorarlberg (22), causes a mild bleeding
(c) Negative descriptions
- lysine and not glycine is seen to replace glutamic acid at position 14
Figure 6.6 Example mutation syntax
Examples of descriptions of mutations are shown, with the elements making up the 
mutation (amino acids and codon numbers) highlighted in red.
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For example the presence of a negative word such as ‘not’ or ‘neither’ between 
adjacent amino acids causes the second amino acid to be omitted. The order of 
matches is also analysed to identify possible lists, such as amino acid sequences. 
After this processing, the matches within a sentence are then analysed to find the 
maximum combinations of amino acid-number-amino acid triples that do not overlap 
with each other (Figure 6.7). The best scoring combination, in terms of how many 
triples are found and how many matches are unaccounted for is used to define the 
mutations.
In addition to this, regular expressions are used to identify the short hand 
notation of mutations such as N123G, allowing for various syntaxes such as 
N(123)G and N-123-G etc. This is to avoid processing irrelevant matches of single 
letters that are incorrectly flagged as amino acids.
6.2.2.8 Benchmarking and Scoring
The methods used to identify mutations were continuously ‘trained’ on a set 
of 13 FX references that were manually processed to identify 258 descriptions of 
mutations. This training set was used to identify pitfalls and problems with the 
techniques used, and develop programming methods accordingly.
In order to test the accuracy of the mutation extraction techniques, the tool 
was tested on six FXI papers describing 135 mutations (Chapter 4), and 28 FH 
papers describing 617 mutations (Chapter 5), where the occurrence of mutations had 
already been manually marked. Accuracy was measured in terms of precision (the 
ratio of correctly identified mutations to the total number of mutations) and recall 
(fraction of the total mutations that were correctly identified by the automatic 
methods).
Precision = True Positives / (True Positives + False Positives)
Recall = True Positives / (True Positives + False Negatives)
6.2.2.9 Mutation Syntax and Numbering
Additional constraints were added in order to reduce the number of false 
positive mutation matches, and to generate a scoring system. Firstly the most likely 
protein that the mutation is associated with is identified by counting the occurrence 
of each protein name within the text.
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s u b s titu t io n s  can be  s e e n ,G lu 3 0 4 -tc  
re sp e c tive ly  (18-22).
Lys ,S e r334 -to -P ro Thr, and Pro343 -to-Ser,
Figure 6.7 Extraction of mutation amino acid, codon and amino acid triples
An example of a sentence is shown with the different combinations of amino acid, 
number triples that can be formed shown in different coloured boxes. The colour of 
the boxes represents the triples that follow the same order and go together in the 
same combination. The red combination covers the most mutations and accounts for 
the most amino acid number elements. Therefore the elements within the red boxes 
would be assigned as mutations.
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The serine protease with the most occurrences is assigned as the mutated protein. 
Regular expressions are used to identify the alternative syntaxes for each of the five 
proteases.
The mutation is then checked against the amino acid sequence of the 
appropriate protein to see if one of the amino acids within the mutation matches to 
the protein sequence. Because different numbering systems are used, and HGVS 
nomenclature is not strictly adhered to, two different methods are implemented to 
account for numbering discrepancies. Firstly the majority of mutations within serine 
proteases are reported where numbering corresponds to the mature protein, with 
amino acid 1 corresponding to the first residue within the mature protein, and amino 
acids within the signal and propeptide numbered negatively. To account for this, the 
database holds information on the length of each serine protease signal peptide, and 
alternative numbering can be calculated to check whether the mutation corresponds 
to a residue within the sequence.
In some cases, mutations are numbered with a different system, and in order 
to map the mutations to the correct numbering system, a sliding window approach is 
used where more than one mutation does not match up to the HGVS numbering, or 
the mature peptide numbering. This method takes each unassigned mutation that 
does not map to HGVS or mature peptide numbering, and scans the sequence for 
amino acids that appear with the same distance between them using regular 
expressions (Figure 6.8). If several amino acids map to the sequence, with ordering 
preserved they are changed to the correct numbering system and flagged for manual 
inspection.
In order to provide HGVS nucleotide syntax for each mutation, and to 
provide another mutation error check to aid scoring, the nucleotide change is also 
calculated. This can identify whether the amino acid substitution is the result of a 
SNP. Information on the amino acid change, the protein nucleotide sequence and the 
genetic code is used to generate a possible substitution. Where the nucleotide change 
cannot be directly calculated from the sequence, for example where a nucleotide 
could change to an A or a T and still produce the same amino acid change, the text is 
checked for nucleotide descriptions using regular expressions. These can then be 
used to assign the correct change, allowing the user to check the relevant nucleotide 
syntax to see if it is referring to the correct mutation.
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Searching for Serl46, Glyl49, Tyrl52 
Ser-X2-Gly-X2-Tyr
Thr Gly CysArg Gly Phe TyrLeu Ser
121  122  123  124  125  126  127  129  130  131
X — v /
Figure 6.8 Search for incorrectly numbered mutations within the sequence
An illustrative example of a search pattern generated to find the positions of 
mutations that are numbered incorrectly within the sequence. If the same pattern of 
amino acids with the same order appears in the sequence, the mutations can be 
mapped to the correct place.
Gly
132
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These error traps and syntax corrections allow the matched mutations to be 
categorised, where mutations that map straight to the sequence and have possible 
nucleotide substitutions are classified as the most likely (and coloured green), those 
that map to the mature peptide or another numbering scheme and have a possible 
nucleotide substitution are categorised as probable (and coloured yellow), and those 
mutations that do not map to a numbering system or do not have a possible 
nucleotide substitution are categorised as unlikely (coloured red).
6.2.3 Consensus Sequence Analysis and Homology Modelling
Experimental structures are available for the majority of the domains within 
the five Vitamin K dependent serine proteases (Table 6.3). Only one protein, 
thrombin has two domains without known structure, namely the Gla domain and the 
first Kringle domain. The structure of this initial fragment is provided by the crystal 
structure of bovine thrombin (PDB code: 2PF2) as a suitable homology modelling 
template structure (Figure 6.9). This homology model was constructed using 
MODELLER v9. The modelling of this structure only required the deletion of one 
residue (Gly4) from the template (PDB code: 2PF2) (Figure 6.9).
Consensus domain sequences were generated from the alignment of the 
coagulation protein domain sequences (Figure 6.10). Since the domains are short in 
length, alignments were generated manually and the consensus sequence was taken 
as the most commonly occurring residue at each position. Where gaps appeared 
more often than residues, a gap was placed in the consensus sequence. Where the 
consensus amino acid could not be defined because there was more than one 
possibility of amino acid, the SMART and pFAM family alignments were used to 
identify the most commonly occurring residue at that position (Letunic et al., 2006; 
Finn et al., 2006). Additional sequences from the Kringle domains within human 
hepatocyte growth factor (SwissProt: HGF_HUMAN) and plasminogen (SwissProt: 
PLMN_HUMAN) were added to the Kringle domain alignment to aid interpretation 
of conserved residues (Figure 6.10d).
In order to visualise the position of mutations within these consensus 
domains, the consensus sequence of each domain was mapped onto the average 
modelled structure of domains with known structure using the alignments shown in 
Figure 6.10 as input to MODELLER v9.
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Table 6.3 Structural information for the Vitamin K dependent Serine proteases
Protein PDB ID Domains Reference
FII 2HPQ Kringle-2, SP Arni et al., 1993
FVII 1DAN Gla, EGF-1, EGF-2, SP Banner et al., 1996
FIX 1NL0 Gla Huang et al., 2004
1EDM EGF-1 Rao et al., 1995
1RFN EGF-2, SP Hopfner et al., 1999
FX IPOS Gla, EGF-2, SP Wang et al., 2003
1XKA EGF-1. EGF-2, SP Kamata et al., 1998
PROTC 1LQV Gla Oganesyan et al., 2002
1AUT EGF-1, EGF-2, SP Mather et al., 1996
These references were unfortunately missed from the alphabetic reference list, but 
are included on page 365.
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5 0  6 0  7 0  8 0  9 0
_ |  |  |  |  |  |  |  |  |  |  | ------
HUMAN ANT-FLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDK 
BOVINE ANKGFLEEVRKGNLERECLEEPCSREEAFEALESLSATDAFWAKYTACESARNPREK
1 0 0  1 1 0  1 2 0  1 3 0  1 4 0  1 5 0
I ---------| ----------- | ----------, ----------- | ---------- | --------- | ---------- | -----------, ---------- | ---------- | ----------
HUMAN LAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENF 
BOVINE LNECLEGNCAEGVGMNYRGNVSVTRSGIECQLWRSRYPHKPEINSTTHPGADLRENF
1 6 0  1 7 0  1 8 0
 I ---------I  I -----------I  I  I -
HUMAN CRNPDSSTTGPWCYTTDPTVRRQECSIPVC 
BOVINE CRNPDGSITGPWCYTTSPTLRREECSVPVC
Figure 6.9 Sequence alignment of the initial fragment of human and bovine 
thrombin
The sequences shown are that of human thrombin (SwissProt: FII_HUMAN) and 
bovine thrombin (SwissProt: FIIJBOVIN). Numbering corresponds to the complete 
human thrombin sequence.
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(a) Gla Domain
10 20 30 40
FII -ANT-FLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYT-
FVII -ANA-FLEELRPGsBpJ|KEEQCSy EAREIFKPAgRTKLFWISYS
FIX -YNSGKLEEFVQGNLEREdME KCSF A  VF :.TER E WK
FX -ANS-FLE MKKGHLERECX ETCSYEEAREV? SDKTNEF§NKYK-
PROC - A N S - F I ^ P H s T B H ^ I C D ^ E E A K E I f O N Y D D T L E F W S K H V -
PROZ -AGSYLLEELFEGNLEKECYEEICVYEEAREVFENEWTDEFWRRYK-
PROS -ANS-LLEETKQGNLERECIEELCNKEEAREVFENDPETDYFYPKYL-
c o n s e n s u s  -a n s -f l e e l r q g n l e r e c m e e t c s y e e a I eM e nB M M M J y k -
DSSP -CCC-SSSCSSSCCSCCCCCTSCCCSSTtJ B S t c HHHHHHHHHHCC-
ACCESS - 2 9 7 - 9 9 9 6 9 9 9 1 6 6 9 9 3 1 9 9 9 9 0 2 9 9 3 0 j p 4 9 6 p 9 9 0 8 8 2 6 9 |6 9 -
Figure 6.10 Sequence alignments and structures of conserved domains 
(continued over page)
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(b) EGF_CA Domain
10 20 30
 I— — I—  - | ------| -------| -------| ------- | —
F V I I  -D G D § Q IW |-S P C Q N G --G S C K D Q L Q S Y IC F C L P A F E G  NCE-
F I X  - DGDQCE S -N P C L N G --G S C K D Q IN S Y E C W C P F G F E G K N C E -
FX - D G D Q C E T-SPC Q N Q —  G K CK DGLGEYTCTCLEGFEGKNCE-
PROC - L E H P C A S — LCCGH- - GT C l D G IGS FS C D C R S GWEGRFCQ-
P R O S l -PD -Q C SP-L PC N E D G Y M SC K D G K A SFT C T C K PG W Q G E K C E -
PR O Z 1 -G G S P C IS -Q P C L H N — G SC Q D SIW G Y TC TC SPG Y E G SN CE -
F X I I l  -V K D H C SK H SPC Q K G — GTCVNM PSGPHCLCPQHLTGNHCQ-
F X I I 2  -A S Q A C R T -N P C L H G — GRCLEV EG H R LCH C PV G Y TG PFCD -
CONSENSUS - D G D M M - S PCLNG— GSCKDGIGSYTCTCPPGFEGKNCE- 
DSSP -CC^^H-CCCCTT— CEEEECSSCEEEECCTTCCSTTCC-
ACCESS -94 91171-811987 —  173962955462933987 959309-
FigUre 6.10 Sequence alignments and structures of conserved domains 
(continued over page)
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(c) EGF Domain
FVII - U L I C V  NgNGgCE -YCSDHTGTKRSCRCHEGYSLLA— DGVSCT-
FIX -LDVTCN IKNG CEQ-FCKHSADNKWCSCTEGYRLAE— NQKSCE-
FX -TRKLCS LDNGDCDQ- FCHEEQ-N SWCSCARGYTLAD— NGKACI-
PROC -SFLNCS iliMcTH-YCLEEV-GW RRCSGAPGYKLGD— DLLQCH-
PROS2 -DINECKDPSNINGGCSQ-ICDNTP-GSYHCSCKNGFVMLS— NKKDCK-
PROS3 -DVDECS LKPSICGTAVCKNIP-GDFECECPEGYRYNL— KSKSCE-
PROS4 -DIDECS ENMCAQ-LCVNYP-GGYTCYCDGKKGFKLAQDQKSCE-
PROZ2 -AKNECH— PERTDGCQH-FCLPGQ-ESYTCSCAQGYRLGE— DHKQCV-
CONSENSUS -DILECS lH M c EQ- FCLNEP-GSYVCSCAEGYRLAD— DGKSCE-
d s s p  -c c c s s t — t^ H c s s -e e e e c s -s s e e e e c c t t c c b c s — s s s c b c -
ACCESS -929938 9f ©0^096-927999-565604239699719— 918419-
.,14
Figure 6.10 Sequence alignments and structures of conserved domains 
(continued over page)
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(d) Kringle Domain
10  2 0  3 0  4 0  5 0  60
 |  1 |  |  |  |  |  |  |  1 | --------
F I I _ 1  -CAEGLGTNYRGHVNITRSGIECQLWRSRYPH K PEIN STTHPG-ADLQENFCRNPDSSTTG
f i i _ 2  - c v p H I q q y q g r l a v t t h g l p c l a w a s a q H B B B I q d f n s a - v q l v e n f c r n p d g d e e g
F X II  -CYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNW-GLGGHAFCRNPDNDIR-
HGF_1 -CIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRG-KDLQENYCRNPRGEEGG
HGF_2 -CMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERYPD-KGFDDNYCRNPDGQPR-
HGF_3 -CIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKC-KDLRENYCRNPDGSES-
HGF_4 -CYRGNGKNYMGNLSQTRSGLTCSMWDKNMEDLHRHIFWEPDA-SKLNENYCRNPDDDAHG
PLMN_1 -CKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPS-EGLEENYCRNPDNDPQG
PLMN_2 -CMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPN-KNLKKNYCRNPDRELR-
PLMN_3 -CLKGTGENYRGNVAVTVSGHTCQHWSAQT PHTHNRTPENFPC-KNLDENYCRNPDGKRA-
PLMN_3 -CYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPN-AGLTMNYCRNPDADKG-
PLMN 3 -CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
CONSENSUS -CYT| 
DSSP -C C
ACCESS - 9  981
|ESYRGTVSTTRSGIPCQPWA5QYPHRH3FLPENYPA-KGLQENYCRNPDGDEGG 
SSCCCCCCBCTTSCBCCCTTS«HHHHTTSSCCCTT-SCCCTTCCBCSSCCSSC 
,9 9 2 9 1 9 4  3 5 0  97 47 7 0 7 4 1 8  2 |^ 8 S i® 2  9 94 94 9 9 9 - 1 3 5 7  92 60  0 0 0 5 3 3 9 4 0
7 0
F I I _ 1  PW CYT-TDPTVRRQECS-IPVC-
F I I _ 2  WCYV-AGKPGDFGYCD-LNYC-
F X II  PWCFVLNRDRLSWEYCD-LAQC-
HGF_1 PW CFT-SNPEVRYEVCD-IPQC-
HGF_2 PWCYT-LDPHTRWEYCA-IKTC-
HGF_3 PWCFT-TDPNIRVGYCSQIPNC-
HGF_4 PW CYT-GNPLIPW DYCP-ISRC-
PLMN_1 PWCYT-TDPEKRYDYCD-ILEC-
PLMN_2 PW CFT-TDPNKRWELCD-IPRC-
PLMN_3 PWCHT-TNSQVRWEYCK-IPSC-
PLMN_3 PWCFT-TDPSVRWEYCN-LKKC-
PLMN 3 PWCYT-TNPRKLYDYCD-VPQC-
CONSENSUS PWCYT-TDPEVRWEYCD-IPQC- 
DSSP C |g 8 C -S S S T T C ® |jC C -C C C C -
ACCESS 0 0 0 0 1 - 4 7 5 9 9 9 6 6 6 1 9 - 2 8 9 9 -
N
\2 55
Figure 6.10 Sequence alignments and structures of conserved domains
(continued over page)
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(e) SP Domain
10 20 30 40 50
THROM IVEGSDAEIGMSPWQVMLFRK-SPQELLCGASLlSDRWVLTA^ttLLYPPWDKNFTENDLLVRIG
FVII IVGGKVCPKGEC PWQVLLLVN GAQLCGGTLINTIWWS.AMM|DK------ 1KNWRNLIAVLG
FIX WGGBDAKPGQFPWQW L N G K  VDAFCGGSIVNEKWTVTft|Bj|KvF.T--------- GVKIT^feG
FX IVGGQECKDGECPWQALLINE— ENEGFCGGTILSEFYILTAAHCLYQ--------- AKRFKVRVG
PROTC LIDGKMTRRGDS PWQWLLDS - - KKKLACGAVLIHP S WVLTaJ ( m DE S KKLLVRLG
FXII WGGLVALRGAHPYIAALYWG HSFCAGSLIAPCWVLTAAHCLQD------RPAPEDLTWLG
FXI IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTA|P©|YG------VESpUjLRVYSG
CONS IVGGKVAKRGES PWQWLLAK-- KQELLCGGSLINEQWVLTa BhB M d----- AAK P KKLTVVLG
DSSP CBSCEECCTTSCTTEEEEECT - -t c c e e e e e e e s s s s e e e e cH | s------ CCCTTTCEEEES
ACCESS 004298098352120000119 — 9962300000l5960000o|si&ip7------ 849998120000
60 70 80 90 100 110
THROM KHSRTRYERNIEKISMLEKIYIHPRYNWREN-LDRDIALMKLKKPVA------ FSDYIHPVCLPD
FVII EHDLSEHD-GDEQS RRVAQVIIP ST YVPGT— TNHDIALLRLHQPW------LTDHWPLCLPE
FIX EHNIEETE-HTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLV------LNS YVTPICIAD
FX DRNTEQEE- GGEAVH EVEWIKHNRFTKET - - YDFDIAVLRLKT PIT------ FRMNVAPACLPE
PROTC EYDLRRWE-KWELPLDIKEVFVHPNYSK T— TDNDIALLHLAQPAT------ LSQTIVPICLPD
FXII QERRNHSC-EPCQTLAVRSYRLHEAFSPVS— YQHDLALLRLQEDADGSCALLSPYVQPVCLPS
FXI I LNj0lfllK-EDTS FFGVQEI11HDQYKMAE— SGYDIALLKLETTVN------ YTDSQRPICLPS
CONS EHNLSEIE-GDEQILDVEEIIIHPNYNKAT— YDHDIALLRLKEPVT------LSDTWPICLPD
DSSP CSBSSSCC-TTCEEEEEEEEEECTTCBTTT— TBTCCEEEEESSCCC------ CCSSCCCCBCCC
ACCESS 23249994-583391829871729948995— 713000002099609------ 749005305519
120 130 140 150 160
THROM j^ pjEAASLLQA- GYKGRVTGWGNLKETWTANVGKGQ P S VLQWNLPI VE|jfV)q|DS T------ RIR
FVII RTFSER LAF-VRFSLVS WGQLLD-------RGATALEL VLNV TQDCLQQSRKVGDSPN
FIX KEYTNIFL K F- - GSGYVSGWGRVFH-------KGRSALVLQYLRVPLVI^^^fcr------KFT
FX ^ ^ ^ H lMT-QKTGIVSGFGRTHE-------KGR TRLKMLEV YVP N S C K L S ------SFI
PROTC P^j^ELNQAGQETLVTgWGYHSS - REKEAKRNRT FVLNFIKI PW P g s M -^----- SNM
FXI I GAARPSETT LCQVAGWGHQFE GAEEYASFLQEAQVPFLSLERCSAPD----VHGSS
FXI PS0RNVIYT DCWVTGWGYRKL-------RDKIQNTLQKAKIPLVTi^f KRY---- RGHK
CONS R Y SELTF-GGTGLVSGWGRLFE-------KGRQASVLQVLNVPLV: RNEGS^jl'------SFN
DSSP HHHHHHTTTT-SSEEEEEESSBSST-------TSCBCSBCEEEEEEEECHHHHHHHC----- SSC
ACCESS |9f0«|8 069-25503000006497------ 93970520210704629|pio|i21------999
170 180 190 200 210 220
THROM ITDNMFCAGYK|HGKRGD. CEGDSGGPFVMKSP-FNNRWYQMGIVSWGEGCDRDGKYGFYTH
FVII ITEYMFCA YSDGSK--- D CKGDSGGPHATHYR--- GTWYLTGIVS GQGCATVGHFGVYTR
FIX IYNNMFCAGFHEGGR--- DSC IGDSGGPHVTEVE--- GTSFLTGIISWGE ECAMKGKYGIYT K
FX ITQNMFCA YDTKQE--- DACQGDSGGPHVTRFK--- DTYFVTGIVSWGEGCARKGKYGIYTK
PROTC VSEN LCAGILGDRQ--- DACEGDSGGPMVASFH--- GTWFLVGLVS EGCGLLHNYGVYTK
FXII ILPGMLCAGFLEGGT--- DACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPGVYTD
FXI ITHKMICAGYREGGK--- DACKGDSGGPLSCKHN--- EVWHLVGITSWGEGCAQRERPGVYTN
CONS IT ENMFCAGYLEGGK--- DACQGDSGGPHVTKFR--- GTWFLTGIVSWGEGCARRGKYGVYTK
DSSP CCTTEEEESCSSSSC--- BCCTTCTTCEEEEEET TEEEEEEEEEEESSSSCTTCCEEEEE
ACCES 119104000589147--- 1009101000000989 —  46740100004342129934200003
Figure 6.10 Sequence alignments and structures of conserved domains
(continued over page)
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Figure 6.10 Sequence alignments and structures of conserved domains
(continued over page)
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Figure 6.10 Sequence alignments and structures of conserved domains 
(continued)
The sequence alignment of each domain is shown, with sequences of coagulation 
proteins included. The DSSP assignment of each coagulation sequence where 
available is highlighted in grey boxes, where darker grey represents helices and 
lighter grey represents p-strands. The consensus sequence is shown, with DSSP and 
accessibility assignments. The positions of missense mutations are marked in red and 
underlined within the sequences. Where mutations have phenotypic assignment they 
are coloured blue to represent Type I mutations, and green to represent Type II 
mutations within the sequence. The consensus domain model is also shown in 
cartoon format, where the Ca positions of mutations are highlighted as red spheres, 
where the size of the sphere is proportional to the number of mutations at that 
position. In all cases, numbering corresponds to the consensus sequence, where 
codon 1 represents the start of the domain. The N and C termini of the modelled 
structures are represented by N and C respectively. Proz = Protein Z, Pros = Protein 
S, FXII = Factor XII.
(a) The Gla domain consensus alignment and model are shown. The nine 
100% conserved Gla residues are highlighted in yellow within the 
sequence and structure.
(b) The EGF_CA consensus alignment and model are shown. The four 
calcium binding residues are highlighted in yellow in both the sequence 
and structure.
(c) The EGF consensus alignment and model are shown.
(d) The Kringle consensus alignment and model are shown. Extra sequences 
from hepatocyte growth factor (HGF) and plasminogen (PLMN) are also 
included in the alignment.
(e) The SP consensus alignment and model are shown. The three catalytic 
triad residues are highlighted in yellow in both the sequence and 
structure.
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6.3 Results
6.3.1 Automatic Extraction of Mutations
A total of 4838 out of 11792 PubMed entries scored above the threshold 
score defined by keyword analysis (Table 6.1 and Figure 6.4). Of these 4838 entries, 
1455 entries were manually tagged for further inspection. Of the 1455 entries, 200 
were publications before 1975, and deemed not relevant to our study since very few 
mutation/protein pairs were reported before 1975 (Rebholz-Schuhmann et al., 2004).
The PDF documents of the remaining 1255 records were downloaded where 
journal subscriptions were available. This gave 625 downloaded PDFs, leaving 630 
records unavailable for download. Of the 625 downloaded PDF documents, the text 
conversion of only 24 was unavailable due to encryption or character encoding.
A total of 832 mutation records were entered into the database after 
processing 601 PDF documents. A further 44 mutations were identified using the 
abstract and titles of the PubMed records that could not be downloaded or converted 
to free text.
In order to test the precision and recall of the mutation finding methods, 
regardless of further processing such as sequence validation, a total of 45 PDFs were 
manually analysed, and compared to the outcome of the automatic analysis. A 
training set of 13 FX papers was continuously used to develop the system. Each 
occurrence of a mutation was manually assigned, and compared to the automatically 
extracted mutations. Within this set, final figures were as follows: out of 13 FX 
papers, 258 mutation occurrences were manually noted. The automatic methods 
found these mutations with a recall of 99.6% and a precision of 87.4%. To test the 
automatic analysis on a previously unseen data set of manually assigned mutations, 6 
FXI papers describing 135 mutation occurrences and 26 articles on FH mutations 
describing 617 mutation occurrences were used. Again, the automatic methods 
compared well with manual assignments and matched with recall of a 96.2% and a 
precision of 92.8% for the FXI papers and a recall of 96.7% and a precision of 
91.7% for the FH papers. It should be noted that these mutation occurrences may 
correspond to the same mutation mentioned twice within the same paper. These 
precision and recall scores are encouraging since these mutations have not been 
validated by the sequence matching methods, and so even though many false 
positives are found, they will not be classified by the mining tool as probable
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mutations. The sequence validation stage is likely to filter these erroneous mutations 
out and classify them as unlikely.
6.3.2 Molecular Modelling
Only two domains of the five coagulation serine protease structures do not 
have an experimental structure available, and so a homology model was constructed. 
These domains, the Gla domain and the first Kringle domain of human thrombin, 
were modelled using the bovine thrombin template (PDB code: 2PF2). This model is 
considered an accurate representation of human thrombin since the bovine structural 
template shares 68% sequence identity with human thrombin, and only requires the 
deletion of one residue, which is on a surface exposed loop and is easily incorporated 
into the modelled structure (Figure 6.9). The conserved a-helical structure of the Gla 
domain and the conserved p-sheet structure of the EGF_CA domain are maintained 
in the homology model.
The consensus domain structures were built from the consensus domain 
sequence as an average model of the available structural templates within the 
Vitamin K dependent SP structures (Figure 6.10). In each case the domain structure 
is likely to provide an accurate model of the consensus domain structure. For 
example, the RMSD of the consensus SP domain with each of its parental template 
structures ranges from 1.2 A to 2.6 A. This is consistent with strong secondary 
structure conservation. The surface accessibility and DSSP assignment of each 
residue is also well conserved. Within the Gla domain model, all conserved glutamic 
acid residues that undergo y-carboxylation are exposed as expected, and the 
conserved central helical structure is present (Figure 6.10a). Both consensus EGF 
domains form a compact shape, with a central two stranded P-sheet, but differ in 
respect of conserved calcium binding residues in EGF_CA that are not present in 
EGF (Figure 6.10b and Figure 6.10c). The Kringle domains form a three-disulphide 
bridge structure, with a two-stranded p-sheet on one face, and a conserved a-helix on 
the other (Figure 6.10d). This secondary structure is seen in the consensus structure, 
although the DSSP assignment of residues in the template structure is not as clear 
(Figure 6.10d). The 14 stranded double P-barrel structure of the SP domain is seen 
conserved throughout the proteins, and in the consensus structure (Figure 6.10e). All 
models satisfy the structural validation of PROCHECK (Laskowski et al., 1993).
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6.3.3 Data Analysis
A total of 875 point mutations were automatically extracted from full length 
papers and PubMed abstracts and entered into the database (Figure 6.11). Almost 
half of these mutations were found within FIX and are associated with Haemophilia 
B (Figure 6.12a). This is not surprising since Haemophilia B has a much higher 
incidence than diseases associated with the other proteins. Only 7% of mutations 
were found within thrombin, and the majority of these were laboratory mutagenesis 
mutations (Figure 6.12a and Figure 6.12b). This is also not surprising since thrombin 
is of pharmaceutical importance in treating thrombosis.
Within each of the proteins, mutations are spread throughout each domain, 
with proteins having similar proportions of mutations within each domain (Figure 
6.12c).
The majority of mutations within the database reside within the SP domain 
(Figure 6.12c). This is not surprising since the SP domain is the largest domain, 
covering 49% of the 2498 residues that make up the sequences of the five serine 
proteases. However, the percentage of mutations within the SP domain is 55% of the 
875 mutations within the database, suggesting this domain is significant not only 
because of its size but also its functional and structural relevance. Both the Gla and 
EGF_CA domains also seem to be significant with 13% of the mutations compared 
to 9% of the total sequence, and 10% of mutations compared to 5% of the total 
sequence respectively. The EGF domain seems to be less significant, but still 
represents roughly the same proportion of mutations compared to the proportion of 
the sequence. The Kringle domains within thrombin contain only four mutations, 
even though the Kringle domains constitute 37% of the total thrombin sequence. The 
lack of mutations within these domains suggests they are not as functionally or 
structurally significant as the SP or Gla domains which contain many more 
mutations. Although the linker regions between domains contribute 14% of the 
sequence, only 6% of mutations are found within these regions. This is not surprising 
since these regions are not associated with function.
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Figure 6.11 Mutation distribution within the five Vitamin K dependent serine
proteases (continued over page)
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(c) FIX
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Figure 6.11 Mutation distribution within the five Vitamin K dependent serine 
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(e) Protein C
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Figure 6.11 Mutation distribution within the five Vitamin K dependent SPs
Domains are drawn to scale. Disease-associated mutations are written in black and 
mutagenesis mutations are written in grey. Numbers represent the start and end of 
each domain, not including linkers. The N and C termini are represented by N and C 
respectively.
(a) Mutations within thrombin (FII).
(b) Mutations within FVII.
(c) Mutations within FIX.
(d) Mutations within FX.
(e) Mutations within Protein C.
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Figure 6.12 Statistics of mutation coverage within the database
(a) The distribution of 875 mutations within the five serine proteases of the 
database.
(b) The distribution of 875 mutations in terms of protein and mutation type.
(c) The distribution of 875 mutations in terms of protein and domain. The term 
‘undefined’ describes mutations within linker regions outside of the domains.
6.3.3.1 Mutations within the Gla Domain
Of the 875 mutations within the database, 116 reside in the Gla domains of 
the serine proteases. Of these mutations, 90 are missense mutations and the positions 
of these mutations correspond to residues distributed throughout the Gla domain 
(Figure 6.10a). The majority of these mutations correspond to substitutions of the 
conserved glutamic acid residues that undergo y-carboxylation which is essential for 
the serine protease to bind to the phospholipid surfaces of platelets (Section 2.5). The 
positions that correspond to the most mutations are unsurprisingly glutamic acid 
residues at positions 12, 16, 25 and 26 of the consensus structure, where mutations 
are seen in all but one of the serine proteases (Figure 6.10a). The residues adjacent to 
these glutamic acid residues are also frequently mutated as seen at position 5, 15 and 
28 of the consensus domain. These mutations may also affect the y-carboxylation, 
blocking the recognition of the Vitamin K dependent carboxylase enzyme. In the 
light of the functional significance of this domain, it is not surprising that of the eight 
mutations with phenotypic classification, seven have been assigned Type II 
functional defects (Figure 6.10).
Mutations are also seen to disrupt the conserved disulphide bridge between 
Cys 17 and Cys22 of the Gla domain consensus sequence, suggesting this disulphide 
bridge is important for the stability of the protein. Interestingly no mutations are seen 
at positions Ala26 and Trp41 that have 100% conservation across proteases, 
although mutations are seen at positions without strong conservation such as Ser34 
(Figure 6.10). Although the presence of mutations identifies possible structural or 
functional significance of their respective amino acids, it is hard to identify a 
common role for an amino acid that is not conserved throughout the protein 
sequences, and the significance of mutated residues that are not conserved may be 
limited to an individual structural or functional property specific for the protein, as 
opposed to a general property of the Gla domain.
Clearly the y-carboxylation of all nine conserved glutamic acids is important 
for the correct functioning of the serine proteases since missense mutations at all of 
these positions within the consensus structure contribute a negative effect on 
phenotype and are associated with disease.
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63.3.2 Mutations within the EGF Domains
The exact functions of the EGF domains are unknown, however they are 
known to be structurally relevant in providing the correct orientation of the Gla and 
SP domains of the protein (Stenflo, 1991). Within the Vitamin K dependent 
proteases, two different EGF domains are present, one that is associated with 
calcium binding (EGF CA) and one that does not bind calcium (EGF).
Calcium is important for cofactor activity, and binding is associated with 
Aspl and Asp3, and the post-ribosomal hydroxylated aspartic acid at Asp 18 of the 
consensus EGF_CA domain (Figure 6.10b). Tyrosine or phenylalanine must also be 
present at position 23 for the correct hydroxylation of Asp 18 (Stenflo, 1991). 
Mutations are seen at all four of these conserved positions, with mutations most 
frequently occurring at position 23. Although one mutation of position 23 within 
FVII (Tyrl28Cys) leads to a Type I phenotype, this could be accounted for by the 
introduction of a cysteine side chain that could form incorrect disulphide bridge 
pairings. It could be suggested that those mutations that do not introduce a cysteine 
residue would lead to Type II functional defects, affecting calcium binding, and 
therefore the activity of the protein (Figure 6.10b).
The positions surrounding these residues, especially those residing on the 
central two stranded P-sheet structure, are also frequently mutated (Figure 6.10b). 
Mutations at these positions could be indirectly related to calcium binding, although 
no phenotypic classification is available within the database to support this. 
Mutations also frequently occur at five of the six conserved cysteine residues apart 
from Cys27 (Figure 6.10b). These mutations are likely to affect the structural 
stability of the EGF domain, and may affect its function as a spacer between the Gla 
and SP domain, as evidenced by the Type I phenotypic classification of a mutation 
within FX (Cysl21Tyr). Several mutations are seen towards the C-terminal region of 
the EGF_CA domain at positions 30 to 34 (Figure 6.10b). This region is not 
associated with calcium binding but must have other functional or structural 
relevance since mutations that occur within this region have a phenotypic outcome, 
where both Type I and Type II mutations are observed (Figure 6.1b).
The lower percentage of mutations within the second EGF domain, compared 
to the first EGF domain suggests that the second EGF domain is less relevant to the 
correct activity of the protein. This is not surprising since the second EGF domain 
does not have calcium binding residues, so mutations within this domain are unlikely
314
to affect calcium binding. It is more likely mutations within this domain affect the 
structural stability of the EGF domain, and affect the conformation between the Gla 
and SP domain. This is supported by the fact that many of the mutations within this 
domain correspond to buried positions such as position 5, 14, 30 and 31 or conserved 
cysteine residues at position 5, 16, 25 and 40 of the consensus EGF domain (Figure 
6.10c). For example mutations at the 100% conserved GlylO position occur in all 
five of the proteases, where the substitution of a larger side chain into a buried 
position is likely to cause atom clashes and structural rearrangement of the domain. 
In addition, five of the seven mutations with phenotypic classification represent Type 
I mutations and affect structural stability, in direct contrast with the EGF_CA 
domain, where the majority of classified mutations are Type II functional defects 
(Figure 6.10b and Figure 6.10c).
6.3.3.3 Mutations within the Kringle Domains
Although the Kringle domains constitute a large proportion of thrombin, only 
four mutations within the database correspond to amino acids within the Kringle 
domains. This is surprising since they are functionally important, and are associated 
with protein-protein interactions. For example, the second Kringle domain of 
thrombin is associated with binding to both FIX and FX (Baglia et al., 2000; Taneda 
et al., 1994). Three of the four mutations within this conserved domain correspond to 
residues that are 100% conserved throughout different proteins, at position 52, 55 
and 76 of the Kringle consensus sequence (Figure 6.10d). These residues are likely 
to be associated with structural properties of Kringle domains that are conserved 
throughout different domains in different proteins, as opposed to individual 
functional properties, such as binding regions, which differ in individual Kringle 
domains. In support of this interpretation, one of these mutations corresponds to a 
conserved cysteine residue which breaks the disulphide bridge between Cys50 and 
Cys74 of the consensus Kringle structure.
The mutation at position 59 within Kringle I corresponds to an exposed 
residue that is highly variant throughout other Kringle domains (Figure 6.10). Since 
this residue is not fully conserved, it could be relevant for the function of the Kringle 
I domain that has been shown to interact with FV during the activation of thrombin 
(Deguchi et al., 1997).
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6.3.3.4 Mutations within the SP Domain
A total of 477 missense mutations occur within the SP domain of the serine 
proteases. This high figure is not surprising due to the functional significance of this 
catalytic domain. Mutations are distributed throughout the domain, although 
clustering is seen close to the active site, with both the residues involved in catalysis 
and surrounding residues affected (Figure 6.10e). The majority of mutations within 
the SP domain correspond to buried residues, which is not surprising since residues 
with side chains exposed on the surface have little structural or functional relevance 
within this domain.
The classification of 35 mutations within the SP domain allows further 
analysis of phenotypic patterns of conservation. As would be expected, where two 
mutations occur at the same position, frequently they have the same classification 
within different proteins, as seen at position 28, 93, 159, 175, 183 and 208 of the 
consensus sequence (Figure 6.10e). This is seen for both Type I and Type II 
mutations where positions maintain their structural and functional properties 
throughout different proteins. The only position where this is not the case is position 
171, where a mutation within FVII (Met387Ile) is assigned a Type I defect, whereas 
a mutation within Protein C (Met385Ile) is assigned a functional Type II defect 
(http://www.biochem.ucl.ac.uk/~becky/SP). It seems difficult to understand how 
exactly the same residue substitution in one protein can cause a functional defect 
with normal levels of one protein, yet knock out a different protein and lead to 
reduced levels. It could be this assignment has been made in error, for example in a 
reference for the Type II Met385Ile Protein C mutation, the level of the Protein C in 
a heterozygous patient was 87% of normal (Gandrille and Aiach, 1995). This could 
be classified incorrectly since the protein in plasma could represent the wild type 
allele and not the dysfunctional mutant. Alternatively the packing of nearby residues 
could be affected, as shown by the presence of a detrimental 1144 lPhe mutation 
within FX, even though phenylalanine exists at this position in active thrombin 
(Deam et al., 2003). This highlights the importance of bringing structural, 
phenotypic and clinical analysis together in order to make correct analysis and 
interpretation of mutation data.
There are a large number of Type II mutations that cluster between position 
140 and 160 of the consensus structure (Figure 6.10e). This region forms a loop 
composed of a P-strand followed by an a-helix that is close to the surface but not in
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close proximity to the active site (Figure 6.10e). This region is, however close to the 
pocket into which the N-terminal residue of the SP domain is inserted during 
activation and Type II mutations here would be expected to effect serine protease 
activation.
6.3.4 SP mutation Web Database
The Vitamin K dependent SP mutation database is available at the following 
URL http://www.biochem.ucl.ac.uk/~becky/SP. It is maintained and updated on the 
server of the Department of Biochemistry and Molecular Biology at UCL. The 
database was constructed using mySQL (http://www.mysql.com) and is displayed 
and navigated on the web via PHP (http://www.php.com), Javascript and HTML 
programming. The data was first published on the website in February 2007.
The SP web database is fully interactive with a user-friendly graphical 
interface. Page navigation differs slightly to the web sites in Chapter 4 and Chapter 5 
(Figure 6.13). Although the SP mutation database does not contain patient 
information, it has additional functionality compared to the previous websites in that 
mutations can be analysed in terms of consensus domain structures and alignments.
The website contains comprehensive search functionality, allowing mutations 
within all the proteins to be compared and analysed (Figure 6.14a). In addition, 
mutation analysis and lists are displayed and grouped in terms of protein or domain 
structure. These pages provide dynamic sequence maps and alignments showing the 
position of mutations within the protein sequence, and dynamic structure maps 
showing the position of mutations within the protein structure or consensus domain 
structure. Mutations within the consensus structure are highlighted corresponding to 
their codon position, where codons that have mutations within more than one protein 
are displayed bigger to represent how many mutations are at that position (Figure 
6.14b).
Each individual mutation can be analysed in the context of what is already 
known about other mutations within the database (Figure 6.14c). For example, the 
analysis can highlight whether the mutation occurs within a position that is common 
to other mutations within a conserved domain, whilst also displaying the distribution 
of mutations within the protein in question. Structural properties of the residues can 
also be highlighted, such as surface accessibility and DSSP assignment.
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This analysis can also be provided for any user-defined substitution, 
presenting the user with information that can be used to assess whether a novel point 
mutation may perturb structural stability (Type I) or biological function (Type II), or 
alternatively may be a non-disease-causing polymorphism.
Grouping the data together can show useful analysis of the distribution of 
mutations within the database, such as the most common domain, the most common 
mutated amino acid position within a domain, and information such as how many 
buried and exposed residues correspond to mutation sites. All of these statistics can 
be automatically generated on the website for any user defined search or residue 
substitution.
6.4 Discussion
6.4.1 Comparison of Automatic Mutation Extraction with other Automatic Methods
During the duration of this project, in addition to the 2004 study that 
automatically extracted mutations from Medline abstracts (Rebholz-Schuhmann et 
al., 2004), two other groups have made progress developing automatic methods of 
detecting mutations from text (Baker and Witte, 2006; Lee et al., 2007). The Baker 
and Witte group is developing a pipeline called Mutation Miner designed to integrate 
information retrieval and information extraction of mutation data together with 
protein sequence retrieval and mutant residue mapping onto structural information. 
The group focus on extracting experimentally introduced mutations from full-length 
papers, and do not explicitly look or decipher between disease associated mutations. 
The Lee et al., (2007) study again focuses on experimentally introduced mutagenesis 
data, developing a tool called Mutation GraB that searches for mutations within full 
length articles, but again does not decipher between disease-associated mutations 
and mutagenesis data. Neither of the tools are available to search for a user-defined 
query, however both groups have applied their systems to specific protein families to 
assess whether automatic mutation extraction is feasible.
Since both groups are designing tools that can be applied to any protein 
family, the main focus of the studies is the assignment of each mutation to a relevant 
protein and organism, if more than one protein or organism is mentioned in an 
article. Protein names and organisms are recognised using regular expressions 
generated from manually and automatically created dictionaries from databases such 
as SwissProt. With the Mutation Miner pipeline, authors built on a natural language
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processing (NLP) subsystem GATE (Cunningham et al., 2002) to use part-of-speech 
tagging (for example, verb, adjective or noun) to identify likely protein norms that 
are linked to a mutation that is defined as a gazetteer (similar to a regular 
expression). The authors of the Mutation GraB technique focus on statistical 
methods to identify associated organisms and proteins, without considering NLP, 
using graph analysis of node words within a sentence. This considers not only the 
distance between the mutation and protein or organism word but also applies 
statistical methods to analyse the frequency of that word within the text. The 
advantages of the Mutation GraB technique is that it does not require the protein 
name to be in the same sentence as the mutation, whereas the Mutation Miner only 
considers individual sentences. The initial study extracting mutations within Medline 
abstracts also deciphered between protein-mutation pairs using syntactical and 
proximity parameters (Rebholz-Schumann et al., 2004).
The mining techniques presented in this study map only the most commonly 
occurring protein to the mutation. Because the system allows for manual 
interpretation, if more than one protein is mentioned in the text, the user can 
manually select the associated protein and override the automatic assignment if it is 
incorrect. This is simple to do, since protein names are highlighted within the user 
interface so it is immediately apparent if more than one protein should be considered. 
Since this technique focuses on disease associated mutations, the problem can be 
simplified this way, since the majority of papers will only present mutations within 
one protein. The mutagenesis data extraction is more difficult since large scale 
studies frequently focus on the activities of many proteins within a protein family. 
However the majority of papers only discuss mutations within one protein (Lee et 
al., 2007). The organism that the mutation and protein refer to is also not relevant in 
this study, since only human disease associated mutations are considered, and 
mutations within other organisms are frequently filtered out with the search terms.
The text recognition of mutations has previously been studied on the basis of 
regular expressions. The three other studies all combine various regular expressions 
using amino acid nomenclature to identify mutations in syntax such as Argl23Leu, 
R123L or 123Arg>Leu. The methods applied to the SP database differ since they 
apply regular expressions to find only the positions or amino acids and numbers 
within a sentence, and then combine these with distance measurement rules to find 
the most likely combinations of amino acid number groups that could be describing
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mutations. This is useful since regular expressions alone could miss the descriptions 
of mutations since not every publication follows the same syntax. This is not so 
important in finding mutagenesis mutations since most mutations are described in a 
syntactically clear manner and it was shown that less than 1% of papers described 
mutagenesis mutations in a grammatical way (Lee et al., 2007). It is however 
important in our study, since disease associated mutations are often described in 
medical reports, in a grammatical NLP manner, and the utility of the database 
requires all of these mutations to be recognised (Figure 6.6). In order to adapt regular 
expressions to find mutations described in this way, they have to consider much 
more variety in the text. Regular expressions made to encompass more patterns, in 
turn become too vague and ambiguous and often match false positive descriptions. 
For this reason, within the SP mining system, instead of generating a long list of 
possible combinations of different ways of describing a mutation, the position and 
order of the occurrence of amino acids and mutations within text was considered and 
rules were generated to assign the most likely amino acid number combinations that 
described mutations. This method is likely to improve mutation recall because it 
allows for more complex grammatical mutation patterns; however the precision can 
be lower since more sentences can match.
The document retrieval method also differs across the different studies. The 
Rebholz-Schuhmann study looks at all Medline abstracts provided on the public 
server before September 2001. The authors of the Mutation Miner and Mutation 
GraB techniques search Medline and PubMed using IR techniques and search terms 
to identify likely publications to download for full text analysis (Witte and Baker, 
2006; Lee et al., 2007). Within these two studies, mutations within specific protein 
families are analysed, so search terms are created using the protein family names and 
the keywords ‘mutagenesis’, ‘mutant’ and ‘mutation’. Within the SP study, broader 
search terms are used, using OMIM and SwissProt alternative syntaxes and disease 
names in order to identify publications. This is important since basic search terms 
may miss relevant publications. For example, several publications that contained 
mutations within thrombin were returned using the search phrase ‘thrombin 
mutation’ but not ‘FII mutation’. To cover all possible publications, various search 
terms were used for each SP, to account for synonyms and different disease 
nomenclature (Table 6.1). Since these search terms returned a larger number of 
PubMed records, abstracts and titles of records were ordered as relevant using a
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scoring system. Although the scoring system may miss some relevant publications 
that achieve a low score but still contain mutations, this system is still considered 
more accurate than only using basic search terms that return fewer articles.
As already stated in the results section, the SP mining tool achieved high 
levels of precision and recall, even before sequence validation. The main sources of 
error were incorrectly assigning nucleotide changes as amino acid mutations and 
incorrect text conversion, which caused spelling mistakes and syntax errors. The 
accuracy of the Mutation Miner pipeline and the Mutation GraB technique are 
reported after sequence validation of the mutations, and so recall and precision 
cannot be directly compared to our scores, although it should be noted that both 
systems perform well (Witte and Baker., 2006; Lee et al., 2007). A direct 
comparison with the Medline study is more appropriate since precision and recall of 
mutations is measured in terms of recognising mutations without validating with 
sequence information. Using a set of random manually assigned mutations from 
Medline abstracts, the authors calculated recall at 74.7% and precision at 98.6% 
(Rebholz-Schuhmann et al., 2004). This SP study performs just as well giving 96.7% 
recall and 91.7% precision on the FH test data set. As would be expected, the recall 
for our methods is much higher since a wider range of mutation descriptions can be 
recognised without the need to generate more and more complex regular expressions, 
which the Rebholz-Schumann system relies on. Although the precision is a little 
lower with the SP system, it is not so important since sequence validation can 
classify those false positives that represent unlikely mutations.
The mutation classification system within the SP mining methods relies on 
validating each mutation occurrence against the sequence of the associated protein. 
This aids the user, since either green or orange mutations directly map to the 
sequence and are very likely to be mutations, whereas red mutations mostly 
correspond to the extra erroneous mutations picked up because checking for 
grammatical syntax allows more vague mutation descriptions. The Mutation GraB 
method also uses sequences to validate identified mutations, but does not allow for 
incorrect or different numbering systems (Lee et al., 2007). The Mutation Miner 
pipeline uses sequence information not to validate the extracted mutations, but to 
map the mutations onto 3-D structures (Witte and Baker, 2006). Only the SP mining 
system highlights mutations with a classification score that defines how likely it is 
that the extracted mutation is a true mutation.
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A common issue seen with these mining tools relates to the distinction 
between an amino acid change or a nucleotide change when the two amino acids are 
described as one letter code and are one of C, T, G or A. All systems have techniques 
to analyse whether or not it may be a nucleotide or protein substitution. This is not so 
relevant to the SP mining tool, since user interaction can easily decipher between a 
DNA and a protein change. In addition, the mutation is checked against the protein 
sequence, so in the majority of cases, DNA alterations do not correspond to the 
protein sequence and are scored as unlikely amino acid substitutions.
6.4.2 Problems with Automatic Extraction from Full Text Articles
Abstracts are freely available and can easily be analysed by computational 
methods using the eUtils system at the NCBI 
(http://www.ncbi.nlm.nih.gov/entrez/query/static/eutils_help.html). However, full 
text articles are more informative than abstracts, and of more relevance to the 
compilation of a large data set of disease associated mutations.
The retrieval of mutations for the SP database was limited by the availability 
of full length articles since the full text version of 625 PubMed records out of 1239 
could not be downloaded due to lack of a journal subscription or lack of electronic 
resources. Although this constitutes almost 50% of the references, this problem 
should be resolved in the future as technology improves and more publications are 
now become available on line. For example, of the 630 references that could not be 
downloaded, 472 were published before 1995, and only 75 were published after 
1999. Several of these later publications could not be downloaded because of 
subscription requirements as opposed to the electronic version of the reference being 
unavailable.
Problems also arise in the conversion of PDF or HTML articles to machine 
readable text. Firstly some journals encrypt PDFs, and in these cases pdftotext 
cannot convert them to text. Additionally the order of the text within the article is 
often misjudged by pdftotext and sentences are truncated and joined with figure 
legends and other sections of text. This leads to problems with word distance 
calculations and combinations. Finally some character sets, such as Greek letters and 
arrows are incorrectly converted. In many examples, the arrow character is changed 
to a 3, so in the case of the Ault et al., (1997) paper, the Cys518 —► Arg becomes 
Cys518 3 Arg. Usually the mutations are mentioned elsewhere in the article in other
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syntax, or grammatically so these erroneous mutations are not picked up, and the 
correct mutation is found. In addition the formatting of tables is lost during PDF 
conversion. This can often lead to incorrect text ordering, and cause mutations to be 
split and written in the wrong order, so that they cannot be automatically extracted.
6.4.3 Automatic Analysis Compared to Semi-Automatic
The main focus of this study was to provide a tool to aid the curation of the 
SP mutation database. Since it is important the mutation data within the database is 
accurate and represents only true disease causing mutations, any automatic tools will 
require manual input to check the automatic output. Although these methods do not 
allow for a completely automatic and self renewing database, they still reduce the 
time and effort required to keep the data accurate and organised. The authors of 
mutGrab suggest that even after taking into account manual correction of precision 
and recall errors, the automatic system they developed would only take 20% of the 
time it would take to for manual annotation (Lee et al., 2007). It is a similar case 
with the SP mining interface, where a paper can be uploaded, converted to free text 
and analysed for mutations that are automatically put into the database in as little as 
two minutes, compared to manually reading a paper and inserting mutation data 
which could take up to 30 minutes, depending on the length and amount of mutations 
within the paper. Together with other database administration tasks, the mining tool 
can be combined to provide a back-end web interface to allow database modification 
and updates without the knowledge of database programming.
6.4.4 Comparison of Combined SP Database with other Coagulation LSDBs
Cross-checking the mutations collected from automated methods against a 
dataset of manually curated mutations can be useful to analyse the feasibility of 
automatic mutation extraction. Within the FIX mutation database held at Kings 
College London (http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html), 620 
unique missense and nonsense mutations within FIX were reported in the latest 2004 
version 13 as of February 2007. Of these 620 mutations, 352 mutations cross 
correlated to our data set obtained from automatic methods. Although this figure 
seems low, 127 of the 268 missing mutations were unpublished, and entered into the 
FIX database by personal submission. The automatic methods missed the remaining 
141 mutations for various reasons, which highlight the limitations of automatic
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methods. These 141 mutations corresponded to 39 references. Only three of these 
references were filtered out incorrectly from the PubMed record scoring systems 
because they scored lower than the threshold. These references were unfortunately 
missed because the abstracts were not available, and the title text was vague and did 
not contain more than two keywords. Other missing references were all processed 
within the database, however, 18 references could not be downloaded from journal 
websites, and only abstracts were processed. One reference had published erroneous 
mutations that were entered correctly in the FIX database, but were assumed 
incorrect with automatic methods. Text conversion problems with 11 references 
meant that mutations could not be automatically recognised. Most frequently tables 
were incorrectly processed or missed out completely in the plain text version of the 
reference. The reason for missing the remaining reference was undetermined since 
the citation from the FIX database could not be found in PubMed and could not be 
checked on the journal website.
Although 141 out of the 493 published FIX mutations were missed with 
automatic methods, the majority were missed from references that were not 
electronically available. This problem, as already stated will improve in future, as 
more and more electronic papers become available. In fact, all of the 18 references 
we could not download were published before Dec 1999. Text conversion is also the 
second major limiting factor, but as text PDF conversion technology improves and 
journals adopt specific HGVS nomenclature (http://www.hgvs.org/mutnomen/), this 
problem should also be resolved. This could be improved by processing HTML 
versions of references, as well as PDF documents.
It is disappointing that the PubMed scoring filter missed references that 
contained mutations. For future updates this filter can be made less stringent, and the 
threshold can be lowered since the number of abstracts processed will not be as large 
when updating on a monthly basis, as opposed to processing all previous published 
abstracts.
Although this experiment suggests automatic extraction can never be 
expected to achieve 100% recall, many mutations are mentioned more than once, and 
in more than one reference.
Automatic analysis extracted 63 mutations that were not listed in the FIX 
mutation database. Many of these (17) were mutagenesis mutations, which are not 
included in the FIX data set. However, several mutations were extracted from
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references that were published before the last update of the FIX mutation database, 
and were therefore missed using manual extraction. This highlights how both 
automatic and manual methods can be used together to provide a more complete 
coverage.
6.4.5 Consensus Domain Structures and Analysing Mutations
Analysis of mutations within the consensus domain structures and sequences 
shows that the majority of mutations occur at positions that are conserved throughout 
domains, and likely represent functionally and structurally important residues 
specific to that domain. The phenotypic classification can aid interpretation of these 
mutations, and suggest the residues within a domain that are most likely to be 
involved in structural stability or functional activity. This can be useful when 
interpreting domain structure, analysing protein interactions, and designing 
mutagenesis experiments.
. The large scale identification of SNPs has brought a new challenge in 
understanding how, when and why certain SNPs cause disease, whereas other amino 
acid changes within the same protein cause no phenotypic effects. To complicate 
matters further, many SNPs are associated with a disease, but also seen within a 
large percentage of the population, making the molecular effect of the amino acid 
change uncertain. The fact that phenotypic classification is regularly conserved at a 
position within the consensus domains suggests that this type of mutation analysis in 
terms of consensus domain structures could be useful to aid prediction of the 
molecular effect of point mutations. Together with protein sequence information and 
evolutionary sequence conservation this information can act as a powerful indicator 
of which SNPs are likely to cause to disease and which are likely to be benign 
polymorphisms.
To improve the consensus domain analysis within the database, it would be 
useful to have better classification of phenotype, so that more data could be 
presented in order to analyse new mutations. This could be achieved by developing 
the automatic mutation extraction methods to also extract phenotypic data by using 
key words such as ‘CRM reduced’ and Tow antigen’, however it would be a 
complex issue to resolve the description that belonged to the correct mutation and is 
beyond the scope of this project.
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6.4.4 Future Directions
The design of the database and mining tools will allow other coagulation 
proteases to be incorporated into the Vitamin K serine protease dependent mutation 
database. The structure of the database tables would allow all other coagulation 
proteins, and other conserved domains such as the Apple domains of coagulation 
FXI to be included. The automatic extraction methods can easily be adapted to find 
mutations in other proteins by inputting additional protein syntaxes and sequence 
data into the program files and pattern definitions (Figure 6.2).
The techniques used to automatically extract mutations were successful, but 
could be improved by processing and testing a larger data set. It would also be useful 
to automatically extract other data associated with the mutations, such as phenotype 
and clinical history. In a similar way, the MutMiner and MutGrab tools of other 
groups can successfully automatically identify mutagenesis mutations within 
proteins, but they do not identify the effects of those mutations, which would be 
useful to know when analysing enzymes and possible drug targets (Lee et al., 2007; 
Witte and Baker, 2006). The challenge lies in adapting a system to recognise 
phenotype for generic proteins, since it is mostly described in natural language and 
differs for different protein families and diseases.
The large number of LSDBs available on the World Wide Web highlights the 
relevance of genetic disease causing mutations. A generic tool for processing 
references to identify mutations of any defined protein would be extremely useful to 
the research community. The methods and the user interface used to automatically 
extract mutations within this project could also be adapted into a generic web tool 
where a user could upload references and process them to identify mutations in any 
protein of interest. This would be possible to generate, since the information specific 
to each protein could be generated from a SwissProt ID, where the user could specify 
a protein, and the tool could automatically generate sequences and alternative 
syntaxes in order to search references for mutations. To my knowledge, only one 
such tool exists. OSIRIS is available on the web and integrates information from 
Medline abstracts and dbSNP to provide literature about sequence variants (Bonis et 
al., 2006). Although this tool is useful it focuses on finding the literature describing 
sequence variants within dbSNP, as opposed to identifying the mutations that the 
literature describes.
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The main limiting factor in automatically extracting mutations is the 
availability and conversion of full text electronic articles. Automatic extraction 
missed mutations in a number of references because of incorrect table conversion. 
HTML references often provide better formatting of tables, and it may improve 
mutation coverage if where available, both HTML and PDF references were 
analysed and compared to extract mutations.
The comparison of the automatic extraction methods compared to the manual 
curation of the FIX Haemophilia B mutation database (Section 6.4.2) highlights 
advantages and disadvantages of both systems. Reaching a compromise would be to 
reduce the manual interpretation while maintaining accuracy. Since there are already 
manual sources of information that collate mutation information together (Table 3.3), 
although they are not updated, a logical exercise would be to automatically link to 
these data sources and extract mutation information, while using automatic 
extraction using full length articles to update the dataset. This highlights the 
importance of nomenclature systems and integration, in order to apply the full 
benefits of all the available data by linking it together in a central resource.
6.5 Conclusions
This study provides the first analysis of the automatic extraction of disease 
associated mutations from full length publications. In addition, the automatic 
methods used can also extract nonsense mutations, and allow the user to decipher 
between disease causing mutations, mutagenesis experiments and polymorphisms. 
This work has also for the first time, considered the management of LSDBs, with 
specific focus on the design of a database administration suite, allowing updates and 
maintenance without prior knowledge of database or web programming. Until now, 
there was no available way to collect mutation data and input it into a database, 
without manually extracting it by hand from published manuscripts. It is hoped this 
semi-automatic administration software will reduce the time it takes to maintain the 
SP database and this in turn will help avoid the fate of other now redundant LSDBs 
(Soussi et al., 2006). This administration software has also been integrated into the 
FXI deficiency database (Chapter 4) and the FH-HUS database (Chapter 5).
The comparison between the automatically curated SP database and the 
manually curated Haemophilia FIX database highlights the advantages of combing 
automatic and manual methods together to incorporate a wider dataset, while still
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maintaining accuracy. Although manual work is still required with this new 
automatic system, the time it takes to process one paper has reduced to an average of 
three to four minutes, as opposed to the 20-30 minutes it would take for a human to 
read the paper and extract mutation information.
The analysis of mutations in terms of protein families and domain 
conservation suggests useful methods to predict the phenotypic outcome of SNPs. 
Not only must the residue properties and substitution be considered, but also 
structural and sequence conservation as well as individual functional activities of 
residues also play a role. Studying mutations within consensus domains not only aids 
the interpretation of the molecular basis of disease, leading to improved diagnostic 
techniques, but may also lead to clearer clarification of the functional and structural 
roles of specific residues, increasing understanding of domain and protein 
interactions and activities.
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C h a p te r  7 
C onclusions
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The three databases presented in this thesis provide the first interactive 
central repositories for mutations and polymorphisms associated with (i) FXI 
deficiency, (ii) aHUS, MPGN II and AMD, and (iii) FX deficiency, Thrombin 
deficiency, Haemophilia B, FVII deficiency and Protein C deficiency. These 
databases are widely used throughout the research community, with over 4000 
visitors to date. The structure and content of the databases correspond to the LSDB 
recommendations of the HGVS (Claustres et al 2002).
The FXI deficiency database (Chapter 4) is the first interactive mutation 
database involving a coagulation protein. Unlike other static databases of 
coagulation protein mutations that consist only of a mutation list, the FXI deficiency 
database uses relational database technology to provide data that can be queried and 
searched at the user’s discretion. For the first time, mutation and phenotypic data are 
integrated with interactive structural analysis, initially provided by homology 
models, and later updated to utilise the recent crystal structure of FXI (Papagrigoriou 
et al., 2006). The initial analysis of mutations with homology models compared to 
the later analysis using the FXI crystal structure shows that where experimental 
structures are not available, homology models are of value to investigators seeking to 
predict the effect of new mutations and can provide accurate analysis. This work has 
also classified all known FXI disease-associated mutations as Type I, Type II, or 
unknown. This classification based on phenotypic information such as FXI antigen 
levels and supported by structural analysis serves to further rationalise the causative 
role of these disease-associated mutations, which are mostly associated with the 
disruption of the FXI protein structure, as opposed to causing functional defects.
The FH-HUS database (Chapter 5) provides the first complete resource of 
information regarding aHUS patients and mutations within CFH, IF  and MCP. This 
information is again integrated with structural analysis that facilitates Type I/Type II 
phenotypic classification of mutations. The classification of aHUS mutations within 
FH suggests that Type I phenotypes may mostly result from mutations in cysteine 
residues or at buried positions, while Type II phenotypes may often result from 
alterations in the central P-sheet structural core and loops at surface-exposed 
positions. The incorporation of polymorphism data suggests that polymorphic 
locations often correspond with sites consistent with Type II phenotypes. There is an 
almost complete absence of aHUS mutations in the inter-SCR linker sequences,
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suggesting they are of little functional importance. This phenotypic classification has 
further highlighted the functional importance of the C-terminal domains, with the 
majority of Type II mutations mapped to SCR-19 and SCR-20. It also suggests that 
mutations within N-terminal domains are more structurally relevant, since the 
majority of these mutations are classified as Type I (Figure 5.21). The work 
described in Chapter 5 has found application in several publications (Joszi et al., 
2006; Licht et al., 2006; Edey et al., 2007).
The mutations within FH that are associated with aHUS are most frequently 
functional Type II mutations. This is in direct contrast to the FXI deficiency 
mutations, which are most frequently classified as Type I destabilising mutations. 
FH exists as a folded back chain of 20 SCR domains (Aslam and Perkins, 2001). 
These SCR domains form small compact P-sheet structures that are stabilised by 
conserved cysteine residues. In contrast to this, FXI forms a globular dimeric 
structure, with each monomer comprising four Ap domains and a large SP domain. It 
is interesting that so many mutations are found in FH that do not reduce plasma 
levels by destabilising the structure, whereas those mutations within FXI frequently 
reduce plasma levels.
The Vitamin K dependent serine protease mutation database (Chapter 6) is 
the first study to analyse mutations in the context of what is known about other 
mutations within this family of closely related proteins. This provides useful analysis 
of the patterns of missense mutations and the conservation within conserved regions 
of related proteins and domains. The proposal of a consensus SCR domain structure 
(Figure 5.19) allowed us to analyse the aHUS SCR mutations in the context of other 
SCR mutations and polymorphisms. This work highlighted the functional 
importance of the hypervariable loop within the SCR domain, where Type II 
mutations are clustered. In application to the Vitamin K dependent serine proteases, 
the concept of consensus domains again proved to be of value. The use of a 
consensus Gla domain highlighted the functional importance of all nine conserved 
Gla residues since mutations mapped to all of these positions. The consensus domain 
structures of the EGF_CA and EGF domains (Figure 6.10) highlighted the 
differences between these two domains, where the analysis of mutations suggested 
the EGF_CA domain was of greater functional significance than the EGF domain, 
therefore showing that the two domains should be considered as separate entities. 
This is in contrast to the two Kringle domains, which show strong conservation and
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can be considered as a single entity in terms of a consensus structure. The consensus 
SP domain has confirmed that mutations can be distributed throughout the SP 
domain, and the disruption of structural stability is apparently as important as the 
disruption of catalytic functional residues.
This approach can potentially aid the structural interpretation of SNPs, 
especially where phenotype is strongly conserved at a specific domain position. 
However, this work has also highlighted the variability of mutation outcome, 
suggesting that any method to predict the phenotypic outcome of a SNP must not 
only consider the properties of the residues involved, but also consider structural and 
sequence conservation as well as individual functional activities. Classifying 
mutations, and predicting the phenotypic outcome of SNPs not only aids the 
interpretation of the molecular basis of disease, leading to improved diagnostic 
techniques, but may also lead to clearer clarification of the functional and structural 
roles of specific residues, increasing understanding of domain and protein 
interactions and activities. The prediction of the structural effects of mutations would 
also aid the design of mutagenesis experiments.
The text mining analysis carried out in Chapter 6 provides the first 
application of automatic extraction of disease associated mutations from full length 
publications. This also considers the management of LSDBs, with specific focus on 
the design of a database administration suite that can allow updates and maintenance 
with as little human interpretation as possible, in order to avoid the fate of previous 
LSDBs that are now redundant due to lack of funding (Soussi et al., 2006). Until 
now, there was no available way to collect mutation data and input it into a database, 
without manually extracting it by hand from published manuscripts. The comparison 
between the automatically curated serine protease database and the manually curated 
haemophilia FIX database (http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html) 
highlights the advantages of combing automatic and manual methods together to 
incorporate a wider dataset, while still maintaining accuracy.
Although manual work is still required to maintain the three databases 
described in this thesis, the experience gained in constructing these databases has led 
to the development of automatic methods to reduce this maintenance. These methods 
do not require knowledge of web programming or database design. The main 
limiting factor in automatically extracting mutations is the availability and 
conversion of full text electronic articles; however this will improve in the future as
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more electronic articles become available. Interactive LSDBs such as the FXI 
deficiency database, the FH-HUS database and the Vitamin K dependent serine 
protease database allow mutations to be viewed in the full context of what has been 
previously elucidated for other mutations within the same proteins, or within similar 
homologous protein domains. This provides a means to rapidly analyse new 
mutations and to distinguish between possible disease-causing mutations or neutral 
polymorphisms.
337
References
338
Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka 
C, Jozsi M, Zipfel PF, Hageman GS, Smith RJ. 2006. Variations in the complement 
regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with 
membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 
43:582-589.
Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP. 1991. Contribution of the repeating 
domains of membrane cofactor protein (CD46) of the complement system to ligand 
binding and cofactor activity. J Immunol 147:3005-3011.
Alhaq A, Leach ME, Pepper D, Smith M, Savidge G. 2000. Novel mutations in heterozygous 
factor XI deficiency and hemorrhagic tendency. Blood 96: 80b.
Alhaq A, Mitchell M, Sethi M, Rahman S, Flynn G, Boulton P, Caeno G, Smith M, Savidge G.
1999. Identification of a novel mutation in a non-Jewish factor XI deficient kindred. Br J 
Haematol 104: 44-49.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J 
Mol Biol 215:403-410.
Altschul SF, Koonin EV. 1998. Iterated profile searches with PSI-BLAST - a tool for discovery in 
protein databases. TIBS 23:444-447.
Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, 
Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully 
HF, Tully SP, Walker P, Welsh M, Wurzner R, Zipfel PF. 2005. Membranoproliferative 
glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 
16:1392-403.
Asakai R, Chung DW, Ratnoff OD, Davie EW. 1989. Factor XI (plasma thromboplastin 
antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three 
types of point mutations. PNAS 86:7667-7671.
Aslam M, Guthridge JM, Hack BK, Quigg RJ, Holers VM, Perkins SJ. 2003. The extended 
multidomain solution structures of the complement protein Crry and its chimeric 
conjugate Crry-Ig by scattering, analytical ultracentrifugation and constrained modelling: 
implications for function and therapy. J Mol Biol 329:525-550.
Aslam M, Perkins SJ. 2001. Folded-back solution structure of monomeric factor H of human 
complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation 
and constrained molecular modelling. J Mol Biol 309:1117-1138.
Asakai R, Chung DW, Davie EW, Seligsohn U. 1991. Factor XI deficiency in Ashkenazi Jews in 
Israel. N Engl J Med 325: 153-158.
Asakai R, Chung DW, Ratnoff OD, Davie EW. 1989. Factor XI (plasma thromboplastin 
antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three 
types of point mutations. PNAS 86:7667-7671.
Asakai R, Davie EW, Chung DW. 1987. Organization of the gene for human factor XI. 
Biochemistry 26:7221-8.
339
Au WY, Cheung JW, Lam CC, Kwong YL. 2003. Two factor XI mutations in a Chinese family 
with factor XI deficiency. Am J Hematol 74:136-138.
Ault BH. 2000. Factor H and the pathogenesis of renal diseases. Pediatr Nephrol 14:1045-1053.
Ault BH, Schmidt BZ, Fowler NL, Kashtan CE,. Ahmed AE, Vogt BA, Colten HR. 1997. Human 
factor H deficiency; mutations in framework cysteine residues and block in H protein 
secretion and intracellular catabolism. J Biol Chem 272:25168-25175.
Badellino KO, Walsh PN. 2001. Localization of a heparin binding site in the catalytic domain of 
factor XIa. Biochemistry 40:7569-7580.
Baglia FA, Badellino KO, Ho DH, Dasari VR, Walsh PN. 2000. A binding site for the kringle II 
domain of prothrombin in the apple 1 domain of factor XI. J Biol Chem 275:31954- 
31962.
Baglia FA, Badellino KO, Li CQ, Lopez JA, Walsh PN. 2002. Factor XI binding to the platelet 
glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem 
277:1662-8.
Baglia FA, Gailani D, Lopez JA, Walsh PN. 2004. Identification of a binding site for glycoprotein 
Ibalpha in the Apple 3 domain of factor XI. J Biol Chem 279:45470-45476.
Baglia FA, Jameson BA, Walsh PN. 1990. Localization of the high molecular weight kininogen 
binding site in the heavy chain of human factor XI to amino acids phenylalanine 56 
through serine 86. J Biol Chem 265:4149-4154.
Baglia FA, Jameson BA, Walsh PN. 1991. Identification and chemical synthesis of a substrate- 
binding site for factor IX on coagulation factor XIa. J Biol Chem 266:24190-24197.
Baglia FA, Jameson BA, Walsh PN. 1995. Identification and characterization of a binding site for 
platelets in the Apple 3 domain of coagulation factor XI. J Biol Chem 270:6734-6740.
Baglia FA, Walsh PN. 1996. A binding site for thrombin in the apple 1 domain of factor XI. J Biol 
Chem 271:3652-3658.
Baglia FA, Walsh PN. 2000. Thrombin-mediated feedback activation of factor XI on the activated 
platelet surface is preferred over contact activation by factor Xlla or factor XIa. J Biol 
Chem 275:20514-20519.
Baird TR, Walsh PN. 2003. Factor XI, but not prekallikrein, blocks high molecular weight 
kininogen binding to human umbilical vein endothelial cells. J Biol Chem 278:20618- 
20623.
Baker CJO, Witte R. 2006. Mutation mining-A prospector’s tale. Inf Syst Front 8:47-57.
Baracho GV, Nudelman V, Isaac L. 2003. Molecular characterization of homozygous hereditary 
factor I deficiency. Clin Exp Immunol 131:280-286.
Barlow PN, Norman DG, Steinkasserer A, Home TJ, Pearce J, Driscoll PC, Sim RB, Campbell 
ID. 1992. Solution structure of the fifth repeat of factor H: a second example of the 
complement control protein module. Biochemistry 31:3626-3634.
Barlow PN, Steinkasserer A, Norman DG, Kieffer B, Wiles AP, Sim RB, Campbell ID. 1993. 
Solution structure of a pair of complement modules by nuclear magnetic resonance. J 
Mol Biol 232:268-284.
340
Benedetti E, Morelli G, Nemethy G, Scheraga HA. 1983. Statistical and energetic analysis of side- 
chain conformations in oligopeptides. Int J Pept Protein Res 22:1-15.
Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. 2006. GenBank. Nucleic Acids 
Res 34:D16-20.
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE.
2000. The Protein Data Bank. Nucleic Acids Res 28:235-242.
Berman S, Gewurz H, Mold C. 1986. Binding of C-reactive protein to nucleated cells leads to 
complement activation without cytolysis. J Immunol 136:1354-1359.
Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C. 2000. UMD (Universal mutation 
database): a generic software to build and analyze locus-specific databases. Hum Mutat 
15:86-94.
Betz SF. 1993. Disulfide bonds and the stability of globular proteins. Protein Sci 2:1551-1558.
Blackmore TK, Fischetti VA, Sadlon TA, Ward HM, Gordon DL. 1998. M protein of the group A 
Streptococcus binds to the seventh short consensus repeat of human complement factor 
H. Infect Immun 66:1427-1431.
Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL. 1996. Identification of a heparin 
binding domain in the seventh short consensus repeat of complement factor H. J 
Immunol 157:5422-5427.
Blake CC, Harlos K, Holland SK. 1987. Exon and domain evolution in the proenzymes of blood 
coagulation and fibrinolysis. Cold Spring Harb Symp Quant Biol 52:925-931.
Blaschke C, Valencia A. 2001. The potential use of SUISEKI as a protein interaction discovery 
tool. Genome Inform 12:123-134.
Bodfish P, Wame D, Watkins C, Nyberg K, Spurr NK. 1991. Dinucleotide repeat polymorphism 
in the human coagulation factor XI gene, intron B (FI 1), detected using the polymerase 
chain reaction. Nucleic Acids Res 19:6979.
Bolton-Maggs PH. 1998. The management of factor XI deficiency. Haemophilia 4:683-688.
Bolton-Maggs PH, Butler R, Mountford R, Gailani D. 2003. Eleven novel mutations in non- 
Jewish factor XI deficient kindreds detected by SSCP with heteroduplex analysis 
followed by sequencing. J Thromb Haemost l[Suppl. 1]:P1687.
Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. 1995. Definition of the bleeding 
tendency in factor Xl-deficient kindreds - a clinical and laboratory study. Thromb 
Haemost 73: 194-202.
Bolton-Maggs PH, Butler R, Mountford R. 1999. Eight novel mutations in factor XI deficient 
kindreds in northern europe. Thromb Haemost (suppl): P2542.
Bolton-Maggs PH, Peretz H, Butler R, Mountford R, Keeney S, Zacharski L, Zivelin A, Seligsohn 
U. 2004. A common ancestral mutation (C128X) occurring in 11 non-Jewish families 
from the UK with factor XI deficiency. J Thromb Haemost 2:918-924.
Bonis J, Furlong LI, Sanz F. 2006. OSIRIS: a tool for retrieving literature about sequence variants. 
Bio informatics 22:2567-2569.
341
Bouma B, de Groot PG, van den Elsen JMH, Ravelli RBG, Schouten A, Simmelink MJA, 
Derksen RHWM, Kroon J, Gros P. 1999. Adhesion mechanism of human 
(32-glycoprotein I to phospholipids based on its crystal structure. EMBO J 18:5166-5174.
Bouma BN, Griffin JH. 1977. Human blood coagulation factor XI. Purification, properties, and 
mechanism of activation by activated factor XII. J Biol Chem 252:6432-6437.
Braxton BL, Mullins LS, Raushel FM, Reinhart GD. 1996. Allosteric effects of carbamoyl 
phosphate synthetase from Escherichia coli are entropy-driven. Biochemistry 35:11918- 
11924.
Brown AF, McKie MA. 2000. MuStaR and other software for locus-specific mutation databases. 
Hum Mutat 15:76-85.
Brown PJ, Gill AC, Nugent PG, McVey JH, Tomley FM. 2001. Domains of invasion organelle 
proteins from apicomplexan parasites are homologous with the Apple domains of blood 
coagulation factor XI and plasma pre-kallikrein and are members of the PAN module 
superfamily. FEBS Lett 497: 31-38.
Brown PJ, Mulvey D, Potts JR, Tomley FM, Campbell ID. 2003. Solution structure of a PAN 
module from the apicomplexan parasite Eimeria tenella. J Struct Funct Genomics 4:227- 
234.
Broze GJ Jr. 2001. Protein Z-dependent regulation of coagulation. Thromb Haemost 86:8-13.
Bru C, Courcelle , Carrdre S, Beausse Y, Dalmar S, Kahn D. 2005. The ProDom database of 
protein domain families: more emphasis on 3D. Nucleic Acids Res. 33: D212-D215.
Budayova-Spano M, Lacroix M, Thielens NM, Arlaud GJ, Fontecilla-Camps JC, Gaboriaud C. 
2002. The crystal structure of the zymogen catalytic domain of complement protease Clr 
reveals that a disruptive mechanical stress is required to trigger activation of the Cl 
complex. EMBO J 21:231-239.
Buddies MR, Donne RL, Richards A, Goodship JA, Goodship THJ. 2000. Complement factor H 
gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. 
Am J Hum Genet 66:1721-1722.
Butler MG, Parsons AD. 1990. RFLP for intron E of factor XI gene. Nucleic Acids Res 18:5327.
Caprioli J, Bettinaglio P, Zipfel PF, Amadei B, Daina E, Gamba S, Skerka C, Marziliano N, 
Remuzzi G, Noris M. 2001. The molecular basis of familial hemolytic uremic syndrome: 
Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am 
Soc Nephrol 12:297-307.
Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, 
Daina E, Remuzzi G, Noris M. International Registry of Recurrent and Familial 
HUS/TTP. 2003. Complement factor H mutations and gene polymorphisms in 
haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms 
are strongly associated with the disease. Hum Mol Genet 12:3385-3395.
Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis 
L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, 
Kavanagh D, Atkinson JP, Remuzzi G. 2006. Genetics of HUS: the impact of MCP, CFH
342
and IF mutations on clinical presentation, response to treatment, and outcome. Blood 
108:1267-1279.
Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, 
Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, 
Daley GQ, Lander ES. 1999. Characterization of single-nucleotide polymorphisms in 
coding regions of human genes. Nat Genet 22:231-238.
Carroll MC, Alicot EM, Katzman PJ, Klickstein LB, Smith JA, Fearon DT. 1988. Organization of 
the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and 
C4-binding protein in the RCA locus on human chromosome 1. J Exp Med 167:1271- 
1280.
Casasnovas JM, Larvie M, Stehle T. 1999. Crystal structure of two CD46 domains reveals an 
extended measles virus-binding surface. EMBO J 18:2911-2922.
Castelletti F, Bucchioni S, Brioschi S, Poratti S, Bresin E, Caprioli J, Pianetti G, Remuzzi G, 
Noris M. 2006. Combined mutations in Factor H (CFH) and membrane cofactor protein 
(MCP) in hemolytic uremic syndrome. Mol Immunol 43:122-191.
Chamberlain D, Ullman CG, Perkins SJ. 1998. Possible arrangement of the five domains in human 
complement factor I as determined by a combination of X-ray and neutron scattering and 
homology modeling. Biochemistry 37:13918-13929.
Cheng Q, Sun MF, Kravtsov DV, Aktimur A, Gailani D. 2003. Factor XI apple domains and 
protein dimerization. J Thromb Haemost 1:2340-2347.
Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, Choi Y. 2004. Attempted treatment of 
factor H deficiency by liver transplantation. Pediatr Nephrol 19:454-458.
Chothia C, Lesk AM. 1986. The relation between the divergence of sequence and structure in 
proteins. EMBO J 5:823-826.
Christiansen D, Deleage G, Gerlier D. 2000. Evidence for distinct complement regulatory and 
measles virus binding sites on CD46 SCR2. Eur J Immunol 30:3457-3462.
Claustres M, Horaitis O, Vanevski M, Cotton RG. 2002. Time for a unified system of mutation 
description and reporting: a review of locus-specific mutation databases. Genome Res 
12:680-688.
Colman RW, Scott CF, Pixley RA, de la Cadena RA. 1989. Effect of heparin on the inhibition of 
the contact system enzymes. Ann N Y Acad Sci 556:95-103
Cooper DN, Tuddenham EG. 1994. Molecular genetics of familial venous thrombosis. Br Med 
Bull 50:833-50.
Creighton TE. 1993. Proteins, structures and molecular properties. 2nd ed. New York: W H 
Freeman & Co.
Cuff JA, Clamp ME, Siddiqui AS, Finlay M, Barton GJ. 1998. Jpred: A Consensus Secondary 
Structure Prediction Server. Bioinformatics 14: 892-893.
Cunningham H, Maynard D, Bontcheva K, Tablan V. 2002. GATE: A framework and graphical 
development environment for robust NLP tools and applications. In: Proceedings o f the 
40th Anniversary Meeting of the Association for Computational Linguistics 2002.
343
Cupp-Vickery JR, Poulos TL. 1995. Structure of cytochrome P450eryF involved in erythromycin 
biosynthesis. Nat Struct Biol. 2:144-153.
Dahlback B. 1995. Inherited thrombophilia: resistance to activated protein C as a pathogenic 
factor of venous thromboembolism. Blood 85:607-614.
Dai L, Mitchell M, Carson P, Creagh D, Cutler J, Savidge G, Alhaq A. 2004. Severe factor XI 
deficiency caused by compound heterozygosity. Brit J Haematol 125: 814-820.
Dantzer J, Moad C, Heiland R, Mooney S. 2005. MutDB services: interactive structural analysis 
of mutation data. Nucleic Acids Res 33:W311-W314.
Danziger O, Rivenzon-Segal D, Wolf SG, Horovitz A. 2003. Conversion of the allosteric 
transition of GroEL from concerted to sequential by the single mutation Asp-155 -> Ala. 
PNAS 100:13797-13802.
de Moerloose P, Germanos-Haddad M, Boehlen F, Neerman-Arbez M. 2004. Severe factor XI 
deficiency in a Lebanese family: identification of a novel missense mutation (Trp501Cys) 
in the catalytic domain. Blood Coagul Fibrinolysis 15: 269-272.
Deam S, Uprichard J, Eaton JT, Perkins SJ, Dolan G. 2003. Factor X Leicester: Ile411Phe 
associated with a low antigen level and a disproportionately low functional activity of 
factor X. J Thromb Haemost 1:603-5.
Deguchi H, Takeya H, Gabazza EC, Nishioka J, Suzuki K. 1997. Prothrombin kringle 1 domain 
interacts with factor Va during the assembly of prothrombinase complex. Biochem J 
321:729-735.
Deng H, Bannister TD, Jin L, Babine RE, Quinn J, Nagafuji P, Celatka CA, Lin J, Lazarova TI, 
Rynkiewicz MJ, Bibbins F, Pandey P, Gorga J, Meyers HV, Abdel-Meguid SS, Strickler 
JE. 2006. Synthesis, SAR exploration, and X-ray crystal structures of factor XIa 
inhibitors containing an alpha-ketothiazole arginine. Bioorg Med Chem Lett 16:3049- 
3054.
Devine DV, Rosse WF. 1987. Regulation of the activity of platelet-bound C3 convertase of the 
alternative pathway of complement by platelet factor H. PNAS 84:5873-5877.
Dill KA, Bromberg S, Yue KZ, Fiebig KM, Yee DP, Thomas PD, Chan HS. 1995. Principles of 
protein folding - A perspective from simple exact models. Protein Sci 4:561-602.
DiScipio RG, Daffem PJ, Schraufstatter IU, Sriramarao P. 1998. Human polymorphonuclear 
leukocytes adhere to complement factor H through an interaction that involves 
alphaMbeta2 (CD1 lb/CD18). J Immunol 160:4057-4066.
Dobson C, Sali A, Karplus M. 1998. Protein folding: A perspective from theory and experiment. 
Angew Chem Int Ed 37:868-893.
Dolmer K, Gettins PGW. 2005. Complement-Like Repeats in Proteins of the Complement 
System. In “Structural Biology of the complement system” (eds. Morikis D, Lambris JD) 
pp. 265-189. CRC Press, Boca Raton.
Doolittle RF. 1995. The multiplicity of domains in proteins. Annu Rev Biochem 64:287-314.
Dorfman R, Walsh PN. 2001. Noncovalent interactions of the Apple 4 domain that mediate 
coagulation factor XI homodimerization. J Biol Chem 276:6429-6438.
344
Dorig RE, Marcil A, Chopra A, Richardson CD. 1993. The human CD46 molecule is a receptor 
for measles virus (Edmonston strain). Cell 75:295-305.
Dossenbach-Glaninger A, Krugluger W, Schrattbauer K, Eder S, Hopmeier P. 2001. Severe factor 
XI deficiency caused by compound heterozygosity for the type III mutation and a novel 
insertion in exon 9 (codons 324/325 +G). Br J Haematol 114:875-877.
Dossenbach-Glaninger A, Krugluger W, Hopmeier P. 2002. Hereditary factor XI deficiency: 
Novel and rare mutations and polymorphisms in Austrian patients. J Lab Med 26:219.
Dossenbach-Glaninger A, Hopmeier P. 2003. Hereditary factor XI deficiency: Novel and rare 
mutations in austrian patients Ann Hematol 82 (Sup 1):039.
Dossenbach-Glaninger A, Hopmeier P. 2006. Coagulation factor XI gene analysis in three factor 
XI deficient Austrian patients. Eur J Haematol 76:317-21.
Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, 
Herman Fridman W, Weiss L. 2004. Heterozygous and homozygous factor H 
deficiencies associated with hemolytic uremic syndrome or membranoproliferative 
glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15:787- 
95.
Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, 
Fremeaux-Bacchi V. 2005. Anti-Factor H autoantibodies associated with atypical 
hemolytic uremic syndrome. J Am Soc Nephrol. 16:555-563.
Edey MM, Mead PA, Saunders RE, Perkins SJ, Goodship THJ, KanagasundaramN. 2007. Factor 
H associated haemolytic uraemic syndrome following a diarrhoeal illness. Submitted for 
publication.
Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. 2005. Complement 
factor H polymorphism and age-related macular degeneration. Science 308:421-424.
Eriksson AE, Baase WA, Zhang XJ, Heinz DW, Blaber M, Baldwin EP, Matthews BW. 1992. 
Response of a protein structure to cavity-creating mutations and its relation to the 
hydrophobic effect. Science 255:178-183.
Esparza-Gordillo J, Jorge EG, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P, 
Rodriguez de Cordoba S. 2005. Predisposition to atypical hemolytic uremic syndrome 
involves the concurrence of different susceptibility alleles in the regulators of 
complement activation gene cluster in lq32. Hum Mol Genet 14:703-712.
Esparza-Gordillo J, Jorge EG, Garrido CA, Carreras L, Lopez-Trascasa M, Sanchez-Corral P, de 
Cordoba SR. 2006. Insights into hemolytic uremic syndrome: segregation of three 
independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 
43:1769-1775.
Estaller C, Schwaeble W, Dierich M, Weiss EH. 1991. Human complement factor H: two factor H 
proteins are derived from alternatively spliced transcripts. Eur J Immunol 21:799-802.
Fass D, Blacklow S, Kim PS, Berger JM. 1997. Molecular basis of familial hypercholesterolaemia 
from structure of LDL receptor module. Nature 388:691-693.
345
Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. 2000. Factor H binding to bone 
sialoprotein and osteopontin enables tumor cell evasion o f complement-mediated attack. 
J Biol Chem 275:16666-16672.
Fernando AN, Furtado PB, Clark SJ, Gilbert HE, Day AJ, Sim RB, Perkins SJ 2007. Associative 
and structural properties of the region of complement Factor H encompassing the 
Tyr402His disease-related polymorphism and its interactions with heparin. J Mol B io l, 
doi: 10.1016/j .jmb.2007.02.03 8.
Filler G, Radhakrishnan S, Strain L, Hill A, Knoll G, Goodship TH. 2004. Challenges in the 
management of infantile factor H associated hemolytic uremic syndrome. Pediatr 
Nephrol 19:908-911.
Finn RD, Mistry J, Schuster-Bockler B, Griffiths-Jones S, Hollich V, Lassmann T, Moxon S, 
Marshall M, Khanna A, Durbin R, Eddy SR, Sonnhammer ELL, Bateman B. 2006. Pfam: 
clans, web tools and services. Nucleic Acids Research Database Issue 34:D247-D251.
Fokkema IF, den Dunnen JT, Taschner PE. 2005. LOVD: easy creation of a locus-specific 
sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat 26:63-68.
Fredman D, Siegfried M, Yuan YP, Bork P, Lehvaslaiho H, Brookes AJ. 2002. HGVbase: a 
human sequence variation database emphasizing data quality and a broad spectrum of 
data sources. Nucleic Acids Res 30:387-391.
Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat 
C, Rondeau E, Fridman WH. 2004. Complement factor I: a susceptibility gene for 
atypical haemolytic uraemic syndrome. J Med Genet 41 :e84.
Fremeaux-Bacchi V, Regnier C, Blouin J, Dragon-Durey MA, Fridman WH, Janssen B, Loirat C. 
2006. Protective or aggressive: Paradoxical role of C3 in atypical hemolytic uremic 
syndrome. Mol Immunol 44:172.
Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson PJ, Kawabata S, Huber 
R, Bode W, Bock PE. 2003. Staphylocoagulase is a prototype for the mechanism of 
cofactor-induced zymogen activation. Nature 425:535-539.
Fujikawa K, Chung DW, Hendrickson LE, Davie EW. 1986. Amino acid sequence of human 
factor XI, a blood coagulation factor with four tandem repeats that are highly 
homologous with plasma prekallikrein. Biochemistry 25: 2417-2424.
Furie B, Furie BC. 1992. Molecular and cellular biology of blood coagulation. N Engl J Med 
326:800-6.
Furtado PB, Whitty PW, Robertson A, Eaton JT, Almogren A, Kerr MA, Woof JM, Perkins SJ.
2004. Solution structure determination of monomeric human IgA2 by X-ray and neutron 
scattering, analytical ultracentrifugation and constrained modelling: a comparison with 
monomeric human IgAl. J Mol Biol 338:921-941.
Furtado PB, Huang CY, Ihyembe D, Hammond RA, Marsh HC, Perkins SJ. 2006. The partly- 
folded back solution structure arrangement of the 30 SCR domains in human complement 
receptor type 1 (CR1) indicates inter-SCR flexibility. Abstract Submitted.
346
Ganesh VK, Smith SA, Kotwal GJ, Murthy KH. 2004. Structure of vaccinia complement protein 
in complex with heparin and potential implications for complement regulation. PNAS 
101:8924-8929.
Gailani D,Broze GJ Jr. 1991.Factor XI activation in a revised model of blood coagulation. Science 
253:909-912.
Gailani D, Ho D, Sun MF, Cheng Q, Walsh PN. 2001. Model for a factor IX activation complex 
on blood platelets: dimeric conformation of factor XIa is essential. Blood 97:3117-3122.
Gaizauskas R, Demetriou G, Artymiuk PJ, Willett P. 2003. Protein structures and information 
extraction from biological texts: the PASTA system. Bioinformatics 19:135-143.
Gandrille S, Aiach M. 1995. Identification of mutations in 90 of 121 consecutive symptomatic 
French patients with a type I protein C deficiency. The French INSERM Network on 
Molecular Abnormalities Responsible for Protein C and Protein S deficiencies. Blood 
86:2598-2605.
Garnier J, Gibrat JF, Robson B. 1996. GOR secondary structure prediction method version IV. 
Meth Enzymol 266: 540-553.
Germanos-Haddad M, De Moerloose P, Neerman-Arbez M. 2003. Molecular analysis of factor XI 
deficiency in 8 lebanese families: identification of two novel mutations. J Throm Haem 1 
Suppl :P1207.
Giannakis E, Jokiranta TS, Ormsby RJ, Duthy TG, Male DA, Christiansen D, Fischetti VA, 
Bagley C, Loveland BE, Gordon DL. 2002. Identification of the streptococcal M protein 
binding site on membrane cofactor protein (CD46). J Immunol 168:4585-4592.
Giannakis E, Jokiranta TS, Male DA, Ranganathan S, Ormsby RJ, Fischetti VA, Mold C, Gordon 
DL. 2003. A common site within factor H SCR 7 responsible for binding heparin, C- 
reactive protein and streptococcal M protein. Eur J Immunol 33:962-969.
Gilbert HE, Eaton JT, Hannan JP, Holers VM, Perkins SJ. 2005. Solution structure of the complex 
between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and 
sedimentation modelling study. J Mol Biol 346:859-873.
Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, 
Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S. 2007. Gain- 
of-fimction mutations in complement factor B are associated with atypical hemolytic 
uremic syndrome. PNAS 104:240-245.
Gojobori T, Ikeo K. 1994. Molecular evolution of serine protease and its inhibitor with special 
reference to domain evolution. Philos Trans R Soc Lond B Biol Sci 344:411-415.
Gorelick A, Oglesby T, Rashbaum W, Atkinson J, Buyon JP. 1995. Ontogeny of membrane 
cofactor protein: phenotypic divergence in the fetal heart. Lupus 4:293-296.
Greer J. 1990. Comparative modeling methods: application to the family of the mammalian serine 
proteases. Proteins 7:317-334.
Guigonis V, Fremeaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, Mougenot B, 
Rosenblatt DS, Deschenes G. 2005. Late-onset thrombocytic microangiopathy caused by 
cblC disease: association with a factor H mutation. Am J Kidney Dis 45:588-595.
347
Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, 
Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance 
MA. 2005. Complement factor H variant increases the risk of age-related macular 
degeneration. Science 308:419-421.
Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, 
Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, 
Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, 
Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. 2005. A common 
haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes 
individuals to age-related macular degeneration. PNAS 102:7227-7232.
Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. 2005. Online Mendelian
Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. 
Nucleic Acids Res 33:D514-D517.
Hatskelzon L, Dvilansky A, Holcberg G. 1996. Factor XI deficiency in a Bedouin family. Am J 
Hematol 52:121.
Hayashi T, Satoh S, Suzuki S, Yahagi A, Yoshino M, Sasaki H 1997. Cross-reacting material 
positive (CRM1) factor XI deficiency, XI Yamagata, with a GT to AT transition at donor 
splicing site in intron J of the factor XI gene. Thromb Haemost 78:PS1883.
Heeb MJ, Espana F, Geiger M, Collen D, Stump DC, Griffin JH. 1987. Immunological identity of 
heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator 
inhibitor-3. J Biol Chem 262:15813-15816.
Hellwage J, Jokiranta TS, Friese MA, Wolk TU, Kampen E, Zipfel PF, Meri S. 2002. 
Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding 
sites on the most carboxyl-terminal domain of complement factor H. J Immunol 
169:6935-6944.
Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, Zipfel PF. 1999. Functional properties 
of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of 
C3b and differential regulation by heparin. FEBS Lett 462:345-52.
Hegasy GA, Manuelian T, Hogasen K, Jansen JH Zipfel PF. 2002. The molecular basis for 
hereditary porcine membranoproliferative glomerulonephritis Type II. Point mutations in 
the factor H coding sequence block protein secretion. Am J Pathology 161:2027-2034.
Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, Skerka C, Jokiranta 
TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J, Rodriguez de Cordoba S, 
Zipfel PF, Goodship TH. 2006. De novo gene conversion in the RCA gene cluster (lq32) 
causes mutations in complement factor H associated with atypical hemolytic uremic 
syndrome. Hum Mutat 27:292-293.
Herbert AP, Uhrin D, Lyon M, Pangburn MK, Barlow PN. 2006. Disease-associated sequence 
variations congregate in a polyanion recognition patch on human factor H revealed in 
three-dimensional structure. J Biol Chem 281:16512-16520
348
Higgins D, Thompson J, Gibson T. 1994. CLUSTAL W: improving the sensitivity of progressive 
multiple sequence alignment through sequence weighting, position-specific gap penalties 
and weight matrix choice. Nuc Acids Res 22:4673-4680.
Hill M, McLeod F, Franks H, Gordon B, Dolan G. 2005. Genetic analysis in FXI deficiency: six 
novel mutations and the use of a polymerase chain reaction-based test to define a whole 
gene deletion. Br J Haematol 129:825-829.
Ho DH, Badellino K, Baglia FA, Walsh PN. 1998. A binding site for heparin in the apple 3
domain of factor XI. J Biol Chem 273:16382-16390.
Ho DH, Baglia FA, Walsh PN. 2000. Factor XI binding to activated platelets is mediated by 
residues R(250), K(255), F(260), and Q(263) within the apple 3 domain. Biochemistry 
39:316-323.
Holers VM, COle JL, Lublin D, Seya T , Atkinson JP. 1985. Human C3b- and C4b regulatory 
proteins a new multi-gene family. Immunol today 6: 188-192.
Hohenester E, Sasaki T, Timpl R. 1999. Crystal structure of a scavenger receptor cysteine-rich
domain sheds light on an ancient superfamily. Nat Struct Biol 6:228-232.
Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. 1988. Antiphagocytic activity of 
streptococcal M protein: selective binding of complement control protein factor H. PNAS 
85:1657-1661.
Hourcade D, Holers VM, Atkinson JP. 1989. The regulators of complement activation (RCA) 
gene cluster. Adv Immunol 45:381-416.
Hsu EC, Sabatinos S, Hoedemaeker FJ, Rose DR, Richardson CD. 1999. Use of site-specific 
mutagenesis and monoclonal antibodies to map regions of CD46 that interact with 
measles virus H protein. Virology 258:314-326.
Hsu TC, Shore SK, Seshsmma T, Bagasra O, Walsh PN. 1998. Molecular cloning of platelet 
factor XI, an alternative splicing product of the plasma factor XI gene. J Biol Chem 
273:13787-13793.
Hubbard SJ, Thornton JM. 'NACCESS', Computer Program, Department of Biochemistry and 
Molecular Biology, University College London. 1993.
Huizinga EG, Schouten A, Connolly TM, Kroon J, Sixma JJ, Gros P. 2001. The Structure of 
Leech Anti-Platelet Protein, an Inhibitor of Haemostasis. Acta Crystallogr D57: 1071.
Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW. 1990. Amino acid sequence of 
human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res 
Commun 172:1139-1144.
Iijima K, Udagawa A, Kawasaki H, Murakami F, Shimomura T, Ikawa S. 2000. A factor XI 
deficiency associated with a nonsense mutation (Trp501stop) in the catalytic domain. Br 
J Haematol 111:556-558.
Imanaka Y, Lai K, Nishimura T, Bolton-Maggs PH, Tuddenham EG, McVey JH. 1995. 
Identification of two novel mutations in non-Jewish factor XI deficiency. Br J Haematol 
90: 916-920.
349
Innis CA, Hyvonen M. 2003. Crystal structures of the heparan sulfate-binding domain of 
follistatin. Insights into ligand binding. J Biol Chem 278:39969-39977.
Iwata K, Seya T, Yanagi Y, Pesando JM, Johnson PM, Okabe M, Ueda S, Ariga H, Nagasawa S. 
1995. Diversity of sites for measles virus binding and for inactivation of complement 
C3b and C4b on membrane cofactor protein CD46. J Biol Chem 270:15148-15152.
James HL, Girolami A, Fair DS. 1991. Molecular defect in coagulation factor XFriuli results from 
a substitution of serine for proline at position 343. Blood 77: 317-323.
Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. 1999. Regulation of complement activation 
by C-reactive protein: targeting the complement inhibitory activity of factor H by an 
interaction with short consensus repeat domains 7 and 8-11. J Immunol 163:3957-3962.
Jayandharan G, Shaji RV, Nair SC, Chandy M, Srivastava A. 2005. Novel missense mutations in 
two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with 
combined factor XI and factor IX deficiency (Phe349Val). J Thromb Haemost. 3:808- 
811.
Jin L, Pandey P, Babine RE, Gorga JC, Seidl KJ, Gelfand E, Weaver DT, Abdel-Meguid SS, 
Strickler JE. 2005. Crystal structures of the FXIa catalytic domain in complex with ecotin 
mutants reveal substrate-like interactions. J Biol Chem 280:4704-4712.
Jin L, Pandey P, Babine RE, Weaver DT, Abdel-Meguid SS, Strickler JE. 2005. Mutation of 
surface residues to promote crystallization of activated factor XI as a complex with 
benzamidine: an essential step for the iterative structure-based design of factor XI 
inhibitors. Acta Crystallogr D Biol Crystallogr 61:1418-1425.
Johnstone RW, Loveland BE, McKenzie IF. 1993. Identification and quantification of 
complement regulator CD46 on normal human tissues. Immunology 79:341-347.
Jokiranta TS, Cheng ZZ, Seeberger H, Jozsi M, Heinen S, Noris M, Remuzzi G, Ormsby R, 
Gordon DL, Meri S, Hellwage J, Zipfel PF. 2005. Binding of complement factor H to 
endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. 
Am J Pathol 167:1173-1181.
Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. 2000. Each of the three binding sites on 
complement factor H interacts with a distinct site on C3b. J Biol Chem 275:27657-62.
Jokiranta TS, Jaakola VP, Lehtinen MJ, Parepalo M, Meri S, Goldman A. 2006. Structure of 
complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic 
uremic syndrome. EMBO J 25:1784-1794.
Jones TA, Zou JY, Cowan SW, Kjeldgaard. 1991. Improved methods for building protein models 
in electron density maps and the location of errors in these models. Acta Crystallogr 47: 
110-119.
Jozsi M, Heinen S, Hartmann A, Ostrowicz CW, Halbich S, Richter H, Kunert A, Licht C, 
Saunders RE, Perkins SJ, Zipfel PF, Skerka C. 2006. Factor H and atypical hemolytic 
uremic syndrome: mutations in the C-terminus cause structural changes and defective 
recognition functions. J Am Soc Nephrol 17:170-177.
350
Kabsch W, Sander C. 1983. Dictionary of protein secondary structure: pattern recognition of 
hydrogen-bonded and geometrical features. Biopolymers 22:2577-2637.
Karplus K, Barrett C, Cline M, Diekhans M, Grate L, Hughey R. 1999. Predicting Protein 
Structure using Only Sequence Information. Proteins Suppl. 3: 121-125.
Karplus K, Barrett C, Hughey R. 2004. Hidden Markov Models for Detecting Remote Protein 
Homologies. Bioinformatics 14: 846-856.
Karplus K, Sjolander K, Barrett C, Cline M, Haussler D, Hughey R, Holm L, Sander C. 1997. 
Predicting Protein Structure Using Hidden Markov Models. Proteins Suppl 1:134-139.
Karpman D, Manea M, Vaziri-Sani F, Stahl AL, Kristoffersson AC. 2006. Platelet activation in 
hemolytic uremic syndrome. Semin Thromb Hemost 32:128-145.
Kawaguchi T, Koga S, Hongo H, Komiyama Y, Li K, Ishihara S, Horikawa K, Hidaka M, 
Mitsuya H, Nakakuma H. 2000. A novel type of factor XI deficiency showing compound 
genetic abnormalities: a nonsense mutation and an impaired transcription. Int J Hematol 
71:84-89.
Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, 
Goodship JA, Goodship TH. 2003. Mutations in complement factor I predispose to 
development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:2150-2155.
Kim DD, Song WC. 2006. Membrane complement regulatory proteins. Clin Immunol 118:127- 
136.
Kirkitadze MD, Barlow PN. 2001. Structure and flexibility of the multiple domain proteins that 
regulate complement activation. Immunol Rev 180:146-61.
Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, Sangiovanni JP, Mane 
SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. 2005. Complement 
factor H polymorphism in age-related macular degeneration. Science 308:385-389.
Koistinen V. 1992. Limited tryptic cleavage of complement factor H abrogates recognition of 
sialic acid-containing surfaces by the alternative pathway of complement. Biochem J 
283:317-319.
Koistinen V. 1993. Effects of sulphated polyanions on functions of complement factor H. Mol 
Immunol 30:113-118.
Kotarsky H, Hellwage J, Johnsson E, Skerka C, Svensson HG, Lindahl G, Sjobring U, Zipfel PF.
1998. Identification of a domain in human factor H and factor H-like protein-1 required 
for the interaction with streptococcal M proteins. J Immunol 160:3349-3354.
Kraiczy P, Hellwage J, Skerka C, Kirschfink M, Brade V, Zipfel PF, Wallich R. 2003. Immune 
evasion of Borrelia burgdorferi: mapping of a complement-inhibitor factor H-binding site 
of BbCRASP-3, a novel member of the Erp protein family. Eur J Immunol 33:697-707.
Kraulis PJ. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of 
protein structures. J Appl Cryst 24:946-950.
Kravtsov DV, Monahan PE, Gailani D. 2005. A classification system for cross-reactive material- 
negative factor XI deficiency. Blood 105:4671-4673.
351
Kravtsov D, Wu W, Meijers JCM, Sun M-F, Blinder MA, Dang TP, Wang H, Gailani D. 2004. 
Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. 
Blood 102: 128-134.
Krawczak M, Ball EV, Fenton I, Stenson PD, Abeysinghe S, Thomas N, Cooper DN. 2000. 
Human gene mutation database-a biomedical information and research resource. Hum 
Mutat 15:45-51.
Kunkel TA. 2004. DNA replication fidelity. J Biol Chem 279:16895-16898.
Laskowski RA, Hutchinson EG, Michie AD, Wallace AC, Jones ML, Thornton JM. 1997. 
PDBsum: a Web-based database of summaries and analyses of all PDB structures. Trends 
Biochem Sci 22:488-490.
Laskowski RA, Mac Arthur MW, Moss DS, Thornton JM. 1993. PROCHECK: a program to check 
the stereochemical quality of protein structures. J Appl Cryst 26:283-291.
Law SKA, Reid KBM. 1995. Complement (Second edition), IRL Press, Oxford.
Lazarova TI, Jin L, Rynkiewicz M, Gorga JC, Bibbins F, Meyers HV, Babine R, Strickler J. 2006. 
Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of 
factor XIa. Bioorg Med Chem Lett 16:5022-5027.
Lee B, Richards FM. 1971. The interpretation of protein structures: estimation of static 
accessibility. J Mol Biol 55:379-400.
Lee LC, Horn F, Cohen FE. 2007. Automatic Extraction of Protein Point Mutations Using a Graph 
Bigram Association. PLoS Comput Biol 2007 3:el6
Lesk AM, Chothia C. 1982. Evolution of proteins formed by beta-sheets. II. The core of the 
immunoglobulin domains. J Mol Biol 160:325-342.
Letunic I, Copley RR, Schmidt S, Ciccarelli FD, Doerks T, Schultz J, Ponting CP, Bork P. 2004. 
SMART 4.0: towards genomic data integration. Nucleic Acids Res 32(Database 
issue):D142-D144.
Levinthal C.1968. Are there pathways for protein folding? J Chim Phys 65:44-45.
Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, 
Kirschfink M, Hoppe B, Zipfel PF. 2006. Deletion of Lys224 in regulatory domain 4 of 
Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney 
Int 70:42-50.
Lin PJ, Jin DY, Tie JK, Presnell SR, Straight DL, Stafford DW. 2002. The putative vitamin K- 
dependent gamma-glutamyl carboxylase internal propeptide appears to be the propeptide 
binding site. J Biol Chem 277:28584-28591.
Liszewski MK, Atkinson JP. 1996. Membrane cofactor protein (MCP; CD46). Isoforms differ in 
protection against the classical pathway of complement. J Immunol 156:4415-21.
Liszewski MK, Kemper C, Price JD, Atkinson JP. 2005. Emerging roles and new functions of 
CD46. Springer Semin Immunopathol 27:345-358.
Liszewski MK, Leung MK, Atkinson JP. 1998. Membrane cofactor protein: importance of N- 
and O-glycosylation for complement regulatory function. J Immunol 161:3711-3718.
352
Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, Barlow PN, Manchester M, 
Atkinson JP. 2000. Dissecting sites important for complement regulatory activity in 
membrane cofactor protein (MCP; CD46). J Biol Chem 275:37692-37701.
Liszewski MK, Post TW, Atkinson JP. 1991. Membrane cofactor protein (MCP or CD46): newest 
member of the regulators of complement activation gene cluster. Annu Rev Immunol 
9:431-455.
Lublin DM, Liszewski MK, Post TW, Arce MA, Le Beau MM, Rebentisch MB, Lemons LS, Seya 
T, Atkinson JP. 1988. Molecular cloning and chromosomal localization of human 
membrane cofactor protein (MCP). Evidence for inclusion in the multigene family of 
complement-regulatory proteins. J Exp Med 168:181-194.
Maisner A, Liszewski MK, Atkinson JP, Schwartz-Albiez R, Herrler G. 1996. Two different 
cytoplasmic tails direct isoforms of the membrane cofactor protein (CD46) to the 
basolateral surface of Madin-Darby canine kidney cells. J Biol Chem 271:18853-18858.
Male DA, Ormsby RJ, Ranganathan S, Giannakis E, Gordon DL. 2000. Complement factor H: 
sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and 
fHR-3 genes. Mol Immunol 37:41-52.
Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi 
G, Zipfel PF. 2003. Mutations in factor H reduce binding affinity to C3b and heparin and 
surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 
111:1181-1190.
Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B. 2002. Linking innate 
and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced 
inflammation. Nat Immunol 3:659-666.
Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, Thornton JM.
2002. Integrating mutation data and structural analysis of the TP53 tumor-suppressor 
protein. Hum Mutat 19:149-164.
Martin AC, MacArthur MW, Thornton JM. 1997. Assessment of comparative modeling in 
CASP2. Proteins. Suppl 1:14-28.
Martincic D, Zimmerman SA, Ware RE, Sun MF, Whitlock JA, Gailani D. 1998. Identification of 
mutations and polymorphisms in the factor XI genes of an African American family by 
dideoxyfmgerprinting. Blood 92: 3309-3317.
Mathonnet F, Miri N, Maouel S, Boucly C, Mathieu B, Van Amerongen G, de Mazancourt 
P. 1999. E296K substitution in factor XI deficiency. Thromb Haemost (suppl):P1078.
McGufFin LJ, Bryson K, Jones DT. 2000. The PSIPRED protein structure prediction server. 
Bioinformatics 16: 404-405.
McKusick, V.A.: Mendelian Inheritance in Man. Baltimore: Johns Hopkins University Press, 1998 
(12th edition).
McMullen BA, Fujikawa K, Davie EW. 1991. Location of the disulfide bonds in human 
coagulation factor XI: the presence of tandem apple domains. Biochemistry 30:2056- 
2060.
353
McVey JH, Lai K, Imanaka Y, Kemball-Cook G, Bolton-Maggs PH, Tuddenham EG. 2005. 
Characterisation of blood coagulation factor XIT475I. Thromb Haemost 93:1082-1088.
Meijers JC, Davie EW, Chung DW. 1992. Expression of human blood coagulation factor XI: 
characterization of the defect in factor XI type III deficiency. Blood 79:1435-1440.
Meijers JC, McMullen BA, Bouma BN. 1992. The contact activation proteins: a structure/function 
overview. Agents Actions Suppl 38:219-230.
Merali Z, Giles J. 2005. Databases in peril. Nature 435:1010-1011.
Merritt EA, Murphy MEP. 1994. Raster3D version 2.0. A program for photorealistic molecular 
graphics. Acta Cryst D50:869-873.
Mitchell M, Cutler J, Thompson S, Moore G, Jenkins Ap Rees E, Smith M, Savidge G, Alhaq A.
1999. Heterozygous factor XI deficiency associated with three novel mutations. Br J 
Haematol 107:763-765.
Mitchell M, Harrington P, Cutler J, Rangarajan S, Savidge G, Alhaq A. 2003. Eighteen unrelated 
patients with factor XI deficiency, four novel mutations and a 100% detection rate by 
denaturing high-performance liquid chromatography. Br J Haematol 121: 500-502.
Mitchell M, Mountford R, Butler R, Alhaq A, Dai L, Savidge G, Bolton-Maggs PH. 2006. 
Spectrum of factor XI (FI 1) mutations in the UK population—116 index cases and 140 
mutations. Hum Mutat 27:829.
Mollnes TE, Kirschfink M. 2006. Strategies of therapeutic complement inhibition. Mol Immunol 
43:107-121.
Montelione GT, Wuthrich K, Burgess AW, Nice EC, Wagner G, Gibson KD, Scheraga HA. 1992. 
Solution structure of murine epidermal growth factor determined by NMR spectroscopy 
and refined by energy minimization with restraints. Biochemistry 31:236-249.
Montelione GT, Wuthrich K, Nice EC, Burgess AW, Scheraga. 1987. Solution structure of murine 
epidermal growth factor: determination of the polypeptide backbone chain-fold by 
nuclear magnetic resonance and distance geometry. PNAS 84:5226-5230.
Morgenstern B, Freeh K, Dress A, Werner T. 1998. DIALIGN: finding local similarities by 
multiple sequence alignment. Bioinformatics 14:290-294.
Morishita E, Kuroda K, Ohtake S, Ontachi Y, Mizutani T, Yamazaki M, Asakura H, Nakao S.
2003. Three novel point mutations that cause severe factor XI deficiency in two unrelated 
Japanese families. J Thromb Haemost 1 [Suppl. 1 ] :P 1211.
Morley BJ, Bartok I, Spath PJ, Vyse TJ, Schneider PM, Walport MJ. 1998. Molecular basis of 
hereditary factor I deficiency. Mol Immunol 35:344.
Morley BJ, Campbell RD. 1984. Internal homologies of the Ba fragment from human 
complement component Factor B, a class III MHC antigen. EMBO J 3:153-7.
Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Bateman A, Binns D, Bradley P, Bork P, 
Bucher P, Cerutti L, Copley R, Courcelle E, Das U, Durbin R, Fleischmann W, Gough J, 
Haft D, Harte N, Hulo N, Kahn D, Kanapin A, Krestyaninova M, Lonsdale D, Lopez R, 
Letunic I, Madera M, Maslen J, McDowall J, Mitchell A, Nikolskaya AN, Orchard S, 
Pagni M, Ponting CP, Quevillon E, Selengut J, Sigrist CJ, Silventoinen V, Studholme DJ,
354
Vaughan R, Wu CH. 2005. InterPro, progress and status in 2005. Nucleic Acids Res. 33 
(Database Issue):D201-5.
Mulloy B, Forster MJ, Jones C, Davies DB. 1993. NMR and molecular modelling studies of the 
solution conformation of heparin. Biochem J 293:849-858.
Murphy B, Georgiou T, Machet D, Hill P, McRae J. 2002. Factor H-related protein-5: a novel 
component of human glomerular immune deposits. Am J Kidney Dis 39:24-27.
Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of Macromolecular Structures by the 
Maximum-Likelihood Method. Acta Cryst D53: 240-255.
Murthy KH, Smith SA, Ganesh VK, Judge KW, Mullin N, Barlow PN, Ogata CM, Kotwal GJ.
2001. Crystal structure of a complement control protein that regulates both pathways of 
complement activation and binds heparan sulfate proteoglycans. Cell 104:301-311.
Murzin AG, Brenner SE, Hubbard T, Chothia C. 1995. SCOP: a structural classification of 
proteins database for the investigation of sequences and structures. J Mol Biol 247:536- 
540.
Nagar B, Jones RG, Diefenbach RJ, Isenman DE, Rini JM. 1998. X-ray crystal structure of C3d: a 
C3 fragment and ligand for complement receptor 2. Science 280:1277-1281.
Naito K, Fujikawa K. 1991. Activation of human blood coagulation factor XI independent of 
factor XII. Factor XI is activated by thrombin and factor XIa in the presence of 
negatively charged surfaces. J Biol Chem 266:7353-7358.
Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D. 
1993. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles 
virus. J Virol 67:6025-6032.
Navaneetham D, Jin L, Pandey P, Strickler JE, Babine RE, Abdel-Meguid SS, Walsh PN. 2005. 
Structural and mutational analyses of the molecular interactions between the catalytic 
domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2. J Biol 
Chem. 280:36165-36175.
Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, 
Cybulla M, Riegler P, Konigsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke 
G, Zipfel PF. 2003. Haemolytic uraemic syndrome and mutations of the factor H gene: a 
registry-based study of German speaking countries. J Med Genet 40:676-681.
Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. 2000. Mechanism of rescue of 
common p53 cancer mutations by second-site suppressor mutations. EMBO J. 19:370- 
378.
Nillson UR, Mueller-Eberhard HJ. 1965. Isolation of Beta IF-Globulin from Human Serum and its 
Characterization as the fifth component of complement. J Exp Med 122:277-298.
Nitu-Whalley IC, Riddell A, Lee CA, Pasi KJ, Owens D, Enayat MS, Perkins SJ, Jenkins PV.
2000. Identification of type 2 von Willebrand disease in previously diagnosed type 1 
patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb 
Haemost. 84:998-1004.
355
Noris M, Brioschi S, Caprioli J, Todeschini M, Bresin E, Porrati F, Gamba S, Remuzzi G. 2003. 
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362:1542-1547.
Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, 
Scheiflinger F, Remuzzi G. 2005. International Registry of Recurrent and Familial 
HUS/TTP. Complement factor H mutation in familial thrombotic thrombocytopenic 
purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 
16:1177-1183.
O’Connell NM, Saunders RE, Lee CA, Perry DJ, Perkins SJ. 2005. Structural interpretation of 42 
mutations causing factor XI deficiency using homology modelling. J Thromb Haemost 
3:127-138.
Oglesby TJ, Allen CJ, Liszewski MK, White DJ, Atkinson JP. 1992. Membrane cofactor protein 
(CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J 
Exp Med 175:1547-1551.
Olson ST, Bjork I, Shore JD. 1993. Kinetic characterization of heparin-catalyzed and uncatalyzed 
inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 222:525- 
559.
Oppermann M, Manuelian T, Jozsi M, Brandt E, Jokiranta TS, Heinen S, Meri S, Skerka C, Gotze 
O, Zipfel PF. 2006. The C-terminus of complement regulator Factor H mediates target 
recognition: evidence for a compact conformation of the native protein. Clin Exp 
Immunol 144:342-352.
Orengo CA, Jones DT, Thornton JM. 2003. Bioinformatics. Genes, Proteins and Computers. IRL 
BIOS Scientific Publishers, Oxford.
Orengo CA, Michie AD, Jones S, Jones DT, Swindells MB, Thornton JM. 1997. CATH-a 
hierarchic classification of protein domain structures. Structure 5:1093-1108.
Ormsby RJ, Jokiranta TS, Duthy TG, Griggs KM, Sadlon TA, Giannakis E, Gordon DL. 2006. 
Localization of the third heparin-binding site in the human complement regulator factor 
HI. Mol Immunol 43:1624-1632.
Osterud B, Rapaport SI. 1977. Activation of factor IX by the reaction product of tissue factor and 
factor VII: additional pathway for initiating blood coagulation. PNAS 74:5260-5264.
Pan LC, Price PA. 1985. The propeptide of rat bone gamma-carboxyglutamic acid protein shares 
homology with other vitamin K-dependent protein precursors. PNAS 82: 6109-6113.
Pangbum MK. 2000. Host recognition and target differentiation by factor H, a regulator of the 
alternative pathway of complement. Immunopharm 49:149-157.
Pangburn MK. 2002. Cutting edge: localization of the host recognition functions of complement 
factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J 
Immunol 169:4702-4706.
Pangbum MK, Atkinson MAL, Meri S. 1991. Localization of the heparin-binding site on 
complement factor H. J Biol Chem 266:16847-16853.
Papagrigoriou E, McEwan PA, Walsh PN, Emsley J. 2006. Crystal structure of the factor XI 
zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 13:557-558.
356
Patthy L, Trexler M, Vali Z, Banyai L, Varadi A. 1984. Kringles: modules specialized for protein 
binding. Homology of the gelatin-binding region o f fibronectin with the kringle 
structures of proteases. FEBS Lett 171:131-136.
Pauling L, Corey RB. 1951. The pleated sheet, a new layer configuration of polypeptide chains. 
PNAS 37:251-256.
Pauling L, Corey RB, Branson HR. 1951. The structure of proteins; two hydrogen-bonded helical 
configurations of the polypeptide chain. PNAS 37:205-211.
Pearson WR, Lipman DJ. 1988. Improved tools for biological sequence comparison. PNAS 
85:2444-2448.
Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, Sommerhoff CP, Bode 
W. 1998. Human beta-tryptase is a ring-like tetramer with active sites facing a central 
pore. Nature 392:306-311.
Peretz H, Zivelin A, Usher S, Seligsohn U. 1996. A 14-bp deletion (codon 554 del 
AAGgtaacagagtg) at exon 14/intron N junction of the coagulation factor XI gene disrupts 
splicing and causes severe factor XI deficiency. Hum Mutat 8:77-78.
Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, Vera M, Lopez-Trascasa M, Rodriguez de 
C6rdoba S, S&nchez-Corral P. 2001. Clustering of missense mutations in the C-terminal 
region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 68:478-484.
Perkins SJ, Haris PI, Sim RB, Chapman D. 1988. A study of the structure of human complement 
component Factor H by Fourier transform infrared spectroscopy and secondary structure 
averaging methods. Biochemistry 27:4004-4012.
Perkins SJ, Goodship THJ. 2002. Molecular modelling of mutations in the C-terminal domains of 
factor H of human complement: a new insight into haemolytic uraemic syndrome. J Mol 
Biol 316:217-224.
Perkins SJ, Nealis AS, Sim RB. 1991. Oligomeric domain structure of human complement factor 
H by X-ray and neutron solution scattering. Biochemistry 30:2847-2857.
Peyvandi F, Jenkins PV, Mannucci PM, Billio A, Zeinali S, Perkins SJ, Perry DJ. 2000. 
Molecular characterisation and three-dimensional structural analysis o f  mutations in 21 
unrelated families with inherited factor VII deficiency. Thromb Haemost 84: 250-257.
Perkins SJ, Sim RB. 1986. Molecular modelling of human complement component C3 and its 
fragments by solution scattering. Eur J Biochem 157:155-168.
Peyvandi F, Mannucci PM. 1999. Rare coagulation disorders. Thromb Haemost 82:1207-1214.
Peyvandi F, Menegatti M, Santagostino E, Akhavan S, Uprichard J, Perry DJ, Perkins SJ, 
Mannucci PM. 2002. Gene mutations and three-dimensional structural analysis in 13 
families with severe factor X deficiency. Br J Haematol. 117:685-692.
Polley MJ, Nachman RL. 1979. Human complement in thrombin-mediated platelet function: 
uptake ofthe C5b-9 complex. J Exp Med 150:633-645.
Ponder JW, Richards FM. 1987. Tertiary templates for proteins. Use of packing criteria in the 
enumeration of allowed sequences for different structural classes. J Mol Biol 193:775- 
791.
357
Post TW, Liszewski MK, Adams EM, Tedja I, Miller EA, Atkinson JP. 1991. Membrane cofactor 
protein of the complement system: alternative splicing of serine/threonine/proline-rich 
exons and cytoplasmic tails produces multiple isoforms that correlate with protein 
phenotype. J Exp Med 174:93-102.
Pruitt KD, Tatusova T, Maglott DR. 2005. NCBI Reference Sequence (RefSeq): a curated non- 
redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 
33:D501-D504.
Ptitsyn OB. 1996. How molten is the molten globule? Nat Struct Biol 3:488-490.
Pugh RE, McVey JH, Tuddenham EG, Hancock JF. 1995. Six point mutations that cause factor XI 
deficiency. Blood 85: 1509-1516.
Purcell DF, Russell SM, Deacon NJ, Brown MA, Hooker DJ, McKenzie IF. 1991. Alternatively 
spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement 
activation. Immunogenetics 33:335-344.
Quelin F, Francois D, d'Oiron R, Guillet B, de Raucourt E, de Mazancourt P. 2005. Factor XI 
deficiency: identification of six novel missense mutations (P23L, P69T, C92G, E243D, 
W497C and E547K). Haematologica 90:1149-1150.
Quelin F, Mathonnet F, Potentini-Esnault C, Trigui N, Peynet J, Bastenaire B, Guillon L, Bigel 
ML, Sauger A, Mazurier C, de Mazancourt P. 2006. Identification of five novel 
mutations in the factor XI gene (FI 1) of patients with factor XI deficiency. Blood Coagul 
Fibrinolysis 17:69-73.
Quelin F, Trossaert M, Sigaud M, Mazancourt PDE, Fressinaud E. 2004. Molecular basis of 
severe factor XI deficiency in seven families from the west of France. Seven novel 
mutations, including an ancient Q88X mutation. J Thromb Haemost 2:71-76.
Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. 1993. Dental extractions in 
patients with bleeding disorders. The use of fibrin glue. Oral Surg Oral Med Oral Pathol 
75:280-282.
Ram S, Sharma AK, Simpson SD, Gulati S, McQuillen DP, Pangburn MK, Rice PA. 1998. A 
novel sialic acid binding site on factor H mediates serum resistance of sialylated 
Neisseria gonorrhoeae. J Exp Med 187:743-752.
Rebholz-Schuhmann D, Marcel S, Albert S, Tolle R, Casari G, Kirsch H. 2004. Automatic 
extraction of mutations from Medline and cross-validation with OMIM. Nucleic Acids 
Res 32:135-142.
Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, Gridelli B. 2002. 
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. 
Lancet 359:1671-1672.
Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P, Bucchioni S, 
Sonzogni A, Bonanomi E, Sonzogni V, Platt JL, Perico N, Noris M. 2005. Hemolytic 
uremic syndrome: a fatal outcome after kidney and liver transplantation performed to 
correct factor h gene mutation. Am J Transplant. 5:1146-1150.
358
Renne T, Dedio J, David G, Muller-Esterl W. 2000. High molecular weight kininogen utilizes 
heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 
275:33688-33696.
Renne T, Gailani D, Meijers JG, Muller-Esterl W. 2001. Characterization of the H-kininogen- 
binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol 
Chem 277:4892-4899.
Richards A, Buddies MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship 
JA, Goodship THJ. 2001. Factor H mutations in hemolytic uremic syndrome cluster in 
exons 18-20, a domain important for host cell recognition. Am J Hum Genet 68:485-490.
Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, 
Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. 2003. Mutations in 
human complement regulator, membrane cofactor protein (CD46), predispose to 
development of familial hemolytic uremic syndrome. PNAS 100:12966-12971.
Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP. 2004. CD46: expanding 
beyond complement regulation. Trends Immunol 25:496-503.
Riley-Vargas RC, Lanzendorf S, Atkinson JP.2005. Targeted and restricted complement activation 
on acrosome-reacted spermatozoa. J Clin Invest 115:1241 -1249.
Ritchie GE, Moffatt BE, Sim RB, Morgan BP, Dwek RA, Rudd PM. 2002. Glycosylation and the 
complement system. Chem Rev 102:305-20-19.
Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, 
Sanchez-Corral P. 2004. The human complement factor H: functional roles, genetic 
variations and disease associations. Mol Immunol 41:355-367.
Rost B, Sander C. 1993. Prediction of protein secondary structure at better than 70% accuracy. J 
Mol Biol 232: 584-599.
Russell SM, Sparrow RL, McKenzie IF, Purcell DF. 1992. Tissue-specific and allelic expression 
of the complement regulator CD46 is controlled by alternative splicing. Eur J Immunol 
22:1513-1518.
Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, 
Goodship TH. 2006. Favorable long-term outcome after liver-kidney transplant for 
recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J 
Transplant 6:1948-1952.
Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. J 
Mol Biol 234:779-815.
Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, Steinberg DM, Rosove 
MH, O'Connell N, Lee CA, Seligsohn U. 2003. Prevalence, causes, and characterization 
of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 101:4783- 
4788.
Sanchez-Corral P, Bellavia D, Amico L, Brai M, Rodriguez de Cordoba S. 2000. Molecular basis 
for factor H and FHL-1 deficiency in an Italian family. Immunogenetics 51:366-369.
359
Sanchez-Corral P, Perez-Caballero D, Huarte O, Simckes AM, Goicoechea E, Lopez-Trascasa M, 
de Cordoba SR. 2002. Structural and functional characterization of factor H mutations 
associated with atypical hemolytic uremic syndrome. Am J Hum Genet 71:1285-1295.
Sato E, Kawamata N, Kato A, Oshimi K. 2000. A novel mutation that leads to a congenital factor 
XI deficiency in a Japanese family. Am J Hematol 63:165-169.
Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, 
Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez de Cordoba S, 
Sanchez-Corral P, Skerka C, Zipfel PF, Perkins SJ. 2007. The interactive Factor H- 
atypical hemolytic uremic syndrome mutation database and website: update and 
integration of membrane cofactor protein and Factor I mutations with structural models. 
Hum Mutat 28:222-234.
Saunders REj Goodship TH, Zipfel PF, Perkins SJ. 2006. An interactive web database of factor H- 
associated hemolytic uremic syndrome mutations: insights into the structural 
consequences of disease-associated mutations. Hum Mutat 27:21-30.
Saunders RE, O'Connell NM, Lee CA, Perry DJ, Perkins SJ. 2005. Factor XI deficiency database: 
an interactive web database of mutations, phenotypes, and structural analysis tools. Hum 
Mutat 26:192-198.
Sayle RA, Milner-White EJ. 1995. RASMOL: biomolecular graphics for all. Trends Biochem Sci 
20:374.
Schlott B, Wohnert J, Icke C, Hartmann M, Ramachandran R, Guhrs KH, Glusa E, Flemming J, 
Gorlach M, Grosse F, Ohlenschlager O. 2002. Interaction of Kazal-type inhibitor 
domains with serine proteinases: biochemical and structural studies. J Mol Biol 318:533- 
546.
Schiffman S, Yeh CH. 1990. Purification and characterization of platelet factor XI. Thromb Res 
60:87-97.
Schmidt A, Ogawa T, Gailani D, Bajaj SP. 2004. Structural role of Glyl93 in serine proteases: 
Investigations of a Gly555Glu (Glyl93 in chymotrypsin) mutant of blood coagulation 
factor XI. J Biol Chem 279: 29485-29492.
Scriver CR, Nowacki PM, Lehvaslaiho H. 1999. Guidelines and recommendations for content, 
structure, and deployment of mutation databases. Hum Mutat 13:344-350.
Seaman FS, Baglia FA, Gurr JA, Jameson BA, Walsh PN. 1994. Binding of high-molecular-mass 
kininogen to the Apple 1 domain of factor XI is mediated in part by Val64 and Ile77. 
Biochem J 304:715-721.
Sejima H, Hayashi T, Deyashiki Y, Nishioka J, Suzuki K. 1990. Primary structure of vitamin In­
dependent human protein Z. Biochem Biophys Res Commun 171:661-668.
Seligsohn U. 1978. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 
51:1223-1228.
Seya T, Hara T, Iwata K, Kuriyama S, Hasegawa T, Nagase Y, Miyagawa S, Matsumoto M, 
Hatanaka M, Atkinson JP, et al. 1995. Purification and functional properties of soluble
360
forms of membrane cofactor protein (CD46) of complement: identification of forms 
increased in cancer patients' sera. Int Immunol 7:727-736.
Seya T, Hirano A, Matsumoto M, Nomura M, Ueda S. 1999. Human membrane cofactor protein 
(MCP, CD46): multiple isoforms and functions. Int J Biochem Cell Biol 31:1255-1260.
Seya T, Turner JR, Atkinson JP. 1986. Purification and characterization of a membrane protein 
(gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med. 163:837-855.
Sharma AK, Pangbum MK. 1997. Localization by site-directed mutagenesis of the site in human 
complement factor H that binds to Streptococcus pyogenes M protein. Infect Immun 
65:484-487.
Shenkin PS, Yarmush DL, Fine RM, Wang HJ, Levinthal C. 1987. Predicting antibody 
hypervariable loop conformation. I. Ensembles of random conformations for ringlike 
structures. Biopolymers 26:2053-2085.
Sherry ST, Ward M, Sirotkin K. 1999. dbSNP-database for single nucleotide polymorphisms and 
other classes of minor genetic variation. Genome Res 9:677-679.
Shia S, Stamos J, Kirchhofer D, Fan B., Wu J., Corpuz RT, Santell L, Lazarus RA, Eigenbrot C.
2005. Conformational lability in serine protease active sites: Structures of hepatocyte 
growth factor activator (HGFA) alone and with the inhibitory domain from HGFA 
inhibitor-1 B. J Mol Biol 346:1335-1349.
Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, Stern C, Weiss E, Seligsohn U. 
1995. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews 
(type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. 
Blood 85: 429-432.
Sibanda BL, Thornton JM. 1985. Beta-hairpin families in globular proteins. Nature 316:170-174.
Soames CJ, Sim RB. 1997. Interactions between human complement components factor H, factor 
I and C3b. Biochem J 326:553-561.
Soares DC, Barlow PN. 2005. Complement control protein modules in the regulators of 
complement activation. In “Structural Biology of the complement system” (eds. Morikis 
D, Lambris JD) pp. 19-62. CRC Press, Boca Raton.
Soares DC, Gerloff DL, Syme NR, Coulson AF, Parkinson J, Barlow PN. 2005. Large-scale 
modelling as a route to multiple surface comparisons of the CCP module family. Protein 
EngDes Sel 18:379-388.
Sofi F, Cesari F, Fedi S, Abbate R, Gensini GF. 2004. Protein Z: "light and shade" of a new 
thrombotic factor. Clin Lab 50:647-652.
Solda G, Asselta R, Ghiotto R, Tenchini ML, Castaman G, Duga S. 2005. A type II mutation 
(Glull7stop), induction of allele-specific mRNA degradation and factor XI deficiency. 
Haematologica 90:1716-1718.
Soussi T, Kato S, Levy PP, Ishioka C. 2005. Reassessment of the TP53 mutation database in 
human disease by data mining with a library of TP53 missense mutations. Hum Mutat 
25:6-17.
361
Soussi T, Ishioka C, Claustres M, Beroud C. 2006. Locus-specific mutation databases: pitfalls and 
good practice based on the p53 experience. Nat Rev Cancer 6:83-90.
Stenflo J. 1991. Structure-function relationships of epidermal growth factor modules in vitamin In­
dependent clotting factors. Blood 78:1637-1651.
Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, 
Cooper DN. 2003. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 
21:577-581.
Steward RE, MacArthur MW, Laskowski RA, Thornton JM. 2003. Molecular basis of inherited 
diseases: a structural perspective. Trends Genet. 19:505-513.
Sun MF, Baglia FA, Ho D, Martincic D, Ware RE, Walsh PN, Gailani D. 2001. Defective binding 
of factor XI-N248 to activated human platelets. Blood 98:125-129.
Sun MF, Zhao M, Gailani D. 1999. Identification of amino acids in the factor XI apple 3 domain 
required for activation of factor IX. J Biol Chem 274:36373-36378.
Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P. 2001. Prediction of 
deleterious human alleles. Hum Mol Genet 10:591-597.
Tainer JA, Roberts VA, Getzoff ED. 1992. Protein metal-binding sites. Curr Opin Biotechnol 
3:378-387.
Takamiya O, Machida S, Yamamoto M. 2005. Factor XI deficiency with a novel homozygous 
mutation Trp599Arg near the C-terminal region. Haematologica 90:999-1001.
Taneda H, Andoh K, Nishioka J, Takeya H, Suzuki K. 1994. Blood coagulation factor Xa interacts 
with a linear sequence of the kringle 2 domain of prothrombin. J Biochem (Tokyo) 
116:589-597.
Terado T, Nonaka MI, Nonaka M, Kimura H. 2002. Conservation of the modular structure of 
complement factor I through vertebrate evolution. Dev Comp Immunol 26:403-413.
Thompson RE, Mandle R Jr, Kaplan AP. 1977. Association of factor XI and high molecular 
weight kininogen in human plasma. J Clin Invest 60:1376-1380.
Todd AE, Orengo CA, Thornton JM. 2001. Evolution of function in protein superfamilies, from a 
structural perspective. J Mol Biol 307:1113-1143.
Tordai H, Banyai L, Patthy L. 1999. The PAN module: the N-terminal domains of plasminogen 
and hepatocyte growth factor are homologous with the apple domains o f the prekallikrein 
family and with a novel domain found in numerous nematode proteins. FEBS Lett 461: 
63-67.
Tress M, Ezkurdia I, Grana O, Lopez G, Valencia A. 2005. Assessment of predictions submitted 
for the CASP6 comparative modeling category. Proteins 61 Suppl 7:27-45.
Tsiftsoglou SA, Willis AC, Li P, Chen X, Mitchell DA, Rao Z, Sim RB. 2005. The catalytically 
active serine protease domain of human complement factor I. Biochemistry 44:6239- 
6249.
Tsukahara A, Yamada T, Takagi A, Murate T, Matsushita T, Saito H, Kojima T. 2003. Compound 
heterozygosity for two novel mutations in a severe factor XI deficiency. Am J Hematol 
73:279-284.
362
Uprichard J, Perry DJ. 2002. Factor X deficiency. Blood Rev 16:97-110.
Vaziri-Sani F, Holmberg L, Sjoholm AG, Kristoffersson AC, Manea M, Fremeaux-Bacchi V, 
Fehrman-Ekholm I, Raafat R, Karpman D. 2006. Phenotypic expression of factor H 
mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 69:981-988.
Ventura C, Santos AI, Tavares A, Gago T, Lavinha J, McVey JH, David D. 2000. Molecular 
genetic analysis of factor XI deficiency: identification of five novel gene alterations and 
the origin of type II mutation in Portuguese families. Thromb Haemost 84: 833-840.
Voet D, Voet J. 1995. Biochemistry (2nd edition), John Wiley and Sons.
Volanakis JE, Kaplan MH. 1974. Interaction of C-reactive protein complexes with the 
complement system. II. Consumption of guinea pig complement by CRP complexes: 
requirement for human C1 q. J Immunol 113:9-17
Volanakis JE, Wirtz KW. 1979. Interaction of C-reactive protein with artificial 
phosphatidylcholine bilayers. Nature 281:155-157.
Vyse TJ, Bates GP, Walport MJ, Morley BJ. 1994. The organization of the human complement 
factor I gene (IF): a member of the serine protease gene family. Genomics 24:90-98.
Vyse TJ, Morley BJ, Bartok I, Theodoridis EL, Davies KA, Webster AD, Walport MJ. 1996. The 
molecular basis of hereditary complement factor I deficiency. J Clin Invest 97:925-933.
Walker FJ. 1981. Regulation of activated protein C by protein S. The role of phospholipid in 
factor Va inactivation. J Biol Chem 256:11128-11131.
Walsh PN. 2001. Roles of platelets and factor XI in the initiation o f blood coagulation by 
thrombin. Thromb Haemost 86:75-82.
Wang Z, Moult J. 2001. SNPs, protein structure, and disease. Hum Mutat 17:263-270.
Warwicker P, Goodship THJ, Donne RL, Pirson Y, Nicholls A, Ward RM, Goodship JA. 1998. 
Genetic studies into inherited and sporadic haemolytic uraemic syndrome. Kidney Int 
53:836-844.
Wetlaufer DB. 1973. Nucleation, rapid folding, and globular intrachain regions in proteins. PNAS 
70:697-701.
Wiles AP, Shaw G, Bright J, Perczel A, Campbell ID, Barlow PN. 1997. NMR studies of a 
viral protein that mimics the regulators o f complement activation. J Mol Biol 272:253- 
265.
Wilton AN, Johnstone RW, McKenzie IF, Purcell DF. 1992. Strong associations between RFLP 
and protein polymorphisms for CD46. Immunogenetics 36:79-85.
Wistinghausen B, Reischer A, Oddoux C, Ostrer H, Nardi M, Karpatkin M. 1997. Severe factor 
XI deficiency in an Arab family associated with a novel mutation in exon 11. Br J 
Haematol 99:575-577.
Wolberg AS, Morris DP, Stafford DW. 1997. Factor IX activation by factor XIa proceeds without 
release of a free intermediate. Biochemistry 36:4074-4079.
Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, Boeckmann B, Ferro S, Gasteiger E, 
Huang H, Lopez R, Magrane M, Martin MJ, Mazumder R, O'Donovan C, Redaschi N,
363
Suzek B. 2006. The Universal Protein Resource (UniProt): an expanding universe of 
protein information. Nucleic Acids Res 34:D187-D191.
Wu WM, Wang HL, Wang XF, Chu HY, Fu QH, Ding QL, Hu YQ, Shen ZX, Wang ZY. 2003. 
Identification of two novel factor XI non-sense mutation Trp228stop and Trp383stop in a 
Chinese pedigree of congenital factor XI deficiency. Zhonghua Xue Ye Xue Za Zhi 
24:126-128.
Wu WM, Ding QL, Wang XF, Fu QH, Wang WB, Dai J, Fang Y, Zhou RF, Xie S, Hu YQ, Sheng 
ZX, Wang HL, Wang ZY. 2004. FXI gene mutations in two pedigrees of congenital 
clotting factor XI deficiency. Zhonghua Xue Y e Xue ZaZhi25:132-135.
WulfFK, Herrmann FH. 2000. Twenty two novel mutations of the factor VII gene in factor VII 
deficiency. Hum Mutat 15:489-496.
Xie S, Wang HL, Wang XF, Wu WM, Zhou RF, Wang WB, Hu YQ, Wang ZY. 2005. The 
inherited coagulation factor XI deficiency caused by intronic mutation IVS J-4delgttg. 
Zhonghua Xue Ye Xue Za Zhi 26:144-147.
Yue P, Li Z, Moult J. 2005. Loss of protein structure stability as a major causative factor in 
monogenic disease. J Mol Biol 353:459-473.
Zacharski LR, French EE. 1978. Factor XI (PTA) deficiency in an English-American kindred. 
Thromb Haemost 39:215-222.
Zadra G, Asselta R, Malcovati M, Santagostino E, Peyvandi F, Mannucci PM, Tenchini ML, 
Duga S. 2004. Molecular genetic analysis of severe coagulation factor XI deficiency in 
six Italian patients. Haematologica 89:1332-1340.
Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R, Schmaier AH. 2001. Assembly and 
activation of HK-PK complex on endothelial cells results in bradykinin liberation and 
NO formation. Am J Physiol Heart Circ Physiol 280:H1821-H1829.
Zhou H, Mazzulla MJ, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA. 
1998. The solution structure of the N-terminal domain of hepatocyte growth factor 
reveals a potential heparin-binding site. Structure 6: 109-116.
Zipfel PF, Heinen S, Jozsi M, Skerka C. 2006. Complement and diseases: defective alternative 
pathway control results in kidney and eye diseases. Mol Immunol 43:97-106.
Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S. 1999. The factor H protein family. 
Immunopharm 42:53-60.
Zipfel PF, Skerka C. 1999. FHL-l/reconectin: a human complement and immune regulator with 
cell-adhesive function. Immunol Today 20:135-140.
Zivelin PF, Bauduer F, Kombrot N, Ducout L, Rosenberg N, Seligsohn U. 1999. Identification of 
5 novel factor XI mutations in french basques. Haematologica 84(Suppl2):0549.
Zivelin A, Peretz H, Kombrot N, Livnat T, Bulvik S, Kenet G, Seligsohn U. 1999. Identification 
of 3 novel mutations in the factor XI gene in Jewish patients. Thromb Haemost 
(suppl): 1999:P893.
364
Zivelin A, Bauduer F, Ducout L, Peretz H, Rosenberg N, Yatuv R, Seligsohn U. 2002. Factor XI 
deficiency in French Basques is caused predominantly by an ancestral Cys38Arg 
mutation in the factor XI gene. Blood 99: 2448-2454.
Zivelin A, Schmidt AE, Ogawa T, Toomey JR, Rosenberg N, Cohen-Landau M, Seligsohn U, 
Gailani D, Bajaj SP. 2003. Investigations of Gly555Glu CRM positive factor XI mutant: 
Structural role of Gly555 (193 in Chymotrypsin) in serine proteases. Blood 102: 301a.
Ami RK, Padmanabhan K, Padmanabhan KP, Wu TP, Tulinsky A. 1993. Structures of the 
noncovalent complexes of human and bovine prothrombin fragment 2 with human 
PPACK-thrombin. Biochemistry. 32:4727-4737.
Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, 
Kirchhofer D. 1996. The crystal structure of the complex of blood coagulation factor 
Vila with soluble tissue factor. Nature. 380:41-46.
Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh 
RA. 1999. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate 
binding. Structure. 7:989-996.
Huang M, Furie BC, Furie B. 2004. Crystal structure of the calcium-stabilized human factor IX 
Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 
279:14338-46.
Kamata K, Kawamoto H, Honma T, Iwama T, Kim SH. 1998. Structural basis for chemical 
inhibition of human blood coagulation factor Xa. PNAS 95:6630-6635.
Mather T, Oganessyan V, Hof P, Huber R, Foundling S, Esmon C, Bode W. 1996. The 2.8 A 
crystal structure of Gla-domainless activated protein C. EMBO J. 15:6822-6831.
Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, Esmon CT. 2002. The 
crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol 
Chem 277:24851-24854.
Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG, Stuart D. 1995. The structure of a 
Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein 
interactions. Cell. 82:131-141.
Wang SX, Hur E, Sousa CA, Brinen L, Slivka EJ, Fletterick RJ. 2003 .The extended interactions 
and Gla domain of blood coagulation factor Xa. Biochemistry 42:7959-7966.
365
Full Length Publications
O'Connell NM, Saunders RE, Lee CA, Perry DJ, Perkins SJ. 2005. Structural 
interpretation of 42 mutations causing factor XI deficiency using 
homology modeling. J Thromb Haemost 3:127-138.
Saunders RE, O’Connell NM, Lee CA, Perry DJ, Perkins SJ. 2005. Factor XI 
deficiency database: an interactive web database of mutations, 
phenotypes, and structural analysis tools. Hum Mutat 26:192-198.
Saunders RE, Goodship TH, Zipfel PF, Perkins SJ. 2006. An interactive web 
database of factor H-associated hemolytic uremic syndrome mutations: 
insights into the structural consequences of disease-associated mutations. 
Hum Mutat 27:21-30.
Jozsi M, Heinen S, Hartmann A, Ostrowicz CW, Halbich S, Richter H, Kunert A, 
Licht C, Saunders RE, Perkins SJ, Zipfel PF, Skerka C. 2006. Factor H 
and atypical hemolytic uremic syndrome: mutations in the C-terminus 
cause structural changes and defective recognition functions. J Am Soc 
Nephrol 17:170-177.
Saunders RE, Perkins SJ. 2006. A user's guide to the interactive Web database of 
factor H-associated hemolytic uremic syndrome. Semin Thromb Hemost 
32:160-168.
Licht C, Heinen S, Jozsi M, Loschmann I, Saunders RE, Perkins SJ, Waldherr R, 
Skerka C, Kirschfink M, Hoppe B, Zipfel PF. 2006. Deletion of Lys224 in 
regulatory domain 4 of Factor H reveals a novel pathomechanism for 
dense deposit disease (MPGNII). Kidney Int 70:42-50.
Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge 
E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi 
G, Rodriguez de Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, 
Perkins SJ. 2007. The interactive Factor H-atypical hemolytic uremic 
syndrome mutation database and website: update and integration of 
membrane cofactor protein and Factor I mutations with structural models. 
Hum Mutat 28:222-234.
367
Full Length Publications in Preparation
Edey MM, Mead PA, Saunders RE, Perkins SJ, Goodship THJ, Kanagasundaram 
N. 2007. Factor H associated haemolytic uraemic syndrome following a 
diarrhoeal illness. Submitted for publication.
Saunders RE, Perkins SJ. The Coagulation Serine Protease Missense Mutation 
Database: A text mining approach to analysing mutations within domain 
structures. 2007. In preparation.
Saunders RE, Perry DJ, Perkins SJ. 2007. Factor XI deficiency database: Update 
to include structural analysis of mutations within crystal structure of FXI. 
In preparation.
Meeting Abstracts
O'Connell NM, Saunders RE, Lee CA, Perry DJ, Perkins SJ. 2004. Homology 
modelling of mutations causing FXI deficiency using related crystal 
structures and bioinformatics. British Society for Haematology 44th 
Annual Meeting, Cardiff, UK. 19-21 April 2004.
Saunders RE, Neumann HPH, Zipfel PF, Perkins SJ. 2004. Factor H-associated 
Haemolytic Uraemic Syndrome: Structural consequences of disease 
associated mutations. XXth International Complement Workshop, 
Honolulu, Hawaii, USA. 13-18 June 2004.
Saunders RE & Perkins SJ. A website for factor H-Associated haemolytic 
uraemic syndrome and disease-associated mutations. British Society of 
Immunology Meeting, Harrogate, UK. 6-9 December 2004.
Saunders RE, Goodship THJ, Zipfel PF, Perkins SJ. 2005. An interactive web 
database of Factor H-associated Haemolytic Uraemic Syndrome 
mutations: Insights into the structural consequences of disease associated 
mutations. 2nd International Workshop on Thrombotic Microangiopathies 
Jena, Germany. 27-28 May 2005.
Saunders RE, O'Connell NM, Lee CA, Perry DJ, Perkins SJ. 2005. The Factor XI 
deficiency database: an interactive web database of mutations, phenotypes 
and structural analysis tools. International Society on Thrombosis and
368
Haemostasis (ISTH) Conference, Sydney, Australia. 6-12 August 2005.
Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge 
E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi 
G, Rodriguez de Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, 
Perkins SJ. 2006. Factor H- HUS Mutation Database and Website: Update
tViand Integration of MCP and FI mutations with structural models. XXI 
International Complement Workshop, Beijing, China. 22-27 Oct 2006.
Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge 
E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi 
G, Rodriguez de Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, 
Perkins SJ. 2006. The interactive Factor H associated atypical haemolytic 
uraemic syndrome mutation database and website: update and integration 
of membrane cofactor protein and factor I mutations with structural 
models. 2nd Bergamo Workshop on HUS, Bergamo, Italy. 30 Nov - 1 
Dec, 2006.
369
HUMAN MUTATION 28(3), 222-234 ,2007
DATABASES
The Interactive Factor H -A typical Hemolytic 
Uremic Syndrome Mutation Database and Website: 
Update and Integration of Membrane 
Cofactor Protein and Factor I  Mutations 
With Structural Models
Rebecca E. Saunders,1 Cynthia Abarrategui-Garrido,2 Veronique Fremeaux-Bacchi,3 Elena Goicoechea de 
Jorge,4 Timothy H.J. Goodship,5 Margarita Lopez Trascasa,6 Marina Noris,7 Isabel Maria Ponce Castro,6 
Giuseppe Remuzzi,7 Santiago Rodriguez de Cordoba,4 Pilar Sanchez-Corral,2 Christine Skerka,8 
Peter F. Zipfel,8 and Stephen J. Perkins1*
1Department of Biochemistry and Molecular Biology, Royal Free and University College Medical School, University College London, London, United 
Kingdom; 2Umdad de Investigacion, Hospital Universitario La Paz, Madrid, Spain; 3Service d’lmmunologie Biologique, Hopital Europeen Georges Pompidou, 
Assistance Publique-Hdpitaux de Paris (AP-HP), Bergamo Paris, France; 4Departamento de Inrmmohga, Centro de Invesdgadones Bblogcas (CS1C), 
Madrid, Spain; institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; 6Unidad de Imnunologia, 
Hospital Universitario La Paz, Madrid, Spain; 7Clinical Research for Rare Diseases, “Aldo e Cele Dacco, ” Mario Negri Institute for Pharmacological 
Research, Ranica, Bergamo (BG), Italy; department of Infection Biology, Hans Knoll Institute for Natural Products Research, Jena, Germany
Communicated by Alastair Brown
Atypical hemolytic uremic syndrome (aHUS) is a disease of hemolytic anemia, thrombocytopenia, and renal failure 
associated with defective alternative pathway (AP) complement control. Previously, we presented a database 
(www.FH-HUS.org) focusing on aHUS mutations in the Factor H  gene (CFH). Here, new aHUS mutations are 
reported for the complement regulatory proteins Factor H (FH), Factor I (FI), and membrane cofactor protein 
(MCP). Additional mutations or polymorphisms within CFH have been associated with membranoproliferative 
glomerulonephritis (MPGN) and age-related macular degeneration (AMD). Accordingly, the database now 
includes substitutions that predispose to aHUS, MPGN, and AMD. For this, structural models for the domains in 
MCP and FI were developed using homology modeling. With this new database, patients with mutations in more 
than one gene can be displayed and interpreted in a coherent manner. The database also includes SNP 
polymorphisms in CFH, MCR and IE There are now a total of 167 genetic alterations, including 100 in CFH, 43 
in MCP and 24 in IF. The mutations characterize clinical outcomes that vary from several AMD-associated 
polymorphisms to those associated with aHUS, MPGN, or FI deficiency. A consensus short complement regulator 
(SCR) domain structure facilitated the interpretations of aHUS mutations. Specific locations within this consensus 
domain often correlate with the occurrence of clinical phenotypes. The AMD 'Iyr402His polymorphism is 
structurally located at a hotspot for several aHUS mutations. The database emphasizes the causative role of the 
alternative pathway of complement in disease and provides a repository of knowledge to assist future diagnosis and 
novel therapeutic approaches. Hum Mutat 28(3), 222-234, 2007. © 2006 Wiley-Liss, Inc.
key  w o r d s : Factor H; CFH; hemolytic uremic syndrome; Factor I; IF; membrane cofactor protein; MCP; 
complement; mutation database; immunodeficiency diseases
INTRODUCTION
Hemolytic uremic syndrome (HUS) is characterized by a 
phenotype of microangiopathic hemolytic anemia, thrombocyto­
penia, and acute renal failure in affected individuals [Perkins and 
Goodship, 2002]. The majority of diarrheal HUS cases are caused 
by toxic Escherichia coli bacteria. Alternatively, there are cases that 
are not associated with diarrhea and which have a poorer 
prognosis, known as atypical HUS (aHUS). aHUS is strongly 
associated with mutations in the gene encoding the complement 
regulator Factor H protein (FH) [Saunders et al., 2006]. FH is a
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central regulator in the alternative pathway of activation, in which 
it acts as a cofactor for Factor I (FI) in the inactivation of the 
central complement protein C3b to form iC3b [Law and Reid, 
1995; Rodriguez de Cordoba et al., 2004]. It also accelerates the 
decay of the C3 convertase C3bBb, and competes with Factor B 
for binding to C3b. FH consists of 20 short complement regulator 
(SCR) domains, also known as short consensus repeat or 
complement control protein domains, each about 61 residues in 
length (Fig. la).
In addition to mutations within the FH gene (CFH; 
MIM# 134370), further mutations implicated with aHUS 
have recently been identified in the gene encoding the comple­
ment regulator membrane cofactor protein (MCP; approved 
symbol, CD46; MIM# 120920) [Richards et al., 2003; 
Noris et al., 2003; Esparza-Gordillo et al., 2005; Caprioli et al., 
2006; Fremeaux-Bacchi et al., 2006]. MCP is a widely-expressed 
transmembrane protein that inhibits alternative pathway 
activation on host cells. MCP and FI degrade C3b and C4b 
bound to cell surfaces. The extracellular amino terminus of MCP 
consists of four SCR domains. Following this is an alternatively 
spliced region for extensive glycosylation, a transmembrane 
domain, and a cytoplasmic domain (Fig. lb). Additional aHUS 
mutations have also been identified in the regulatory serine 
protease FI gene (IF; approved symbol, CFI; MIMif 217030) 
[Fremeaux-Bacchi et al., 2004; Esparza-Gordillo et al., 2005; 
Kavanagh et al., 2005]. FI is synthesized as a single precursor of 
565 amino acids. Four basic amino acids are then excised from this
precursor chain prior to secretion. The active form of FI is 
composed of a heavy chain comprising a FI membrane attack 
complex (FIMAC) domain, a CD5 domain (also known as a 
scavenger receptor cysteine-rich domain), and two low-density 
lipoprotein receptor (LDLR) domains (Fig. lc) [Chamberlain 
et al., 1998]. The light chain consists of only the catalytic serine 
protease (SP) domain. Mutations within CFH, MCFj and IF result 
in impaired protection of host surfaces against complement 
activation and lead to endothelial cell activation [Ballermann, 
1998].
The interactive FH-HUS mutation database (www.FH-HUS. 
org) was established in November 2004 [Saunders et al., 2006]. 
Initially this provided the research community with a central 
resource of FH-HUS-associated mutations combined with struc­
tural models of FH domains. Recently, mutations within IF and 
MCP were recognized to play an important role in aHUS. 
Likewise, SNPs in CFH have recently been associated as a risk 
factor for diseases such as age-related macular degeneration 
(AM D). Here we describe the extension of the database to include 
both MCP and IF mutations alongside structural models of MCP 
and FI domains and to include SNPs within CFH, MCP and 
IF. Our homology modeling provides possible insights into the 
structural consequences of newly discovered MCP and FI 
mutations. With this new version of the database, it is now 
possible to provide an integrated view of 63 FH and MCP 
mutations in terms of a consensus SCR structure, and data on 
patients with mutations in more than one protein can be displayed
(a)
C.79J2telAGAA
A/g53Cys
Val62Iie*
ArgTSGty 
I
Q ul«9X
I
GW O X ys 
H«W2Tyr* 
Ato307Ab* Cys431Ser?Tyr 
I I
Cys536Aiq 
I
Cys630Trp
Cys673Ser/Tyr 2303_2304dupA 
I    I ! !
k h i  | sew; |j sc m  j scm  j ten s  j |  sen? |  * » »  j| |  yenio j se m i j i c n u  j  m n u  |  a n  |
He881Leu
Ser89Cie
Mts893Arg Thr987AU
HOOK*
t 3C32delG
Fvrl021Phe
*Cysl043Arg
AsplU9GI>
Yalll34Giy
TyrlH 2A s^C ys
T rpll57A rj
c.3486delA
Cysll63Trp
C,3493+1G>A
SCR 16 U SCR 17 I St HIS B SCR 19 I SCHJO
|1-1* 21 »  
cl-2S7C>T*
(b)
as- hi 
I
710-262
I
767-570 S25-3» 389-442 4® - SOS 
I
C- 35lde4G Lys2240el AI»473Aia*
c.371_»7D el Pre2S8Uu C 14940-IA
A rgl27U u
Ser2*DPro
Phe242Cy*
Cys99Afg Tyr248X Aia353Val
AnjlQ3Trp <.747_751delAGCAA |
c.389-lG>C C-799_831delAC c 946  7aG>A* c.2337T>C*
569-625 630-684
I
Pro621Thr
691 -744 755-303 *11-864 870 - 926 931 -984 989-10*3 1048-1102 1109-1163 1167-1228 1231
I I I I I
S«714X  V9I83SUU
GkiSSOlys
- o t  rr~| SCfti | SCRJ | SCR 4
34 95
I
C.95-1G>C
Cys35Tyr
Arg59X
(c.192T>C;
C.193_l98del]
c .2 K -lG > C
c2#6+2T>€
c.2B7-2A>G
I 161,224 227 28* 301-329 3*4 366 377-392
I I I
Prol£5Ser c.gOO B 2ftte C.1127+639G>A« 
Qul79GKi c.821 8lMeiGACAG7 
Aspl85A5n [C 815 829del;c.832C>T]
TyrlMAsp C.899-2A>G 
O yt96A rj
(c) 17P145X
I
c.893delC
Cl!90J19lI«A T
H s4 i3 U u
Ary474X
c 1446J45Ckten7CAC
C.1534 + 5G>T
Asp5l9A$n
A5p524Val
c.l610_I6U InsA T
Tfp546X
Glu936Asp* Valt060Al8 Q u n ? 2 X
Gln950Htt G hI076G lu A/9U82SO-
TyrSSlHis C.3546_3581*ip36
T?ir956M*t Trpl 1 S3Arg,>'Lew'X
Cys959Tyf ThrllW A rg
!le970Val t« jU 89A rg /P he
Cys9737yr S8fU9Hj8w/Tfp
Trp978Cys GlyU94Asp
V*!1197Ala
Gtull93Ala,1ys/)(
P h e ll9 9 S er
Qyl2(l4Giu
A >9l2JX ys
Argl215Gly,*Gln
Thrl216D*l
[c,3674A>T;
c3675 .3699del]
Prol226S«f
C.369S 2693de
»EH
Mi
3 E T E }— Sf?nr«L' Fforrasf221-256 258293
I [c.9o'7G>A,
Ala240G‘v IJ
Cw24?Gly Ar93l7Trti 
C.772G>A
FIGURE l. Distribution of disease-associated mutations within individual domains of FH, MCP, and FI. Mutations are written above 
and below their respective domains. Domains are drawn to scale.The gray box indicates the coding segment for the signal peptide. 
The numbering underneath the domains indicates the range of amino acids from the start to the end of the domain. Linkers are not 
included. N and C indicate the N-terminus and C-terminus, respectively. Mutations followed by an asterisk represent disease-asso­
ciated polymorphisms, a: Domain structure of FH. b: Domain structure of MCP. ST, serine/threonine rich region;TM, transmembrane 
helix region; Cy, cytoplasmic region, c: Domain structure of FI. FIMAC, FI membrane attack complex; CD5, cluster of differentiation 
5. LDR, low-density lipoprotein receptor.
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in a coherent manner. These database enhancements have 
improved its ability to be a central information resource, providing 
further insight into the role of the complement proteins in these 
diseases, and indicating possible reasons for the clinical hetero­
geneity of the outcome of aHUS depending on the underlying 
genetic cause.
FH-HUS MUTATION DATABASE UPDATES
The FH-HUS mutation database is available at the following 
website: www.FH-HUS.org. It is maintained and updated on the 
server of the Department of Biochemistry and Molecular Biology 
at University College London. The database is constructed 
using mySQL (www.mysql.com) and is displayed and navigated 
on the web via PHP (www.php.com), JavaScript, and HTML 
programming.
The FH-HUS mutation database was extended to include 
mutations and structural models for domains within MCP and FI. 
This involved the reconstruction of several pages and submenus. 
Quick, basic, and advanced searches can now be carried out for 
CFH, MCP and IF mutations. Mutation maps based on both 
protein and nucleotide sequences are available for each protein, as 
well as information pages and reference libraries. Statistics can be 
displayed to show the distribution of mutations within all three 
proteins. The database was also extended to include SNP records 
from the SNP database (www.ncbi.nlm.nih.gov/projects/SNP). 
SNPs are defined as point mutations that occur in over 1% of 
the general population. To avoid confusion, we refer to SNPs that 
are not associated with disease as non-disease-causing polymorph­
isms within the database. There are several SNPs that are 
associated with a disease risk such as the His402Tyr SNP within 
FH that is associated with AMD and the c .l-2 5 7 C > T , 
c.2016A >G  (Gln672GIn), and c .2808G > T  (Glu936Asp) SNPs 
within FH that are associated with aHUS. These SNPs are referred 
to as disease-associated polymorphisms. Genetic alterations that 
are extremely rare within populations and are thought to be the 
major cause of disease or deficiency are referred to as disease- 
associated mutations. All the genetic alterations within the 
database are numbered according to the HGVS (www.hgvs.org/ 
mutnomen) guidelines for mutation nomenclature, where nucleo­
tide +1 refers to the A  of the initiating ATG codon. Amino acids 
are also numbered starting from the initiating Met residue. The 
reference sequences for the protein and genetic sequences are 
taken from the RefSeq database (www.ncbi.nlm.nih.gov/RefSeq/) 
with the following accession numbers NM _000186.I (CFH), 
NM_000204.1 (IF), and NM_002389.3 (MCP). To avoid confu­
sion, the website now also includes a description of how the 
alteration was originally reported if the numbering is not 
consistent with HGVS guidelines.
IDENTIFICATION OF NEW MUTATIONS 
IN CFH, MCP, AND IF
In addition to the 54 disease-associated mutations that were 
classified within CFH  in the original description of the database 
[Saunders et al., 2006], 16 more novel mutations were identified 
in CFH (Fig. 1; Supplementary Table SI [Supplementary material 
available online at http://www.interscience.wiley.com/jpages/1059- 
7794/suppmat]), 11 of which were from collaborating laboratories. 
Four novel mutations were identified in Spanish patients by 
automatic DNA sequencing of the CFH exons as previously 
described [Perez-Caballero et al., 2001], Two novel CFH 
mutations in Italian patients were identified by SSCP followed
by sequencing and one novel nonsense mutation was identified by 
direct sequencing [Caprioli et al., 2006], One and three additional 
CFH mutations from the Newcastle (UK) and Jena (Germany) 
laboratories, respectively, were identified using methods described 
previously [Saunders et al., 2006]. A  total of 25 disease-associated 
mutations were identified within MCP, 16 of which are novel and 
were identified by collaborating laboratories. Nine novel MCP 
mutations were identified in French patients, as described 
elsewhere [Fremeaux-Bacchi et al., 2006]. Six novel MCP 
mutations were identified in Italian patients using SSCP followed 
by sequencing, as described elsewhere [Caprioli et al., 2006]. Two 
novel mutations within MCP were found in three Spanish aHUS 
patients using standard procedures previously reported [Esparza- 
Gordillo et al., 2006]. Within IF, 16 disease-associated mutations 
were identified, seven of which are novel and were identified by 
collaborating laboratories. Five novel FI mutations were identified 
by DHPLC followed by sequencing, as described elsewhere 
[Caprioli et al., 2006]. Two novel FI mutations were identified 
in patients using cD N A  generated from skin biopsy fibroblasts and 
verified on genomic D N A  with appropriate primers (I.M. Ponce 
Castro and M. Lopez Trascasa, unpublished results). Previously 
reported mutations were identified by searching the Human 
Gene Mutation database (http://archive.uwcm.ac.uk/uwcm/mg/ 
hgmd0.html), the literature database PubMed (www.ncbi.nih.gov/ 
entrez/query.fcgi), and the SNP database (www.ncbi.nlm.nih.gov/ 
projects/SNP).
STRUCTURAL MODELS FOR FH, MCP, FI, 
AND THE CONSENSUS SCR DOMAIN
A  total of 18 out of the 20 SCR domain structure models used 
previously for FH were reused in the improved database [Saunders 
et al., 2006]. Those for SCR-19 and SCR-20 were replaced by 
the recently-solved nuclear magnetic resonance (NMR) and X-ray 
crystal structures (Protein Data Bank [PDB] codes 2bzm and 2g7i) 
[Herbert et al., 2006; Jokiranta et al., 2006]. These experimental 
three-dimensional coordinates for SCR-19 and SCR-20 enable 
mutations to be analyzed based on more accurate side-chain 
accessibilities and loop regions. They also permit comparisons with 
our two previous homology models [Aslam and Perkins, 2001; 
Saunders et al., 2006]. The angle between SCR-19 and SCR-20 
are 165° and 150° in the NMR and crystal structures, respectively 
(as defined in Gilbert et al. [2005]), indicating some possible 
flexibility between the domains. Superimpositions of the SCR-19 
and SCR-20 a-carbon atoms gave root mean square deviation 
(RMSD) of 0.19 and 0.28 nm, respectively, with the greatest 
differences occurring at surface loop regions, possibly indicating 
flexibility in these (Fig. 2a). On a residue-by-residue basis using 
a three-state analysis (helix, strand, or loop), Dictionary of 
Secondary Structures in Proteins (DSSP) analysis showed that the 
NMR and crystal secondary structures of SCR-19 and SCR-20 
(excluding the linker) are in 87 and 90% agreement, respectively 
(Fig. 2b). The same comparison of the crystal structure with the 
homology model gave more varied agreements of 80 and 58%. 
W hen accessibilities were considered in a two-state analysis (using 
0-19% to denote buried side-chains and 20-100% to denote 
exposed side-chains), both the NMR and crystal structures of 
SCR-19 and SCR-20 (excluding the linker) showed 85% 
agreement (Fig. 2b). The main differences are seen 
in the |32-strand of SCR-20 and in the side-chain accessibility of 
Leu 1189 (buried in the NMR structure; exposed in the crystal 
structure). The same comparison of the crystal structure with the 
homology model gave similar agreements of 87 and 81%. The
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(a)
SCR-19 1110 1120 1130 1140 1150 1160
— j----- | ------ | ------, ------1------, ------ | ----- | ------| ------ 1----- 1------| ------ |_
S«q: EAEFGKgGPPPPIDNGDITSFPLSVYAPASSVEYQgQNLYQLEGNKRITgRNGQWSEPPKgLHP
Secondary structure:
NMR: CCSCCCCCSCCCCTTEEESSCCCSSCCTTCEECEEESTTCEEESCCCEECBTTBCCCCCEEECC
XRAY: CCBCSCCCBTTEEESSCCCSCBCTTCEEEEEECTTCEEESCSEEEEETTEECCCCEEECC
MODEL: CCSCCCCTTEEECCSSCSSCCSSCEECEEECTTCCCBSSSSEEBSSSCBCCCCBC
b2 b4 b5 b6 b7 b8
Accessibilities:
NMR: 9999290281471980406997689355822290809965509587904099492290191190
XRAY: 6903814939409375969971567360609279657386999010992944 92191082
MODEL: 43817939716454 98967278836090918999939399902099596549193
SCR-20 1170 1180 1190 1200 1210 1220 1230
—  I -------- | -------- | ---------| ---------| ---------| ---------, ---------| ---------| --------- | -------- | -------- | ----------| -
Seq: gviS^ftWBgpjIALRWTAKQKLYSRTGESVEFVgKRGYRLSSRSHTLRTTgWDGKLEYPTgAKR
Secondary structure:
NMR: e e c c t t i J M B t c e e t t c s s c c c e e c t t s r e e e e c t t t e e c c s s c c c s e e e c b t t b c c c c c c e e c
XRAY: E E C C f ( H B B ^ EESCTTSCCSEECTTCEEEEEECTTCEECTTCCCSEEECBTTBCCCCCEEC
MODEL: CCCSCSCSSSCEECSSSCCCTTCCCSSCCCBCEBCCTTCCCCCSSCCCCBEBSSSEESCCCC
bl helix b2 b3 b4 b5 b6 b7 b8
Accessibilities :
NMR: 0614995H|Bl01099759490729049606032992596399195393608739088040499
XRAY: 0 8 3 2 9 9 S l8 ^ f  3032 9 9 9 9 9 9 8 8 9 0 6 0 4 7 2 0 5 0 4 3 6 9 5 7  9 8 3 9 9 3 5 9 3 9 0 6 0 9 6 4  9 0 9 2 0 4 0 5 9
MODEL: 559949399007449999399944 69953409262997998549493990319933869053
5 10 15 20 25 30 35 40 45 50
CONSENSUS -SCPPPPDIENGHTS KNYPYGDSVTYSCNPG-YRLIGS-SITCTG-GWSP-APRCE-
Xray SCR-19: gGPPPPIDNGDITSFPLSVYAPASSVEYQgQNL YQLEGNKRITgRNGQWSE PPKg
Robson 1988: ------------------EEEE - - EEEEEE--- EEEE- -EEEEEE------ E---EEEE
ChouFas 1988:-----------EEEE--- EEE- -EEEEEE----EEE-- EEEEEE--E--------EE-
bl b2 b3 b4 b5 b6
DSSP E E------- E E E E---- E E E E — E E E E E E--- E E E ----E E E E E  — E E E  E E E  -
2003 bl b2 b3 b4 b5 b6
2006 bl b2 b3 b4 b5 b6
(b)Nomenclature bl----------b2----b3----- b4------ b5-----b6-----b7---- b8 —
FIGURE 2. Front and back views of aHUS mutation sites in the crystal and NMR structures of FH SCR-19 and SCR-20. a:The experimen­
tally-determined crystal structure (thick cyan ribbon) and NMR structures (thin purple ribbon) are compared with each other in two 
views rotated by 180“.The NMR structures of the SCR-19 and SCR-20 domains were separated and superimposed individually on the 
crystal structure using a-carbon positions only. Only the side-chains of the five missense mutations in SCR-19 and 18 mutations in SCR- 
20 at 13 positions are shown.The clinical phenotype assignments are denoted as red forType I, green forType II, and gray for unclassified 
[Saunders et al., 2006] .The a-carbon positions of eight residues implicated in heparin binding by NMR are highlighted by cyan spheres 
in the bottom right corner. b:The DSSP secondary structures and side-chain solvent accessibilities of the NMR and crystal structures are 
compared with our previous homology model. a-Helix and (3-strand residues are denoted by H (cyan) and E (yellow), respectively, with 
the eight (3-strands labeled as b l to b8.The side-chain accessibilities in these structures are numbered; 0 denotes 0 to 9% accessibility, 1 
denotes 10 to 19% accessibility, and so on up to 9. Residues with accessibilities up to 19% are considered to be buried. The different 13- 
strand nomenclatures for SCR domains starting from their first definition in 1988 [Perkins et al., 1988] are compared with those deter­
mined from DSSP analyses in 2003 and 2006 [Aslam et al., 2003; Saunders et al., 2006] and the nomenclature used in NMR studies 
[Soares and Barlow, 2005]. Not all the (3-strands are necessarily observed in any given structure.
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reduced accuracies for the SCR-20 homology model compared to 
that for SCR-19 is attributed to the unusual substitution of a four- 
or seven-residue a-helix for a loop structure immediately before 
the 02 strand, even though the main SCR 0- sheet structure is fully 
conserved in SCR-20.
Experimentally-solved NMR structures are available for SCR-1 
and SCR-2 of MCP [Casasnovas et al., 1999]. The remaining two 
SCR domains in MCP and all five domains in FI were constructed 
using MODELLER v7 (http://salilab.org/modeller/FAQ.html). 
Structural templates were identified using PSI-BLAST [Altschul 
and Koonin, 1998] and aligned using CLUSTAL [Higgins et al., 
1994]. Using this alignment, the closest match in terms of 
sequence identity and number of insertions and deletions was 
chosen as the template structure for the homology model. The 
details of the modeled domains, together with their closest 
structural template, are described in Table 1. Sequence alignments 
of the template and domain sequences are shown in Figures 3 and
4. Although the sequence identity of 19 to 45% between some of 
the domain and template pairs was occasionally low, the secondary 
structure was fully conserved in all alignments, with residue 
insertions and deletions confined only to the loop regions. The 
cores of these protein models are expected to be well predicted, 
while their accuracy is expected to diminish in the regions of 
insertions and deletions in loops at the protein surfaces. This is 
sufficient to locate the positions of individual amino acids while 
the positions of their side-chains may not be as well determined. 
Conserved disulfide bridges were also maintained in the majority 
of models with two exceptions: 1) The FI CD5 domain has a 
disulfide bridge alteration. The Cys31-Cys95 (corresponding to 
Cysl41 and Met204 of FI) disulfide bridge within the CD5 
template domain of MAC-2 binding protein is not conserved in 
the FI CD5 sequence (Fig. 4b). There is however, a cysteine 
residue (Cysl81) within the FI CD5 domain that is aligned with 
Leu70 of the MAC-2 binding protein. Leu70 lies in close proximity 
to Cys31 in the CD5 domain of the MAC-2 binding protein, so 
the disulfide bridge connectivity could be maintained within the 
modeled structure. 2) The FI LDLR-1 domain loses a disulfide 
bridge at the position corresponding to that between Cys5 and 
Cysl7 in the LDLR domain (Fig. 4c). The bond lengths and bond 
angles within all modeled domains were verified using PRO- 
CHECK [Laskowski et al., 1993].
SCR domains generally contain six to eight 0-strands numbered 
PI to P8 with a hypervariable sequence loop between strands P2 
and P3 (Fig. 2b) [Aslam et al., 2003; Soares and Barlow, 2005; 
Saunders et al., 2006]. To clarify the literature, the different 
nomenclatures used in the original P-strand predictions [Perkins 
et al., 1988] and the DSSP summaries of experimental structures
[Aslam et al., 2003; Saunders et al., 2006, Soares and Barlow,
2005] is summarized in Figure 2b. The consensus of 124 SCR 
sequences found in the human complement proteins is shown in 
Figure 5a. Our previous study identified 14 different experimen­
tally solved structures in the PDB that contain a total of 27 unique 
SCR domains [Saunders et al., 2006]. When superimposed, these 
27 structures show high structural conservation. From these, an 
averaged structure of the consensus SCR sequence was modeled in 
order to permit a unified discussion of the known aHUS 
mutations. The six central P-strands (P2—P7) are present within 
this structure (Fig. 5b); however, the N-terminal strand (PI) and 
the C-terminal strand (P8) are missing because there are no 
residues preceding the first and last cysteine of the SCR domain. 
The averaged side-chain accessibility of the 27 experimental SCR 
structures aligned to the consensus sequence is also shown on 
Figure 5a.
ANALYSIS OF NEW DISEASE-ASSOCIATED 
MUTATIONS WITHIN CFH
The Version 2 update of the FH-HUS database contains 100 
genetic alterations within CFH as of June 2006. Type I disorders 
occur when the protein level is low and indicates defective 
secretion or rapid degradation, while Type II disorders arise when 
the protein level is normal but its functional activity is reduced. 
For FH, such an assignment scheme is not straightforward due to 
the large variation of FH levels in plasma and the different 
methods used for the clinical assays; accordingly, phenotypes were 
assigned following our previous procedure [Saunders et al., 2006]. 
Since our first report, 16 additional disease-associated mutations 
in CFH have been identified (Supplementary Table SI). Three of 
these mutations (c.351delG, c.670_672deLAAG, and c.3032deIG) 
result from amino acid deletions and two of these (c.351delG and 
c.3032delG) result in a truncated polypeptide chain. Interestingly, 
c.670_672delAAG causes the removal of Lys224, but since the 
reading frame is not disturbed, the polypeptide is not truncated 
and this resulted in a Type II phenotype. This was the first case 
of an membranoproliferative glomerulonephritis (MPGN) patient 
reported with normal levels of FH in plasma, as other cases of 
MPGN have all been associated with a Type I phenotype [Licht 
et al., 2006].
O f the 13 remaining CFH  mutations, only two show a Type I 
phenotype (Pro258Leu and Pro621Thr). Pro258 and Pro621 lie on 
the loop after 07 just before the fourth cysteine residue within 
SCR-4 and SCR-10, respectively (Fig. 5a). Sequence analysis 
of other SCR domains shows this proline to be well conserved, 
implying that this is important for correct protein folding. Two
t a b l e  i. Structural Templates Used for the Homology Modeling of the FI and MCP Domains*
Domain Template PDBa Template protein Insertions Deletions Sequence identity
FI FIMAC Ur7 Follistatin 2 6,2,1 23%
FICD5 lby2 MAC-2 binding protein 2,1 2 25%
FI LDR-1 lajj LDL receptor module None None 40%
FILDR-2 lajj LDL receptor module None None 45%
FISP lybw Hepatocyte growth factor 2,2,1 2,1,2,4,1 32%
MCP SCR-3 lgpz (SCR-1) Complement protease C1R None 1 19%
MCP SCR-4 lg40  (SCR-4) VCCP None None 39%
T he templates used for homology modeling of the individual FH SCR domains are identified by their PDB codes. The number of insertions and dele­
tions indicate how many residues had to be inserted or deleted from the template structure to model the domain structure in question. Values separated 
by a comma indicate there are insertions and deletions at more than one place in the model. The sequence identity is a pairwise comparison of the 
sequence of the FI or.MCP domain with the sequence of the domain in the template structure.
“The PDB codes are identified as follows: Ur7 [Innis and Hyvonen, 2003]; lby2 [Hohenester et al., 1999); lajj [Fass et al., 1997]; lybw [Shia et al., 2005]; 
lgpz [Budayova-Spano et al., 2002]; lg40 [Murthy et al., 2001].
VCCP, vaccinia virus complement control protein.
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FIGURE 3. Multiple sequence alignments of MCP domains with closely related templates. The sequence of the SCR-3 and SCR-4 
domains are shown aligned with their template SCR domain sequences (PDB codes lgpz [Budayova-Spano et al., 2002] and 
lg 4 0  [Murthy et a l., 2001]).The [3-strand secondary structure is highlighted in gray boxes and labeled from (31 to (38 when present, 
and conserved cysteine and tryptophan residues are highlighted in black. Residue numbering corresponds to the MCP protein 
sequence detailed in the RefSeq ifNM_002389.3 file, where numbering starts from +1 at the A of the ATG initiating codon.
other mutations within CFH (Arg78Gly and Prol226Ser) are seen 
at this structural position in the consensus alignment (Fig. 5a).
There are five novel Type II mutations (Ile970Val, TyrI142Cys, 
c.3546_3581dup36, GluI198Lys, and G lyl204Glu). IIe970Val 
replaces a large hydrophobic residue within the conserved [34 
strand of SCR-16 with a smaller hydrophobic residue. SC R -16 is 
implicated in C3d binding [Sharma and Pangburn, 1996] and 
disruption of this surface-exposed region may affect binding 
directly or indirectly. Tyrll42 is situated just before the (35 strand 
within the X-ray structure of SCR-19 on the interface between 
SCR-19 and SCR-20. A nother m utation, T yrll42A sp, which is 
also seen at this position, results in a Type II phenotype. This 
suggests that Tyrll42 is important for the functional activity of
FH. Although c.3546_3581dup36 involves the duplication of 
A rg ll8 2 -G ly ll9 4 , the patient plasma levels are normal, suggest­
ing that the m utant protein is secreted [Filler et al., 2004]. T he X- 
ray structure of SCR-20 shows that A rgl 182-Glyl 194 forms a 
large loop on the surface of SCR-20. The introduction of 12 amino 
acids here may extend the loop structure, which could either 
directly or indirectly perturb the predicted C3d binding site 
[Jokiranta et al., 2006] while m aintaining a stable FH structure. 
Analysis of the other two Type II m utations shows that both 
G lu ll9 8  and Glyl204 are surface-exposed within the SCR-20 
structure. G lul 198 is part of a cluster of residues implicated in C3d 
binding [Jokiranta e t al., 2006] but is also affected by heparin 
binding [Herbert et al., 2006]. T he G lyl204G lu m utation involves 
the replacement of a small glycine side-chain with a larger 
negatively-charged side-chain adjacent to A rgl203 th at is 
associated with heparin binding [Ganesh e t al., 2004; Herbert 
et al., 2006; Jokiranta et al., 2006]. This m utation could therefore 
affect the attachm ent of FH to the surface of host cells.
Patient serum levels do not distinguish between a Type I or Type 
II phenotype in the remaining six novel m utations (Arg53His, 
Cys431Tyr, Ile881Leu, Vall060Ala, T rpll83X , and G Iu ll98X ). 
Arg53 resides on a surface-exposed loop between (33 and (35 of 
SCR-1. Sequence analysis of SCR domains show that Cys431Tyr 
occurs at the same position as five other mutations within CFH 
(Cys431Ser, Cys673Ser/Tyr, Cys915Ser, and Cys973Tyr) (Fig. 5a). 
These mutations replace the third conserved cysteine residue and 
are expected to result in an unstable SCR domain structure and a 
predicted Type I phenotype. Ile881Leu involves the replacement 
of a surface-exposed residue residing on (31 within SCR -15.
Vall060A la occurs on a surface-exposed loop between [32 and [33 
of SCR -18. A lthough SCR -16 to SCR-20 has been implicated in 
C3d binding [Sharma and Pangburn, 1996] it is not clear what 
effect this m utation could have. This m utation is referenced 
within the SNP database, and it is not certain whether this 
m utation is disease-associated or a commonly occurring SNR 
Trpl 183X results in a truncated FH peptide missing 48 C-terminal 
residues and G lu ll9 8 X  results in a truncated FH peptide missing 
33 C-term inal residues.
ANALYSIS OF DISEASE-ASSOCIATED  
MUTATIONS WITHIN MCP
A total of 43 genetic alterations were found within M CP This 
includes 13 non-disease-associated polymorphisms, five disease- 
associated polymorphisms, six mutations in introgenic splice-site 
regions, six deletions, two nonsense mutations, and 11 missense 
mutations. The location of these alterations is summarized in 
Figure lb. O f the five SNPs within MCP that are associated with 
aHUS, functional analyses have demonstrated that SNPs C.-625G 
and C.-366G  decrease transcription from the MCP promoter 
[Esparza-Gordillo e t al., 2005]. These MCP SNPs are in strong 
linkage disequilibrium, organizing an SNP haplotype block 
denom inated MCPggaac. Replication studies in three different 
HUS cohorts have shown that MCPggaac is an important aHUS 
risk factor [Esparza-Gordillo et al., 2005, Fremeaux-Bacchi et al., 
2006].
The remaining 25 disease-associated mutations are distributed 
within the four N-term inal SCR domains, with one m utation 
falling within the transmembrane domain (Supplementary 
Table S2). Six of these alter the exon/intron boundary and 
splice sites of intron 1 (c .9 5 - lG > C ), intron 2 (c .2 8 6 + lG > C , 
c.286 +  2 T > G , and c .2 8 7 -2 A > G ), intron 3 (c .3 8 9 -lG > C ), 
and intron 7 (c .899-2A >  G). Six of these mutations
([c.1 9 2 T >  C;c.l93_198del], c.747_751delAGCAA, c.799_801 
delAC, c.800_820del, c.81 l_815delGACAGT, and [c.815_829 
del; c .8 3 2 C > T ]) involve deletion of nucleotides. These 12 
mutations all result in truncated polypeptides that are not 
expected to be present on host cell membranes. Similarly, two 
nonsense mutations Arg59X and Tyr248X cause premature 
termination of the MCP peptide with the transmembrane domain
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FIGURE 4. Multiple sequence alignments of FI domains with closely related templates. The sequences of all six FI domains are shown 
aligned with the template domain sequences (PDB codes llr7 [Innis and Hyvonen, 2003], lby2 [Hohenester et al., 1999], lajj [Fass 
et al., 1997], and lybw [Shia et al., 2005]).The secondary structure is highlighted in gray boxes, and conserved cysteine residues are 
highlighted in black. Residue numbering corresponds to the FI protein sequence starting from the beginning of the 18-residue signal 
peptide as residue 1 (RefSeq 5NM_000204.1).
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FIGURE 5. Location of aHUS mutations in terms of a consensus SCR domain.The FH and MCP missense mutations are highlighted in 
terms of a consensus sequence and structure for a SCR domain, a: Consensus sequence from a CLUSTAL alignment of 124 SCR do­
main sequences from human com plem ent proteins. Residues are shown only if they occur at that position in the alignment for over 
half of the sequences.The most com monly occurring residue is shown at each position. The mutations are mapped to their positions 
(boxed) within the consensus sequence. Where mutations align with insertion regions that have not been modeled in the consensus 
structure, the mutation is mapped to the position before the insertion. Red text denotesType I mutations, green denotes Type II muta­
tions, and orange indicates mutations in which the phenotype cannot be defined. Six of the eight (3-strands are shown in yellow and 
labeled in blue underneath. The averaged consensus accessibilities for 27 SCR structures are defined, b: Front and back view of a 
secondary structure cartoon derived from the averaged structural model of 27 different experimental template SCR structures. The 
numbers within the spheres correspond to the residue position in the consensus sequence. Mutations are highlighted as colored 
spheres to follow the colors defi ned in (a) .The size of the individual spheres indicates the number of mutations found at that position, 
and ranges from one to six.
deleted. Therefore, MCP is not expected to be present in normal 
amounts on cell membranes.
Turning to the II missense mutations, three show Type I 
phenotypes (Cys35Tyr, Cys99Arg, and ProI65Ser), and five show 
Type II phenotypes (Argl03Trp, Glul79Gln, Ser206Pro, 
Phe242Cys, and Ala353Val). Two of the Type I mutations 
(Cys35Tyr and Cys99Arg) involve the replacement of the first 
conserved cysteine residue (C l) of the SCR domain and would 
disrupt the disulfide bond and reduce the structural stability of the 
SCR domain. The Type I mutation Prol65Ser is on a surface loop 
near the N-terminal of SCR-3. Prol65 is adjacent to Prol66 and 
the backbone is conformationally more restricted in this area due 
to the cyclic nature of proline side-chains. Substitution of one of
these proline residues with a small serine residue may change the 
backbone conformation to destabilize the domain. This would 
result in a predicted Type I phenotype, as observed. Four of the 
Type II mutations (ArgI03Trp, Glul79Gln, Ser240Pro, and 
Phe242Cys) involved surface-exposed residues within SCR 
domains. Argl03 resides on a surface-exposed loop within SCR-
2. This could be functionally significant since mutational studies 
have mapped several residues on the surface of SCR-2 that are 
associated with cofactor activity [Christiansen et al., 2000]. 
Glul79 resides on a surface-exposed loop within SCR-3 that could 
be significant since SCR-3 has surface-exposed residues associated 
with both C3b and C4b binding [Liszewski et al., 2000]. Both 
Ser240 and Phe242 reside on a surface-exposed loop between (32
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and (34 of SCR-4 that is also associated with C3b and C4b binding 
and cofactor activity [Liszewski et al., 2006]. The remaining Type 
II missense mutation (Ala353Val) occurs within the transmem­
brane region of MCP and may affect the hydrophobicity of this 
region and interaction with the membrane without affecting 
expression of MCP [Caprioli et al., 2006]. There are three 
missense mutations found within SCR-3 that have undetermined 
phenotypes. One of these mutations (Aspl85Asn) is found on a 
surface exposed loop within SCR-3 whereas the other two 
mutations (Tyrl89Asp and Glyl96Arg) are found on conserved 
[3-strands. Disruption here could affect the structural stability of 
the SCR domain or indirectly alter the position o f surface exposed 
residues. Hence, the consequences of the disease-associated 
mutations are generally consistent with the known biochemical 
function of MCE
ANALYSIS OF DISEASE-ASSOCIATED 
MUTATIONS WITHIN IF
The database contains a total of 24 genetic alterations within IF. 
This includes seven missense mutations, three nonsense muta­
tions, two insertions, two deletions, and two splice site alterations 
(Supplementary Table S3), together with eight non-disease- 
causing polymorphisms in the database. Their domain locations 
are summarized in Figure lc, and the structural models on the web 
database provide the first three dimensional views of mutations in
FI. The majority of the 16 disease-associated mutations are within 
the SP domain, and other missense mutations are found in the two 
LDLR domains, suggesting that both are important for function, 
but no missense mutations have been so far identified in the 
FIMAC or CD5 domains.
Four mutations (Ala240GIy, Arg317Trp, c.1 5 3 4 + 5 G > T , and 
Asp524Val) involve a Type II functional alteration, where FI 
plasma levels are normal or higher than normal in heterozygous 
patients. Ala240 lies within the LDLR-1 domain of FI. LDLR 
domains are cysteine-rich domains of 40 to 50 residues that occur 
within several complement component proteins. Very little work 
has been carried out classifying these domains and it is not clear 
how an alteration within this domain could affect FI function. X- 
ray and neutron scattering work on serum-derived FI predicted 
that the FIMAC, CD5, and LDLR-1 domains form a compact 
triangular arrangement within the FI structure [Chamberlain 
et al., 1998]. This model postulates that the SE CD5, and LDLR-1 
domains constitute exposed surfaces of FI that may interact 
separately with its substrates C3b and C4b and with cofactor 
proteins. The Ala240Gly mutation could affect these surface 
exposed regions. Arg317 lies within the 40-residue connecting 
region between the light and heavy chains, 17 residues down­
stream of the cleavage site between the light and heavy chains. 
Replacement of Arg317 with a hydrophobic Trp residue would 
reduce the positive surface charge in this region and may alter the 
activation of FI. The c.1 5 3 4 + 5 G > T  mutation affects the donor 
site of intron 12, which could lead to an alternatively-spliced FI 
molecule that is present in normal amounts but is not functioning 
correctly. The Asp524Val mutation involves the substitution of a 
residue that lies next to Ser525, which is part of the catalytic triad 
(His380-Asp429-Ser525). The homology model of the FI SP 
domain indicates that this residue side-chain points away from the 
catalytic triad. A  residue substitution in such close proximity may 
cause a sufficient rearrangement of the catalytic triad to perturb 
function, while not affecting the overall stability of the protein.
A total of 10 other mutations within IF involve Type I 
phenotypes, in which the residue alteration affects the stability,
secretion, or synthesis of the FI protein, and patients have reduced 
amounts of FI in their serum. The majority of these Type I 
mutations are readily explained by the occurrence of truncated 
polypeptides, with three nonsense mutations (Trpl45X, Arg474X, 
and Trp546X) and three nucleotide changes (c.893delC,
c.ll90_1191insAT, and c.l610_1611insAT) that cause a shift in 
the reading frame of IF and result in a premature stop codon. The 
remaining Type I mutations involve a splice-site change within the 
5' donor splice-site of intron 5 (c.772G >A ), the alteration 
of two nucleotides ([c.907G > A ;c.913G >T ]) within the
linker region connecting the light and heavy chains, and two 
missense mutations (Cys247Gly and His418Leu). The
[c.907G > A ;c.913G >T ] mutation involves the substitution of 
Glu303Lys followed by the change from Glu305 to a premature 
stop codon. This produces a truncated polypeptide without the SP 
domain that is not detected in patient plasma [Morley et al., 
1998]. The Cys247Gly missense mutation involves the substitu­
tion of one of the conserved cysteine residues of the LDLR1 
domain that may perturb its correct folding. Similarly, replacement 
of His418 within a buried (3-strand of the SP domain may interfere 
with protein folding.
Only two mutations (c.l446_1450delTTCAC and Asp519Asn) 
could not be phenotypically classified as the patient serum levels of 
FI are inconclusive. The c.l446_1450delTTCAC deletion results 
in a truncated polypeptide that would be expected to be unstable; 
however, the patient’s FI serum level is 77% of normal, and since 
the patient is heterozygous it is difficult to say whether the levels 
result from the wild-type or mutant IF allele [Caprioli et al., 2006]. 
Asp519 lies seven residues downstream of Ser525 in the catalytic 
triad and may affect the functional activity of FI; however, it could 
equally affect structural stability, since the homology model shows 
that it is not in close proximity to the active site but lies within a 
buried part of the structure.
O f the 16 genetic alterations reported to predispose to 
disease, six changes (Cys247Gly, c .772G >A , c.893delC, 
[c.907G >  A;9.13G >  T ], c.ll90_1191insAT, and His418Leu) 
result in FI deficiency as opposed to aHUS. All of these mutations 
are reported in homozygosity or compound heterozygosity and 
result in the complete absence of FI in plasma. FI deficiency, like 
aHUS results in incorrect regulation of the alternative pathway, so 
there is consumptive depletion of C3, Factor B, and FH. The 
clinical outcome results in recurrent pyogenic infections, usually 
beginning in early childhood. A  distinction between aHUS and FI 
deficiency can be made since FI deficiency invariably involves the 
absence of FI, whereas aHUS involves patients that are 
heterozygous for IF mutations, having one normal copy of the IF 
allele. This mirrors the situation with CFH mutations, where 
heterozygous patients frequently suffer from aHUS, whereas those 
patients who have little or no FH present in plasma suffer from 
MPGN [Ault et al., 1997; Dragon-Durey et al., 2004]. There are 
five nonsynonymous polymorphisms within IF (Ala300Thr, 
Arg406His, Lys441Arg, Glu548Gln, and Tyr571Ser) that cause 
substitution of amino acid residues but do not alter phenotype. 
The homology models of the FI domains indicate that, with the 
exception of Ala300Thr, all the residues are on surface exposed 
loops. Residue alterations in these exposed areas are not expected 
to cause damaging structural effects, and it is unlikely that they are 
associated with the function of FI. Ala300Thr lies within the 
connecting region between the light and heavy chains of FI. 
Although another mutation within this region (Arg317Trp) is seen 
to have a functional affect on FI activation, it is not expected that 
the Ala300Thr mutation would have any structural or functional 
affects.
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MUTATIONS WITHIN SCR DOMAINS
The SCR domain is the most abundant domain type in the 
complement system. There are now a sufficient number of known 
new SCR mutations to permit an analysis of the location of 
mutations within a typical SCR domain. A  consensus SCR 
structural model was created from 27 different experimental 
template structures (Fig. 5b). This model displays all six of the 
main p-strands P2 to P7 seen in SCR domains (Fig. 2b). All 63 
known missense mutations within the SCR domains of CFH and 
MCP are highlighted in this. Overall the mutations are fairly 
uniformly distributed in the central region of the SCR consensus 
sequence, with not much clustering of the Type I or Type II 
mutations. Frequently mutations are seen at the same structural 
position in different SCR domains, indicated by the larger 
spheres.
Phenotype is regularly conserved within a consensus SCR 
residue position. Type I mutations frequently involve buried 
residues, and these predominate at residue positions 1, 4, 18, 24, 
26, 37, 39, and 47. These include the two Cys residues (C2 and 
C3) that occur within the middle of the four Cys residues in the 
SCR (Fig. 5 a). This suggests that the correct folding of the SCR 
disulfide bridges is central to protein expression levels. Type II 
mutations frequently occur at surface exposed residues, and these 
predominate at residue positions 5, 11, 13, 14, 15, 22, 23, 29, 30, 
34, 36, 38, and 43. As these positions include residues located in 
all six P-strands P2 to P7 of the consensus SCR domain, this 
suggests that both the amino acid conservation at a surface 
exposed loop conformation and the correct side-chain arrange­
ment within the central P-sheet framework of the SCR domain are 
central to function. Of interest are buried residues that lead to 
Type II phenotypes. Only one of these is observed at position 22, 
and is discussed below.
It is possible that a given position within the consensus SCR 
structure can show both phenotypes. Only one case was seen at 
position 47. Two mutations at this position present Type I 
mutations (Pro258Leu, Pro621Thr) whereas one mutation within 
SCR-20 at this position (Prol226Ser) presents a Type II 
phenotype. These mutations involve conserved proline residues 
that occur near the last Cys residue of the SCR domain. It would 
be expected that this proline residue is structurally significant since 
it is conserved and in close proximity to the last Cys residue of the 
SCR domain. The reason this change can be accommodated into 
SCR-20 and not into SCR-4 or SCR-10 while maintaining a stable 
FH structure is not clear. It is possible that the proline residue at 
position 47 is generally important for SCR-SCR linker contacts; 
this becomes unimportant for SCR-20, as this is the C-terminal 
domain with no following linker and these factors are not 
important. This varied distribution of mutation phenotypes shows 
that the structural outcomes of mutations may not be straightfor­
ward to predict, even with previous examples of similar mutations 
and homologous proteins.
This survey provides insight on the location of 12 FH 
polymorphisms. Their positions within the consensus sequence 
are varied. Three are nonsynonymous disease-associated ones 
(Glu936Asp at position 6, Tyr402His at position 13, and Val62Ile 
at position 35). Two correspond to surface-exposed positions 6 and 
35 where disease-associated mutations are not seen. The AMD- 
associated polymorphism at Tyr402His corresponds to the most 
frequently occurring surface-exposed Type II position 13 in the 
consensus SCR (Fig. 5a). There are nine nonsynonymous, non­
disease-causing polymorphisms (His332Tyr, Arg493Thr, Thr519A- 
la, Arg780Ile, Asn997Thr, AlalOlOTyr, Asnl050Tyr, Leul207Arg,
and Serl211Pro) distributed along the length of FH. Only four 
polymorphisms (His332Tyr at position 8, Asn997Thr at position 9, 
Asnl050Tyr at position 3, and Leul207Arg at position 32) 
correspond to surface-exposed positions where disease-associated 
mutations are not seen. Three others correspond to Type II 
locations in the consensus SCR domain (Arg493Thr at position 
38, Thr519Ala at position 11, and Serl211Pro at position 34). 
The remaining polymorphisms correspond to an exposed position 
with unknown phenotype (Arg780Ile at position 25) and an 
exposed position where one Type I mutation and one unclassified 
mutation are seen (AlalOlOTyr at position 18). This highlights the 
functional variability of SCR domains, where a mutation at the 
same position in one SCR domain can cause a different outcome in 
another. All 10 polymorphisms are predicted to result in a stable 
folded FH protein, as expected, as none of them involve Cys 
residues in the disulfide bridges at positions 1, 26, 39, or 49, or 
correspond to buried Type I locations at positions 4, 24, 26, 37, or 
47 (see above).
It is notable that the database only contains one nucleotide 
change (Thr987Ala) in the inter-SCR linker regions, even though 
88 residues in FH (7% of the total) are found within these linkers. 
The linker regions between SCR domains show a large sequence 
and length variability, in which the length can range between two 
to eight residues. Both the length and inter-SCR contacts of 
adjacent SCR domains determine the relative orientation of 
domain pairs. Experimental structures show that SCR domain 
pairs can be either completely extended (|32-glycoprotein I) or 
folded back (CR2) [Perkins et al., 2002]. Sequence analysis of five 
FH SWISSPROT protein sequences (CFAHJHUMAN, CFAH_- 
MOUSE, Q3MHF3_BOVIN, Q91YB6_RAT, and Q8MI72_PIG) 
shows that the sequence conservation of the linker regions is not 
significantly different from that of residues within the first and last 
Cys residues that define the SCR domain. It is also known that the 
linker regions in FH and in complement receptor types 1 and 2 
lead to a significant degree of flexibility in their overall 20 SCR, 30 
SCR, and 15 SCR domain structures, respectively [Aslam Perkins, 
2001] [Furtado PB, Huang CY, Ihyembe D, Hammond RA, 
Marsh HC, Perkins SJ, unpublished results; Gilbert et al., 2006]. 
The absence of disease-associated mutations in the linker regions 
is further evidence to show that SCR proteins are formed as a 
series of structurally well-defined, functionally-active globular 
domains that are connected by conformationally disordered linkers 
with little functional importance apart from their flexibility. In the 
case of FH, the existence of aHUS mutations between SCR-15 
to SCR-20 suggests that all these C-terminal domains may be 
involved in interactions with its C3b ligand [Saunders et al., 
2006].
SCR-19 and SCR-20 contain 33 out of 84 disease-associated 
genetic alterations in FH, including the five new ones from this 
update (Supplementary Table SI), resulting in an increased total 
of 23 missense mutations at 18 sites in these two domains. The 
variable conformations of the crystal and NMR structures of SCR- 
19 and SCR-20 are illustrated by the ribbon pairs, secondary 
structures, and accessibilities in Figure 2. Most of the side-chains 
in the new NMR and crystal structures were located in similar 
positions. The most notable exception was the side-chain of 
L eu ll89  (exposed in the crystal structure; buried in the NMR 
structure), which is an aHUS mutation site, followed by more 
marginal differences for Vail 134 and Seri 191. The quantitative 
side-chain accessibilities for 15 of these 18 aHUS sites were almost 
all correctly predicted when the crystal structure was compared to 
our earlier homology models (Fig. 2b) [Perkins and Goodship, 
2002; Saunders et al., 2006]. One of these three exceptions is
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Seri 191; this exception is attributed to an unusual bridge formed 
between its side-chain that was reoriented inside the SCR domain 
to form a contact with a buried water molecule [Jokiranta et al., 
2006]. The other two exceptions at Cys 1163 and P h e ll9 9  are 
marginally incorrect. The clinical phenotypes for Serll91L eu and 
Cysll63Trp are not defined, while that for P hell99Ser is Type I, 
which is now better reconciled with its buried position in the 
crystal structure.
Interestingly, the NMR and crystallography studies did not 
consider Type I or Type II phenotypes when interpreting the 
consequences of aHUS mutations. Thus the crystallographic study 
proposed that nine aHUS mutations in SCR-19 and SCR-20 
resulted in structural disruptions, implying that these caused Type 
I phenotypes [Jokiranta et al., 2006]. In conflict with this 
reasoning, the quantitative accessibilities for two of these 
(Tyrl 142Asp, Trpll57Arg) show that they are surface-exposed, 
not buried as stated (Fig. 2), and the clinically-observed 
phenotypes for four of these (Valll34Gly, Tyrll42Asp, 
Trpll57Arg, and Valll97Ala) corresponded to Type II mutations 
(Fig. 2) [Saunders et al., 2006]. The NMR study also implied that 
Glyll94Asp, Valll97Ala, Phell99Ser, and Prol226Ser are 
associated with Type I defects [Herbert et al., 2006], even though 
the observed phenotypes are Type II for Vail 197Ala and 
Prol226Ser [Saunders et al., 2006]. For those mutations 
with buried accessibilities but with observed Type II phenotypes, 
it would appear that internal rearrangements inside the SCR 
domain have resulted in surface alterations to result in a 
dysfunctional protein. This applies to both Valll34G ly and 
Vail 197Ala, which occupy the same SCR consensus position 22 
(Fig. 5a).
The discrepancies between the different studies show that, in 
general, predictions of the effect of aHUS-associated mutations 
from structures require experimental verifications. This is 
emphasized by the case of the p53 tumor suppressor, which with 
14,000 mutations has the most known for a human protein, yet 
only 34.4 to 55.6% of 882 distinct mutations could be explained in 
simple structural terms using the p53 crystal structure [Martin 
et al., 2002]. In this context, the NMR study provided evidence 
from the lack of spectral changes in two mutants W1183L and 
R1215G that supported their Type II phenotype assignments 
[Herbert et al., 2006; Saunders et al., 2006]. The prediction 
of a heparin binding site at R1182, K1186, K1188, and R1192 
in SCR-20 from the crystal structure of the acidic fibroblast 
growth factor-heparin complex [Perkins and Goodship, 2002] is 
consistent with both NMR observations of shifts in R1182, 
K1186, and K1188 in the presence of heparin, and peptide spot 
analyses that showed residues N1178 to Q1187 mediate binding 
interactions with heparin [Herbert et al., 2006; Jozsi et al., 
2006]. Likewise the prediction of another heparin binding site 
at R1203, K1230, and R1231 based on docking of a heparin 
model with a SCR-20 homology model [Hellwage et al., 2002] 
and the crystal structure of the vaccinia coat protein-heparin 
complex [Ganesh et al., 2004] is supported by experimental 
data [Herbert et al., 2006; Jozsi et al., 2006]. While the general 
region of a heparin binding site in SCR-20 is becoming clearer 
(Fig. 2), we have not presented another putative docking 
model of the SCR-20 complex with heparin, given that possibi­
lities have already been discussed in the literature. Figure 2 
suggests that many of the aHUS mutations are associated with 
the heparin binding region, while it is likely that others on 
the other face of SCR-20 and in other C-terminal SCR domains 
may be associated with C3b and/or C3d binding [Saunders et al.,
2006].
CONCLUSIONS
We have significantly updated the FH-HUS database to provide 
a central complete resource of information regarding HUS patients 
and mutations. We have summarized the number of known CFH 
genetic alterations (including novel ones), which has doubled in 
the past year from 54 to 100. This CFH database has also 
benefited from recent NM R and crystal structures for SCR-19 and 
SCR-20; these permit more accurate predictions of the conse­
quence of a residue change in these domains, but will not 
necessarily provide definitive explanations [Martin et al., 2002]. 
The database now includes 43 MCP genetic alterations. The new 
proposal of a consensus SCR structure (Fig. 5) will facilitate future 
aHUS mutation interpretations. There are now a sufficient 
number of available SCR mutations to suggest that Type I 
phenotypes may mostly result from mutations in their Cys residues 
or at buried positions, while Type II phenotypes may often result 
from alterations in the central (3-sheet structural core at surface- 
exposed positions. The incorporation of polymorphism data 
suggests that their locations often correspond with sites consistent 
with TVpe II phenotypes, while there is an almost complete 
absence of aHUS mutations in the inter-SCR linker sequences. 
The availability of 24 IF genetic alterations, together with the FI 
homology models, provide the first structural view of how 
mutations affect FI function. The updated database will enable 
the clinician to easily cross-correlate mutations between these 
three different proteins for a given patient. In the case of AMD, 
the database highlights the risk factors associated with associated 
polymorphisms, and whether or not there are any links with 
aHUS. The AMD-associated TVr402His polymorphism and many 
other aHUS Type II mutations (green in Fig. 5a) lie within the 
hypervariable loop between P-strands p2 and p3 (Fig. 2b), 
suggesting that this loop is frequently involved in function. 
Overall this database upgrade has provided us with further insight 
into the susceptibility factors for the development of aHUS, and 
has gathered information together for future investigations of 
aHUS. For these reasons, “The European Working Party on the 
Genetics of H US” has been set up; this web database will provide a 
focal point of its activities. Its membership is listed on our website 
(www.fh-hus.org) under “Collaborators.” Clearer definitions of the 
various forms of aHUS will help in defining treatment strategies 
and determining whether transplantation should be performed.
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